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Abstract 
 
 
Hepatitis C virus is an infectious disease affecting millions of people worldwide and 
causing chronic liver disease. The current standard of care is not only long but causes 
numerous side effects. Due to incomplete virological response and poor tolerability, 
only 50% of the patients are cured, with variability by genotype. Despite the 
development of non-enzymatic viral protein inhibitors, new therapies target mainly 
enzymes responsible for viral replication or translation. Being commonly used for 
antiviral and anticancer therapy, nucleosides analogues have played an important role as 
anti-HCV agents. 
 
Despite their potency and selectivity, nucleoside analogues appear to be poor substrates 
for metabolic enzymes. In particular, the first essential phosphorylation step is often 
rate-limiting thus, resulting in poor bioactivation to the active triphosphate form. Hence, 
monophosphate prodrug strategies have been applied to efficiently deliver 
intracellularly the key monophosphate derivatives. Such strategies have been 
successfully used for anti-HCV therapy and the phosphoramidate ProTide INX-08189, 
discovered in our lab, is one such example. 
 
Aiming at developing back-up molecules of INX-08189, we report in the present work, 
the synthetic strategies to obtain several modified β-2’-C-methyl-6-O-methyl guanosine 
and other modified β-2’-C-methyl purine nucleoside analogues. The phosphoramidate 
ProTide approach and the phosphorodiamidate approach were applied to these modified 
nucleosides. In-vitro, and sometimes in-vivo evaluation against HCV replication is 
reported, and the mechanism of bioactivation to their corresponding monophosphate 
species is discussed. Enzymatic experiments using carboxypeptidase Y and Huh-7 cell 
lysates were carried out to investigate the release of the monophosphate forms. We also 
investigated the hydrolysis of the 6-O-methyl group at the nucleoside level with 
adenosine deaminase enzyme, and at the monophosphate level using molecular docking 
in adenosine deaminase like protein-1. Eventually, the intracellular putative mechanism 
of activation of the ProTides was studied using molecular modeling with cathepsin A 
enzyme and human Hint-1 phosphoramidase. 
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Chapter One: Introduction 
 
 
1. Hepatitis C Virus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
About 130 to 170 million1 people worldwide are infected by hepatitis C virus (HCV). 
This spherical2 small-enveloped single-stranded positive-sense RNA hepacivirus 
(Figure 1.1) belongs to the Flaviviridae family3 and affects only humans.1 It spreads by 
blood-to-blood contact4 and causes liver disease in 60-70%5 of cases, often resulting in 
liver failure or cancer6 and transplantation need.7 
 
 
Figure 1.1. HCV structure.3 
 
 
1.1.  History and Epidemiology 
Following the differentiation of hepatitis A and hepatitis B viruses, a “non-A, non-B” 
entity was discovered during the second part of the 20th century.8 After Micheal 
Houghton’s group developed new molecular biological techniques to characterise the 
viral genome,9 it became known as hepatitis C virus.10 The viral pandemia has mainly 
been influenced by inadequately screened blood used for transfusion, unsafe injection 
equipment or illegal injection of drugs11 affecting 3 to 4 million people each year.5 The 
HCV infection prevalence varies geographically with the highest rate for Egypt.12  In 
each geographic region predominates one of the six major genotypes of HCV13 (Figure 
1.2), among which genotype 1a being the most widespread. 
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Figure 1.2. HCV prevalence worldwide.14 
 
 
 
 
1.2.  HCV infection 
After exposure to the virus, the disease develops slowly through different stages. The 
acute phase corresponds to the first 6 months after infection15 and is difficult to 
diagnose because of the lack of symptoms16 or specific diagnostic tests.17 However, 
non-specific symptoms might occur during this phase, such as loss of appetite, 
abdominal pain, fatigue, nausea and jaundice18 and HCV antibodies can only be 
detected after 15 weeks of exposure in 80% of cases.16 Spontaneous viral clearance is 
still likely during this phase,17 with variability from 10% to 50% depending on the 
genotype,19 whereas 60% to 80% of infected individuals develop persistent infection.20 
The natural evolution of acute HCV infection depends on the transmission pattern, the 
viral factors and the ability of developing a strong immune response to eliminate the 
virus.3 During the chronic phase of the disease the clinical symptoms are still minor3 
and symptoms of liver failure such as accumulation of fluid in the abdomen, bruises and 
bleeding only develop at a later stage, sometimes decades after the infection, once the 
disease has progressed to cirrhosis or liver cancer.3 
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1.3.  HCV genome 
The HCV genome is approximately 9600 base pairs long21 containing a single open 
reading frame (ORF) encoding for a polyprotein of 3011 amino acids,22 and is divided 
into two non-translated regions and three functional regions (Figure 1.3).  
5’NTR structural proteins non-structural proteins 3’NTR
  
Figure1.3. HCV genome.3, 23 
 
The most conserved segment of the HCV genome is the 5’ non-translated region 
containing the structured internal ribosomal entry site (IRES) at which binding initiates 
the first step of viral RNA polyprotein translation.24 
The 5’-terminal region contains the structural proteins C,23 E125 and E2,26 which form 
respectively the viral capsid27 and envelope essential for viral entry28 and fusion.29  
Seven non-structural proteins30 complete the HCV genome: NS2,31, 32 zinc-
metalloprotease, and p7 (NS1),33 integral membrane protein, are not essential for 
replication but play an essential role in virion formation and membrane permeability.34 
The 3’-terminal segment comprises the proteins NS3, NS4A, NS4B, NS5A and NS5B 
assembling as a replicase complex required for replication of the viral genome. While 
NS3-NS4A protease catalyses HCV polyprotein cleavage,35, 36, 37 NS4B induces a 
special membranous web-like compartment in which replication occurs.38 Interactions 
between the multi-functional protein NS5A and host proteins regulate viral genome 
replication and assembly,39, 40 whereas the error-prone NS5B RNA-dependant-RNA-
polymerase (RdRp) enables the synthesis of positive- and negative- strand HCV 
RNAs,41 hence resulting in the genetic variability of the virus.42, 43 
The sequence of the 3’ non-translated region is genotype-variable44 and takes part in 
RNA replication.45, 46 
Claire Bourdin  Chapter One: Introduction !
! 4 
1.4.  HCV life cycle 
Common to all flaviviruses, six key steps (Figure 1.4) taking place outside the host cell 
nucleus are required for HCV life cycle: binding to receptors and entry into the host cell 
(1; Figure 1.4), uncoating of the viral genome (2; Figure 1.4), translation (3; Figure 1.4) 
followed by replication (4; Figure 1.4), viron assembly (5; Figure 1.4) and eventually 
release of the newly formed virions (6; Figure 1.4).47 
 
1
2
3
4
5
6
 
Figure 1.4. HCV life-cycle steps.48 
 
Molecular recognition between glycoproteins at the surface of the virus and specific 
host cell receptors49 triggers the virus attachment, and allows its entry into cells via 
endocytosis (Figure 1.4, step 1).46, 50   
Fusion of the viral envelope with the cellular membrane is pH-dependant,51 enabling the 
removal of the nucleocapsid and release of the positive-stranded genomic RNA into the 
cytosol (Figure 1.4, step 2).52 
Acting as messenger RNA (mRNA), it then undergoes translation via binding of the 
IRES of the 5’ non-translated region and 40S ribosome subunit containing the initiation 
codon of the host system (Figure 1.4, step 3).25 A single polyprotein of approximately 
3000 amino acids is produced and cleaved by the viral protease complex NS3-NS4B 
releasing ten viral proteins, essential for the viral replication machinery.30, 53  
Semi-conservative and asymmetric, HCV replication takes place in a membranous web 
induced by NS4B23 and occurs in two steps catalysed by NS5B RdRp. Firstly, the 
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positive strand RNA serves as a template for the synthesis of negative-strand RNA, 
which then becomes a template for several nascent positive-strand viral RNAs (Figure 
1.5) ready to be encapsulated.54 
!"#$
!"#$
!%#$
!%#$
!"#$
 
Figure 1.5. Mechanism of RNA replication.23 
 
Virion assembly involves interactions between the 5’ non-translated region of new 
positive-strand RNAs and the core protein (C)55, 56 enabling the formation of a viral 
internal coat with subsequent encapsidation of the viral genome (Figure 1.4, step 5).54  
Further interactions between structural proteins and NS2 control excretion of nascent 
viral particles outside the host cell by exocytosis (Figure 1.4, step 6).23 
 
1.5.  Current treatment 
As mentioned earlier, acute HCV infection evolves to either spontaneous viral clearance 
or to chronic infection leading to cirrhosis, liver failure or cancer at a later stage. 
Neither a protective vaccination currently exists, nor a highly effective antiviral agent 
allows total eradication of the virus. Thus the use of combination therapies, which are 
not always efficient in all patients at long term and often cause side effects. 
Three responses to anti-HCV therapy are described: lack of detectable HCV RNA 
during and six months after the end of the treatment known as sustained virological 
response (SVR), end of treatment response and relapse or non-response to the therapy. 
The recent discovery and FDA approval of two NS3 protease inhibitors, telaprevir57 
(Vertex, 1) and boceprevir (Merck, 2) (Figure 1.6),58 has slightly changed the optimal 
current therapy. To avoid resistance if these protease inhibitors were dosed alone,59 the 
new standard of care comprises a triple combination therapy with one protease inhibitor 
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and the two non-specific antiviral agents pegylated interferon-α and ribavirin (3, Figure 
1.6).60 
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Figure 1.6. Structures of telaprevir (1), boceprevir (2) and ribavirin (3). 
 
The multi-functional protein pegylated interferon-α is involved in cell regulation, 
antiviral defense and activation of the immune mechanism.59 Pegylated interferon-α is 
slowly absorbed thus reducing the dosing from three to one sub-cutaneous injection per 
week during the treatment.61 
1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, also known as ribavirin (3, Figure 
1.6), has a broad spectrum of antiviral activities against DNA and RNA viruses.62 First, 
the inhibitory effect of the ribavirin 5’-monophosphate towards the inosine 5’-
monophosphate dehydrogenase (IMPDH) has an indirect effect on the synthesis of the 
viral RNA.63 However the antiviral mechanism has not yet been entirely understood and 
recently ribavirin has shown enhancement of antiviral response of lymphocytes Th1, 
responsible for the activation of B and T cells and for immune cell response, and 
suppression of lymphocytes Th2, responsible for hypersensitive immune reaction.64 In 
addition to its mutagenic action leading to virion mutations,65 the misincorporation of 
ribavirin monophosphate into viral RNA increases the frequency of mutations, and 
eventually leads to a reduction of the virus replication.61  
The new triple combination therapy applied to genotype 1 infected patients improved 
SVR to 70%66 in comparison with the 55%67 obtained with dual combination pegylated 
interferon-α and ribavirin. However the treatment still lasts 24 to 48 weeks and is not 
only high-dosing (750-800 mg tablets, three times a day)60 but also causes side effects 
such as anaemia, severe rash and gastrointestinal symptoms.59 To face the need for more 
effective HCV therapy, the development of potent and selective virus inhibitors suitable 
for clinical application is essential. 
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1.6.  Clinical candidates for HCV treatment 
Every steps of the HCV life cycle is a potential target for HCV treatment. Many 
molecules targeting the viral proteins have been designed and synthesised,68, 69 and 
several are currently in clinical trial or under clinical investigation. Despite the recent 
development of non-enzymatic viral protein inhibitors,38 the two favoured viral targets 
are the HCV NS3 protease and the NS5B polymerase, since biochemical assays are 
readily available.68 Currently, approximately 100 potential drugs have been advanced to 
clinical development and aim at targeting directly HCV; some of them are reported 
Table 1.1, while others are tested in drug combination to improve HCV antiviral 
therapy.69 These enzymatic viral protein inhibitors are either nucleoside analogues or 
non-nucleosides agents. 
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 Table 1.1. Non-nucleosides and nucleosides inhibitors of HCV polymerase  
and protease currently in clinical trials.69 
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2. Classes of inhibitors for HCV therapy 
Despite their potent antiviral activity, respectable safety profile and good tolerability in 
HCV-treated patients, nucleos(t)ide analogues and non-nucleoside inhibitors differ by 
their mode of action, efficacy and resistance profile as well as their activity against the 
different genotypes. 
2.1.  Non-nucleoside inhibitors 
Non-nucleoside analogues, such as telaprevir (1, Figure 1.6) or BMS-79005 (Table 1.1), 
target specifically the allosteric sites of the enzyme.70 Their properties define the area of 
binding, altering the conformation of the enzyme active site and disrupting the steps 
prior to or during the initiation phase of the viral RNA synthesis.71 
As mentioned earlier, mutations occur easily and result in genetic variability,71 therefore 
the rapid emergence of resistance constitutes the main drawback of non-nucleoside 
inhibitors. Hence numerous mutations at allosteric sites happen without impairment of 
the enzyme function72 but conferring resistance to the inhibitor. This is the main reason 
for the failure of some clinical developments and for the limited activity across 
genotypes.73 However, resistance mutations at one allosteric site do not usually show 
cross-resistance to other inhibitors binding at other allosteric sites of the enzyme, thus 
the importance of combination therapy74 for HCV treatment is evident. 
 
2.2.  Nucleoside and nucleotide analogues  
Nucleoside analogues are widely used in antiviral and anticancer therapies as they 
mimick the role of natural nucleosides essential for genome replication and 
transcription.75 Upon cellular uptake via specific nucleoside transporters, nucleoside 
analogues undergo bioactivation in the presence of three kinases to release the active 
triphosphate form (Figure 1.7).75, 76, 77  The latter binds to the enzyme active site and 
competes with natural nucleotides for incorporation into growing DNA or RNA 
strands,70 resulting in chain termination or inhibition of the viral polymerase. 
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Figure 1.7. Activation pathway of nucleoside analogues (NK: nucleoside kinase, NKM: 
nucleoside monophosphate kinase, NKD: nucleoside diphosphate kinase). 
 
Over the past decades, several modified ribonucleosides such as 4’-azidocytidine 
(R1479)78 and 2’-C-methylcytidine (NM107)79 have been reported as potent inhibitors 
of HCV RNA replication in replicon assays. Acting as non-obligate chain terminators, 
their lack of bioavailability and enzymatic stability, together with their poor conversion 
to the bioactive triphosphate, as for the majority of nucleoside analogues, led to the 
investigation of prodrug strategies. 
 
2.2.1. Prodrugs  
An inactive pharmacological substance, undergoing physico-chemical or enzymatic 
transformations in vivo, to afford the active metabolite was defined in 1951 by Adrien 
Albert80 as a prodrug.   
Such a prodrug should not only display a good stability towards enzymes or other 
chemical reactions occurring during the absorption, sufficient solubility, good 
membrane permeability and good distribution, but also be less toxic than the related 
drug, stable in plasma and blood, and eventually intravenously or orally dosed.81 After 
cell permeation, efficient and selective activation82, 83 should generate the desired 
metabolite at the site of action, allowing higher exposure of the drug, thus enhancing 
therapeutical effects towards the target.84 Optimisation of the drug physico-chemical 
properties should enable better selectivity towards its target.85  
The site of conversion of prodrug into its active form defines the two different classes. 
In some cases, such as antiviral nucleotide analogues, the conversion takes place 
intracellularly; whereas others are converted outside the cells and will not further 
discussed in this thesis. 
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Many issues encountered with nucleos(t)ide analogues can be overcome by application 
of the prodrug strategy. 
 
2.2.2. Nucleoside prodrugs  
Many pharmaceutical companies have investigated nucleoside prodrugs as anti-HCV 
agents targeting essentially the enzyme for viral replication, with consequent inhibition 
of the NS5B polymerase to stop the synthesis of viral RNA (Figure 1.8).  
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Figure 1.8. Nucleoside prodrugs as NS5B RdRp inhibitors. 
 
Despite their potency and selectivity, nucleoside prodrugs appear to be poor substrates 
for metabolic enzymes.86 Resistance is most likely to develop due to poor membrane 
permeability, lack of transporters, poor affinity towards targeted enzyme and thus poor 
bioactivation.87 Moreover, the first phosphorylation step is often the rate limiting,88 
preventing sufficient exposure of triphosphate at the active site to compete with natural 
substrates.71 Research on nucleotide analogues is currently heavily conducted to 
overcome these major issues, by enhancing the formation of the active triphosphate 
form, and therefore potentially increasing antiviral activity.89 
 
2.2.3. Nucleotide prodrugs 
Despite their interesting biological activities in a variety of assays and the discovery of 
potential drug candidates, nucleotides bear negative charges responsible for high 
hydrophilicity, resulting in poor membrane permeability and instability in cell media.90 
Nucleotide prodrug technology, aiming at delivery of the monophosphate directly inside 
the cells following passive diffusion and hydrolytic or enzymatic metabolism,80, 91 was 
successfully applied in anticancer and antiviral therapies.92, 93, 94 Once the highly polar 
and charged monophosphate is trapped inside the cell, it either acts as the bioactive 
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form or it undergoes enzymatic conversion to its corresponding di- and tri-phosphate 
forms. This technology may improve potency as well as selectivity, while decreasing 
toxicity. 
Several nucleotide prodrug methodologies have been developed based on enhancement 
of cell permeability and enzymatic stability by introducing neutral lipophilic moieties at 
the phosphorus center.81 The most interesting approaches are described below and 
combine ester, ether or amino acid masking groups. 
 
2.2.3.1. Phosphonate and tri-esters approaches 
Farquhar and co-workers were the first to report a phosphotriester approach by 
developing mono(POM) and later on bis(POM) derivatives (4, Figure 1.9).95 The latter 
enhances cellular delivery of the 5’-monophosphate species inside the cells after two 
enzymatic hydrolysis by carboxyesterase and/or phosphodiesterase96 resulting in release 
of potentially cytotoxic formaldehyde.  
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Figure 1.9. Structure of bis(POM) 4 and prodrugs: adefovir dipivoxil 4a  
and tenofovir disoproxil 4b. 
 
With the exception of marketed adefovir dipivoxil 4a and tenofovir disoproxil 4b for 
the treatment of hepatitis B (HBV) (Figure 1.9), the poor stability of such prodrugs in 
plasma has mainly limited their development to in vitro assessments.97 
Undergoing similar enzymatic mediated hydrolysis via the action of a reductive 
enzyme, Imbach and co-workers developed bis(S-acyclic-2-thioethyl) phosphotriester 
(SATE) 5a, and later on bis(dithioethyl) phosphotriester (DTE) 5b (Scheme 1.1).  The 
thioethyl intermediate formed by release of the S-acyl-2-thioethanol or thioethanol 
masking groups,98 liberates the highly toxic ethylene sulfide. Thus limiting their 
advancement into in-vivo studies.  
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Scheme 1.1. Mechanism of activation of bis(SATE) 5a or bis (DTE) 5b. 
 
 
2.2.3.2. Cyclic phosphotriester approaches 
Because of early cleavage of phosphotriester prodrugs in plasma, cyclic analogues were 
designed in order to enhance their stability in plasma and avoid the release of toxic 
metabolites. 
HepDirect prodrugs are designed to undergo specific activation within the liver99 via 
oxidation triggered by a single enzyme, cytochrome P450 (CYP450), affording the cyclic 
hemiketal (Scheme 1.2). The later undergoes a spontaneous ring opening releasing the 
free monophosphate and an aryl vinyl ketone.  
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Scheme 1.2. HepDirect phosphotriester and mechanism of activation. 
 
 
Several agents are based on this strategy, for example the HepDirect prodrug of 2’-C-
methyladenosine 6 (Figure 1.10) improved dramatically the triphosphate exposure.100 
Nevertheless, these agents have not progressed to clinical trials for HCV treatment but 
only for HBV.101  
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Figure 1.10. HepDirect prodrug of 2’-C-methyladenosine. 
 
In contrast with the use of enzymatic metabolism, Meier developed an approach 
describing the release of 5’-monophosphates from cyclic phosphotriesters via a 
controlled and selective chemical hydrolysis mechanism of the benzylic and phenolic 
phosphate ester bonds  (Scheme 1.3).100  
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Scheme 1.3. CycloSal phosphotriesters and mechanism of activation. 
 
 
This approach was applied successfully to different antiviral and antiviral 
nucleosides,102, 103 however it was less efficient than strategies involving enzymatic 
activation.104 
 
2.2.3.3. Phosphoramidate di- and  mono-ester approaches 
The first aryl phosphoramidate prodrug was designed by McGuigan.105 The introduction 
of an amino acid ester moiety and an aryl group attached to the phosphorus center was 
applied to a large number of nucleoside monophosphate analogues. Later on, Wagner 
and co-workers designed an achiral phosphorus center by masking only one negative 
charge of the monophosphate (phosphoramidate monoester).106 Despite improvement of 
hydrophilicity and stability in plasma, the later displayed poor oral bioavailability 
compared to the aryloxyphosphoramidate (ProTides),107 whose general structure is 
described below (Figure 1.11).  
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Figure 1.11. General structure of ProTide. 
 
Despite the obtention of diastereoisomeric mixtures at the phosphorus center, the 
advantage of this strategy is the release of natural or metabolites with relatively low 
toxicity.  
 
2.2.3.3.1. Mechanism of ProTide activation 
Valette and co-workers studied extensively the enzymatic decomposition of aryl 
phosphoramidate prodrugs.108, 109 Once inside the cells, the first step of activation 
consists of the ester cleavage by an esterase or carboxypeptidase type enzyme (Scheme 
1.4).  
Interactions between the ester moiety and the three catalytic residues of human 
lysosomal carboxypeptidase (cathepsin A)109 trigger the initial ester cleavage in the 
activation of the ProTide.110 While Ser146 attacks the ester carbonyl group, the two 
glycines (Gly53 and Gly52) stabilise the resulting intermediate.110 Conversion to the 
phosphoramidate monoester intermediate (or amino-acyl intermediate) occurs via an 
intra-molecular attack of the nucleophilic oxygen at the phosphorus atom, releasing the 
aryl moiety and followed by spontaneous hydrolysis of the putative unstable cyclic 
anhydride intermediate.110 
The discovery of adenosine monophosphate-bound amines as substrates111 of histidine 
triad nucleotide-binding proteins family (Hint-1),112, 113 indicates its possible role in the 
convertion of the phosphoramidate monoester into its corresponding nucleoside 
monophosphate.114 Interactions between the key residues Ser107, His112 and His114115 
of these phosphoramidase-type enzymes and the phosphorus center, catalyse the 
hydrolysis of the P-N bond of the phosphoramidate monoester intermediate.  
The resulting 5’-monophosphate can then undergo two phosphorylation steps to afford 
the bioactive 5’-triphosphate species. 
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Scheme 1.4. Putative mechanism of ProTide activation. 
 
 
 
2.2.3.3.2. Structure activity relationship 
Numerous aryl phosphoramidates have been synthesised on various nucleosides. An 
extensive SAR was built varying the amino acid, ester or aryl moieties, and results from 
in vitro evaluation suggest that the efficacy of ProTides varies significantly depending 
on the nucleoside. However from these studies resulted a general trend usually 
considered for designing new ProTide families. 
The first part considered for the ProTide activation is the ester moiety. Linear, 
branched, cyclic and aromatic esters have been considered as substrates for esterases. In 
general, tertiary ester such as the tert-butyl group is not cleaved, whereas ProTides 
bearing the benzyl ester proved to be highly potent.110, 116 
The investigation of the aryl moiety resulted in enhanced activity for aryl 
phosphoramidates bearing more lipophilic moieties such as naphthyl instead of phenyl. 
Variety of aryl group can generally be used to enhance lipophilicity, hence better cell 
permeation, and eventually activity of the ProTides.116 
Natural amino acids tend to be preferred than unnatural amino acids, with the exception 
of α,α-dimethylglycine that showed interesting efficacy.117 Only α-amino acids deliver 
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the 5’-monophosphate,110 and in terms of stereochemistry the L-series is often more 
active than the D-series.118 These results are probably due to the substrate specificity of 
the carboxypeptidase/esterase and phosphoramidase/human Hint enzymes responsible 
for bioactivation. L-Alanine usually gives the best results in terms of activity compared 
to other amino acids.  
 
2.2.3.3.3. Stereochemistry of ProTide 
The chirality issue at the phosphorus center is the one of the limitation of this strategy. 
The diastereoisomeric ratio is usually 1:1, but often varies depending on the SAR 
considered, making the separation of both diastereoisomers difficult. Since cellular 
targets are chiral, either only one isomer may fit in the pocket,98 or if both fit, one may 
be processed faster than the other, thus resulting in difference of activity.119 However, 
because the chirality is lost during the activation of ProTide, even diastereoisomeric 
mixtures can be highly potent, and progress into clinical trials such as the anti-HCV 
BMS-986094 (known as INX-08189, Figure 1.12) from Inhibitex Inc..120 In 
comparison, Pharmasset recently developed a separation technique to pursue the clinical 
trials with only one isomer GS-7977 (known as PSI-7977, Table 1.1).121 
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Figure 1.12. Structures of ProTides progressed in clinical trials for HCV treatment. 
 
2.2.3.4. Phosphorodiamidate approach 
To overcome the problems encountered due to chirality, another prodrug approach was 
developed and consisted in attaching two identical amino acid moieties at the 
phosphorus center. 
This approach was first reported by McGuigan and co-workers,122 but was not further 
explored until recently. Similarly to the phosphodiester approach, such 
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phosphorodiamidate prodrugs bear an achiral phosphorus center. The lack of electronic 
charges enables passive diffusion as well as increases hydrophilicity.  
Recently, phosphonic diamidate prodrugs have been reported with good activity against 
various viruses (Figure 1.13) and further studies indicate delivery of the parent molecule 
into the cells.98 
O
P
NS
H2N
O
NH
HN
OO
O
O PO NH
HN
O
O
O
O
O NN
N
N NH
NH2
7 8
 
Figure 1.13. Structures of phosphonic diamide against type 2 diabetes (7)  
or orthopox virus (8).98 
 
The mechanism of bioactivation is similar to the aryl phosphoramidate prodrugs, and 
non-toxic amino acids by-products are released. 
 
2.2.3.5. Summary of nucleotide prodrug approaches 
To summarize and facilitate the comparison, Table 1.2 reports the key attributes of the 
different nucleotide prodrug technologies discussed in this section, and whether they 
reached clinical trials in humans. 
Prodrug 
approach 
Prodrug class Bioactivation By-product human 
trials 
Phosphotriester 
Bis(POM) 
Bis(SATE)/Bis(DTE) 
HepDirect 
CycloSal 
Esterase 
Esterase 
Cytochrome P450 
Chemical 
Formaldehyde 
Episulfide 
Aryl vinyl ketone 
Quinone methide 
Yes 
No 
Yes 
No 
Phosphoramidate 
Aryloxyphosphoramidate 
(ProTide) 
 
Phosphoramidate 
monoester (Wagner) 
Esterase, amidase 
 
Amidase 
Phenol, naphtol, 
amino acid 
 
Amino acid 
Yes 
 
No 
Phosphorodiamidate Phosphorodiamidate  Esterase, amidase Amino acid Yes 
Table 1.2. Comparison of prodrug approaches. 
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2.3. Combination for HCV therapy 
In the near future, the therapy of HCV is likely to involve regimens comprising both 
nucleoside analogues and non-nucleoside inhibitors. As an example, the combination of 
GS-7977 and TMC435 (Table 1.1) has been advanced into clinical phase 2 to 
investigate the safety during 12 and 24 weeks treatment.69 
Such therapy would alleviate resistance issues, minimise side effects and enhance 
tolerability in patients while potentially boosting antiviral potency, compared to either 
mono-therapy. Nevertheless, if not carefully applied, such dual combination would 
increase the risk of multi-drug resistance. 
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Chapter Two: Background and aim of the work 
 
 
1. Background relevant to the present work 
1.1. β-2’-C-methyl purines: nucleoside analogues and ProTide strategy 
Among anti-HCV nucleoside analogues, β-2’-C-methyl adenosine (9, Figure 2.1) and β-
2’-C-methyl guanosine (10, Figure 2.1) have shown to inhibit HCV at micromolar 
concentrations, respectively 0.3 µM and 3.5 µM in subgenomic replicon assays.1 
NH
N
N
O
NH2N
O
OHOH
HO
N
NN
N
NH2
O
OHOH
HO
9 10  
Figure 2.1. Structures of β-2’-C-methyl adenosine (9) and β-2’-C-methyl guanosine (10). 
 
However, β-2’-C-methyl guanosine 5’-triphosphate intracellular levels were rather poor 
compared to β-2’-C-methyl adenosine 5’-triphoshate.2 The ProTide approach applied to 
these two nucleoside analogues proved that this difference was related to the β-2’-C-
methyl guanosine not being a good substrate for nucleoside kinases, and thus limiting 
antiviral efficacy.3 While ProTides of β-2’-C-methyl adenosine showed similar 
efficiency to the parent nucleoside in delivering the 5’-monophosphate, ProTides of β-
2’-C-methyl guanosine were 10-30 fold more active in HCV replicon assays than β-2’-
C-methyl guanosine.3  
An extensive structure activity relationship (SAR) on β-2’-C-methyl guanosine 
ProTides was then built within our group.4 Resulting from this work, α-naphthyl as aryl 
moiety increased anti-HCV potency independently from the ester and amino acid 
moieties. The favoured amino acid moiety was the L-Alanine, showing activity against 
HCV replicon in nanomolar range, depending on the ester moiety. ProTides bearing L-
Valine and L-Phenylalanine were more potent than the parent β-2’-C-methyl guanosine, 
but giving molecules more cytotoxic and ten times less potent than L-Alanine ProTides. 
Branched amino acids such as L-Leucine, L-Dimethylglycine or L-Isoleucine were 
slightly or similarly active than the parent nucleoside but more cytotoxic. The ester 
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variations led to the following conclusions: small such as methyl, branched such as 
neopentyl or bigger cyclic ester groups such as benzyl and cyclohexyl, are tolerated in 
the pocket of esterase-type enzymes and relatively quickly processed. Hence, resulting 
in highly potent molecules stable in plasma, delivering efficiently the 5’-
monophosphate species inside the cells and further inhibiting at sub-micromolar 
concentrations the HCV RNA polymerase.4  
 
1.2. β-2’-C-methyl-6-O-modified guanosine analogues 
Following the discovery of the β-2’-C-methyl modified guanosine analogue as an 
inhibitor of the HCV NS5B polymerase,1 and the reported low triphosphate levels after 
dosing,2 further modifications of the nucleobase were applied to boost the lipophilicity 
and increase the cellular uptake. Among other 6-modified nucleosides,5 the β-2’-C-
methyl-6-O-methyl guanosine (11, Figure 2.2) derivative resulted from this work, and 
showed poor replicon activity (EC50 = 3.0 µM) as predicted by the modelling.5 
N
N
N
O
NH2
N
O
OHOH
HO
11  
Figure 2.2. Structure of β-2’-C-methyl-6-O-methyl guanosine 11. 
 
The poor anti-HCV potency observed in general for β-2’-C-methyl-6-O-modified 
analogues can be explained by slow intracellular conversion at a nucleoside or 
nucleotide level, to the β-2’-C-methyl guanosine.5 
 
2. Aim of the work 
The discovery of the poorly active β-2’-C-methyl-6-O-methyl guanosine5 and the 
prediction that its triphosphate binds poorly into the NS5B active site,5 led us to 
investigate prodrug strategies in order to improve cellular uptake and to bypass the first 
phosphorylation step, thus eventually resulting in efficient conversion to the β-2’-C-
methyl guanosine triphosphate.  
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Moreover, the need of more efficient therapy and the use of nucleoside analogues to 
target the essential enzyme responsible for replication of the virus (NS5B RdRp), led us 
to modify several moieties of β-2’-C-methyl-6-O-methyl guanosine 11 depicted in 
Figure 2.3, in order to explore the SAR and understand better the metabolism pathway 
of such nucleoside analogues. 
 
 
Figure 2.3. Modifications of 2’-C-methyl-6-O-methyl guanosine. 
 
Aiming at delivering efficiently inside the cells the desired bioactive triphosphate form 
after metabolism, two prodrugs technologies, the ProTide and phosphorodiamidate 
approaches, were applied during this project, as a tool for potential inhibition of HCV 
replication, improvement of potency and selectivity of these modified nucleosides. 
The following chapters describe the design and synthesis of β-2’-C-methyl-6-O-methyl 
guanosine prodrugs and modified analogues as well as novel acyclic derivatives, a new 
concept in the HCV field. The biological results are reported and correlated with 
mechanistic analysis and enzymatic assays to provide better understanding of the 
metabolic pathway, and to explore the moieties essential for the inhibition of NS5B 
RdRp. 
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 Chapter Three: Phosphate moiety modifications  
of β-2’-C-methyl-6-O-methyl guanosine prodrugs 
 
 
1. ProTide technology applied to β-2’-C-methyl-6-O-methyl guanosine  
Aiming at boosting the anti-HCV activity, the ProTide technology was applied to β-2’-
C-methyl-6-O-methyl guanosine 11, prodrug of β-2’-C-methyl guanosine 10. Aiming at 
enhancing passive cellular uptake and investigating the effect on potency of bypassing 
the first phosphorylation step,1 several ProTides were prepared, with variation at the 
amino acid and the ester moieties.  
 
1.1. Procedure 
1.1.1. Preparation of amino acid tosylate salts 
Several amino acid esters were commercially available, whilst some others were 
prepared as para-toluene sulfonic acid salts (Scheme 3.1).  
Following the path described in Scheme 3.1, tosylate salts of L-phenylglycine neopentyl 
ester (12.a) and L-phenylglycine benzyl ester (12.b) were prepared respectively in 77% 
and 80% yield, over two steps. The last step enabled recovery of a white precipitate in 
both case, while the Boc protected intermediate required flash chromatography. L-
Alanine cyclopropyl methyl ester was provided by Inhibitex Inc. 
     
R2
OH
O
NH
O
O
R2
O
O
NH
O
O
R1
R2
O
O
R1
NH3
+
S
O
-O
O
i. ii.
12.a-b
 
(i. anh.DCM, DCC (1.0 eq), DMAP (0.1 eq), R1OH (1.4 eq), overnight, rt; ii. EtOAc, pTSA (1.0 
eq), overnight, 65 °C.) 
Scheme 3.1. General synthesis of amino acid ester tosylate salts. 
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1.1.2. Preparation of β-2’-C-methyl-6-O-methyl guanosine ProTides 
The naphthyloxy phosphodichloridate (13, Scheme 3.2) was formed in 51% yield by 
addition of α-naphthol to phosphorus oxychloride (POCl3). The 31P-NMR appeared as 
one peak at 3.74 ppm. 
iii.
OH
O
P
O
Cl
Cl
O P
O
Cl
R2
O
O
R1NH
O
O
P
O
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NH
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13
i.
14.a-c
14.a-c
N
N
N
O
NH2
N
O
OHOH
N
N
N
O
NH2
N
O
OHOH
HO
15.a-c11
ii.
 
(i. anh. Et2O, POCl3 (1.0 eq), anh. NEt3 (1.0 eq), 30 min,  -78 °C, 1hr, rt; ii. anh. DCM, anh. 
NEt3 (2.0 eq),12.a-b (1.0 eq), 1 hr, -78 °C, rt, 30 min; iii. anh. THF, tBuMgCl (2.0 eq), 20 min, 
RT, 14.a-c (2.0 eq), overnight, rt.) 
Scheme 3.2. Route to β-2’-C-methyl-6-O-methyl guanosine ProTides. 
 
 
Addition of 13 with 12.a, 12.b and L-alanine-cyclopropylmethyl ester tosylate salt, 
provided by Inhibitex Inc., gave respectively the α-naphtyl amino acid ester 
phosphochloridates 14.a, 14.b and 14.c, all as a mixture of two diastereoisomers at the 
phosphorus center. This was confirmed by 31P-NMR with the apparition of two peaks 
around 7-8 ppm. Without further protection of the nucleoside hydroxyl groups, 
phosphorochloridates 14.a-c were reacted with β-2’-C-methyl-6-O-methyl guanosine 11 
following the Uchiyama procedure,2 using the Grignard reagent tert-butyl magnesium 
chloride (tBuMgCl) as a base. The desired ProTides (15.a-c, Scheme 3.2) were formed 
as mixtures of unseparable diastereoisomers in different ratio (Table 3.1). Substitution 
of the remaining chlorine of 14 by the 5’-oxigen results in an upfield 31P-NMR peaks, 
shifting from 7-8 (14) to 4 ppm (15).  
 Amino acid Ester Yield  31P (ppm) in CDCl3 / ratio 
15.a L-PhGly tBuCH2 46% 3.97, 3.60 (62/38) 
15.b L-PhGly Bn 32% 3.82, 3.41 (20/80) 
15.c L-Ala cProp-CH2 32% 4.07, 3.90 (43/57) 
Table 3.1. Yields, 31P NMR and diastereoisomer ratio  
of β-2’-C-methyl-6-O-methyl guanosine ProTides. 
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1.2. Structure activity relationship 
Upon completion of the family of β-2’-C-methyl-6-O-methyl guanosine ProTides, 
which majority were synthesised previously, three additional ProTides were 
synthesised. Bearing respectively L-phenylglycine neopentyl ester (15.a), L-
phenylglycine benzyl ester (15.b) and L-Alanine cyclopropyl methyl ester (15.c) 
moieties. The most important results of the SAR are reported in Table 3.2. 
 Amino acid Ester EC50 (µM) CC50 (µM) ClogP** 
10* - - 3.5 >100  
11* - - 5.2 >100  
10a* L-Ala tBuCH2 0.057 >100 1.3 
15.a L-PhGly tBuCH2 0.032 n.d 4.5 
15.b L-PhGly Bn 0.028 n.d 4.3 
15.c L-Ala cProp-CH2 n.d n.d 2.40 
15.d* L-Ala tBuCH2 0.01 7 3.3 
15.e* L-Ala Bn 0.03 12 3.1 
15.f* D-Ala tBuCH2 0.24 51 3.3 
15.g* L-Met tBuCH2 0.06 28 3.4 
15.h* L-Leu tBuCH2 0.07 14 4.7 
15.i* L-Ile tBuCH2 0.86 18 4.7 
15.j* L-Val tBuCH2 0.19 33 4.2 
15.k* L-Ala cHex 0.03 6 3.5 
* synthesised by previously.1, 3, 4 
** ClogP from CS ChemDraw Ultra 11.0 software. 
Table 3.2. Activity (EC50) in HCV replicon assays and cytotoxicity (CC50) in Huh-7 cells of β-
2’-C-methyl-6-O-methyl guanosine ProTides. 
 
Considering the L-Alanine amino acid moiety, the neopentyl ester (15.d) not only 
exhibits a 500-fold boost in potency compared to the parent nucleoside β-2’-C-methyl-
6-O-methyl guanosine (11), but also enhances activity and has greater lipophilicity than 
its β-2’-C-methyl guanosine analogue (10.a), facilitating cellular uptake.1 Similar trends 
were observed when the lipophilic benzyl ester (15.e) was used.1  
Variation of the amino acid was studied while retaining the neopentyl ester moiety. 
Exhibiting a 24-fold reduction of activity compared to 15.d, the D-Ala ProTide (15.f) 
proves the importance of intracellular metabolism for potency.1 Bigger or branched 
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amino acid moieties (15.a-b, 15.g-j) decrease anti-HCV activity compared to 15.d, but 
in general are more potent than their β-2’-C-methyl guanosine analogues.1 
 
1.3. From bench to clinical trials 
From this study, 15.d (known as INX-08189 or BMS-986094) emerged as the most 
promising candidate. Separated diastereoisomers showed similar activity in replicon 
assays.1 In addition to excellent properties, such as cell permeability and good 
bioavailability,5 good metabolism and high triphosphate levels detected in plasma,5 15.d 
is potent against multiple HCV genotypes,1 exhibiting IC50s in replicon assays of 12, 10 
and 0.9 nM versus genotype 1a, 1b and 2 respectively.5 Moreover, in combination with 
the standard of care therapy, 15.d showed high synergy with ribavirin.5, 6 These data 
made 15.d one of the most potent NS5B polymerase inhibitors ever reported. 
Unfortunately, its clinical development has recently been discontinued due to 
cardiotoxicity developed by patients during phase 2b clinical.7 
 
1.4. Conclusion of the ProTide approach 
The ProTide technology was successfully applied for anti-HCV therapy, to the poorly 
active β-2’-C-methyl-6-O-methyl guanosine 11, affording mixtures of diastereoisomers 
at the phosphorus center, releasing the same metabolite and showing submicromolar 
potency against HCV.  
The only disadvantage of the ProTide approach is the difficulty of separating the two 
diastereoisomers using common separation techniques. As a result, only the mixture 
was tested. Because metabolic enzymes are substrate specific, one diastereoisomer 
might not be processed or processed slower than the other, thus affecting the overall 
potency.  
Hence to avoid isolation of a diastereoisomeric mixture, the notion of achiral phosphate 
prodrugs was investigated by application of the phosphorodiamidate approach. 
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2. Phosphorodiamidates of β-2’-C-methyl-6-O-methyl guanosine 
A new motif was designed in order to investigate the effect of an achiral phosphate 
prodrug on delivering the β-2’-C-methyl guanosine 5’-triphosphate, and eventual 
inhibition of HCV replication. The phosphoramidate core was retained and preferably 
non-toxic natural moieties such as amines and amino acids were considered, affording 
phosphorodiamidates8 which general structure is depicted in Figure 3.1. 
 
N
N
N
O
NH2
N
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OHOH
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P
N
H
O
NH
R1
R2  
Figure 3.1. General structure of phosphorodiamidate prodrug of β-2’-C-methyl-6-O-methyl 
guanosine (R1: amine 1 or amino acid 1, R2: amine 2 or amino acid 2). 
 
 
2.1. Synthetic route 
Little is reported in the literature about phosphorodiamidate motif on nucleosides, 
however our group was among the first to explore synthetic pathways of such 
prodrugs.9, 10 Nevertheless a new synthetic route had to be adapted for β-2’-C-methyl-6-
O-methyl guanosine 11. 
 
2.1.1. 2,2,2-trichloroethyl approach 
Described by Sheeka,11 the first approach considered aimed at forming either the 2,2,2-
trichloroethyl (2,2,2-TCE) phosphorochloridate or dichloridate, followed by sequential 
displacement of TCE with amines, as shown in Scheme 3.3. 
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(i. anh. Et2O, anh. NEt3, -80  °C then rt, 6hrs 30min; ii. anh. DCM, anh. NEt3, -80 °C then rt, 
1hr 30min; iii. anh. THF, NMI, rt, 8hrs 30min; iv. CsF, rt / i’. anh. Et2O, anh. NEt3, -80 °C then 
rt, overnight; ii’. pyridine, rt, 2 days; iii’. CsF, rt, 2 weeks.) 
Scheme 3.3. Synthetic routes to phosphorodiamdates using TCE.  
 
Both the 2,2,2-TCE phosphodichloridate (16) and phosphochloridate (20) were 
synthesized from phosphorus oxychloride (POCl3) and 2,2,2-TCE, and were obtained in 
relatively low yields (2 to 6%) after distillation. Their formation was monitored by 31P-
NMR showing a phosphorus chemical shift recorded was in accordance with the 
substituents and the number of substitutions at the phosphorus center. Bis-substitution 
of TCE shields the phosphorus, hence lowers the chemical shift recorded for 20 (3.10 
ppm) compared to the phosphorodichloridate 16 (7.70 ppm). 
Following the substitution of 16 with L-Alanine methyl ester, 17 (R1: 
CH(CH3)COOCH3) was coupled with β-2’-C-metyl-6-O-methyl guanosine 11 provided 
by Inhibitex Inc. While the 1H-NMR and mass spectrum proved formation of the 
desired molecule 18.a (R1: CH(CH3)COOCH3), 31P-NMR recorded a single peak 
instead of the two expected due to the presence of a chiral phosphorus center. Either the 
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signals are overlapping each other or less likely only one isomer has been formed. 
However, too little amount was recovered to be able to conclude on the formation of 
both diastereoisomers by HPLC or for further experiments leading to 19.a (R1: 
CH(CH3)COOCH3) or to the phosphoramidate monoester intermediate. 
Coupling of 20 with 11 afforded 21, which was sent for biological evaluation in HCV 
replicon. Unfortunately, displacement of the TCE groups by N-butylamine to afford 
19.b (R1=R2: CH2CH2CH2CH3, R3: H) failed. 
 
Due to the lack of reaction and material recovered, and the poor properties of TCE as a 
leaving group, this approach was eventually abandoned. The next approach considered 
was based on the lability of the P-Cl bond towards substitution. 
 
2.1.2. Phosphorus oxychloride approach 
Considering the lability of the P-Cl bond and reported synthetic routes on 
phosphorodiamidates of AZT,10 the unprotected nucleoside was treated with phosphorus 
oxychloride (POCl3) to generate in-situ the phosphorodichloridate (22, Scheme 3.4), 
which formation was monitored by 31P-NMR (~8.00 ppm). Subsequently various 
amines or amino acid esters were added to obtained either symmetrical or asymmetrical 
phosphorodiamidates (12 ppm < 31P NMR < 18 ppm).  
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(i. anh. THF, anh. NEt3 (1.2 eq), RT, 30 min, POCl3 (1.2 eq), -78 °C, 30 min, rt, 30 min; ii. anh. 
DCM, A1, A2 (5.0 eq), NEt3 (10.0 eq), -78 °C to rt, overnight.) 
Scheme 3.4. Phosphorus oxychloride approach to phosphorodiamidates. 
(A1 = A2 or A1 ≠ A2, A1: amine 1 or amino acid 1, A2: amine 2 or amino acid 2) 
 
The formation of the intermediate 22 usually takes place under Yoshikawa conditions12 
to give the regioselectivity of the reaction at the 5’-hydroxyl. However here the 
regioselectivity is obtained using triethylamine as a base and only 1.2 equivalents of 
phosphorus oxychloride in tetrahydrofuran. To prevent degradation and hydrolysis, 
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formation of 22 is monitored by 31P-NMR after an average optimum reaction time of 30 
min. Symmetrical phosphorodiamidates required the addition of 5.0 eq of amino acid 
ester or amine. The only asymmetrical phosphorodiamidate 23 synthesised, was 
obtained by addition of 1.0 eq of the L-Alanine cyclohexyl ester para-toluene sulfonic 
acid salt affording the phosphochloridate seen by NMR, and then addition of 5.0 eq of 
L-Alanine cyclopentyl ester para-toluene sulfonic acid salt. 
 
A wide structure activity relationship (SAR) was built following this synthetic route. 
The benzyl, cyclohexyl, neopentyl and methyl esters were selected from the ProTide 
SAR results.  
The tosylate salts of L-Leucine benzyl ester, L-Phenylalanine benzyl ester, and both L-
Alanine cyclopentyl ester and L-Alanine cyclopropyl methyl ester, were supplied by 
Inhibitex Inc. Except L-Tyrosine and S-methyl-L-Cysteine, all amino acid ester tosylate 
salts (12.c-f, 12.j) were synthesised in relatively good yields (44-94%) from the Boc 
protected amino acid as described in Scheme 3.1.  S-methyl-L-Cysteine amino acid ester 
tosylate salts (12.g-i) were obtained by reaction of the free S-methyl-L-Cysteine with an 
excess of the desired alcohol (13 to 15 eq) using the Dean-Stark apparatus.  
Synthesis of L-Tyrosine phosphorodiamidates (25 a-d) was first undertaken with 
commercially available L-Tyrosine–O-methyl chloridate salt, and afforded L-Tyrosine 
and an achiral specie different from the one desired. Because of the non-protected 
phenol, competitive substitution on the phosphorus can occur, hence resulting in the 
formation of three products: the phosphorodiamidate desired, the phosphotriester and 
the mixed phosphoramidate. To prevent such competition, the commercially available 
phenolic protected Boc-L-Tyrosine(tBu) amino acid was used to yield the 
corresponding amino acid esters as tosylate salts, with the exception of the 
commercially available L-Tyrosine(tBu)-O-methyl chloridate salt. The standard 
procedure used for the formation of amino acid ester tosylate salts (Scheme 3.1) 
resulted in the cleavage of both the Boc and tBu protecting groups. Attempt of re-
protection of the free phenolic alcohol by refluxing overnight using potassium 
hydrogencarbonate and methyl iodide13 failed, and the starting material was recovered. 
To enable orthogonal deprotection, Fmoc instead of Boc protecting group appeared to 
be a wise choice since it is cleaved under mild basic conditions,14 which would not 
affect the phenolic tBu ether. Scheme 3.5 describes the route to L-Tyrosine 
phosphorodiamidates, starting from commercially available Fmoc-L-Tyrosine(tBu)-OH 
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to obtained desired amino acid esters, followed by selective deprotection of Fmoc using 
morpholine/DMF to afford the free amino acid esters (12.k-m, Scheme 3.5). Successful 
coupling with β-2’-C-methyl-6-O-methyl guanosine 11, as described in Scheme 3.5, 
afforded 24.a-d in moderate yields (18-31%). Eventually the tBu ether group was 
cleaved with trifluoroacetic acid (TFA)15 to afford the desired phosphorodiamidates 
(25.a-d, 24-49%). 
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min to rt, 30 min; b) anh. DCM, anh. NEt3, -78 °C to rt, overnight; iv. anh. DCM, TFA, 30 min, 
rt.) 
Scheme 3.5. Route to L-Tyrosine ester phosphorodiamidates. 
 
The synthesis of L-Isoleucine benzyl ester (26.c), dimethylglycine neopentyl and benzyl 
ester phosphorodiamidates failed. The non-natural amino acid is probably too hindered 
to allow two consecutive substitutions at the phosphorus center, while the reaction with 
L-Isoleucine benzyl ester was carried out with too little material to enable the coupling. 
The poor solubility of L-Asparagine did not allow formation of amino acid ester 
chloridate salts using thionyl chloride, as decribed by Turner16, but free amino acid 
esters along with the starting material were obtained instead. Second reaction to obtain 
tosylate salt by reaction with pTSA was attempted in vain.  
The phosphorus oxychloride route enabled the recovery of one asymmetrical 23 and 
twenty-two symmetrical phosphorodiamidates (19.b, 24.a-d, 25.a-d, 27.e-f, 29.a-c, 
32.a-c, 34.a, 35.a-c, 36).  
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2.2. Biological evaluation 
2.2.1. In-vitro results 
2.2.1.1. Replicon assays 
The potency and cytotoxicity of phosphorodiamidates synthesised were tested in HCV 
replicon assays at Inhibitex Inc. and are reported in Table 3.3.  
 
 
* synthesised by co-workers.8 
** scaled up for in-vivo studies.8 
Table 3.3. Biological activity (EC50) and cytotoxicity (CC50) of phosphorodiamidates in 
replicon-based assays.8 
 
 
The biological results clearly indicate that phosphotriester 21 and phosphorodiamidate 
prodrugs bearing simple amines (19.b and 36) are, at best, poorly active in HCV 
replicon. The inactivity of 36 is likely to result from non-permeation of the host cell 
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membrane since its ClogP is low (0.85), while 19.b (ClogP~2.31) is probably not a 
good substrate for intracellular metabolism. The latter suggestion will be studied later in 
this chapter. 
 
Switching from simple amines to amino acid ester moieties (23-35) has a significant 
impact on the activity against HCV, however cellular toxicity is observed for some 
amino acids different than the L-Alanine.  
The SAR of the ester moiety shows that the benzyl and methyl esters (c and d) give 
similar activities for all amino acid moieties, while the cyclohexyl and neopentyl esters 
(b and a) allow discrimination. In general, bigger (32-33 and 24-25) or more branched 
(26, 28-31 and 35) amino acid moieties result in poor activity, with the exception of L-
Phenylalanine neopentyl ester diamidate 32.a, L-Tyrosine(tBu)-methyl ester and S-
methyl-L-Cysteine neopentyl ester diamidates (24.d and 35.a). The extra methylene 
group present in L-Methionine phosphorodiamidates (30.a-b) results in a significant 
loss of potency in comparison with S-methyl-L-Cysteine phosphorodiamidates (35.a-b). 
Results from phosphoramidates 24.a-d, 25.a-d and 32.a-c indicate that substitution of 
the phenyl group has a negative impact on HCV potency, with the tBu group being the 
less tolerated, with the exception of 24.d which has a ClogP value similar to 
phosphoramidates 25.a-c (5.45 < ClogP < 6.0). The low potency exhibited by such 
molecules is probably due to poor cell permeation resulting from their high 
liphophilicity (5.45 < ClogP < 9.8). However, with the lowest ClogP value (2.02), 
phosphoramidate 25.d is also poorly active in replicon. This biological evaluation 
suggests that the pocket where the amino acid moiety lies in the metabolic enzymes 
accommodates preferentially small groups, such as methyl. Among the L-Alanine 
family, phosphorodiamidates bearing the neopentyl (27.a), cyclohexyl (27.b) and 
cyclopentyl (27.e) ester moieties are potent inhibitors of HCV replication, hence well 
tolerated by the metabolic esterase-type enzymes. Bigger ester moieties (27.c) decrease 
significantly the anti-HCV activity and exhibit 5 to 10-times loss of potency compared 
to alkyl or cyclic esters. 
 
Surprisingly, the unnatural D-Alanine neopentyl ester diamidate (34.a) retains the 
selectivity (TI = 909) and exhibits only a 2-fold lost in potency compared to its 
analogue in the L-series 27.a (TI = 1666). Similar results were not expected since the D-
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Alanine neopentyl ester ProTide was 24-fold weaker than 15.d in HCV replicon 
assays.1 
 
From this study, 27.a, 27.e and 34.a were selected for further in-vitro and in-vivo 
studies performed at Inhibitex Inc. 
 
2.2.1.2. Intracellular triphosphate level 
Phosphorodiamidates 27.a, 27.e and 34.a were incubated at a concentration of 10 µM in 
human hepatocytes, and levels of triphosphate were measured after 2, 6 and 24 hours 
using LC-MS/MS spectroscopy (Graph 3.1). ProTide 15.d was also incubated for 
comparison. This work was done by Inhibitex Inc. 
 
!"
#!!"
$!!"
%!!"
&!!"
'!!"
(!!"
$" &" (" )" #!" #$" #&" #(" #)" $!" $$" $&"
!
"#
$
%
&
'(
)
*
+
,
"-
.
''
/0
"
1%."#23/0"
4567"#89:'79;9<.&$.<=>'0"
456."#89:'79;9-?.<=0"
@A67"#B9:'79;9<.&$.<=>'0"
)C6D"#EFG9*H)HI0"
 
Graph 3.1. Intracellular triphosphate concentrations (C) in human hepatocytes. 
 
 
Similarly to the lead compound 15.d, phosphorodiamidates deliver efficiently the 
bioactive triphosphate form inside the cells, with 27.e being the less efficient. While the 
maximum concentration of triphosphate is achieved after 6 hours of incubation in the 
case of 15.d, both its diamidate derivatives 27.e and 34.a produce triphosphate levels up 
to 24 hours after incubation, thus increasing its bioavailability.  
 
2.2.2. In-vivo results 
The three phosphorodiamidates selected (27.a, 27.e and 34.a) were formulated (95% 
Capmul MCM / 5% Tween 80) and orally dosed to rats. Concentrations were collected 
up to 24 hours post administration using LC-MS/MS spectroscopy. This work was done 
by Inhibitex Inc. 
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2.2.2.1. Pharmacokinetics 
The pharmacokinetic profiles of the selected phosphorodiamidates together with 15.d 
were evaluated after dosing 10 mg/kg orally to rats (Graph 3.2 and Graph 3.3).   
 
 34.a (D-Ala-O-neopentyl)
 15.d (INX-08189)
 27.e (L-Ala-O-cPent)
 27.a (L-Ala-O-neopentyl)
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Graph 3.2. Concentrations of β-2’-C-methyl guanosine 10 in rat plasma. 
 
The exposure of parent nucleoside β-2’-C-methyl guanosine 10 in rat plasma was 
measured as a biomarker to monitor liver pharmacokinetics of β-2’-C-methyl guanosine 
triphosphate in-vivo.5 The three phosphorodiamidates selected (27.a, 27.e and 34.a) 
release similar or lower maximum concentrations of the parent nucleoside β-2’-C-
methyl guanosine 10 in comparison with 15.d, hence suggesting relatively good 
stability of β-2’-C-methyl guanosine triphosphate in the liver.  
The liver concentrations of β-2’-C-methyl guanosine triphosphate were also determined 
(Graph 3.3) at Inhibitex Inc. 
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Graph 3.3. Concentrations of β-2’-C-methyl guanosine triphosphate in rat liver. 
 
 
After 24 hours, all phosphorodiamidates but 27.a show a concentration of 2’-C-methyl 
guanosine triphosphate in liver similar or higher than 15.d, and most importantly above 
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the concentration necessary to achieve 90% of inhibition of HCV replication (EC90 ~ 
243 pmol/g liver).8 
These combined results prove that phosphorodiamidates 27.a, 27.e and 34.a, are 
effective prodrugs delivering the desired 2’-C-methyl guanosine triphosphate in high 
concentrations and inhibiting effectively HCV replication. 
 
2.2.2.2. Toxicology studies 
Preliminary 14 days toxicity studies were performed by Inhibitex Inc. Rats were 
administered orally a 30 mg/kg formulation containing each of the three most potent 
phosphorodiamidates (27.a, 27.e and 34.a). The body weight was measured daily pre-
dosing. All three diamidates exhibit a more favourable toxicity profile than 15.d (Graph 
3.4 b-d), with 34.a showing the best profile (Graph 3.4 c), with less variation in body 
mass compared with the vehicule group. Its analogue in the L-series (27.a) exhibits high 
gastrointestinal tract toxicity leading to morbidity in both groups of rats. 
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vehicule
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Graph 3.4. Toxicity studies in rats (30 mg/kg dose). 
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2.3. Mechanistic studies 
To probe and better understand the mechanism of activation of phosphorodiamidate 
prodrugs inside the host cells, enzymatic studies were performed and metabolic steps 
were monitored by 31P-NMR.  
The putative mechanism of activation is described in Scheme 3.6.8 The first step 
consists of the cleavage of the ester moiety by esterase-type enzymes to afford 37 or 38, 
followed by intramolecular attack of the charged oxygen onto the phosphorus center 
forming a putative five-membered ring intermediate 39. The latter opens by attack of a 
water molecule releasing the amino-acyl intermediate 40 (also called phosphoramidate 
monoester), which P-N bond is then cleaved by phosphoramidase-type enzymes to 
afford the desired 5’-monophosphate 41. 
 
Scheme 3.6. Putative mechanism of activation of phosphorodiamidates. 
 
 
2.3.1. Carboxypeptidase Y assays 
The commercially available carboxypeptidase Y (CPY) is an esterase type enzyme 
known to carry out the initial cleavage of the ester moiety. This assay was performed 
incubating 35.a (3.5 mg in 0.140 mL d6-acetone) with carboxypeptidase Y (0.1 mg) in 
Trizma buffer (pH~7, 0.420 mL), and 31P-NMR experiments were run every 7 minutes 
at room temperature (25 °C) (Figure 3.2). While the peak corresponding to 35.a (purple) 
slowly disappears with time, one new species is formed (peak at 6.45 ppm, orange). 
According to the literature,17 this species corresponds to the amino-acyl intermediate 40. 
Due to its putative transient nature, the 31P-NMR peak corresponding to the 5-
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membered ring intermediate 39 is not detectable.  37 and 38 are also not detected by 
31P-NMR suggesting instability of 37, which cyclises and undergoes fast hydrolysis 
following the cleavage of one or both esters. This experiment does not discriminate if 
both esters need to be cleaved to afford 40, however based on the ProTide mechanism 
(Scheme 1.4, Chapter 1) the cleavage of only one ester should be sufficient for 
delivering the amino-acyl intermediate. 
 
 
Figure 3.2. Carboxypeptidase Y catalysed ester hydrolysis of phosphorodiamidate 35.a (purple: 
35.a, orange: hydrolysed specie 40). 
 
 
Results from the carboxypeptidase Y assay (0.1 mg) with the morpholine 
phosphorodiamidate 36 (5.0 mg in 0.200 mL deuterated water) in Trizma buffer (pH~7, 
0.600 mL) are reported Figure 3.3. The peak of 36 remains stable overnight, suggesting 
no metabolism by carboxypeptidase Y to the key intermediate. This data correlates with 
the biological results observed in replicon for both 19.b and 36 (Table 3.3) and indicates 
that at least one ester moiety is required for activation of phosphorodiamidates to the 
key intermediate, essential for delivery of the 5’-monophosphate. 
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Figure 3.3. Carboxypeptidase Y catalysed hydrolysis of phosphorodiamidate 36.  
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Similar assays were performed with phosphorodiamidates 24.c and 25.c, bearing L-
Tyrosine as amino acid and benzyl as ester moiety, only differing by the presence of the 
tert-butyl group. 25.c (3.1 mg) was dissolved in deuterated acetone (0.124 mL) and 
incubated with CPY (0.1 mg) in Trizma buffer (pH~7, 0.372 mL). Similarly, 24.c (1.6 
mg) was dissolved in deuterated acetone (0.064 mL) and incubated with CPY (0.1 mg) 
in Trizma buffer (pH~7, 0.192 mL). 31P-NMR experiments were recorded every 7 
minutes for 14 hours. The data are represented in Graph 3.5. 
 
 
Graph 3.5. Graphic representation of carboxypeptidase Y assay experiments of 24.c (blue) and 
25.c (purple) (green: amino acyl intermediate of 25.c, red: amino acyl intermediate of 24.c, x: 
time in min, y: % of molecule present during the experiment). 
 
 
This graph indicates slow ester cleavage of 25.c to its amino-acyl intermediate, whereas 
24.c is not processed. L-Tyrosine amino acid is probably too big to fit properly in the 
esterase enzymatic pocket, hence poor hydrolysis to its amino-acyl intermediate. 
 
2.3.2. Cell lysate  
A study of the second metabolic step was performed at 37 °C in deuterated water (0.200 
mL) incubating Huh-7 cell lysate with 35.a (1mg in 0.05 mL of DMSO) and was 
monitored by 31P-NMR overnight (Figure 3.4).  This experiment was not conclusive on 
the delivery of the 5’-monophosphate 41 (green), since the 31P-NMR peak at 2.54 ppm 
corresponds to the cell lysate and not the desired metabolite, which 31P-NMR peak 
should appear more upfield (~0.9 ppm).18 However, if conversion to the 5’-
monophosphate occurs, it is relatively slow since 35.a remains after 24 hours. 
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Figure 3.4. Huh-7 cell lysate assay of 35.a  
(purple: 35.a). 
 
2.3.3. Molecular modelling  
2.3.3.1. Docking with cathepsin A enzyme 
Cathepsin A is an esterase-type enzyme sharing similar structural homology and 
substrate specificity with carboxypeptidase Y.19, 20 The crystal structure of cathepsin, 
available in the protein data bank (PNB 1YSC),21 was used for docking studies. 
Interactions between the carbonyl group of the ester moiety and Ser146, Gly53, and 
Gly52 are essential for ester catalytic cleavage. 
 
In order to investigate the ester cleavage step, phosphoramidates 35.a, 24.c and 25.c 
were docked into the catalytic site of cathepsin A. Figure 3.5 and Figure 3.6 report the 
molecular modelling predictions. Docking of 35.a (Figure 3.5) suggests that one 
carbonyl group of the S-methyl-Cysteine neopentyl ester moiety is in the right position 
for ester cleavage (in comparison with the L-Alanine-neopentyl ester β-2’-C-methyl-6-
O-methyl guanosine ProTide 15.d). It correlates with the formation of the amino-acyl 
intermediate 40 observed in the carboxypeptidase Y experiment (Figure 3.2). 
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Figure 3.5. Docking of S-methyl-Cysteine neopentyl ester phosphorodiamidate 35.a (grey) and 
15.d (orange line) in the catalytic site of cathepsin A enzyme (red: oxygen, blue: nitrogen, pink: 
phosphorus, yellow: sulfur). 
 
 
    
Figure 3.6. Docking of L-Tyrosine benzyl ester phosphoramidate 25.c (yellow) and L-Tyrosine-
O-tert-butyl benzyl ester phosphoramidate 24.c (blue) in the catalytic site of cathepsin A 
enzyme (red: oxygen, blue: nitrogen, pink: phosphorus). 
 
Docking of 24.c and 25.c predicts that the combination of the bulky L-Tyrosine amino 
acid together with the benzyl ester moiety does not accommodate easily in the catalytic 
pocket of cathepsin A. The tert-butyl group of 24.c makes it even worse and provokes a 
clash with the surface of the pocket preventing good fit for catalytic mechanism; hence 
no delivery of the amino acyl intermediate is predicted and correlates with the 
observations of the carboxypetidase Y assay (Graph 3.5). Whereas 25.c accommodates 
tightly in the pocket, enabling the ester carbonyl group to lie in proximity to the 
catalytic residues. This prediction may explain the extremely slow conversion to the 
amino-acyl intermediate (Graph 3.5) and the low antiviral activity exhibited in replicon-
based assays. 
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2.3.3.2. Docking with Hint-1 enzyme 
Human histidine triad nucleotide-binding proteins (Hint) are a superfamily of nucleotide 
transferases and hydrolases which are thought to be responsible for the P-N bond 
cleavage of phosphoramidate monoesters into nucleoside monophosphates.22, 23 
Adenosine monophosphate-bound amines are the natural substrates of Hint, and 
hydrolysis of the P-N bond occurs via interaction of the key residue Ser107, His112 and 
His114.24 Interactions between the substrate and the histidines are key for catalytic 
hydrolysis (Figure 3.7).25 One of the three histidines (blue) attacks the phosphorus 
center resulting in release of the amino acid moiety, which is subsequently protonated 
by the serine (green). Attack of a molecule of water triggers the hydrolysis to the 5’-
monophosphate and release the histidine (blue).  
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Figure 3.7. Mechanism of action of Hint enzyme. 
 
Docking studies with the amino acyl intermediate 40 of phosphorodiamidate 35.a were 
carried out with human Hint-1 enzyme (PNB 1KPF)20  and the co-crystallised structure 
of adenosine monophosphate (AMP, orange line), in order to identify the active site of 
this enzyme (Figure 3.8).23 
 
 
Figure 3.8. Docking of S-methyl-Cysteine amino acyl intermediate 40 within the catalytic 
pocket of human Hint-1 enzyme. 
 
This docking predicts that the phosphate moiety lies far from the catalytic residues. In 
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comparison with AMP, the carbonyl group of the amino acyl intermediate 40 lies where 
the phosphorus moiety should be accommodated for efficient hydrolysis. This might be 
the reason of poor intracellular conversion of 35.a to its 5’-monophosphate, as 
suggested by the cell lysate assay (Figure 3.4), and thus, might explain the biological 
activity reported against HCV (Table 3.3). 
 
2.4. Summary and conclusions 
The phosphorodiamidate technology applied to β-2’-C-methyl-6-O-methyl guanosine 
11 was successful and resulted in L-Alanine neopentyl ester ProTide as a mixture of 
diastereoisomers (15.d). The diastereoisomers being hardly separable by flash 
chromatography, the mixture was advanced up to phase 2 clinical trials for hepatitis C 
treatment, at which stage severe cardiac and liver toxicity were found and halted its 
progression. As a back-up project, new achiral phosphate prodrugs were investigated for 
delivery of the same bioactive form, β-2’-C-methyl guanosine triphosphate, inside the 
cells. Novel phosphorodiamidates were designed and synthesised successfully and 
exhibited good inhibitory potency in HCV replicon assays. A large SAR was built and 
enzymatic assays showed that at least one amino acid ester moiety is essential for 
activity. Biological results showed that alkyl ester moieties and small amino acid 
moieties were preferred. Enzymatic assays and molecular docking experiments predict 
that long chains or bigger groups at the amino acid Cα may not only slow down or 
prevent hydrolysis to the amino acyl intermediate (CPY and cathepsin A), but also may 
lead to incomplete or relatively poor metabolism in Huh-7 cells (cell lysate and Hint-1). 
These data reflect the reported anti-HCV activity in replicon assays.  
From this study, three of the most potent molecules in-vitro were selected and dosed to 
rats. High β-2’-C-methyl guanosine triphosphate levels were measured in-vivo and good 
pharmacokinetics profiles were obtained. In particular, the unexpected promising results 
of the D-Alanine neopentyl ester phosphorodiamidate 34.a, which appeared as the best 
back-up molecule for 15.d.  
To conclude, phosphorodiamidate is a new and effective phosphate prodrug motif, 
which may enhance the properties and selectivity index of ProTide analogues. 
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Chapter Four: Nucleobase modifications 
of β-2’-C-methyl-6-O-methyl guanosine 
 
 
1. Background and Objectives 
Numerous heterobase modifications of nucleoside analogues have resulted in potent 
antiviral agents, such as anti-HCMV acyclic uracil analogues1 or the anti-HCV N-1-
hydroxy-inosine (42, Figure 4.1)2 and β-D-N-4-hydroxycytidine (43, Figure 4.1).3 
Within the β-2’-C-methyl ribonucleoside family, modifications are mainly reported at 
positions C-2,4 C-64,5,6 and C-7 of the nucleobase.7,8 While C-6 modifications increase 
significantly the lipophilicity and eventually result in retention or enhancement of 
potency against HCV,6 the 7-deaza modified adenosine analogue (44, Figure 4.1) 
exhibits significant in-vivo potency against HCV.9 Whereas the C-8 position has never 
been explored on the 2’-C-methyl series, it has been extensively studied on other 
nucleoside analogues10 such as guanosine and its 2’-deoxy derivatives as anti-
proliferative agents.11  
O
OHOH
HO
N
N
N
N
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N
NN
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O
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HO
42
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HO N
N
HN
O
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43 44  
Figure 4.1. Structures of anti-HCV base modified purine and pyrimidine nucleosides. 
 
Considering the antiviral success of these nucleobase modifications, C-8 and 7-deaza 
modifications were investigated on β-2’-C-methyl-6-O-methyl guanosine 11 in order to 
explore the impact of steric, electronic and hydrogen bonding changes on the anti-HCV 
activity.  
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2. 8-modifications of β-2’-C-methyl-6-O-methyl guanosine  
 2.1. Introduction  
Since Holmes and al. reported the preparation of the active 8-bromoguanosine (45, 
Figure 4.2),12 numerous C-8  modified purine nucleosides have been designed and 
synthesised as anticancer13 and antiviral agents,13-16 and have also been used for the 
study of DNA modifications caused by carcinogenic agents.17-21 The introduction of C-8 
substituents do not affect the base pairing with pyrimidines, thus the ability to form 
nucleic acid duplexes is retained. Pointing outside the DNA minor groove, 8-
substituents only modulate the interaction within proteins.22 
 
      45
NH
NN
N
O
O
OHOH
HO NH2
Br
 
Figure 4.2. Structure of 8-bromoguanosine. 
 
 
Modifications at the C-8 position of guanosine have been extensively investigated and 
reactions such as halogenation, oxidation and nucleophilic addition of various amines or 
aryl groups are largely reported in the literature. However, as mentioned previously, 
these modifications have never been explored in the HCV field and it was decided to 
address the effect of C-8 steric hindrance on HCV activity when applied to β-2’-C-
methyl-6-O-methyl guanosine 11.  
 
 2.2. Synthesis of 8-modified nucleosides 
Modifications including amino, ether and cyano groups, were considered for 
substitution at the 8-position of the β-2’-C-methyl-6-O-methyl guanosine 11 (Scheme 
4.1). These were obtained starting from the halogenated derivatives previously prepared 
by electrophilic addition23 at C-8 of β-2’-C-methyl-6-O-methyl guanosine 11, provided 
by Inhibitex Inc. 
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    b) R: OH 52
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     b) R: CN 56
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(i. anh. MeOH, NBS (1.2 eq), rt, 90 min, 96%; ii. anh. THF, NIS (2.6 eq), rt, 3 days, in the dark, 
25%; iii. anh. THF, NCS (1.2 eq), rt, 3 days, in the dark, 66%; iv. a) anh. MeOH, BnNH2 (2.5 
eq), sealed vessel, 115 °C, 3 days, 6.6%; b) anh. DMF, NH(CH3)2 (1.2 eq), anh. NEt3 (2.6 eq), 
115 °C, 3 days, 51%; v. a) anh. DMF, pyrrolidine (1.2 eq), anh. NEt3 (2.6 eq), 115 °C, 3 days, 
9%; b) anh. pyridine, NaOAc (10 eq), NMI (0.38 eq), Ac2O (10.6 eq), (NH4)HCO3, relux, 
overnight; c) DMSO, NaN3 (3.0 eq), 75 °C, overnight; d) anh. BnOH, NaOBn (3.0 eq), 85 °C, 
48 hrs; vi. a) hydrazine hydrate, 100 °C, 42 hrs; b) anh. DMF, tributyltin cyanide (1.1 eq), Pd 
Tetrakis (0.05 eq), 95 °C, 3 days; vii. a) anh. MeOH, anh. NHMe (1.3 eq), 115 °C, 18hrs, 37%; 
b) anh. MeOH, anh. aniline (2.0 eq), 115 °C, 3 days, 32%; c) anh. MeOH, N-butylamine (2.0 
eq), sealed vessel, 115 °C, 3 days, 27%; d) anh. EtOH, NaOEt (3.0 eq), reflux, overnight; e) 
anh. MeOH, 2-aminopentane (2.0 eq), sealed vessel, 115 °C, 3 days; f) H2O, hydrazine 
dihydrate, reflux, 2 hrs) 
Scheme 4.1. Synthetic pathway to  
8-modified β-2’-C-methyl-6-O-methyl guanosine nucleosides. 
   
2.2.1. Preparation of β-2’-C-methyl-6-O-methyl-8-halogeno guanosine  
Halogenation at C-8 postion of purine analogues is extensively reported in the 
literature.14, 24, 25 The most common reagent for iodination, chlorination or bromination 
is the corresponding N-halogeno succinimide, known as a source of halogens in various 
electrophilic additions.26 N-halogeno succinimide reagents were used either in methanol 
or tetrahydrofuran27 for the preparation of molecules 46, 47 and 48 (Scheme 4.1) in 
moderate to good yields (25 to 96%). The electron rich heterobase acts as nucleophile 
by total delocalization of the π-electrons, while the N-succinimide releases the 
corresponding electrophilic halogen at a low concentration in the media. Since β-2’-C-
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methyl-6-O-methyl guanosine 11 is soluble in both methanol and tetrahydrofuran, 
protection of the hydroxyl groups on the sugar was not required.  
Bromination at the 8-position was fast (one hour at room temperature) in comparison 
with the chlorination or iodination reactions. Moreover, the later was kept in the dark to 
avoid decomposition due to the presence of the photolabile iodine atom. All novel 8-
halogenated nucleosides 46, 47 and 48 were then subject to various aromatic 
nucleophilic substitutions.  
 
2.2.2. Substitutions of β-2’-C-methyl-6-O-methyl-8-halogeno guanosine 
The electronic effect of the halogen has an impact on the stability of the carbon-halogen 
bond, hence it is expected that 8-iodo derivative (47) would react quicker than the 8-
bromo derivative (46), which should be more reactive than the 8-chloro derivative (48). 
In addition, substitution of halogens with various groups at the C-8 of the heterobase is 
not usually regioselective and depending on the electron density of the ring the attack 
can be favoured in position C-6 of the purine ring.28 However, in the case of 46, 47 and 
48, the methoxy group at C-6 is much less reactive than the halogen at C-8 towards 
substitutions. Furthermore, even in case of 6,8-dihalogenopurine the nucleophilic 
displacement occurs primarily at C-8 even in the case of weakly basic nucleophilic 
reagent.28 Hence, explaining the regioselectivity observed at C-8 with our nucleoside 
during the nucleophilic aromatic substitution. 
 
 2.2.2.1. 8-N-modified β-2’-C-methyl-6-O-methyl guanosine 
Substitution of C-8 halogens was first performed with primary and secondary alkyl or 
aryl amines such as methylamine, dimethylamine, aniline, benzylamine, pyrrolidine, N-
butylamine, 2-aminopentane or hydrazine hydrate; as already reported on 2’-
deoxyguanosine, guanosine or adenosine.29  
High temperature and pressure were necessary to achieve most of these aromatic 
aminations, while the same reaction at room temperature led to the recovery of the 
unreacted 8-halogeno β-2’-C-methyl-6-O-methyl guanosine (46-48).  
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2.2.2.1.1. C-8 substitution by primary amines 
Substitution of chlorine (48) or bromine (46) in 8-position with primary amines was 
relatively easy, as previously reported in the literature in the case of several other purine 
analogues.29 Nucleosides 49, 57 and 58 were obtained in low to moderate yields (7 to 
37%), only changing the equivalent of primary amine to reduce the eventual double 
substitution (C-8 and C-6). However, even addition of 2.0 equivalents of primary amine 
did not substitute the 6-O-methyl group. The use of anhydrous solvent with liquefied 
amines was required to avoid side reactions and degradation.30  
Aromatic groups being synthetically tolerated at C-8, substitutions of longer alkyl 
amine and branched alkyl amine were then investigated. Reaction of 48 with N-
butylamine afforded 59 in 27% yield, following the experimental conditions previously 
mentioned. In contrast, substitution with 2-aminopentane did not occur. More reactive 
8-bromo analogue 46, was subject to similar conditions. However, introducing 
triethylamine or switching from polar protic solvent (methanol) to polar aprotic solvent 
(dimethyl formamide and tetrahydrofuran) did not allow the formation of the desired 
molecule 61, but only degradation and recovery of unreacted starting material. This 
behaviour would suggest that branched alkyl amines are not tolerated at position 8 of 
the nucleobase in this reaction. This result is contradictory to the successful substitution 
of more hindered phenylamine (58) and benzyl amine (49). 
 
Following the conditions reported in the literature for the synthesis of 8-hydrazino 
guanosine,31 reaction between compound 47 and hydrazine hydrate led to total 
degradation. The synthetic conditions reported31 to form 8-hydrazino guanosine uses 
hydrazine 60% instead of hydrazine 25%, at high temperature (90-100 °C). When the 
procedure described by Holmes & al.32 was followed, only the parent nucleoside 11 was 
recovered. Several papers report degradation and also cleavage of the glycosidic bond 
when using aqueous hydrazine.30, 32 Unfortunately, the degradation products were not 
successfully isolated and characterised.  
Another route for the synthesis of 62 was explored by treating β-2’-C-methyl-6-O-
methyl guanosine (11) with hydroxylamine-O-sulfonic acid (HAOS) in water and 
maintaining acidic conditions.33, 34 The mechanism (Scheme 4.2) of this reaction is 
described to go through the formation of the 7-amino derivative as a result of an 
electrophilic addition at the nucleophilic position N-7 by HAOS. This 7-amino 
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intermediate is then converted to 7,8-dihydro-7-amino-8-hydroxyamino intermediate by 
nucleophilic attack of hydroxylamine, which then undergoes aromatisation to 8-
hydroxyamino derivative, which is eventually reduced to its 8-amino derivative.34, 35 
Unfortunately, the reaction did not allow the formation of 62 in our case.  
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Scheme 4.2. Mechanism of formation of 8-NH2 derivatives using HAOS. 
 
2.2.2.1.2. C-8 substitution by secondary amines 
Substitutions by secondary amines (dimethylamine and pyrrolidine) proved to be more 
difficult than with the primary amines. The first attempt of substitution of 48 with 
dimethylamine was performed under similar conditions used in the case of 
methylamine. Too little crude material was recovered that no pure desired material 
could be isolated in significant quantity to be able to carry out a complete NMR 
characterisation. No improvement was observed when starting from the 8-bromo 
derivative 46. Similar conditions were applied to the 8-iodo derivative 47, but the 
reaction did not take place and only unreacted 47 was recovered. More recent literature 
describing substitution of proline on protected 8-bromoguanosine suggests the use of 
triethylamine in the mixture.36 Acting as a base, triethylamine enhances the 
nucleophilicity of the secondary amine by partially removing the proton, enabling better 
reactivity towards substitution. As last attempt, 46 in anhydrous dimethylformamide 
was treated with 2.6 equivalents of triethylamine followed by 1.2 equivalents of 
dimethylamine. Under these conditions, nucleosides 50 and 51 were obtained in 51% 
and 9% yields respectively, along with unreacted 46.  
 
 2.2.2.2. 8-O-modified β-2’-methyl-6-O-methyl guanosine 
Previous work in our group enabled the formation of 8-O-methyl modified β-2’-methyl-
6-O-methyl guanosine. Further work was undertaken to synthesise other 8-O-alkyl and 
8-O-aryl modified nucleosides as well as 8-oxo derivatives. 
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The same experimental conditions reported in the literature for the synthesis of 8-O-
ethyl derivatives,32 were applied to 48 with an unsuccessful outcome. Neither increasing 
the number of equivalents of sodium ethoxide, nor changes on reaction or temperature 
enabled formation of desired molecule 60. Similarly to the formation of 8-
benzyloxyguanosine,11, 12 46 was treated with commercially available sodium 
benzyloxide in dimethyl sufloxide. Unfortunately only unreacted starting material 46 
was recovered. Another attempt was carried out similarly to the introduction of ether 
modifications at the 6-position,32 ie. using benzyl alcohol (BnOH) as solvent instead of 
dimethyl sulfoxide (DMSO), with excess of sodium benzyloxide (NaOBn, 3.0 
equivalents). Neither the desired material 60 nor the 6-substitued derivative were 
formed, and degradation products were recovered. 
In contrast with guanosine but similarly to adenosine, the basic conditions applied to 8-
bromo derivative 46, ie. sodium ethoxide or sodium benzyloxide, should not affect the 
nucleophilic attack at the 8-position since N-1 does not bear any acidic proton, which  
could form an anion and would then resist to the introduction of another negatively 
charged nucleophile.12, 28 Hence, in our case the experimental conditions to form 8-O-
alkyl modified nucleosides would have needed further optimisation. 
 
8-oxo modification on β-2’-C-methyl-6-O-methyl guanosine 11 was also of interest as a 
biological marker. In the early 60s, 8-hydroxynucleosides were synthesised not only as 
intermediates for the synthesis of cyclonucleosides37 but also for their biological 
interest.38 Numerous publications report the work on 8-oxo-guanosine, and activation of 
humoral immune response was detected.10, 39-41 The 8-oxo is one of the only 8-
modifications on nucleoside to be enzymatically tolerated by adenosine deaminase 
(ADA).37 
 
The first route towards the synthesis of 2’-C-methyl-8-oxo guanosine 63,!was to react 
46 with sodium acetate (NaOAc) and glacial acetic acid under reflux,42 but only 
degradation was observed. Recent literature published formation of 2’-deoxy-8-oxo 
guanosine via Fenton reaction, a radical reaction using hydrogen peroxide in water.42 
The conditions of Fenton carbonylation were applied to β-2’-C-methyl guanosine 10 
without any success. Another attempt consisted of treatment of 46 with sodium acetate, 
silver acetate and 1-methylimidazole (NMI) in acetic anhydride.42 The residue was 
purified on Sephadex G-10,43 and two fractions were recovered. The NMR spectra were 
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analysed to confirm the formation of corresponding to β-2’-C-methyl-8-oxo guanosine 
63 and the β-2’-C-methyl-6-O-methyl-8-oxo guanosine protected by the acetate group 
on the exocyclic amine 64 (Figure 4.3). They were obtained respectively in 2% and 5% 
yield. Pendant 13C-NMR in deuterated dimethylsulfoxide confirmed the presence of 
quaternary carbons, appearing at 155.3 ppm (C-6), 149.6 ppm (C-8) for 63, and at 166.6 
ppm (NHCOCH3), 158.4 ppm (C-6), 149.9 ppm (C-8) for 64. The latter structure was 
also confirmed by 1H-NMR. The spectra revealed a broad peak corresponding to a 
proton next to N-7 appearing at 11.43 ppm, which type of proton was not seen for 63. 
Hence, the most stable form probably depends on the substituent at the 6-position of the 
nucleobase.  
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Figure 4.3. Structures of 8-oxo derivatives 63 and 64. 
 
More recent literature describes the oxidation of guanidinium iodide by hydrogen 
peroxide.44 The preparation of such halide should also have been an easy way of 
oxidation at C-8. 
 
 2.2.2.3. Others 8-modifications of β-2’-C-methyl-6-O-methyl guanosine 
In addition to the 8-amino family, other substituents were considered such as 8-azido 
and 8-cyano however none of the reaction performed was successful. 
Substitution of the azido group at position 8 of the nucleobase was performed under 
reflux in dimethylsulfoxide using sodium azide (NaN3) as nucleophilic reagent.12 Being 
light sensitive, the azido group tends to be very unstable. In fact only the starting 
material 46 was recovered from the reaction together with degradation products.  
Based on palladium-catalysed chemistry, attempts for substitution of the cyano group at 
C-8 to form compound 56 from the 8-iodo derivative 47, failed. The mechanism of 
Stille coupling is described in Scheme 4.3 and is divided in four steps: first the 
reduction of the palladium (II) to the active specie, palladium (0), then oxidative 
addition of the palladium with the halide, followed by transmetallation with the 
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tributyltin cyanide to afford an intermediate, which collapses to the desired molecule 
after reductive elimination of the palladium (II) to palladium (0).  
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Scheme 4.3. Mechanism of Stille coupling. 
 
A first reaction was carried out with palladium-Tetrakis, as described by Shen and co-
workers,45 but only β-2’-C-methyl-6-O-methyl guanosine 11 was recovered. The 
importance of the palladium catalyst and its ligands in such coupling is well known46 
and the key step in the mechanism is the oxidative addition, which occurs faster if the 
palladium (0) complex is electron-rich, hence the importance of strong donating ligands. 
Taking into consideration this view, sterically hindered hydrophilic and electron rich 
TPPTS (tris(3-sulfonatophenyl)phosphine)47 was used as a ligand with palladium 
acetate in order to form a strong palladium catalyst.17 This palladium-ligand complex is 
mainly used in aqueous phase for cross-coupling reaction.17 However, Wolf and co-
workers showed that such catalyst system could be used for Stille coupling in aqueous 
phase.48 Once again the starting material was degraded to β-2’-C-methyl-6-O-methyl 
guanosine 11 and no further attempts were performed; however further investigations 
on the type of palladium catalyst to use for this specific reaction would be necessary. 
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2.2.3. Conclusion and characterisation of 8-modified nucleosides 
High temperature and pressure were needed for aromatic substitutions of 8-halogeno 
nucleosides, and the reactions gave low to moderate yields (7 to 51%). Introduction of 
triethylamine seemed essential for substitutions of secondary amines. Substitutions of 
halogens by electron-withdrawing O-alkyl/aryl or cyano groups were unsuccessful, as 
well as electron-donating azido group. However, further investigation of palladium 
catalyst or other routes49 for the synthesis of 8-modified nucleosides maybe interesting.  
Eleven 8-modified nucleosides were successfully synthesised, purified, characterised 
and were sent for biological evaluation in HCV replicon assays.  
 
8-amino modified nucleosides (46-51, 54, 57-59) together with β-2’-C-methyl-6-O-
methyl guanosine 11, were dissolved in phosphate buffer (0.05M, pH~7.4) to reach a 
concentration of approximatively 50 µM, and characterised by ultra-violet spectroscopy 
(Graph 4.1). 
2’-C-Me-6-OMe Guanosine 11
8-NHMe 2’-C-Me-6-OMe Guanosine 57
8-N(Me)2 2’-C-Me-6-OMe Guanosine 50
8-NHBu 2’-C-Me-6-OMe Guanosine 59
8-Cl 2’-C-Me-6-OMe Guanosine 48
8-NHPh 2’-C-Me-6-OMe Guanosine 58
8-Br 2’-C-Me-6-OMe Guanosine 46
8-I 2’-C-Me-6-OMe Guanosine 47
8-NHBn 2’-C-Me-6-OMe Guanosine 49
8-pyrrolidine 2’-C-Me-6-OMe Guanosine 51
 
Graph 4.1. UV characterisation of 8-modified nucleosides. 
 
Aromatic groups at C-8 (58 and 49) tend to have bathochromic properties (increase 
λmax), while 8-alkyl amino modified nucleosides (57 and 59) tend to lower the 
wavelenghth to reach a λmax comparable to 8-halogeno nucleosides (46-48). Secondary 
amino groups at C-8 (50 and 51) blue-shift the λmax (hypsochromic effect). 
From this graph, the extinction coefficient (ε) of each nucleoside was extrapolated 
applying the Beer-Lambert law (Table 4.1) with the length of the cuve being 1 cm (l = 1 
cm). 
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Cpd 8-R λmax (nm) Amax ε (L.mol-1.cm-1) 
11 - 245 0.75 15000 
46 Br 249 0.74 14800 
47 I 251 0.94 18800 
48 Cl 249 0.82 16400 
57 NHMe 261 0.93 18680 
50 N(Me)2 257 0.99 19960 
59 NHBu 250 0.52 10400 
58 NHPh 302 0.74 14800 
49 NHBn 255 0.87 17400 
51 Pyrrolidine 255 1.01 20200 
Table 4.1. Maximum length-wave (λmax), maximal absorbance (Amax) 
and calculated extinction coefficient (ε) of 8-modified nucleosides. 
 
Secondary amino groups at C-8 (50 and 51) have the highest extinction coefficient 
(hyperchromic effect), thus are more efficient in absorbing UV light compared to 8-
modified nucleosides bearing primary amines. The 8-bromo modification (46) does not 
have important impact effect on light absorption compared to the parent nucleoside 11, 
whereas both chlorine (48) and iodine (47) atoms exhibit higher extinction coefficients. 
It is also notable that 59, bearing 8-butyl amine, absorbs the least UV-light. 
 
 2.3. ProTide technology applied to 8-modified nucleosides 
Except for 8-oxo derivatives (63 and 64), α-naphthyl L-alanine neopentyl 
phosphoramidates of 8-modified nucleosides were synthesised (Scheme 4.4) according 
to the Uchiyama procedure previously mentioned.  
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*made by K. Madela. 
(i. anh. Et2O, anh. NEt3 (1.0 eq), 30 min, -78 °C to rt, 51%; ii. anh. DCM, anh. NEt3 (2.0 eq), 1 
hr, -78 °C to rt, 78%; iii. anh. THF, tBuMgCl (2.0 eq), rt, overnight.) 
Scheme 4.4. Synthetic scheme to 8-modified ProTides. 
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The reactions were relatively low yielding (2% to 4%) probably due to the steric 
hindrance resulting from the 8-modifications. Interestingly, 8-modified ProTides 
revealed a clear separation of the two diastereoisomers by NMR (0.20 ppm separation 
in 31P NMR), however flash chromatography was unsuccessful at separating them and 
after purity check, they were sent as a mixture of two diastereoisomers for biological 
evaluation against HCV replication. 
 
 2.4. Biological evaluation 
The evaluation of 8-modified β-2’-C-methyl-6-O-methyl guanosine nucleosides and 
their corresponding phosphoramidates in replicon assays using Huh-7 cells was 
performed at Inhibitex Inc., and the potency and toxicity are reported in Table 4.2. 
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ClogP from CS ChemDraw Ultra 11.0 software. 
Table 4.2. Activity (EC50) and cytotoxicity (CC50) in HCV replicon assays of 8-modified 
nucleosides and α-naphthyl L-Alanine neopentyl phosphoramidates. 
 
Only the 8-iodo nucleoside 47 exhibits micromolar potency activity (EC50 = 6 µM). 
Other 8-modified nucleosides are barely inactive against HCV replication and no 
cellular toxicity is detected up to 100 µM.  
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8-modified ProTides improve anti-HCV potency compared to their parent nucleosides 
but are still poor inhibitors. This boost of activity is probably related to greater 
lipophilicity, with ClogP in a range between 4 and 6, optimising the passive cellular 
uptake. The 8-iodo Protide (66) appears to be 300 fold more active against HCV than its 
parent nucleoside (47), while others improve the potency by only 7-fold. Nevertheless, 
further metabolism studies done at Inhibitex Inc. suggested quick de-iodination inside 
the cells, resulting in 2’-C-methyl guanosine analogues. None of the 8-oxo derivatives 
displays activity in HCV replicon assays.  
 
 2.5. Enzymatic hydrolysis study 
The general lack of activity of the 8-modified nucleosides, reported by in-vitro 
evaluation, and the recent discovery of rapid cleavage of the 8-iodo guanosine 
derivatives (47 and 66) encouraged us to further investigate the enzymatic stability of 8-
modified nucleosides. 
 
2.5.1. Hydrolysis study at the nucleoside level 
Adenosine deaminase (ADA) is a key enzyme found widely in cells and in human 
spleen, involved in purine metabolism, playing a critical role in immune competence 
and acting in the metabolism of nucleic acid components,50 particularly the irreversible 
conversion of adenosine into inosine and ammonia.51 While viramidine is enzymatically 
deaminated into ribavirin by adenosine deaminase (Scheme 4.5),52 8-modified 
adenosines bearing a group bigger than a fluorine atom are not reported as substrates for 
ADA.50 
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Scheme 4.5. Deamination of viramidine to ribavirin by ADA.52 
 
To prove the enzymatic stability of 8-amino modified nucleosides towards ADA, an 
enzymatic experiment50 was performed with nucleoside 57 (8-methylamine) bearing the 
smallest substituent at C-8. The metabolism was monitored by UV spectrometry and the 
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UV spectra were recorded every minute for 30 min and then every 20 min for 20 hours 
(Graph 4.2). Despite addition of 100 µL of ADA after 3 hours 45 minutes, 57 remained 
stable to ADA. Therefore, as predicted by the literature, none of 8-modified analogues 
synthesised should undergo hydrolysis of the C-6 position by liver enzymes at a 
nucleoside level, especially bulky groups.53 This result correlates with in-vitro assays 
since none of them are potent against HCV replication. 
 
     
Graph 4.2. Study of enzymatic stability of 57 (0.05 µM in phosphate buffer pH-7)  
in the presence of ADA (50 µL). 
 
Only nucleosides bearing small substituents at C-8 are reported to be substrate of 
ADA,50 hence the 8-oxo nucleoside 64 may be enzymatically converted into the N-2-
acetylated derivative of 63. However, the stability study proved that 64 is not substrate 
of ADA (Graph 4.3), therefore the N-2 acetyl group may prevent 64 to fit in the 
catalytic pocket of ADA. 
 
 a)  b)
G
raph 4.3. Stability study of 64 (a) and 63 (b) (0.05 µM in phosphate buffer pH-7)  
in the presence of ADA (20 µL). 
 
 
2.5.2. Hydrolysis study at the 5’-monophosphate level 
As for many 6-O-subtituted prodrugs in clinical development,6, 54, 55 metabolism to the 
bioactive form requires hydrolysis of the 6-O-substituent of the purine base. Adenosine 
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deaminase-like protein-1 (ADAL-1) has recently been reported as the enzyme 
responsible for effective metabolism of 6-O/N substituted purine, and acts specifically 
at the 5’-monophosphate level.56 
Docking of 5’%monophosphate! of! 57! (8-methylamine 2’-C-methyl-6-O-methyl 
guanosine) was! performed! using! an! homology!model! of! ADAL%1!with! its! natural!substrate! the! 5’%monophosphate! of! adenosine! (AMP).57! The! prediction! is!represented!in!Figure!4.4.! 
 
 
Figure 4.4. 5’-monophosphate of 57 docked in the catalytic site of ADAL-1. 
(grey stick: 5’-monophosphate of 57, light green line: AMP) 
 
The docking suggests that the 5’-monophosphate of 57 would fit in the catalytic pocket 
of ADAL-1. However the 3’-hydroxyl group of AMP usually interacts with the 
Asparagine 28 (Asn28), and in our case it is the Threonine 107 (Thr107) involved in the 
hydrogen bonding interaction. This observation results from the position of the sugar 
moiety, which does not lie in optimal position in the pocket (in comparison with AMP). 
Thus, the hydrolysis of the 6-position of the nucleobase might happen, and the 5’-
monophosphate species of 8-methylamine-2’-C-methyl guanosine might be slowly 
deliver intracellularly. Therefore, if 8-modified 2’-C-methyl-6-O-methylguanosine 
phosphoramidates are efficiently converted to their corresponding 5’-monophosphate 
species, hydrolysis of the 6-O-methyl might take place.  
  
 2.6. Mechanistic studies 
In-vitro evaluation reported the 8-modified β-2’-C-methyl-6-O-methyl guanosine 
phosphoramidates as poor inhibitors of HCV replication. Therefore, enzymatic assays 
were carried out with the intention of studying their putative mechanism of activation,  
already described Chapter 3. Further modelling studies were performed not only to 
Claire Bourdin  Chapter Four: Nucleobase modifications 
!! 67 
support the carboxypeptidase Y assays but also to study the last step of activation to the 
5’-monophosphate. 
 
2.6.1. Carboxypeptidase Y assays 
Carboxypeptidase Y (CPY) is an esterase type enzyme known to be responsible for the 
initial ester cleavage of ProTide. As previously reported in our group,58 the CPY-
mediated ester cleavage of 8-amino modified ProTides can be monitored using 31P-
NMR.  
 
Hydrolysis of α-naphthyl L-Alanine-neopentyl ester ProTides of 8-methylamine β-2’-C-
methyl-6-O-methyl guanosine (68) and 8-butylamine β-2’-C-methyl-6-O-methyl 
guanosine (70) are represented in Graph 4.4 (a and b). ProTide 70 was more unstable to 
CPY than 68, hence converted faster to its phosphoramidate monoester. In both case, 
the ester-hydrolysed species were visible by 31P-NMR. The experiment also suggested 
that the conversion rates of the two diastereoisomers differ slightly (Graph 4.4 c). 
 
   
!"
#$"
$!"
%$"
&!!"
!
&$
#'
(!
)&
%$
&&!
(!!
*'!
!"#$%&#"'(
!"
#$"
$!"
%$"
&!!"
!
&#
(!
)&
%$
&&!
(!!
*'!
!"#$%&#"'(
 b)
!"
&$"
'!"
($"
)!"
! &# (! )& %$ *+ &&! #*$ *($
!"#$%&#"'(
 c)
 a)
 
Graph 4.4. Time course of disappearance of prodrug and appearance of metabolites in CPY 
catalyzed hydrolysis of 68 (a) and 70 (b) (purple: ProTide, blue: ester hydrolysed species, green: 
phosphoramidate monoester).  
Time course of conversion of the two diastereoisomers of 68 (c) (light purple: diastereoisomer 
at 31P of 4.19 ppm, dark purple: diastereoisomer at 31P of 3.69 ppm). 
The percentage of prodrug remaining and metabolites detected at given time is plotted against 
time. 
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All but phosphoramidate 69, bearing 8-dimethylamine at C-8, were easily converted to 
their amino-acyl intermediate, while 69 remains stable to CPY (Figure 4.5). This result 
correlates with in-vitro data, and is even more surprising since 73, bearing a secondary 
cyclic amine at C-8 (8-pyrrolidine), is hydrolysed under similar conditions (Figure 4.6). 
 
     
Figure 4.5. CPY catalysed ester hydrolysis of 69 monitored by 31P NMR  
(pink: ProTide peaks). 
 
 
 
Figure 4.6. CPY catalysed ester hydrolysis of 73 monitored by 31P NMR 
(pink: ProTide peaks, blue: ester hydrolysed species, 
green: phosphoramidate monoester). 
 
Aromatic substitutions at C-8 (71 and 72) appear to slow down the enzymatic cleavage 
of the ester (Graph 4.5). Formation of the ester hydrolysed species was not detectable 
during these assays, suggesting quick conversion into the phosphoramidate monoester. 
However, the introduction of a methylene group between the amine and the phenyl ring 
(72, 8-NHBn) tends to slow down the conversion of the ProTide by about four fold 
compared to 71 (8-NHPh).  
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Graph 4.5. Time course of disappearance of prodrug and appearance of metabolites in CPY 
catalysed hydrolysis of 71 (a) and 72 (b)  
(pink: diastereoisomer 1, blue: diastereoisomer 2, green: phosphoramidate monoester). 
 
 
2.6.2. Molecular modelling 
Molecular modelling was performed to gain deeper understanding of the ester 
hydrolysis step, and to predict the conversion of phosphoramidate monoesters by human 
Hint-1 enzyme into their 5’-monophosphate. 
 
2.6.2.1. Docking with cathepsin A enzyme 
To investigate the unexpected stability of 69 (β-2’-C-methyl-6-O-methyl-8-
dimethylamine guanosine L-Alanine-neopentyl ester ProTide) towards CPY, molecular 
modelling was carried out, docking both 68 (bearing 8-methylamino group) and 69 in 
the catalytic pocket of cathepsin A (Figure 4.7). While the carbonyl group of 68 lies 
close to the catalytic residues (Ser146, Gly53 and Gly52), an extra methyl group seem 
to affect significantly the fitting of 69 in cathepsin, placing the ester carbonyl group 
outside the catalytic pocket. Thus, predicting no conversion into its phosphoramidate 
monoester essential for delivery of the 5’-monophosphate species. 
      
Figure 4.7. Docking of SP isomers of 68 (orange line) and 69 (brown stick) in cathepsin A (grey 
sticks: catalytic residues). 
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In contrast but in correlation with the CPY assays, a secondary cyclic amine at C-8 (73) 
enables better fitting in the enzyme placing the carbonyl group of both isomers far from 
the catalytic residues, but still inside the pocket (Figure 4.8). This might explain the 
slow conversion rate into its corresponding phosphoramidate monoester species, with a 
slight preference for the SP isomer. 
 
     
Figure 4.8. Docking of SP (yellow stick) and RP (brown stick) isomers of 73 in cathepsin (grey 
lines: catalytic residues). 
 
Longer alkyl chains at C-8 (70) allow a good fit into the catalytic pocket of cathepsin A, 
especially for the SP diastereoisomer, for which the distance to the catalytic residue is 
similar to the SP isomer of 68 (Figure 4.9). The proximity of the Gly52 (4.54 Å) and 
Gly53 (3.34 Å) seems to have an influence on the rapidity of the processing of 
phosphoramidate diester to phosphoramidate monoester. The more the intermediate 
formed is stablilized by the glycine residues, the quicker is the phosphoramidate 
monoester released. Thus, this might explain the different conversion rate of the two 
diastereoisomers observed during CPY assays. 
 
  
Figure 4.9. Docking of SP  (left) and RP (right) diastereoisomers of 68 (brown stick) and 70 
(yellow stick). 
 
In contrast, bulky aromatic amino groups at C-8 (71 and 72) do not allow the molecules 
to fit within the catalytic pocket, thus supporting the results observed during the CPY 
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experiments (Graph 4.5). In these cases, the ester carbonyl group of the RP 
diastereoisomer lies in a better position for enzymatic hydrolysis than the SP 
diastereoisomer. 
 
2.6.2.2. Docking with human Hint-1 enzyme 
As already mentioned in Chapter 3, human Hint enzymes are known to hydrolyse the P-
N bond of phosphoramidate monoesters. Phosphoramidate monoesters of 8-amino 
modified ProTides together with the natural substrate adenosine 5’-monophosphate 
(AMP), were docked within the active site of Hint-1 enzyme with the intention to 
investigate the step of intracellular release of the corresponding 5’-monophosphates. 
While the phosphorus center of aminoacyl intermediate of 68 (ProTide of β-2’-C-
methyl-6-O-methyl-8-methylamino guanosine) lies far from the catalytic triad, longer 
alkyl chain at C-8, such as 70 (ProTide of 8-butylamine β-2’-C-methyl-6-O-methyl 
guanosine), might favour the P-N bond cleavage position of phosphoramidate 
monoester (in comparison with the phosphate of the reference AMP) (Figure 4.10). As a 
result, the intracellular delivery of the 5’-monophosphate of 70 may be quicker than 68, 
and therefore may result in higher anti-HCV activity in in-vitro assays. Thus, molecular 
modelling in both cathepsin A and Hint-1 does not offer a clear correlation between the 
observed higher potency of 68 and its enzymatic bioactivation.  
 
    
Figure 4.10. Docking of phosphoramidate monoester of 68 (yellow stick) and 70 (brown stick) 
in the catalytic pocket of human Hint-1 enzyme (AMP in red line). 
 
Similarly, phosphoramidate monoesters of 69 and 73, bearing respectively secondary 
alkyl and cyclic amine at C-8, are well positioned in the catalytic pocket (Figure 4.11). 
Nevertheless, as suggested by the CPY assays and predicted by cathepsin docking, the 
phosphoramidate monoester of 69 may not be formed, so unless other liver enzymes 
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hydrolyse the latter, 69 may not exhibit activity against HCV replication, as supported 
by biological testing. Predicted slow ester hydrolysis of phosphoramidate monoester of 
73 may result in a slow conversion into the 5’-monophosphate by Hint-1 enzyme. In 
this case molecular modelling offers a prediction of the slightly higher in-vitro potency 
of 73 compared to 69. 
 
     
Figure 4.11. Docking of phosphoramidate monoester of 69 (yellow stick) and 73 (pink stick) in 
the catalytic pocket of human Hint-1 enzyme (AMP in red line). 
 
Docking of 8-aryl amine modified phosphoramidate monoesters of 71 (8-phenylamino) 
and 72 (8-benzylamino) into human Hint-1 enzyme predicts faster P-N bond hydrolysis 
for 72 than 71 (Figure 4.12). Therefore, long and bulky groups at C-8 might position the 
phosphorus center in optimal position within the catalytic site! for release of 5’-
monophosphate (in comparison with the phosphate group of AMP). This prediction 
supports the in-vitro data, suggesting that 72 is a stronger inhibitor of HCV replication 
than 71. 
 
     
Figure 4.12. Docking of phosphoramidate monoester of 71 (grey stick) and 72 (orange stick) in 
the catalytic pocket of human Hint-1 enzyme (AMP in red line). 
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 2.7. Conclusion and perspectives 
Before initiating this project, modifications at C-8 position of the nucleobase of 2’-C-
methyl nucleosides had never been investigated and were totally unknown in the HCV 
field. A novel synthetic approach to synthesise 8-amino modified β-2’-C-methyl-6-O-
methyl guanosine analogues was developed, and the ProTide technology was 
successfully applied to the new nucleoside analogues in order to boost the anti-HCV 
activity. 
Despite a boost of potency exhibited by 8-modified ProTides in comparison with their 
corresponding nucleosides, none appears as strong inhibitor of HCV replication as 15.d 
(α-naphthyl L-Alanine-neopentyl ester Protide of β-2’-C-methyl-6-O-methyl 
guanosine).  
Enzymatic experiments performed with adenosine deaminase together with the 
molecular docking using a model of ADAL-1, suggest that the 6-O-methyl might be 
hydrolysed at the monophosphate level only. Therefore, 8-modified 2’-C-methyl 
guanosine phosphorylated species might be delivered inside the cells, if their 
corresponding 6-O-methyl monophosphate analogues are released after metabolism of 
the ProTides. 
Molecular modelling supports the results of both carboxypeptidase Y assays and anti-
HCV in-vitro results. While small groups at C-8 may enable quick ester hydrolysis (68), 
long and bulky group may favour efficient P-N bond cleavage (72). However, 8-
modified primary amines phosphoramidates (68, 70, 71, 72) are stronger inhibitors of 
HCV replication than 8-modified analogues bearing secondary amines (69, 73). While 
cyclic secondary amines at C-8 might result in relatively slow bioactivation of the 
ProTide (73) to its 5’-monophosphate species, the ester hydrolysis might be the limiting 
step for phosphoramidates bearing secondary alkyl amine at C-8 (69). 
 
Future expansion of 8-modified nucleosides should focus on synthesis and evaluation of 
8-O-alkyl/aryl and 8-C-alkyl/aryl analogues. The latter would be of particular interest to 
understand the effect on HCV replication of bigger and smaller atoms directly 
connected to C-8. 
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3. 7-deaza modifications  
 3.1. Introduction  
Natural 7-deaza purine nucleosides, such as the antibiotics tubercidin (74) and 
toyocamicin (75) (Figure 4.13),59-62 possess broad biological activity. 7-deaza modified 
purines have been extensively studied for their antiviral63, 64 and cytostatic properties.65, 
66 
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Figure 4.13. Structures of antibiotics tubercidin 74 and toyocamicin 75. 
 
Numerous 7-modified 7-deaza nucleosides are reported in the literature,67-69 among 
which 7-deaza-2’-C-methyl adenosine 449 and its 7-fluorinated derivative 768 (Figure 
4.14) were identified as potent inhibitors of HCV replication. In contrast, the 7-deaza-
2’-C-methyl guanosine analogue 77 (Figure 4.14) did not exhibit anti-HCV activity in 
replicon-based assays, however its 5’-triphosphate inhibits HCV NS5B-mediated RNA 
synthesis at submicromolar concentrations.8  
Since the 6-O-methyl modification has previously been reported as a potential prodrug 
of its guanosine analogue,6 the application of 7-deaza modification on β-2’-C-methyl-6-
O-methyl guanosine 11 should overcome the eventual poor cellular uptake of  77 and 
boost the inhibitory activity in replicon assays. 
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Figure 4.14. Inhibitory activity of 7-deaza-2’-C-methyl adenosine 44, 7-deaza-7-fluoro-2’-C-
methyl adenosine 76 and 7-deaza-2’-C-methyl guanosine 77, inhibitory activity of nucleosides 
in replicon assays (EC50) and inhibitory activity of nucleoside 5’-triphosphates on HCV NS5B-
mediated RNA replication (IC50), cellular toxicity (CC50). 
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 3.2. 7-deaza-6-O-methyl-2’-C-methyl guanosine  
3.2.1. Synthesis of 7-deaza-6-O-methyl-2’-C-methyl guanosine and prodrugs 
Several synthetic approaches for the formation of 7-deazapurine ribonucleosides have 
been developed,70, 71 based on the preparation of the 7-deaza modified nucleobase 
followed by a glycosylation step. 
 
3.2.1.1. Preparation of 7-deaza-6-O-methyl guanine 
En route to 7-deaza-6-O-methyl guanine 81 (Scheme 4.6), 7-deaza-6-chloro guanine 80 
was formed in moderate yield over two steps as reported in the literature.69, 72 Addition 
of α-chloroacetaldehyde to the commercially available 2,4-diamino-6-
hydroxypyrimidine 78 in water enabled the formation of the pyrrole ring via Bischler 
reaction and afforded 7-deazaguanine 79 (Scheme 4.6). The later was treated with 
phosphorus oxychloride (POCl3) under reflux73 over two hours to yield 23% of 80. The 
reflux conditions were preferred since the yield of the same reaction performed over 
two days at room temperature74 was only 16%.  
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(i. NaOAc (1.0 eq), α-chloroacetaldehyde (50% aq., 1.0 eq), DMF/H2O, rt, overnight, 23%; ii. 
POCl3, reflux, 2 hrs, 64%; iii. NaOMe (3.0 eq), anh. MeOH, reflux, 5 days, 3%) 
Scheme 4.6. Route to 7-deaza-6-O-methyl guanine. 
 
Displacement of the 6-chlorine was carried out refluxing 80 with sodium methoxide 
(NaOMe) for five days. Due to similar polarity of 80 and 81, completion of the reaction 
was monitored by 1H-NMR and the presence of a peak around 4.00 ppm in deuterated 
methanol indicated the formation of the 6-O-methyl group. But 81 was formed in very 
poor yield (3%), therefore we decided to change the strategy and perform the aromatic 
nucleophilic substitution directly at the nucleoside level. 
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3.2.1.2. Synthesis of 7-deaza-6-O-methyl-2’-C-methyl guanosine 
Several publications report the synthesis of 2’-C-methylribonucleoside in ‘one-pot’, 
reacting the protected 2’-C-methyl ribofuranose with the heterobase.75, 76 However, 
electrophilic glycosylation is not recommended since the nitrogen of the 7-deaza pyrrole 
ring is part of the aromatic π-system and thus, is inert towards glycosylation; hence 
resulting in either C-nucleosides or reaction of the pyrimidine ring.59, 77, 78 Subsequently, 
nucleobase-anion glycosylation appears as the best step towards the synthesis of 7-
deaza-6-O-methyl-2’-C-methyl guanosine.68 
 
3.2.1.2.1. Glycosylation with fully protected 2’-C-methyl ribofuranose 
Preparation of the fully protected 2’-C-methyl ribofuranose was required before the 
glycosylation step (Scheme 4.7).  
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(i. anh. acetone, HClO4 (60% aq., 1.6 eq), rt, overnight, 76%; ii. anh. DMF, imidazole (2.0 eq), 
TBDMSCl (2.0 eq), rt, overnight, 28%; iii. anh. THF, DIBAL-H (1M in hexanes, 3.0 eq), -78 
°C, 1hr, -15 °C, 3-4hrs, 28%.) 
Scheme 4.7. Synthetic route to fully protected 2’-C-methyl ribofuranose 85. 
 
Glycosylation with a heterobase bearing a non-protected exocyclic amine is reported to 
be more efficient when using the isopropylidene protected ribofuranose,59 subsequently 
this group was chosen as protecting group for 2’- and 3’-hydroxyls starting from the 
commercially available 2’-C-methyl-1-ribonolactone 82, to obtain compound 83. The 
latter was further protected at the 5’-hydroxyl with tert-butyl-dimethyl-silyl chloride 
(TBDMSCl) to form 84. The protected lactone was then reduced to a primary alcohol 
using diisobutylaluminium hydride (DIBAL-H) as electrophilic reducing reagent to 
afford both anomers of the fully protected 2’-C-methyl ribofuranose 85. The mixture of 
both anomers was fully characterised by 1H-NMR and 13C-NMR. It is important to 
notice that the signals of H-3’ protons differs, one appearing as a broad singlet and the 
other as a doublet. Calculation of the coupling constant J3’,4’  gave a value of 10.5 Hz, 
reported to be characteristic of the β-anomer,79, 80 hence assuming that the broad singlet 
corresponds to the α-anomer. The 13C-NMR has also significant difference in chemical 
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shifts and the α-anomer peaks appear more downfield.  
With 85 in hand, the glycosylation step was performed as described in Scheme 4.8. 
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(i. anh. toluene, CCl4 (15 eq), P(NMe2)3 (1.3 eq), -35 °C to 0 °C, 1hr 30min; ii. anh. toluene, 
KOH (2.3 eq), TDA-1 (0.5 eq), rt, overnight; iii. anh. MeOH, NaOMe (3.3 eq), rt, overnight.) 
Scheme 4.8. Synthetic scheme of glycosylation with  
fully protected 2’-C-methyl ribofuranose 85. 
 
The chloro derivative 86 was formed in situ using the mild conditions of Appel’s 
chlorination (Scheme 4.9).65 Activation using carbon tetrachloride (CCl4) and 
tris(dimethylamino)phosphine (P(NMe2)3) enables deprotection of the anomeric 
hydroxyl of 85 and formation of the 1’-hexamethyl phosphorus triamide intermediate 
85.a. The later is then displaced under nucleophilic substitution conditions and should 
yield the only α-anomer of 86 in the presence of tris(dimethylamino)phosphine oxide.81 
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Scheme 4.9. Mechanism of Appel’s chlorination. 
 
The conformation of compound 86 was not confirmed because of its reported 
instability,65 however it is known to be a successful reagent for the synthesis of 
anomerically pure enantiomers.81 86 in toluene was then directly added into a well-
stirred mixture of 80, tris(2-(2-methoxyethoxy)ethylamine (TDA-1) and potassium 
hydroxide (KOH). These conditions, known as Ugarkar conditions,65, 82 are reported to 
yield the only β-anomer after direct Walden inversion occurring during nucleophilic 
substitution type 2 (SN2) of the chlorine atom with the entry of nitrogen N-9 of the 
Claire Bourdin  Chapter Four: Nucleobase modifications 
!! 78 
potassium salt of 80 formed in situ. In our case, 1H-NMR of the crude product clearly 
indicated that the coupling did not happen. Similar findings were reported in the 
literature for standard ‘one-pot’ glycosylations using 7-deaza-6-chloro83 in a series of 
ribonucleosides70, 86 among which 2’-C-methyl sugar donor.75 Thus, this route was then 
abandoned and the nucleobase-anion glycosylation procedure developed by Merck was 
tested.8 
 
3.2.1.2.2. Glycosylation with 3,5-bis-O-(2,4-dichlorophenylmethyl)-2’-C-methyl-1-O-
methyl-α-D-ribofuranose  
Merck laboratories have reported the synthesis of 7-nonhalogenated-7-deaza-6-chloro 
purines8 via the formation of an α-epoxide intermediate as ribonucleoside donor.83  
 
Starting from the commercially available 3,5-bis-O-(2,4-dichlorophenylmethyl)-2’-C-
methyl-1-O-methyl-α-D-ribofuranose 89, condensation was performed in acetonitrile by 
in-situ conversion to the 1-bromo derivative followed by subsequent reaction with the 
potassium salt of 80 formed in-situ, to yield 90 (Scheme 4.10). 1H-NMR suggested the 
presence of only one anomer of 90 whose peaks are in accordance with the β-anomer 
reported in the literature (H-7, 6.34 ppm, d, J7-8 = 3.80 Hz; H-1’, 6.23 ppm, s; H-5’, 
3.97 & 3.76 ppm, 2dd, J = 10.5 Hz, 2.0 Hz).8, 85 A NOESY experiment was also 
performed to confirm the conformation of the glycosidic bond, however the presence of 
2,4-dichlorophenylmethyl protecting group affected the spectra and did not allow full 
characterisation. It is also important to note that the use of potassium hydroxide powder 
instead of pellets improved the solubility of 80 and improved the yield of the 
glycosylation reaction by 3-fold.  
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(i. anh. DCM, 0 °C, HBr (33% in acetic acid, 6.7 eq), rt, 2hrs, anh. ACN, KOH (85% powdered, 
3.0 eq), TDA-1 (0.2 eq), rt, 1hr, 31%; ii. anh. DCM, , 0 °C,  BCl3 (10 eq),  -78 °C, 2hrs, -20 °C, 
2hrs 30min, 66%; iii. anh. MeOH, NaOMe (3.0 eq), reflux, overnight, 49%.) 
Scheme 4.10. Merck’s route to 7-deaza-6-O-methyl-2’-C-methyl guanosine 88. 
  
Treatment of 90 with the Lewis acid boron trichloride (BCl3) in dichloromethane, 
afforded the deprotected 2’-C-methyl-6-chloro-7-deazaguanosine 91. Chemical shifts 
and coupling constant (J7,8 = 3.55 Hz) of the 1H-NMR of 91 in deuterated methanol 
corresponded to the assignment of the β-anomer reported by  Merck.8 Substitution of 91 
with sodium methoxide (NaOMe) in methanol under reflux afforded the 6-O-methyl 
analogue 88 in 50-60% yield after purification by flash chromatography. Standard 
conditions of substitution at the 6-position used for the guanosine derivative6 were 
unsuccessful in the case of 7-deaza guanosine, and reflux was essential to form 88.86 
The nucleophilic aromatic substitution was more difficult due to the removal of the 7-
nitrogen lone pair, which is part of the π-system and favours resonance stabilisation of 
the intermediate. A singlet at 4.01 ppm in deuterated chloroform proved the presence of 
the methyl ether group at C-6. The β-configuration has previously been reported by 
Merck,8 however since the Baker trans rule does not apply in this case, NOESY 
experiment was performed.  Selective irradiation of the signal of H-1’ increased the 
intensity of the signal of H-4’, thus, indicating that H-1’ and H-4’ are located on the 
same face of the ribofuranose ring.87 Moreover the signal of H-8 was not enhanced 
when H-1’ was irradiated. This observation confirmed the anti orientation of the 
glycosidic bond68 as reported for 44.28  
 
7-deaza-6-O-methyl-2’-C-methyl guanosine 88 was sent to Inhibitex Inc. for  evaluation 
in HCV replicon-based assays. In the meantime, knowing that the phosphorylation of 
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nucleoside analogues is often the limiting step towards delivery of the 5’-
monophosphate, the ProTide approach was anticipated and applied to 88. 
 
3.2.1.3. ProTide technology applied to 7-deaza-6-O-methyl-2’-C-methyl guanosine 
Three α-naphthyl L-Alanine phosphoramidates with variation at the ester moiety (92, 
93, 94) were synthesised following the standard Uchiyama procedure (Scheme 4.11), 
without requiring protection of the 2’- and 3’- hydroxyl groups of 88.  
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(i. anh. THF, tBuMgCl (2.0 eq), rt, overnight.) 
Scheme 4.11. Synthesis of 7-deaza-6-O-methyl-2’-C-methyl guanosine ProTides. 
 
After flash chromatography and preparative chromatography, the phosphoramidates 92, 
93 and 94 were isolated and characterised by NMR, and analytical HPLC. All the 
compounds were obtained as a mixture of diastereoisomers in 12-13% yield. The two 
diastereoisomers of 92 were separated (92.a and 92.b) by flash chromatography. These 
ProTides were tested for their ability to inhibit HCV replication by Inhibitex Inc. 
 
3.2.2. Biological evaluation  
Cytotoxicity and inhibitory potency of 88, 92.a, 92.b, 93 and 94 were evaluated in 
replicon assays by Inhibitex Inc. The results are reported in Table 4.3 and are compared 
with the β-2’-C-methyl-6-O-methyl guanosine (7-aza) series. 
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Table 4.3. Anti-HCV potency (EC50) and cellular cytotoxicity (CC50) of 7-deaza-6-O-methyl 
guanosine derivatives and their 7-aza analogues. 
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The key observation resulting from these biological tests is that the absence of the 7-
nitrogen on the nucleobase is critical for anti-HCV activity, resulting in a total loss of 
potency at the nucleoside level (88 vs 11) and poor selectivity at the ProTide level.  The 
7-deaza phosphoramidates (92.a, 92.b, 93 and 94) somehow restore the antiviral activity 
from 3- to 10-fold. Hence, the ProTide approach applied to 7-deaza-6-O-methyl 
guanosine is to some extend effective, whereas 88 is either a poor substrate for 
nucleoside kinases or lacks of cellular permeation, hence preventing intracellular 
delivery of the bioactive 5’-triphosphate form. 92.a and 92.b exhibit similar potency, 
thus, the phosphorus stereochemistry does not influence the bioactivation. Moreover, it 
is remarkable that the removal of the 7-nitrogen lead to a loss of efficacy over 1000-fold 
when the neopentyl (93 vs 15.d) and the benzyl (94 vs 15.e) ester moieties are 
considered. With a range of ClogP varying from 3.14 to 4.00, poor cell uptake can not 
be considered as the limiting step. 
Phosphoramidates 92.a, 92.b, 93 and 94 exhibit cellular toxicity in Huh-7 cells in 
comparison to their 7-aza derivatives (15.d, 15.e and 15.k). The 2’-C-methyl 
modification introduced on 7-deaza adenosine has resulted in loss of cytotoxicity.9 
Moreover neither 2’-C-methyl guanosine nor its 7-deaza derivative exhibited 
cytotoxicity in Huh-7 cells.8 In addition the potency of 7-deaza guanosine when 
administered orally in-vivo has been reported against numerous RNA viruses without 
high toxicity despite its lack of antiviral properties in cell cultures.68 Therefore, the 
cytotoxicity exhibited by 7-deaza-6-O-methyl guanosine  phosphoramidates may result 
from the 6-O-methyl modification. This observation has previously been made by our 
group,6 but ideally, the latter modification would be metabolised to its guanosine 
analogue, hence, would result in the intracellular delivery of 2’-C-methyl-7-deaza 
guanine 5’-triphosphate form (IC50 = 0.12 µM).8 
 
To further understand the impact of replacing the 7-nitrogen of the heterobase by a 
methine group in the bioactivation pathway, enzymatic and modelling studies were 
performed to assess the stability of 7-deaza derivatives. 
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3.2.3. Metabolic studies 
Eventual metabolism of 7-deaza-6-O-methyl-2’-C-methyl guanosine 88 and its L-
Alanine neopentyl phosphoramidate 93 to their corresponding 7-deaza guanosine 
analogues was investigated. 
 
3.2.3.1. Adenosine deaminase assay 
88 (44 µM) was incubated with commercially available adenosine deaminase (ADA, 80 
µL, 0.05 mg/mL) in phosphate buffer (0.05M, pH~7.4) at room temperature. The 
reaction was followed by UV spectrometry for four hours and spectra were recorded 
every 15 minutes for one hour, and then at 30 minutes interval (Graph 4.6). Every hour 
80 µL of ADA was added, and at the end of the run 2’-C-methyl-7-deaza guanosine 95 
was added as a reference. 
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Graph 4.6. UV spectra of conversion of 7-deaza-6-O-methyl-2’-C-methyl guanosine 88 into 7-
deaza-2’-C-methyl guanosine 95 by ADA. 
 
 
In contrast with 2’-C-methyl adenosine but similarly to 7-deaza-2’-C-methyl 
adenosine,8 88 is not a substrate for adenosine deaminase. Hence, the combination of a 
7-deaza and 6-O-methyl substituent increases significantly the stability to metabolic 
enzymes responsible for deamination of the 6-position of the nucleobase.  
 
3.2.3.2. Docking study with adenosine deaminase-like protein-1 
Docking studies of 7-deaza-6-O-methyl-2’-C-methyl guanosine 5’-monophosphate 
were performed with an homology model of adenosine deaminase-like protein-1 
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(ADAL-1).57 As previously mentioned, this enzyme is responsible for the hydrolysis of 
the 6-position of guanine on the 5’-monophosphate.56 This study predicted that the 7-
deaza-6-O-methyl-2’-C-methyl guanosine 5’-monophosphate might be a relatively good 
substrate for ADAL-1 (Figure 4.14), in comparison with the natural substrate AMP. 
Thus, as long as the 7-deaza-2’-C-methyl guanosine 5’-monophosphate is released from 
the metabolism of the ProTide, 7-deaza-2’-C-methyl guanosine 5’-monophosphate 
might be delivered intracellularly.  
 
     
Figure 4.14. Docking of 7-deaza-6-O-methyl-2’-C-methyl guanosine 5’-monophosphate (grey 
stick) into the catalytic pocket of ADAL-1 (green line: AMP). 
 
3.2.4. Mechanistic studies 
Aiming at understanding better the bioactivation pathway resulting in the intracellular 
release of 5’-monophosphate (97), enzymatic and docking experiments were performed 
to probe the two steps of activation of phosphoramidate 93, analogue of 15.d (Scheme 
4.12).  
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Scheme 4.12. Putative mechanism of activation of α-naphthyl L-Alanine neopentyl/benzyl ester 
7-deaza-6-O-methyl-2’-C-methyl guanosine ProTide 93. 
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3.2.4.1. Ester hydrolysis  
Phosphoramidate 93 (2.3 mg) was dissolved in a mixture of deuterated acetone (92 µL) 
and Trizma buffer (184 µL), and was incubated with commercially available 
carboxypeptidase Y (CPY) (0.1 mg) in Trizma buffer (92 µL). The enzyme-mediated 
ester hydrolysis was monitored by 31P-NMR, overnight, at room temperature at regular 
intervals, and selected spectra are shown in Figure 4.15.  
  
 
 
Figure 4.15. Carboxypeptidase Y assays with phosphoramidate 93. 
(light blue: diastereoisomers of 93, dark blue: phosphoramidate monoester species 96) 
 
One diastereoisomer of 93 shows to be less stable towards carboxypeptidase Y than the 
other, suggesting better fitting in the enzymatic catalytic site. However, both 
phosphorus signals decrease over time while achiral 96 is formed (δP ~ 7.10 ppm). The 
7-aza analogue 15.d has a metabolic conversion rate 20-times faster than 93.6 It is 
surprising that the remote 7-deaza modification has such an impact on the ester 
hydrolysis step and would explain the significant loss of potency against HCV RNA 
replication. 
 
This notable difference of reactivity towards carboxypeptidase-type enzymes was 
investigated using molecular docking in cathepsin A. Preliminary docking of 93 
suggested its SP isomer to fit better in the catalytic pocket (Figure 4.16 a); hence, SP 
isomers of both 93 and 15.d were docked into the catalytic site of cathepsin A (Figure 
4.16 b). While the carbonyl group of 15.d SP isomer faces towards the key residues 
(Gly52, Gly53 and Ser146) of the catalytic site, replacement of the 7-nitrogen by a 
methine group provokes an undesirable effect affecting the position of the ester 
carbonyl group, now lying towards the front of the pocket. This observation predicts the 
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slow release of the phosphoramidate monoester 96 and might suggest that hydrogen 
bond acceptor at C-7 of the nucleobase is required for locking the configuration of the 
nucleobase so that the ester carbonyl group fits properly into the catalytic site of 
carboxypeptidase-type enzymes.  
 
  
a) b)
 
Figure 4.16. a) Docking of SP (yellow stick) and RP (blue sticks) isomers of 93 in the catalytic 
site of cathepsin. b) Docking of SP isomers of 93 (yellow sticks) and 15.d (blue sticks) into 
cathepsin. (red: oxygen, pink: pphosphorus) 
 
3.2.4.2. P-N bond cleavage 
The release of the 5’-monophosphate 97 was investigated performing metabolic 
experiment with Huh-7 cell lysate. 93 was incubated with Huh-7 cell lysate at 37 °C, 
and 31P-NMR spectra were recorded overnight. However the phosphorus spectra were 
not conclusive due to a peak from the cell lysate, which was probably covering the peak 
of the eventual 5’-monoposphate released. After centrifugation, mass spectra of the 
aliquot suggested the formation of desired 97 (pink circle, M+Na+ = 413). Nevertheless 
conversion of 93 is extremely slow and even after 48 hours, 93 remains the main 
species present in the medium (blue circle, M+H+ = 658, M+Na+ = 680, M+K+ = 696) 
(Figure 4.17).  
            
Figure 4.17. Mass spectra of Huh-7 cell lysate experiment. 
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This observation is supported by the docking of 96 in human Hint-1 enzyme (Figure 
4.18), known to be responsible for P-N bond cleavage. The docking predicts that the 
phosphorus center of 96 lies far from the catalytic residues and is not in the optimal 
position for efficient P-N bond hydrolysis, in comparison with the natural substrate 
adenosine monophosphate (AMP). It is likely that an inefficient P-N bond cleavage 
results in a poor inhibitory activity in replicon-based assays.     
 
     
Figure 4.18. Docking of phosphoramidate monoester 96 (grey stick) and AMP (red line) in the 
catalytic pocket of human Hint-1 enzyme. 
 
3.2.5. Conclusion: 2’-C-methyl-6-O-methyl-7-deaza guanosine analogues 
7-deaza analogues of 2’-C-methyl-6-O-methyl guanosine (nucleoside and 
phosphoramidates) were synthesised and tested against HCV RNA replication. Despite 
the efficiency of the ProTide technology, the loss of the 7-aza of the nucleobase leads to 
dramatic loss of potency and antiviral selectivity. Docking predictions suggest that the 
combination of 6-O-methyl substituent and 7-deaza moiety is acceptable for 
intracellular release of 7-deaza-2’-C-methyl guanosine 5’-monophosphorylated species.  
However, enzymatic experiments support the docking studies, and suggest that the 
release of the 2’-C-methyl-6-O-methyl-7-deaza guanosine 5’-monophosphate is likely 
to be the limiting step. Hence, the poor anti-HCV activity exhibited in-vitro. 
To address this problem and investigate the effect of the removal of the 7-nitrogen on 
anti-HCV activity, 2’-C-methyl-7-deaza guanosine analogues were synthesised and 
evaluated in HCV replicon assays. 
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 3.3. 7-deaza-2’-C-methyl guanosine analogues 
3.3.1. Preparation of nucleoside and ProTides  
7-deaza-2’-C-methyl guanosine nucleoside 95 was prepared following the Merck’s 
route (Scheme 4.10) using 7-deaza guanine 79 (Scheme 4.6) for the glycosylation step. 
However the poor solubility of 79 in dichloromethane resulted in only 9% yield of the 
3’,5’-DCB protected guanosine, followed by deprotection to yield 95. To overcome this 
solubility issue and as an attempt of increasing the yield, 88 was treated with sodium 
iodide (NaI) and trimethylsilyl chloride88 (TMSCl) in acetonitrile (Scheme 4.13) to 
yield 21% of 95. 1H-NMR and 13C-NMR spectra of 95 obtained from both routes were 
similar, and comparison with literature (J7,8 = 3.60 Hz vs 3.70 Hz)89 confirmed the β-
configuration of the nucleobase. 
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OHOH
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O
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9588  
(i. anh. ACN, NaI (1.5 eq), TMSCl (1.5 eq), rt, 1hr, 21%) 
Scheme 4.13. Route to 7-deaza-2’-C-methyl guanosine 95. 
 
The α-naphthyl L-Alanine cyclohexyl ester phosphoramidate of 95  (98) was prepared 
in 34% yield using the conditions described above (Scheme 4.13) starting from its 7-
deaza-6-O-methyl ProTide derivative 92. Both 95 and 98 were sent for biological 
evaluation in HCV cell-based replicon assays. 
 
3.3.2. Biological evaluation 
Bristol-Myers Squibb evaluated the cellular toxicity (CC50) and HCV RNA inhibition 
potency (EC50) of 95 and 98 in cell-based replicon assays. The results reported in Table 
4.4 suggest that the removal of the 6-O-methyl does not enhance in-vitro anti-HCV 
activity, however its presence is responsible for the cytotoxicity reported for 7-deaza-6-
O-methyl-2’-C-methyl derivatives. Hence the 6-O-methyl group is not responsible for 
the dramatic loss of antiviral activity. 
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Table 4.4. Evaluation of anti-HCV activity (EC50) and cytotoxicity (CC50) of 95 and 98 in 
replicon-based assays compared to their 6-O-methyl (88 and 92) and 7-aza (11 and 15.k) 
analogues. 
 
From these results, 98 appears to be a poor inhibitor of HCV replication as well as its 
parent nucleoside 95, hence in this case the ProTide technology seems to be inefficient. 
This result suggests that the first phosphorylation step is not the only limiting step of 
activation to the 5’-monophosphate, and that the removal of the hydrogen bond donor at 
C-7 of the nucleobase might be critical for anti-HCV activity. Not enough material of 
98 was recovered to perform enzymatic experiments, however its metabolism was 
predicted by molecular docking in cathepsin A and Hint-1 enzymes to understand 
whether it was converted to its 5’-monophosphorylated species. 
 
3.3.3. Mechanistic studies 
In first instance, 98 was docked in cathepsin A enzyme (Figure 4.19 a), an esterase type 
enzyme responsible for ester cleavage, followed by docking in Hint-1 enzyme (Figure 
4.19 b) known to be responsible for the last step of ProTide activation to release the 5’-
monophosphate. 
 
 
!" #"
 
Figure 4.19. a) Docking of diastereoisomers of  98 in cathepsin A enzyme (yellow stick: RP 
isomer, grey stick: SP isomer, blue line: 15.d).  
b) Docking of phosphoramidate monoester of 98 in human Hint-1 enzyme (grey stick: 
phosphoramidate monoester specie, red line: AMP). 
(red: oxygen, pink: phosphorus, blue: nitrogen) 
 
Molecular docking predicts that ester carbonyl groups of either isomers of 98 lie far and 
point opposite direction of the catalytic residues in comparison with 15.d. This suggests 
that the conversion to the phosphoramidate monoester derivative will be slow if 
Claire Bourdin  Chapter Four: Nucleobase modifications 
!! 89 
happening at all. The latter fits well into human Hint-1 enzyme catalytic pocket, with its 
phosphorus center lying close to the optimal position for P-N bond cleavage (by 
comparison to the phosphorus center of AMP). 
Eventually, the 7-deaza-2’-C-methyl guanosine 5’-monophosphate species might be 
poorly released due to slow ester cleavage. Hence, resulting in poor intracellular 
concentrations of 7-deaza-2’-C-methyl guanosine 5’-triphosphate. 
 
3.3.4. Conclusion: 7-deaza-2’-C-methyl guanosine analogues 
The 6-O-methyl substituent is not a bad prodrug moiety for 7-deaza derivatives since 
the corresponding 5’-monophosphate species might be metabolised to their guanosine 
derivatives, as predicted by the modeling docking with ADAL-1. However its removal 
does not boost the inhibitory potency at either both nucleoside and ProTide levels. As a 
result, the remarkable loss of potency of 7-deaza species is due to the replacement of the 
nitrogen at C-7 of the nucleobase by a hydrogen donor methine group. The presence of 
a hydrogen bond acceptor at C-7 is apparently required for conversion to the active 
guanosine species (88, 95 and 11). Even the ProTide motif does not salvage the loss of 
selectivity and potency (92 and 98 vs 15.k), and it shows the need to tune the ProTide 
motif on each occasion. 
Molecular docking, biological results and enzymatic experiments of 7-deaza analogues 
predict and confirm that the 7-nitrogen is essential for substrate recognition by 
adenosine deaminase, as previously reported.90 Absence of the hydrogen bond acceptor 
at C-7 contributes significantly to stability towards metabolic enzymes9 involved at 
nucleoside and phosphate levels. 
 
2’-C-methyl-6-O-methyl and 2’-C-methyl guanosine phosphoramidates are very potent6 
against HCV replication, but their 7-deaza analogues display weak potency against 
HCV RNA replication due to very slow enzyme-mediated metabolism to their active 
phosphorylated species. This led us to investigate the release of the potent 7-deaza-2’-
C-methyl guanosine 5’-triphosphate after metabolic conversion of 7-deaza-2’-C-methyl 
inosine analogues. 
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 3.4. 7-deaza-2’-C-methyl inosine analogues 
3.4.1. Introduction 
While 7-deaza inosine 99 (Figure 4.20) is known to be an effective growth inhibitor and 
exhibits better tissue selectivity than tubercidin 74,91 2’-C-methyl inosine 100 is a 
moderate inhibitors of HCV RNA replication (EC50 = 8 µM, CC50 = 300 µM)74 and its 
corresponding 5’-triphospate inhibits more efficiently HCV NS5B polymerase (IC50 = 
4.0 µM).92  
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Figure 4.20. Structures of 7-deaza inosine 99 and 2’-C-methyl inosine 100. 
 
Action of inosine monophosphate dehydrogenase (IMPDH) is responsible for the 
oxidation of 2’-C-methyl inosine 5’-monophosphate (101) to its xanthine (102) 
derivative. As substrate of guanylate monophosphate synthetase (GMP synthetase), the 
later releases 2’-C-methyl guanosine 5’-monophosphate (103)93  (Scheme 4.14).  
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Scheme 4.14. Role of IMPDH in de novo biosynthesis of guanine nucleotides. 
 
Aiming at investigating the release of 7-deaza-2’-C-methyl guanosine phosphorylated 
species after IMPDH-mediated metabolism of their inosine analogues, 7-deaza-2’-C-
methyl inosine derivatives were synthesised and evaluated against HCV replication.  
 
3.4.2. Preparation of nucleoside and ProTides 
7-deaza-2’-C-methyl inosine 107 was prepared according to the Merck’s route using the 
nucleobase-anion glycosylation conditions as described in Scheme 4.15. Starting from 
commercially available 7-deaza-6-chloro pyrimidine 104, 107 was recovered in 47% 
over 3 steps, and 1H-NMR was in correlation with data reported by Merck.81 
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(i. anh. DCM, 0 °C, HBr (33% in acetic acid, 6.7 eq), RT, 2hrs, anh. ACN, KOH (85% 
powdered, 3.0 eq), TDA-1 (0.2 eq), RT, 1hr, 60%; ii. anh. DCM, 0 °C,  BCl3 (10 eq),  -78 °C, 
2hrs, -20 °C, 2hrs 30min, 37%; iii. anh. MeOH, aq. NaOH (1M), reflux, 1hr, 43%.) 
Scheme 4.15. Synthetic route toward 7-deaza-2’-C-methyl inosine 107. 
 
Also in this case, the β-configuration of the glycosidic bond reported by Merck85, 92 was 
determined by comparison of 1H-NMRs (J7,8 = 3.55 Hz vs 3.60 Hz). 
ProTides of 107 were prepared following the standard Uchiyama procedure previously 
described. Coupling with the α-naphthyl L-Alanine cyclohexyl (14.c) or neopentyl 
(14.d) or benzyl ester (14.e) phosphorochloridate yielded respectively 108, 109 and 110 
(1-2%), all as mixtures of two diastereoisomers (Scheme 4.16). 
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(i. anh. THF, tBuMgCl (2.0 eq), rt, overnight.) 
Scheme 4.16. Synthesis of 7-deaza-2’-C-methyl inosine phosphoramidates. 
 
107, and its ProTides 108, 109 and 110, were sent for biological evaluation in HCV 
replicon-based assays. 
 
3.4.3. Biological evaluation  
7-deaza-2’-C-methyl inosine derivatives were tested to evaluate their eventual 
inhibitory activity in HCV replicon assays. This work was carried out by Bristol-Myers 
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Squibb and results of cell-based assays are reported in Table 4.5. 
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Table 4.5. Inhibitor activity (EC50) and cytotoxicity (CC50) of 7-deaza-2’-C-methyl inosine 
derivatives against HCV replication. 
 
These results indicate that neither the nucleoside nor its prodrugs are inhibitors of HCV 
replication and they do not exhibit cellular toxicity. As seen with 7-deaza guanosine 
analogues, the replacement of the 7-nitrogen by a methine group results in loss of 
potency in replicon-based assays. The ProTide technology is inefficient for 7-deaza-
inosine derivatives, hence either the 5’-monophosphate of 7-deaza-2’-C-methyl inosine 
is not delivered due to poor metabolism or it is likely that its triphosphate form is not an 
inhibitor of HCV replication in contrast with its 7-aza derivative (IC50 = 4.0 µM).88 
These results might also suggest that 7-deaza-2’-C-methyl inosine 5’-monophosphate is 
not metabolised by IMPDH and GMP synthetase to its corresponding 7-deaza 
guanosine analogue.  
Because of poor yielding reactions, enzymatic experiments could not be performed. 
Nevertheless, the metabolism of activation of 7-deaza-2’-C-methyl inosine ProTide 108 
was investigated using molecular docking. 
 
3.4.4. Molecular modelling 
3.4.4.1. Ester hydrolysis and P-N bond cleavage 
Docking in the esterase-type enzyme cathepsin A predicts that both diastereoisomers of 
108 might fit similarly within the catalytic pocket (Figure 4.21 a), with the ester 
carbonyl group lying far from the catalytic residues. This observation predicts slow 
release of the phosphoramidate monoester species. On the other hand, docking of the 
latter in phosphoramidase-type enzyme Hint-1 resulted in poor fit within the catalytic 
site (Figure 4.21 b), with the P-N bond lying far from the optimal position (shown by 
phosphorus center of the natural substrate AMP).  
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Figure 4.21. a) Docking of Sp isomer of phosphoramidate 108 (yellow stick) in the catalytic 
pocket of cathepsin A (blue line: SP isomer of 15.d) 
b) Docking of phosphoramidate monoester specie of 108 (yellow stick) in human Hint-1 
enzyme (red lime: AMP). 
(red: oxygen, pink: phosphorus, blue: nitrogen) 
 
Eventually, docking predictions suggest that metabolism of 7-deaza-2’-C-methyl 
inosine phosphoramidates to their 5’-monophosphate species may not be efficient, if at 
all happening. These predictions correlate with the biological results, since no prodrugs 
of 7-deaza-2’-C-methyl inosine exhibit anti-HCV potency in cell-based assays. 
However, evaluation of the inhibitory potency of the 7-deaza-2’-C-methyl inosine 5’-
triphosphate (IC50) against HCV NS5B-mediated replication would have distinguished 
clearly between poor metabolism and inefficacy of the 5’-triphosphate bioactive form. 
 
3.4.4. 2. Molecular docking in IMPDH 
IMPDH is a NAD (nicotinamide adenine dinucleotide)-dependant enzyme that controls 
the purine nucleotides biosynthetic pathway.94 The catalysis of the oxidation of inosine 
5’-monophosphate (IMP) to xanthine 5’-monophosphate (XMP)93 is reported as the rate 
limiting step in the de novo synthesis of guanine nucleotides.95 The mechanism of 
conversion (Scheme 4.17) is triggered by nucleophilic attack of Cys331 on IMP.  A 
hydrogen atom is then trapped by NAD+ to release NADH and intermediate I, which is 
then hydrolysed to liberate XMP via a tetrahedral intermediate II.93 
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Scheme 4.17. Mechanism of biochemical conversion of IMP to XPM by IMPDH. 
(RMP: ribose 5’-monophosphate, B: base, could be water or amino acid residue) 
 
The rationale behind designing 7-deaza-2’-C-methyl inosine ProTides being the 
conversion of their 5’-mophosphate by IMPDH and GMP synthetase to afford the 7-
deaza guanine phosphorylated species. Molecular modelling was carried out using 
human type II IMPDH crystal structure (PNB 1B30)95 to investigate the first metabolic 
step towards the release of 5’-monophosphate 7-deaza-2’-C-methyl xanthine. The result 
of the docking is represented in Figure 4.22. 
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Figure 4.22. a) Docking of 7-deaza-2’-C-methyl inosine 5’-monophosphate (blue stick) in 
human type II IMPDH catalytic pocket. b) Ligand interactions with catalytic residues. 
(red circle: acidic, blue circle: basic, pink: polar, green: greasy, dotted blue arrow: backbone 
acceptor/donor, dotted green arrow: side chain acceptor/donor) 
 
7-deaza-2’-C-methyl inosine 5’-monophosphate fits in a proper direction within the 
IMPDH catalytic site. The ribose and the phosphate moieties lie in the right pockets, 
however, both hydrogen at C-7 and the one at C-2 of the nucleobase provoke a steric 
clash with the pocket as predicted by the ligand interactions diagram (Figure 4.22 b). 
Nevertheless, the key catalytic atom Cys331 lies close to the C-2 position, as expected 
for efficient oxidation to the xanthine derivative. In addition, the ligand interactions 
diagram predicts that the hydrophobic 2’-C-methyl group lies in a rather hydrophilic 
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pocket, next to an Arginine residue (Arg322), hence this might also affect the affinity of 
7-deaza-2’-C-methyl inosine 5’-monophosphate with IMPDH.  
These observations lead to predict that catalytic oxidation of 7-deaza-2’-C-methyl 
inosine 5’-monophosphate might take place, however may not probably be efficient. 
 
3.4.5. Conclusion: 7-deaza-2’-C-methyl inosine analogues 
7-deaza-2’-C-methyl inosine 108 and three phosphoramidates were synthesised and 
evaluated against HCV RNA replication in cell-based assays. None of these molecules 
exhibited inhibitory activity, and this might result from either a poor bioactivation, as 
predicted by molecular docking, or from inactivity of the triphosphate form. Thus, it is 
unlikely that 7-deaza-2’-C-methyl inosine phosphorylated species are delivered 
intracellularly. As previously seen with guanosine derivatives, the subtle alterations 
from 7-aza to 7-deaza seems to be responsible for poor intracellular metabolism of 7-
deaza-2’-C-methyl inosine analogues. 
An enzyme inhibitory assay with the 5’-triphosphate of 7-deaza-2’-C-methyl inosine 
would provide the information of eventual inhibitory activity of 5’-triphosphate of 7-
deaza-2’-C-methyl inosine against HCV NS5B-mediated RNA replication. 
Despite, the molecular docking with IMPDH predicting slow catalytic oxidation, due to 
steric and spatial arrangement that would affect the affinity of 7-deaza-2’-C-methyl 
inosine monophosphate with the enzyme, replicon-based assays suggest that 7-deaza-2’-
C-methyl inosine analogues do not undergo metabolism by IMPDH to the desired 7-
deaza-2’-C-methyl guanosine phosphorylated species.  
 
 3.5. General conclusion  
The replacement of the nitrogen at C-7 of the heterobase by a methine group affects 
greatly the inhibitory activity of parent 2’-C-methyl-6-O-methyl guanosine 11 against 
HCV RNA replication, leading to significant loss of activity and reducing selectivity.  
The ProTide technology applied to the 7-deaza-2’-C-methyl guanosine derivatives does 
not reinstate potency in cell-based assays. Enzymatic experiments and molecular 
modelling prediction performed with both families, conclude on inefficient metabolism 
of the phosphoramidate prodrugs to their corresponding phosphorylated species, in 
marked contrast with 7-aza analogues. Similarly to 7-deaza-2’-C-methyl guanosine 
analogues, more disappointing results were obtained for 7-deaza-2’-C-methyl inosine 
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analogues, which are unlikely to be processed to their 5’-phosphorylated species, hence 
losing the possibility of delivering potent 7-deaza-2’-C-methyl guanosine 5’-
triphosphate after metabolism by IMPDH and further phosphorylation. Nevertheless, 
even if 7-deaza-2’-C-methyl inosine 5’-monophosphate species were delivered 
efficiently, modelling predicts rather poor affinity with IMPDH catalytic site, hence 
expecting rather slow conversion to their xanthine analogues. 
This surprising outcome suggests that the removal of the 7-nitrogen contributes to 
enzymatic stability.8 The presence of a hydrogen-bond acceptor at C-7 of the 
nucleobase seems essential for the substrate recognition for metabolic enzymes 
responsible for the delivery of the 5’-monophosphate species. 
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Chapter Five: Ribonucleoside modifications 
 
  
1. Background and Objectives 
Among the strategies to design potent antiviral or antitumour nucleoside analogues, 
modifications of the carbohydrate moiety have been extensively investigated to alter the 
physico-chemical and biological properties.  
Following the discovery of oxetanocin A (111, Figure 5.1) as an effective anti-HIV1 
and anti-HSV agent, hydroxymethyl alterations were introduced in nucleoside 
analogues.1 Later, other modifications consisted in adding other heteroatoms or 
substituting varied functional groups at the different positions of the nucleoside sugar 
ring.1 Among many, Roche reported 4’-azidocytdine (also known as R1479, Figure 5.1) 
as a potent and selective inhibitor for HCV replication in cell-based assays.2  
 
N
NN
N
NH2
O
HO
HO
111
N
O
OHOH
HO
N
N3
NH2
O
R1479   
Figure 5.1. Structures of oxetanocin A (111) and 4’-azidocytidine (R1479). 
 
Moreover, sugar-modified nucleosides are also commonly used in oligonucleotides for 
antisense therapy.3, 4 In particular, 2’-O-alkyl oligonucleotides5, 6 and 5’-C-branched 
oligodeoxynucleotides7, 8 enhance stability towards nuclease enzymes.9, 10 Despite the 
reported synthetic procedures to access the monomers, little literature is reported on 2’-
O-alkyl and 5’-C-branched modified nucleosides as inhibitors of HCV RNA replication. 
Aiming at developing potential selective and non-toxic anti-HCV agents, we 
investigated the synthetic access to 2’-O-alkyl and 5’-C-methyl substituted analogues of 
2’-C-methyl guanosine 10 and its 6-O-methyl derivative 11. 
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2. Modifications at C-2’ of 6-O-methyl guanosine derivatives 
2.1.  Introduction 
2.1.1. 2’-O-alkylated nucleosides and hepatitis C virus 
Following the isolation of natural 2’-O-methyladenosine (112, Figure 5.2),11 numerous 
compounds of this class have been prepared and used in the field of anti-sense 
oligonucleotides12 and their application to treatment of inflammatory, infectious and 
cardiovascular diseases.13 
 
Despite the modelling prediction that HCV NS5B should accommodate 2’-O-alkylated 
nucleoside triphosphates, due to space available in the proximity of the C-2’ position, 
only few examples have been investigated as inhibitors of HCV replication.14 2’-O-
methyl modified cytidine 113,15 guanosine 114 and adenosine 11216 (Figure 5.2) have 
been prepared via glycosylation of the carbohydrate precursor by Merck laboratories, 
and exhibited low potency (EC50) in HCV cell-based assays, while their triphosphates 
acted as relatively potent chain terminators (IC50) with the exception of the adenosine 
derivative.16 
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HO
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HO
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HO
114
NH2
EC50 > 50 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CC50 > 50 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IC50 = 47 uM
EC50 = 21 uM
CC50 > 100 uM
IC50 = 3.8 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EC50 > 50 uM
CC50 > 50 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= 1.6 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N
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O
 
Figure 5.2. Inhibitory activity against HCV RNA replication of 2’-O-methyl nucleosides in 
replicon (EC50) and their corresponding triphosphates (IC50). 
 
The lack of antiviral potency of the nucleosides 112-114 is likely to be due to inefficient 
cellular uptake and poor intracellular metabolism. On the contrary, incorporation of 2’-
O-modified phosphorylated species may provoke interference with either the 
polymerase or the incoming nucleoside triphosphate, hence resulting in inhibition of 
NS5B-mediated RNA replication.13 
In order to investigate the allowance of steric bulkiness around C-2’ and aiming at 
boosting the inhibitory activity of nucleosides in replicon-based assays, the 2’-O-alkyl 
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modification strategy was applied to 6-O-methyl guanosine analogues. The alkylation 
was performed at a nucleoside level using methyl-, ethyl-, propyl- or isopropyl- iodides. 
 
2.1.2. Synthetic approach to 2’-O-alkylated nucleosides  
Synthetic efforts have been largely stimulated to prepare 2’-O-alkyl nucleosides in a 
selective and cost-effective way for oligonucleotide synthesis. Table 5.1 summarises the 
different approaches towards 2’-O-methylated and other 2’-O-alkylated nucleosides, 
their advantages and drawbacks.14, 17 
 
Despite numerous approaches described in the literature,14, 17 most direct alkylation 
procedures are not applicable to purine nucleosides, and particularly to guanosine 
derivatives. Selective alkylation of the 2’-position usually requires protecting groups 
both at the ribose and nucleobase moieties to avoid side products. 
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 method drawbacks advantages 
From 
carbohydrate 
precursor 
Glycosylation 
No stereoselectivity. 
Glycosylation: limiting step. 
Poor yield for purines. 
Large scale 
synthesis. 
Direct 
methylation of 
ribonucleosides 
Diazomethane 
/ Dimethoxyethane 
Low yield. First practical 
synthesis.  
Methyl(ethyl) sulfate 
/DMF 
Low yield. 
For cytosine and adenosine 
only. 
Different alkylations 
possible. 
NaH/MeI 
Undesired base methylation. 
Requires N-2 and O-6 protection 
for uridine and guanosine. 
Requires separation of 2‘- and 
3’-isomers. 
Applicable for 
adenosine and 
phosphoramidite. 
Ag2O/MeI 
Seldom use for purines. Exclusive 2’-O-
alkylation on 
pyrimidine. 
Metal-directed 
mehylation of 
cis-diol 
SnCl2.2H2O 
Poor yield for guanosine. 
Not suitable for any other alkyl 
groups. 
For all four 2’-O-Me 
nucleosides. 
Absence of base. 
Methylation of 
protected 
nucleosides 
3’,5’-TIPDSi + 
MeI/Ag2O 
Not suitable for guanosine. 
 
Direct 2’-O-
alkylation. 
3’,5’-TIPDSi- 
6-O-TIPSDSi + 
MeI/BEMP 
High cost of BEMP. 
Moderate yield. 
 
5’-O-Trityl + KOH 
Moderate yield. No alkylation on 
nucleobase. 
BEMP 
High cost of BEMP. 
Multistep synthesis. 
High yielding. 
Formation of single 
products. 
Dialkyl sulfate + 
alkali metal 
hydroxide 
No nucleobase alkylation only at 
pH>13. 
No side alkylation. 
 
Other methods 
2,2’-anhydro 
nucleoside 
 Ease of synthesis. 
BEMP: 2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2 -diazaphosphorine  
Table 5.1. Methods for the synthesis of 2’-O-alkylated nucleosides. 
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2.2. 2’-O-alkyl modifications of 2’-C-methyl-6-O-methyl guanosine  
Aiming at developing a selective 2’-O-alkylation of 2’-C-methyl-6-O-methyl guanosine 
11, 3’- and 5’- hydroxyls were protected using silicon-based protecting groups. The 
literature reports use of such protecting groups for a variety of applications thanks to 
their ease of introduction.18, 19 The most commonly used are the 1,1,3,3,-tetraisopropyl-
1,3-dichlorodisilyloxane (TIPDSCl2, 115, Figure 5.3) also known as the Markiewicz 
reagent,20 the methylene-bis-(diisopropylsilyl) chloride (MDPSCl2, 116)16 and the di-
tert-butylsilanedyil (DTBS, 117).20 Similarly hindered, they enable direct alkylation of 
the 2’-hydroxyl. Nevertheless, 115 is less stable under basic conditions required for the 
alkylation step than 116, due to the inductive effect of the oxygen atom connecting the 
two silicon atoms.21  
 
O
Si
Si
Cl
Cl
Si
Si
Cl
Cl
Si
Cl
Cl
115 116 117  
Figure 5.3. Structures of silicon-based protecting groups. 
 
 
2.2.1. Use of Markiewicz protecting group 
The Markiewicz’s reagent 115 was first used as protecting group, previous to the 2’-O-
alkylation, since its isostere 116 is not commercially available. The three-step synthesis, 
consisted of protection-, alkylation- and deprotection- steps, is described in Scheme 5.1. 
 
N
NN
N
O
O
OHOH
HO
NH2
N
NN
N
O
O
OHO
O
NH2Si
Si
O
N
NN
N
O
O
OO
O
NH2Si
Si
O
R
N
NN
N
O
O
OOH
HO
NH2
R
i. ii. iii.
11 118
R: CH3 119.a                
     CH2CH3 119.b         
     CH2CH2CH3 119.c   
     CH(CH3)2 119.d
R: CH3 120                 
    CH2CH3 121          
    CH2CH2CH3 122   
    CH(CH3)2 123  
(i. anh. pyridine, TPDSCl2 (1.2 eq), 0 °C, 30 min, rt, overnight, 45%; ii. anh. DMF, molecular 
sieves 3Å, RI (1.2 eq), NaH (60% dispersion in mineral oil, 1.2 eq), 0 °C, 1hr 30 min; iii. anh. 
THF, TBAF (2.2 eq), 2hr 30 min, rt.) 
Scheme 5.1. Synthetic route to 2’-O-alkyl 2’-C-methyl-6-O-methyl guanosine derivatives.  
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Protection of 11 was accomplished in moderate yield (45%), and 118 was recovered 
after purification on silica gel chromatography. Alkylation of the unprotected 2’-
hydroxyl group was performed accordingly to the literature,22 via Williamson synthesis, 
using the desired alkyl iodide and sodium hydride as a strong base.21 We were confident 
that thanks to the inductive effect of the 6-O-methyl of 118, the N-1 nitrogen would be 
not undergo methylation under such basic conditions.  
Similarly to guanosine derivatives,21 only 2’-O-alkylation occurred without obtaining 
the N-2-alkylated side products. 2’-O-methyl (119.a), 2’-O-ethyl (119.b) and 2’-O-
propyl (119.c) intermediates were obtained in poor to moderate yields after purification 
(5% to 57%, Table 5.2), whereas the 2’-O-isopropyl intermediate (119.d) was not 
formed and only the starting material 118 was recovered. This observation suggests that 
the 2’-position is probably already too hindered and thus, might not favour the 
substitution of a branched alkyl group on the α-phase. The poor yield observed for 
119.a results from the migration of the Markiewicz protecting group from 3’, 5’- to 2’, 
3’- positions or its partial cleavage.23  
Deprotection of intermediates 119.a-c was performed using tetrabutyl ammonium 
fluoride (TBAF) as desilylating agent, which releases the nucleophilic fluorine ion in 
the medium. Desired molecules 120, 121 and 122 were recovered, but only the last two 
were pure enough to be sent for biological evaluation in HCV replicon cells. !
Step / R CH3 CH2CH3 CH2CH2CH3 CH(CH3)2 
ii. 5% 44% 57% 0% 
iii. 20% 55% 82% - 
Table 5.2. Yields of alkylation (ii.) and deprotection (iii.) steps.  
 
The results of this first approach were quite disappointing; either low yields, due to the 
instability of the Markiewicz protecting group, or no reaction was achieved. Thus, since 
higher quantities of 2’-O-methyl, 2’-O-propyl and 2’-O-isopropyl nucleosides were 
needed, in order to prepare a ProTide for each 2’-O-modified nucleoside, another 
approach using tert-butyl dimethyl silyl group (TBDMS) at 3’- and 5’- position was 
considered. 
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2.2.2. Use of tert-butyl dimethyl silyl protecting group 
The stability in basic conditions, the ease of introduction and the high yields reported 
for the protection of ribose hydroxyls24 with the tert-butyl dimethyl silyl (TBDMS) 
group, led us to investigate the latter for selective 2’-O-alkylation of 2’-C-methyl-6-O-
methyl guanosine 11. The retrosynthetic pathway is described in Scheme 5.2. 
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CH3 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CH2CH2CH3 122  
     CH(CH3)2 123
R: CH3 125.a                 
     CH2CH2CH3 125.b  
     CH(CH3)2 125.c
124.a 11
 
Scheme 5.2. Retrosynthetic pathway to  
2’-O-alkylated 2’-C-methyl-6-O-methyl guanosine derivatives. 
 
Contrary to the Markiewicz reagent, tert-butyl dimethyl silyl is not a regiospecific 
group, however the methyl at C-2’ hinders that position, thus allowing the 3’- and 5’-
hydroxyls to be selectively protected. In this case, the nucleophilic exocyclic amine of 
the heterobase reacted equally with the 4.3 equivalents of tert-butyl dimethyl silyl 
introduced, affording a mixture of 3’,5’-TBDMS protected (124.a) and 3’,5’-TBDMS-
N-2-TBDMS protected (124.b, Figure 5.4) nucleosides, in respectively 45% and 55% 
yield.  
The treatment of 124.a with sodium hydride (NaH) and 3.0 equivalents of isopropyl- or 
propyl-iodide was selective at the 2’-position, affording 125.b and 125.c. Deprotection 
step afforded 122 and 123 in respectively 49% and 20% over two steps. These yields 
support the outcome previously mentioned concerning the difficulty of introducing 
branched group at the 2’-position already hindered by the 2’-C-methyl group and the 3’-
protected hydroxyl. 
As reported in the literature,21 alkylation conditions with methyl iodide (MeI) resulted 
in double alkylation at the N-2 and C-2’ (125.d), however, in extremely low yield 
(Table 5.3). Decreasing the number of equivalents of MeI from 4.3 to 1.2, introduced at 
low temperature25 was also unsuccessful. Other methylation reactions performed at low 
temperature with electrophilic gaseous methyl chloride (MeCl) and sodium 
hexamethyldisilazane (NaHMDS)21 resulted in no methylation and in both full and 
partial deprotection at 3’- and 5’- positions of 2’-C-methyl-6-O-methyl guanosine.  
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 Attempt 1 Attempt 2 Attempt 3 Attempt 4 
SM 124.a 124.a 124.a 124.b 
conditions MeI (3.0 eq), NaH, 1 hr, 0 °C 
1.2 eq MeI, 4 
hrs, - 50 °C to 
- 15 °C 
MeCl (g), NaHMDS 
(3.0 eq), 4 hrs, - 20 
°C to RT 
MeI (3.0 eq), 
NaH, 1 hr,  
0 °C 
results 
and 
comments 
125.d 
3-4% 124.a 
Mixture of partially 
and fully deprotected 
SM  
125.e 
5% 
Table 5.3. Conditions attempted for selective 2’-O-methylation. 
 
A last experiment was attempted starting from 124.b and using standard alkylation 
conditions described previously. In this case as well, fully alkylated product 125.e 
(Figure 5.5) was recovered. Deprotection of 125.e provided C-2’ and N-2 methylated 
2’-C-methyl-6-O-methyl guanosine 126 (Figure 5.4). 
 
N
NN
N
O
O
OO
O
N
H
Si
Si
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Si
Si
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Si
Si
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OOH
HO
N
H
126  
Figure 5.5. Structures of 124.b, 125.d, 125.e and 126. 
 
 
From these results, it proved to be necessary to protect the acidic exocyclic amine of the 
heterobase to avoid its inherent reactivity towards methylation.21, 26 As N,N-dialkyl 
formamidines are extensively described in the literature and widely used as a protecting 
group for the exocyclic primary amine of nucleosides,27, 28 2’-C-methyl-6-O-methyl 
guanosine 11 was protected with dimethyl formamide dimethyl acetal29 at room 
temperature overnight to yield 127 (Scheme 5.3).  
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N
NN
N
O
O
OHOH
HO
NH2
11
N
NN
N
O
O
OHOH
HO
N
127
Ni. ii.
N
NN
N
O
O
OHO
O
N
128
N
Si
Si
X
 
(i. anh. DMF, dimethylformamide dimethyl acetate (5.0 eq), rt, overnight, 14%; ii. anh. DMF, 
imidazole (8.1 eq), TBDMSCl (4.3 eq), rt, overnight.) 
Scheme 5.3. Pathway to 3’, 5’-TBDMS and N-2-formamidine protected  
2’-C-methyl-6-O-methyl guanosine. 
 
Then 3’- and 5’- hydroxyls were protected with TBDMS protecting group using the 
previous conditions reported. However, residues recovered from the flash 
chromatography did not correspond to 128, but only to 124.a (Scheme 5.2) along with 
129 (Figure 5.6) were isolated. 
 
N
NN
N
O
O
OHO
O
N
H
O
Si
Si
129  
Figure 5.6. Structure of partially hydrolysed N-2-formamidine intermediate. 
  
 
The structure of 129 was confirmed by mass (M+Na+: 590) and 1H-NMR. The latter 
showed indeed signals characteristic of the partially cleaved formamidine (doublets at 
9.54 ppm (NHCHO) and 8.19 ppm (NHCHO), with a coupling constant J3 of 10.5 Hz). 
This intermediate was not useful for selective 2’-O-methylation, due to the acidic proton 
remaining on the N-2. A second attempt was performed by protecting the exocylic 
amine of 3’,5’-TBDMS protected 2’-C-methyl-6-O-methyl guanosine 124.a with 
dimethyl acetate dimethylformamide. Unfortunately, similar results were obtained.  
 
Hydrolysis of the formamidine protecting group has been reported in the literature, and 
its mechanism has been extensively studied.29, 30 Governed by the acidity of each 
nitrogen atom of the hemiorthoamide intermediate and by the electron-donating 
character of the methyl groups, the hydrolysis is fast and should evolve towards path a 
(Scheme 5.4) as for guanosine nucleosides.27 However in this case, the electron 
donating character and inductive effect of the 6-methoxy group of the heterobase 
influences the basicity of the formamidine nitrogens and as a result, proceeds through 
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path b (Scheme 5.4). Nevertheless the total hydrolysis of the exocyclic amine still 
requires basic conditions.27  
 
R N N
R: nucleoside
R N N
R N
H
N
OH
path a
O
H H
H2O
R-NH2 H
O
N
H2O
R N
H
N H
O
R N
H
H
O
H2O
NH
RNH2
path b
NH
 
Scheme 5.4. Hydrolysis of N-2 formamidine protecting group.27 
 
Drier conditions were then required to enable stability of the required N-2-formamidine 
protecting group. 
 
2.2.3. Use of di-tert-butylsilane and N-2 formamidine protecting group 
Recently, Mukobata et al. published the synthesis of N-2-formamidine-2’-O-methyl 
guanosine combining the use of di-tert-butylsilane (DTBS) for 3’,5’-hydroxyl 
protection and N-2 formamidine.27 This approach was applied to 2’-C-methyl-6-O-
methyl guanosine 11 as described in Scheme 5.5. 
 
N
NN
N
O
O
OHOH
HO
NH2
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N
NN
N
O
O
OHO
O
NH2
130
Si
N
NN
N
O
O
OHO
O
N
131
Si
N
NN
N
O
O
OO
O
N
132
Si
N
N
N
NN
N
O
O
OOH
HO
N
133
i. ii.
iii. iv.
N
N
NN
N
O
O
OOH
HO
NH2
120
v.
 
(i. anh DMF, di-tert-butylsilyl-ditriflate (1.1 eq), 0 °C, 1hr 30min, 26%; ii. anh. DMF, N,N-
dimethyl formamide dimethyl acetal (4.0 eq), rt, overnight, 94%; iii. anh. DMF, molecular 
sieves, NaH (60% dispersion in oil, 1.2 eq), MeI (6.0eq), 0 °C, 1hr, 75%; iv. anh. THF, anh. 
NEt3 (1.8 eq), NEt3.3HF (3.5 eq), rt, 1 hr, 35%; v. THF/H2O (1:1), KOH (powdered, 4.0 eq), rt, 3-
4 hrs, 98%.) 
Scheme 5.5. Towards the synthesis of 2’-O-methyl-2’-C-methyl-6-O-methyl guanosine 
120 using DTBS and formamidine as protecting groups. 
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The 5’- and 3’-hydroxyl groups of the ribose were protected using DTBS to afford 130 
after precipitation in water. Protection of the N-2 exocyclic amine was carried out with 
dimethylformamide dimethyl acetal as previously mentioned, and after basic aqueous 
work up, 131 was directly used crude for the next step. Methylation using standard 
alkylation conditions was performed in 75% yield (step iii, Scheme 5.4), followed by 
subsequent deprotection of the DTBS group of 132 with triethylamine trihydrofluoride 
(NEt3.3HF). The latter being quite hygroscopic, partial hydrolysis of the formamidine 
occurred along with deprotection of the hydroxyls groups (133.a, Figure 5.7) in 
moderate yield after purification. Once again, in this case, the partial hydrolysis of the 
formamidine group tends to proceed via path b (Scheme 5.4), in contrast with path a 
described in the literature for guanosine.27 Contrary to silicon-based protecting groups, 
the N-2-formamidine group has never been reported as unstable during flash 
chromatography purification. Subsequently, the presence of the 6-O-methyl group of 
the heterobase influences the hydrolysis pathway. 
 
N
NN
N
O
O
OOH
HO
N
H
O
133.a  
Figure 5.7. Structure of N-2 partially hydrolysed formamidine group of 133.a. 
 
Total hydrolysis of 133.a to recover the exocyclic amine, required strong basic 
conditions, such as potassium hydroxide (KOH),27 to recover almost quantitatively 
(98%) the desired 2’-O-methyl-2’-C-methyl-6-O-methyl guanosine 120.  
 
This new route was relatively easy and high yielding compared to previous methods, 
and only two purifications were necessary to recover 2’-O-alkylated-2’-C-methyl-6-O-
methyl guanosine derivatives. Despite the partial hydrolysis occurring during the 
deprotection of di-tert-butylsilane (DTBS) group and regeneration of the acidity at the 
N-2 nitrogen after the alkylation, the selectivity at the 2’-position is maintained. 
2’-O-alkylated-2’-C-methyl guanosine derivatives 120, 121, 122, 123 and fully 
methylated 126 were sent to Bristol-Myers Squibb for biological evaluation in HCV 
cell-based assays. 
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2.3. 2’-O-alkyl modifications of 6-O-methyl guanosine  
2’-O-alkylated derivatives of 6-O-methyl guanosine were synthesised with the purpose 
to evaluate the steric hindrance allowed around the 2’-position in the pocket of the HCV 
NS5B polymerase. The synthetic approach required first the formation of 6-O-methyl 
guanosine 137 in a simple three-step synthesis (Scheme 5.6), followed by the protection 
of both 3’,5’-hydroxyls (step iv.) and exocyclic amine (step v.), then alkylation (step 
vi.) and deprotection steps (vii. and viii.) as reported previously. 
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O O
R: CH3 140.a                 
    CH2CH3 140.b          
    CH2CH2CH3 140.c    
    CH(CH3)2 140.d
R: CH3 141.a                 
    CH2CH3 141.b          
    CH2CH2CH3 141.c    
    CH(CH3)2 141.d
R: CH3 142               
     CH2CH3 143        
     CH2CH2CH3 144 
     CH(CH3)2 145
i. ii.
iii. iv. v.
vi. vii. viii.
!
(i. anh. ACN, DMAP (0.1 eq), anh. NEt3 (4.0 eq), Ac2O (3.6 eq), rt, overnight, 87%; ii. anh. 
ACN, BTEA-Cl (2.0 eq), N,N-dimethylaniline (1.1 eq), POCl3 (5 eq), reflux, 2hrs, 72%; iii. anh. 
MeOH, NaOMe (6.6 eq), rt, overnight, 95%; iv. anh DMF, di-tert butylsilyl-ditriflate (1.1 eq), 0 
°C, 1hr 30min, 73%; v. anh. DMF, N,N-dimethyl formamide dimethyl acetal (4.0 eq), rt, 
overnight, 84%; vi. anh. DMF, molecular sieves, NaH (60% dispersion in oil, 1.2 eq), RI 
(6.0eq), 0 °C, 1-2 hrs; vii. anh.THF, NEt3 (1.8 eq), triethylamine trihydrofluoride (3.5 eq), rt, 1 
hr; viii. KOH (4.0 eq), H2O/THF, rt, 3hrs.) 
Scheme 5.6. Pathway to 2’-O-alkylated 6-O-methyl guanosine derivatives. 
 
 
Starting from guanosine 134, protection of the ribose hydroxyls (135) was required 
before chlorinating the 6-position of the nucleobase to afford 136. Displacement of the 
6-chlorine was performed simultaneously with deprotection of the hydroxyl groups 
using 6.6 equivalents of sodium methoxide (NaOMe). 6-O-Methyl guanosine 137 was 
obtained in 84% over three steps.31 Then the approach using DTBS and N-2 
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formamidine protecting groups, as described previously for alkylation of 2’-C-methyl-
6-O-methyl guanosine, was successfully applied for recovery of 2’-O-alkylated-6-O-
methyl guanosine derivatives 142-145.  
The protection steps were higher yielding than in the case of 2’-C-methyl-6-O-methyl 
guanosine, affording compounds 138 and 139 in respectively 73% and 84% yield. 
While the alkylation steps (step vi., Scheme 5.6) were successful and rather high 
yielding (140.a-d, Table 5.4), partially N-2-hydrolysed species (141.a-d) resulting from 
the deprotection of di-tert-butylsilane group were recovered in moderate yield (step vii., 
Table 5.4). Formation of similar species have previously been described with 2’-O-
alkyl-2’-C-alkyl-6-O-methyl guanosine derivatives. Hence, the need of extremely dry 
conditions to keep the N-2-formamidine intact or the necessity of more basic conditions 
to obtained totally hydrolysed species 142.a-d.  
 
Step / R CH3 CH2CH3 CH2CH2CH3 CH(CH3)2 
vi. 70% 67% 80% 61% 
vii. 10% 37% 37% 25% 
viii. 90% 88% 88% 60% 
Table 5.4. Yields of alkylation step (vi.) and deprotection steps (vii. and viii.). 
 
Characteristic 13C-NMR and 1H-NMR peaks of 140.a-d and 141.a-d in deuterated 
chloroform are reported in Table 5.5 (chemical shift in ppm). At first glance, it appears 
that the hindrance of the alkylating group at C-2’ provokes an upfield shift of the peaks 
corresponding to the methyl of the formamidine group of 140.a-d (NCHN(CH3)2) and 
the formaldehydic group of 141.a-d (NHCHO). It is quite surprising that such remote 
groups are affected by the steric bulk of the 2’-O-alkyl substituents. The coupling 
constant J3 corresponding to the partially hydrolysed formamidine group in molecules 
141.a-d varied between 9.5 and 10 Hz, which is in correlation with the data obtained for 
the 2’-C-methyl derivative 129. 
 
6-O-Methyl guanosine 137, intermediate 141.a and 2’-O-alkylated-6-O-methyl 
guanosine derivatives 142, 143, 144 and 145 were sent for biological testing in HCV 
replicon assays. 
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140 141 
NCHN(CH3)2 NCHN(CH3)2 NHCHO NHCHO 
a 
1H 
13C 
3.18, 3.16  
41.23, 40.94 
8.64 
158.39 
9.54 
- 
9.49 
165.58 
b 
1H 
13C 
3.16, 3.13 
41.09, 39.18 
8.64 
158.38 
9.50 
- 
9.51 
163.02 
c 
1H 
13C 
3.02, 3.00 
36.18, 34.74 
8.50 
158.19 
8.67 
- 
9.49 
163.17 
d 
1H 
13C 
2.89, 2.81 
35.55, 35.18 
8.57 
158.83 
8.39 
- 
9.51 
162.88 
Table 5.5. Chemical shifts δ (ppm) of characteristic peaks of N-2-group. 
 
 
2.4. 2’-O-alkyl modified ProTides 
In order to overcome eventual poor cell permeation or poor phosphorylation, α-naphthyl 
L-alanine neopentyl ester phosphoramidates of 2’-O-alkylated-6-O-methyl guanosine 
derivatives were synthesised following the Uchiyama procedure previously mentioned 
(Scheme 5.7). 
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*R1: CH3, R3: H, R2: CH3 120                   
                                   CH2CH3 121            
                                   CH2CH2CH3 122     
                                   CH(CH3)2 123       
*R1 = R2 = R3: CH3 126                          
*R1 = R3: H, R2: CH3 142                          
                            CH2CH3 143                   
                            CH2CH2CH3 144            
                            CH(CH3)2 145                
                            H 137                      
*R1: H, R2: CH3, R3: CHO 141.a
R3
*R1: CH3, R3: H, R2: CH3 146                   
                                  CH2CH3 147             
                                  CH2CH2CH3 148      
                                 CH(CH3)2 149        
*R1 = R2 = R3: CH3 150                          
*R1 = R3: H, R2: CH3 151                          
                           CH2CH3 152                    
                           CH2CH2CH3 153             
                           CH(CH3)2 154                 
                           H 155                       
*R1: H, R2: CH3, R3: CHO 156
R3
 
(anh. THF, tBuMgCl (1.2 eq), α-naphthyl L-Alanine neopentyl phosphochloridate (2.0 eq), rt, 
overnight.) 
Scheme 5.7. Synthetic route to 2’-O-alkylated α-naphthyl L-alanine neopentyl ester ProTides. 
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Compounds 146-156 were isolated as mixtures of diastereoisomers (1% to 6%) except 
in the case of the more lipophilic 150 (20%). The presence of a methyl at C-2’ 
substituent did not improve the solubility or the yield. 6-O-methyl guanosine 137 was 
extremely insoluble in tetrahydrofuran and the addition of pyridine in the reaction 
mixture enable better solubilisation. Nevertheless 155 was obtained in 1% yield. The 
low yields of purified products here may also reflect the need for repeated 
chromatographic purification, hence the necessity of finding better reaction conditions 
for such polar molecules. 
Surprisingly no 3’-ProTide was isolated from nucleosides 137, 142-145 under these 
reaction conditions. Usually, the use of tert-butyl magnesium chloride does not provide 
regioselective phosphorylation at the 5’-position,32 which can instead be achieved with 
N-methylimidazole (NMI).33  
With the exception of 154 whose purity was not satisfactory after several purifications, 
2’-O-alkylated ProTides of the 2’-C-methyl-6-O-methyl guanosine and 6-O-methyl 
guanosine families were sent for HCV replication activity. 
 
2.5. Biological testing in HCV replicon-based assays 
Bristol-Myers Squibb performed the biological evaluation of 2’-O-alkylated nucleosides 
and phosphoramidates. The inhibitory activity of HCV replication (EC50) and cellular 
toxicity (CC50) were evaluated in replicon-based assays, and the results are reported 
Table 5.6. 
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* calculated ClogP from ChemDrawUltra 11.0. 
** purity not satisfactory for biological testing. 
Table 5.6. Inhibitory activity and cytotoxicity of 2’-O-alkylated nucleosides and ProTides. 
 
The data suggest that no nucleoside (120-123, 126, 137, 141-145) is inhibitor of HCV 
RNA replication or toxic towards cells. 2’-O-alkylated nucleosides of both 2’-C-methyl-
6-O-methyl and 6-O-methyl guanosine families are likely to be too hydrophilic to 
permeate cell membranes since their calculated ClogP lies between -1.19 and 1.05. 
Despite increased liphophilicity (2.76 < ClogP < 5.01), the poor potency displayed by 
the ProTides of both families indicates that the bioactivation to their corresponding 5’-
monophosphate is probably not efficient, or the 5’-triphosphates of 2’-O-alkylated 
derivatives might not be efficient inhibitors of HCV RNA replication. In general, the 2’-
O-alkyl substitution was better tolerated without the 2’-C-methyl substituent, and 
however less lipophilic, 2’-O-alkyl-6-O-methyl guanosine ProTides appeared slightly 
more efficient in inhibiting HCV RNA replication than their 2’-O-alkyl-2’-C-methyl-6-
O-methyl guanosine analogues. 
While increasing the hindrance of the 2’-O-alkyl substituent tends to decrease the 
ProTide inhibitory activity against HCV RNA replication (146-149) within the 2’-C-
methyl-6-O-methyl guanosine family, it does not seem to affect the activity of 6-O-
methyl guanosine ProTides (151-155) since similar values of EC50 and CC50 are 
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reported. Hence, among the 2’-C-methyl family, there is an optimal hindrance tolerated 
at the α-face, since nucleosides (122 and 123) and ProTides (148 and 149) bearing 2’-
O-alkyl bigger than ethyl (120/121 and 146/147) are relatively less potent in HCV 
replicon assays. 
 
O-2, N-2 dimethylated ProTide 150 displayed high cellular toxicity with a selectivity 
index of 1. The ProTide bearing partially hydrolysed formamidine group (156) neither 
boosted the activity nor decreased the cytotoxicity seen among the 6-O-methyl 
guanosine family. As a result, the modifications on the exocyclic N-2 do not favour 
efficient metabolism, even if the cellular permeation may be enhanced. 
In order to understand better these results, the mechanism of activation of the 2’-O-
alkylated ProTides was investigated. 
  
2.6. Mechanistic studies 
The yield of 2’-O-alkyl ProTide synthesis being extremely low and the quantity 
recovered being just enough for biological evaluation, enzymatic experiments could not 
be performed. However, docking experiments were carried out with 2’-O-methyl 
Protides of both families (146 and 151), bearing the smallest group introduced at C-2’, 
to investigate the potential intracellular release of their corresponding monophosphate 
form (146.b and 151.b, Scheme 5.8) which would then undergo several phosphorylation 
steps to afford the corresponding 5’-triphosphate species.  
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Scheme 5.8. Putative activation of 2’-O-methylated ProTides (151 and 146) into their 5’-
monophosphate form (151.b and 146.b). 
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2.6.1. Molecular docking with cathepsin A enzyme 
As mentioned earlier, cathepsin A is an esterase-type enzyme, which may be 
responsible for the cleavage of the amino acid ester, during the first step of bioactivation 
of the phosphoramidates. 
Molecular modelling docking was performed with compounds 146 and 151 in order to 
investigate the formation of their corresponding phosphoramidate monoesters 146.a and 
151.a (Figure 5.8).  
Both SP and RP isomers of 146 and 151 were docked into cathepsin A, however the RP 
isomers did not fit into the catalytic site without provoking steric clash with the surface 
of the pocket (results not shown), suggesting that only the SP isomers may be processed 
and are eventually responsible for the observed poor activity in HCV replicon assays. 
 
Figure 5.8. SP isomers of 146 and 151 docked into cathepsin A. 
(blue line: SP isomer of 15.d, grey stick: SP isomer of 151, yellow stick: SP isomer of 146) 
 
SP isomers of 146 and 151 fit in the active site of cathepsin A enzyme (Figure 5.8), 
however in both case the carbonyl group of the ester moiety lies far from the catalytic 
residues Ser146, Gly52 and Gly53 in comparison with 15.d (α-napthyl L-Alanine 
neopentyl 2’-C-methyl-6-O-methyl guanosine ProTide). This observation predicts slow 
cleavage of the ester group, resulting in slow release of the phosphoramidate monoester, 
and only from the SP isomers. Comparing the 2 compounds, it appears that the carbonyl 
group of 151 SP isomer lies further outside the catalytic pocket than 146 SP isomer, 
hence in this case the 2’-C-methyl substituent seems to have a positive effect and may 
result in relatively faster delivery of the phosphoramidate monoester 146.a. 
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2.6.2. Molecular docking with human Hint-1 enzyme 
The second enzymatic step of ProTide activation was investigated and the P-N bond 
cleavage of 146.a and 151.a was predicted by molecular docking studies using human 
Hint-1 enzyme (Figure 5.9). 
 
 
Figure 5.9. Docking of phosphoramidate monoesters 146.a and 151.a  
in human Hint-1 enzyme (yellow: 146.a, grey: 151.a, red line: AMP). 
 
In this case, the docking suggests that the 2’-C-methyl substituent is once again 
responsible for the better fitting of the P-N bond inside the catalytic pocket, in 
comparison with the natural substrate AMP. As a result, the 2’-O-methyl-6-O-methyl 
guanosine derivatives should deliver the corresponding 5’-monophosphate species 
(151.b, Figure 5.9) in a slower rate compared to their 2’-C-methyl analogues (146.b). 
This observation correlates with the anti-HCV activity in replicon assays, since the 2’-
C-methyl derivative 146 is more potent than 151.  
Taking into consideration the fact that the hindrance of the 2’-O-alkyl group does not 
affect much the activity of 6-O-methyl guanosine analogues, it is likely that the 
presence of the methyl on the β-face provides faster metabolism to the 5’-triphosphate. 
 
2.7.  Conclusion and perspectives 
The use of 2’-O-alkylated nucleosides has been widely used in medicinal chemistry, 
however 2’-O-alkylation has never been extensively investigated for HCV therapy.12, 13 
Despite numerous synthetic approaches described in the literature,11 optimisation of 2’-
O-alkylation appeared to be difficult, due to side reactions at the exocyclic N-2 and 3’-
hydroxyl.27 Aiming at investigating the allowance of hindrance at the 2’-position in the 
NS5B polymerase, a new approach was developed to synthesise 2’-O-alkylated 
derivatives of 2’-C-methyl-6-O-methyl guanosine 11 and 6-O-methyl guanosine 137. 
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Despite the modification at C-2’, the molecules synthesised were extremely polar 
making the purification steps difficult and resulting in low yields during the formation 
of corresponding phosphoramidates. While 2’-O-alkylated nucleosides do not exhibit 
activity in replicon assays, the ProTides slightly boost the potency though increase the 
cellular toxicity.  
Varying the bulkiness of the alkyl group does not affect much the potency, however in 
the case of the 2’-C-methyl-6-O-methyl family, the ethoxy at the 2’-position appears to 
be the biggest group tolerated in term of potency boost.  
Molecular modelling using cathepsin A predicts that in both families, the SP isomers are 
more likely to be processed than RP isomers, and might deliver slowly the 
phosphoramidate monoester. The 2’-C-methyl-2’-O-methyl-6-O-methyl guanosine 
phosphoramidate monoester species 146.a also lie in a good position within the active 
site of human Hint-1 enzyme for an efficient P-N bond cleavage compared to the 2’-O-
methyl-6-O-methyl guanosine phosphoramidate monoester analogues. The slow 
delivery of the 2’-O-alkylated 5’-monophosphates might correlates with the poor 
inhibitory activity and poor selectivity index displayed during replicon assays.  
In conclusion, it is likely the 2’-O-alkyl substitutions would affect greatly the 
metabolism and might not allow an efficient intracellular delivery of the potentially 
active 2’-O-alkylated triphosphates.17 Future expansion of 2’-O-alkyl modifications to 
other family of nucleosides, that have previously shown activity in HCV replicon, 
would be of interest in order to define the bulkiness allowed in the catalytic pocket of 
HCV NS5B polymerase. It may be also of interest to tune the ProTide, varying the 
amino acid and ester moieties, to eventually achieve more efficient metabolism. 
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3. Modifications at C-5’ of 6-O-methyl guanosine derivatives 
3.1.  Introduction 
Modifications at C-5’ of nucleosides have mainly been explored for the synthesis of 
RNA and DNA and their incorporation into oligomeric structures for improvement of 
potency and efficacy of antisense compounds.34 Because the 5’-hydroxyl of the 
nucleoside is prone to metabolism in-vivo,35 the development of 5’-modified 
nucleosides has become of interest. Adding a steric bulk adjacent to the 5’-primary 
hydroxyl should improve the pharmacokinetic profile and reduce the metabolic 
lability.35 
Particularly, the 2’-deoxy-5’-methyl DNA7 (157, Figure 5.10) bearing a methyl at the 
5’-position next to the phosphodiester linkage, is known to reduce recognition by 
nuclease.36, 37 Moreover the 5’-methyl facilitates cellular uptake by slightly increasing 
the lipophilicity.7 
B
O
O
O
P
O-
O
B
O
O
O
157  
Figure 5.10. Structure of 5’-methyl DNA.7 
Numerous pathways have been reported for the synthesis of 5’-methyl modified 
nucleosides and most of them described the synthesis of 5’-methyl via oxidation of the 
5’-hydroxyl at the ribose level before condensation with the nucleobase.38-40 In 
particular, Alios developed 5’-C-methyl-2’-C-methyl guanosine and other nucleoside 
analogues via oxidation at the riboside level.41  
Preliminary docking studies into HCV NS5B polymerase predicted that a nucleoside 
triphosphate bearing a methyl group at C-5’ may be a good substrate of the enzyme. 
Moreover, in an attempt to investigate the effect of 5’-methyl group towards the 
reduction of dephosphorylation by phosphatase42 occurring before entrance into the 
cells, and eventually increasing the activity against HCV RNA replication, it was 
decided to develop 5’-C-methyl modification starting from the 2’-C-methyl guanosine 
nucleosides and further transpose the synthetic route to 6-O-methyl-2’-C-methyl 
guanosine derivatives.  
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3.2.  Synthetic route to 5’-C-methyl-2’-C-methyl guanosine 
The common method for methylation at the 5’-position of a nucleoside is reported via 
oxidation of the 5’-hydroxyl to aldehyde. This intermediate is often used for 
introduction of substituents at C-4’ position.43 Nevertheless, only few methods report 
the formation of 5’-methyl modification at a nucleoside level, and they concern mostly 
pyrimidine nucleosides.35, 44 Despite the chemoselectivity of certain oxidising reagents, 
acetonide protection of 2’- and 3’-hydroxyls is most commonly used to avoid formation 
of by-products as well as to increase solubility of guanosine derivatives.45 Substitution 
of the methyl at C-5’ is often accomplished via Grignard reaction onto the 5’-aldehyde 
nucleoside.46 
The retrosynthetic pathway investigated to form 5’-C-methyl-2’-C-methyl guanosine 
161 takes into consideration the different synthetic aspects described above and is 
reported in Scheme 5.9. 
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Scheme 5.9. Retrosynthetic pathway to 5’-C-methyl-2’-C-methyl guanosine 161. 
 
Formation of 2’,3’-isopropylidene protected 2’-C-methyl guanosine 158 was performed 
following standard procedures, using 60% aqueous solution of perchloric acid (HClO4) 
in anhydrous acetone,47 and yielded 32% of 158 after purification by flash 
chromatography.  
The reaction conditions for oxidation of the 5’-position were then investigated. 
Oxidation reactions are extensively used in organic chemistry, and a wide variety of 
reagents have been developed. Nowadays, milder and more selective oxidants are used, 
such as activated dimethysulfoxide reagents,48 enzymes,49 or catalytic oxidants50 as well 
as hypervalent iodine reagent, such as Dess-Martin periodinane.51 Such reagents enable 
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to overcome chemoselectivity issues and are compatible with a variety of functional 
groups.52 
 
3.2.1. Direct oxidations 
3.2.1.1. Oxidizing reagents and mechanisms 
The formation of the 5’-aldehyde 159 (Scheme 5.9) was first performed using direct 
oxidation reaction using reagent such as the Dess-Martin periodinane (162),51, 53-57  
pyridinium chlorochromate58, 59 (163), dimethylsufoxide with oxalyl chloride (164)38 or 
radical reagents such as TEMPO (tetramethylpiperidine-1-oxyl)60 / TCC 
(trichlorocyanuric acid)61 (165) (Table 5.7). Each reagent has specific characteristics 
reported in Table 5.7. 
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Oxidation 
RIOH to 
RCHO 
RIIOH to 
RCO 
RIOH to 
RCHO to 
RCOOH 
RIIOH to RCO 
RIOH to RCHO 
RIIOH to RCO 
RIOH to RCHO  
By-products 
Acetic acid  Carbon dioxide  
Carbon monoxide 
Dimethyl sulfide 
Triethylamonium 
chloride 
 
Advantages 
Mild 
High 
yielding 
Easy work-
up 
High 
selectivity  
Mild  
High 
efficiency 
High 
selectivity 
No 
overoxidation 
Mild 
Wide tolerance to 
functional groups 
Mild 
Basic conditions 
High yielding 
Disadvantages 
Does not 
work well 
for 
adenosine 
Highly toxic by-products are 
volatiles but toxic 
and odorous 
overoxidation to 
carboxylic acid in 
aqueous solvents 
Table 5.7. Characteristics of oxidizing reagents commonly used for direct oxidation. 
The mechanism of the radical reaction using TEMPO/TCC (165) is described in 
Scheme 5.10. While TCC act as a second oxidant to regenerate TEMPO, sodium 
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hydrogenocarbonate (NaHCO3) is used as a base to trap the proton release from the 
reaction. 
The mechanisms and reaction conditions of Dess-Martin (162), Swern oxidations (164) 
or oxidation with PCC (163) are similar. The attack of the primary 5’-hydroxyl of 158 
onto the iodine of 162, chromium of 163 or the sulfur atom of 164, previously activated 
by triethylamine, is followed by deprotonation of 5’-methylene group to afford the 
nucleoside 5’-carboxaldehyde 159 (Scheme 5.9). 
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Scheme 5.10. Proposed catalytic cycle for TEMPO/TCC catalysed oxidation  
under basic conditions.60 
 
 
 
3.2.1.2. Attempts for the formation of 5’-aldehyde by direct oxidation 
Because of eventual hydration, the formation of the nucleoside 5’-aldehyde is extremely 
difficult, and only few examples concerning purine nucleosides are reported in the 
literature.56, 62 Numerous attempts varying the reaction conditions and the reagents 
described previously were unsuccessful (Table 5.8). 
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Attempt Reagent Conditions Work-up  Results and observations 
1 Dess-Martin  (1.4 eq) anh. DCM, rt, 3 hrs 
aq. Na2S2O3/ 
aq. NaHCO3 
TLC base line 
products only 
2 Dess-Martin  (1.5 eq) 
anh. DCM, 0 °C,  
3 hrs 
aq. Na2S2O3/ 
aq. NaHCO3 
TLC base line 
products only 
3 Dess-Martin  (1.5 eq) 
anh. DCM / anh. 
ACN, rt, 4 hrs none 
TLC base line 
products only 
4 PCC (1.3 eq) anh. DCM, rt, 3 hrs none TLC base line products only 
5 
Oxalyl chloride 
(1.4 eq), anh. NEt3 
(4.8 eq) 
anh. DMSO, anh. 
DCM, -70 °C to rt,  
2 hrs 
H2O / DCM 
TLC base line 
products only 
6 TEMPO (0.025 eq) / TCC (0.76 eq) 
anh. DMF, 
NaHCO3 (30.0 eq),  
0 °C, 4 hrs 
none 
Purification by flash 
chromatography 
Table 5.8. Reaction conditions of direct oxidations attempted. 
 
Being compatible with both tert-butyl-dimethyl silyl and isopropylidene protecting 
groups,61 the Dess-Martin oxidation was first attempted on 158. However, changing the 
temperature or the solvent system (attempt 2 and 3, Table 5.8) did not afford the 5’-
aldehyde 159 or the starting material 158, but only degradation products which were not 
characterised.  During the third attempt, no aqueous work-up was performed in order to 
avoid eventual hydration,62 epimerisation of C-4’ or elimination of the acetonide 
function63 of 159. Unfortunately the outcome was similar to the first two attempts. 
Further investigations of the oxidative step with PCC (attempt 4, Table 5.8) or via 
Swern conditions (attempt 5, Table 5.8) were equally vain.  
As a last attempt, the catalytic combination of TEMPO/TCC (attempt 6, Table 5.8) was 
tested. Never reported on nucleosides but on unprotected glycosides,60 these conditions 
were applied both to 2’-C-methyl guanosine 10 and its acetonide protected analogue 
158. NMRs of the purified residue were not conclusive since neither the aldehydic 
proton, nor the riboside or acetonide protons were visible. In both cases, the starting 
material was not recovered. 
These reactions were performed one more time, and without attempting to isolate the 
nucleoside 5’-aldehyde 159, the methylation step was performed with the Grignard 
reagent methyl magnesium bromide (MeMgBr).38 In all cases, NMR and mass 
spectroscopy supported the conclusion that methylation did not happen, hence 
suggesting that the oxidation step failed.  
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3.2.2. Indirect oxidations 
The lack of success of direct oxidations performed at a nucleoside level led us to 
investigate oxidation of the 5’-position via indirect routes.  
 
3.2.2.1. Pfitzner-Moffatt route 
Discovered in 1963,45 the Pfitzner-Moffatt route62 is used to oxidise selectively primary 
and secondary alcohols to aldehydes,63 without reaching the carboxylic acid. The four-
step synthesis described on 2’,3’-isopropylidene-N-6-protected adenosine65 was adapted 
to 2’-C-methyl guanosine starting from 158 (Scheme 5.11).  
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(i. anh. DMSO, DCC (3.0 eq), Cl2CHCOOH (0.5 eq), 0 °C to rt, 1hr 30min, anh. MeOH, oxalic 
acid dihydrate (2.0 eq), rt, 30min, N,N’-diphenylethylene diamine (1.1 eq), rt, 1hr, 62%; ii. 
Dowex 50WX4-50, H2O/THF (1:1), rt, 1hr, 18%; iii. Dean-Stark, toluene, 1hr). 
Scheme 5.11. Pfitzner-Moffatt oxidation route. 
 
Despite requiring several steps, this mild oxidation enables the isolation of the 5’-
aldehyde (159) as a stable 5’-dihydrate (167, Scheme 5.9), after treatment of the 5’, 5’-
(N,N’-diphenylethylenediamine) intermediate 166 with acidic Dowex resin. 
166 was obtained by attack of the 5’-hydroxyl of 158 onto the ylide intermediate 
formed by dichloroacetic acid, followed by release of urea and ylide sulfonium to give 
159. The latter then reacts with N,N’-diphenylethylenediamine (Scheme 5.12) to afford 
166 in 62%. After work-up, the structure was confirmed by the presence of 
characteristic 1H-NMR peaks, such as aromatic protons in the range of 6.82-8.32 ppm 
and a multiplet at 3.72 ppm corresponding to the methylene groups. 166 was then 
treated with strongly acidic Dowex resin to afford the nucleoside 5’-dihydrate 167 
(Scheme 5.11). The spectrum of 13C-NMR confirms the presence of a tertiary carbon at 
88.46 ppm in deuterated methanol, corresponding to the C-5’.  
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Isolation of the desired nucleoside 5’-aldehyde 159 failed and only 167 was recovered 
by precipitation in toluene. The nucleoside 5’-dihydrate 167 appeared extremely stable 
and rather poorly soluble in toluene.  
Aiming at obtaining the nucleoside 5’-methylated intermediate 160 (Scheme 5.9), the 
nucleoside 5’-dihydrate 167 was treated with an excess of Grignard reagent (MeMgBr, 
~10 eq).63 However 167 being poorly soluble in anhydrous dichloromethane, the 
reaction failed and only the starting material was recovered. 
 
Despite the Pfitzner-Moffatt oxidation being widely used in nucleoside chemistry, this 
method failed to provide the desired nucleoside 5’-aldehyde intermediate 159 or its 5’-
methylated derivative 160. This is mainly due to 167 being highly hydrophilic (ClogP ~ 
-2.25) and highly stable to the conditions used. Protection of the exocyclic amine of the 
heterobase with benzyl would probably enhance the solubility of 167. 
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Scheme 5.12. Mechanism of Pfitzner-Moffatt oxidation. 
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3.2.2.2. Route via TEMPO / BAIB and reduction  
The TEMPO (2,2,6,6-tetramethyl-1-piperidinyl oxide) / BAIB ([bis(aceoxy)-
iodo]benzene) route has been reported in the literature on both ribosides and 
nucleosides, and in particular for access to the guanosine 5’-methylcarboxylate via the 
5’-carboxylic acid intermediate.66 While Moffatt and co-workers described similar 
reaction using diazomethane, the combination of TEMPO and BAIB provide a much 
safer route, as described Scheme 5.13. These mild and selective conditions40 are 
compatible with numerous protecting groups as well as variety of functional groups.44 
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Scheme 5.13. TEMPO/BAIB route to 2’,3’-protected 5’-methyl-2’-C-methyl guanosine 160. 
 
The oxidation step of 158 to its corresponding 5’-carboxylic acid 168 proceeds via the 
formation of an N-oxoammonium salt by acetic acid catalysis.40, 44 The former enables 
the oxidation of the alcohol while it is reduced to hydroxylamine. The organic oxidant 
BAIB regenerates TEMPO by oxidation of the hydroxylamine (Scheme 5.14). 
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Scheme 5.14. Mechanism of TEMPO / BAIB oxidation. 
 
 
In contrast with the guanosine derivative, which required the addition of 2.0 eq of 
sodium bicarbonate to obtain its 5’-carboxlic acid in good yield,44 168 was recovered in 
95% yield without purification, and characterised by NMR. The carbonyl group 
appeared at 171.95 ppm in 13C-NMR, and a broad singlet at 10.67 ppm in 1H-NMR 
confirmed the presence of the carboxylic acid group at C-5’.  
Esterification of 168 was performed using thionyl chloride (SOCl2) in methanol via the 
formation of the acyl chloride intermediate. Acting as a good leaving group, the 
chlorine was substituted by methanol and afforded 169 in 18% yield, after flash 
chromatography.  
Reduction of 169 to the nucleoside 5’-aldehyde 159 was attempted using 
diisobutylaluminium hydride (DIBAL-H), which acts a reducing reagent after formation 
of a Lewis acid-base complex. DIBAL-H was introduced at low temperature to form the 
tetrahedral intermediate, which should be converted to the aldehyde by addition of 
hydrochloric acid. Unfortunately, the reaction failed and only compound 169 was 
recovered.  
 
Another attempt of reduction was carried out using either 1.0 or 10 equivalents of the 
Grignard reagent (methyl magnesium chloride) to test the reactivity of the 5’-methyl 
ester derivative 169. The use of Grignard does not favour the formation of secondary 
alcohol because the methyl keto intermediate is much more reactive than the ester 
functionality. Thus, it is likely that the use of Grignard reagent will afford the 5’,5’-
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dimethyl substituted nucleoside 170. However, neither the amount of Grignard 
introduced, nor the control of temperature (-78 °C), enabled the formation of desired 
protected 5’-methyl-2’-C-methyl guanosine 160 or its 5’,5’-dimethylated analogue 170. 
 
A recently published one-pot procedure subjects the 5‘-methyl ester carbocycle 
intermediate, formed using TEMPO/BAIB procedure, to methyl magnesium bromide to 
obtain both the 5’-methyl and 5’-dimethyl analogues.34 Moreover, Verma and co-
workers also propose the use of methyl lithium (MeLi) at low temperature to obtain 5’-
dimethyl carbasugar.35 If time had allowed, these conditions could have been tested on 
2’,3’-isopropylidene 2’-C-methyl guanosine 158. 
 
3.2.2.3. Route via TEMPO / BAIB and Weinreb amide  
Instead of targeting the 5’-aldehyde 159 as an intermediate towards the synthesis of 5’-
methyl-2’-C-methyl-guanosine 161, an alternative method focused on synthesising the 
5’-methylketo intermediate 172 from the 5’-Weinreb amide nucleoside 171 (Scheme 
5.15). The latter is an effective acylating agent due to its highly activated carbonyl 
group. It is reported to be a good intermediate for accessing highly functionalised 
ketones.67 
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Scheme 5.15. Retrosynthesis route to 5’-methyl-2’-C-methyl guanosine 161 via  
5’-methylketo 172 and 5’-Weinreb amide 171 intermediates. 
 
Oxidation to 168 was performed using the TEMPO/BAIB procedure as described 
previously. Considering that the 5’-carboxylic acid is sterically hindered, the formation 
of 5’-carboxylic acid amides, such as 171, requires the use of coupling reagents such as 
1-hydroxybentriazole (HOBt), commonly used for amide synthesis, in combination with 
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an acid activating agent such as bromo-tris-pyrrolidinophosphonium 
hexafluorophosphate (PyBrOP), in the presence of base such as N,N-
diisopropylethylamine (DIPEA).42 N,O-dimethylhydroxylamine hydrochloride was then 
added and 171 was obtained in moderate yield (48%). Anhydrous conditions are 
essential for the success of this reaction, hence the importance of obtaining the starting 
material 168 as a precipitate and drying it over two days. 171 was characterised by 1H-
NMR and 13C-NMR, and characteristic peaks of the 5’-carboxylic acid amide appeared 
at 36.36 ppm (ON(CH3)OCH3), 61.51 ppm (ON(CH3)OCH3) and the peak of the 5’-
carbonyl group shifted upfield (169.5 ppm) compared to its starting material 168.  
The 5’-carboxylic amide function is reported to react quickly with Grignard and 
organolithium reagents to form 5’-alkylketo products, without obatining a tertiary 
alcohols even with an excess of reagent.67 The mechanism of formation of nucleoside 
5’-methylketo 172 is described in Scheme 5.16, and proceeds via the formation of a 
chelated intermediate which prevents the addition of a second nucleophile68 and 
collapses by hydrolysis. 
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Figure 5.16. Reaction mechanism of 171 with organometallic reagents. 
 
In order to investigate the formation of 5’-methylketo 172 from 171, several reaction 
conditions were performed (Table 5.9). Unfortunately, the methyl magnesium bromide 
(MeMgBr, attempts 1.a-e) seemed not to be a suitable reagent for the nucleophilic 
attack onto the Weireb amide intermediate 171. Even under high temperature or high 
concentration of reagent, only the starting material was recovered. As a last attempt, 
butyl lithium (BuLi, attempts 2.a-b) was used to test the reactivity if 171. Introduction 
of the organolithium reagent at low temperature was unhelpful in the recovery of 5’-
butylketo nucleoside, and once again 171 was recovered with some degradation 
products. Mass of the crude confirmed that the reaction did not take place. 
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Attempt Reagent Conditions Observations 
1.a CH3MgBr (3.0 M in Et2O, 2.0 eq) anh. THF, 0 °C, 30 min 171 
1.b  + rt, 30 min 171 
1.c  + CH3MgBr (3.0 M in Et2O, 2.0 eq) + rt, 1 hr 171 
1.d  + rt, overnight 171 
1.e  + 65 °C, 5 hrs  171 
2.a BuLi (2.0 M in pentane, 2.0 eq) anh. THF, -30 °C, 1 hr 171 
2.b  + rt, 3 hrs 
171 and 
degradation 
products 
Table 5.9. Conditions attempted for nucleophilic attack onto 171. 
 
Being unexpected and disappointing, these results suggested the high stability of the 
Weinreb amide intermediate 171, and the use of a stronger nucleophilic reagent would 
be required to obtain of the desired 5’-metylketo 172. Once obtained, the subsequent 
reduction to its secondary alcohol analogue 160, followed by deprotection of 2’,3’-
hydroxyls would provide the desired 5’-methyl-2’-C-methyl guanosine 161, likely as a 
mixture of stereoisomers at C-5’.  
 
3.3.  Conclusion 
Despite numerous routes investigated, attempts to substitute a methyl group at C-5’ of 
2’-C-methyl guanosine 10 remained vain. Direct oxidations of the 5’-hydroxyl 
performed with common oxidative reagents resulted only in degradation products, while 
indirect oxidations were likely to be more successful, however increased considerably 
the number of synthetic steps.  
The TEMPO/BAIB oxidation gave good yields and pure 5’-carboxylic acid 168 without 
purification. However, the 5’-dihydroxy hydrate intermediate 167, resulting from the 
Pfitzner-Moffatt oxidation, the 5’-methylester 169 and the 5’-weinreb amide 
intermediate 171 appeared extremely stable under the reaction conditions used. Thus, 
preventing any nucleophilic substitution at C-5’ or reduction to the 5’-aldehyde 
intermediate 159. 
It would be interesting to enhance the solubility of the 5’-dihydroxy hydrate 167 using a 
protection of the exocyclic amine N-2 with monomethoxytrityl, which is reported to 
increase considerably the solubility of guanosine derivatives.45 Moreover, one-pot 
oxidation-methylation35 should be attempted and the use of organolithium reagents 
should be further investigated. 
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Adaptation of any route performed on 2’,3’-isopropylidene 2’-C-methyl guanosine 158 
to the 2’-C-methyl-6-O-methyl guanosine analogue 10 would require the use of another 
protecting group at 2’- and 3’-hydroxyls since the formation of 2’,3’-isopropylidene 2’-
C-methyl-6-O-methyl guanosine is very low yielding.  
Such 5’-methylated or 5’-dimethylated nucleosides have an important interest for the 
treatment of several diseases, and such modifications have been reported to enhance the 
pharmacokinetic profile compared to their parent nucleosides.35 Their metabolic 
stability make them important compounds, thus, further investigation is necessary to 
develop a quick and efficient synthetic route at a nucleoside level, in comparison to the 
ones already developed at a furanose level.  
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Chapter Six: Acyclic nucleosides and prodrugs 
 
 
1. Introduction and objectives 
In the search of expanding the SAR study of 2’-C-methyl-6-O-methyl guanosine 11, 
disconnection of the chain of the furanose ring was investigated and novel acyclic 
nucleosides were designed as potential inhibitors of the HCV NS5B polymerase. 
1.1. Acyclic nucleosides  
Since 1970 and the discovery of acyclovir (ACV, 173 Figure 6.1) as a potent antiviral 
approved for the treatment of herpes simplex virus (HSV), varicella zoster virus (VZV) 
and human cytomegalovirus (HCMV),1  numerous syntheses of acyclic nucleosides 
have been reported and have led to the development of other antiviral agents displaying 
broad-spectrum activity against several viral infections,2 microbial infections3 and 
cancer.3 Among many purine acyclic nucleosides, penciclovir  (174, Figure 6.1) used 
for the treatment of HSV,4 and other acyclic nucleoside phosphonates, such as (S)-9-(3-
hydroxy-2-phosphonylmethoxypropyl)adenine ((S)-HPMPA, 175, Figure 6.1), exhibited 
activity against DNA viruses.5 The latter served as a template for currently clinically 
used phosphonates, which exhibit prolonged antiviral response and impressive 
resistance profile,6 such as previously mentioned anti-HBV adefovir dipivoxyl 4.a 
(Figure 1.9, chapter 1).5, 6  
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Figure 6.1. Structures of acyclovir 173, penciclovir 174 and (S)-HPMPA 175. 
 
 
Mimicking natural cyclic sugar nucleosides, acyclic nucleosides act as inhibitors7 of 
viral reverse transcriptase, DNA polymerase8 or nucleoside phosphorylase.9 Moreover, 
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the conformation of the acyclic chain is essential for interaction and affinity with 
metabolic enzymes.10  
Aiming at developing highly potent and selective molecules, alterations of the 
nucleobase11 and/or acyclic chain have been extensively investigated.12, 13 
 
1.2.  Acyclic nucleosides and analogues for HCV treatment 
The lack of efficient therapy against HCV has led several groups to investigate acyclic 
nucleosides and phosphonates as inhibitors of HCV RNA replication, however this field 
is still to be further explored.  
Several triazole-based acyclic nucleosides have been designed as anti-HCV agents,14, 15  
and micromolar activity against HCV RNA replication was reported when the triazole 
bore a rigid triple bond linked to a π-conjugated aromatic system, such as 176 (Figure 
6.2).14 Despite exhibiting lower potency (EC50 = 22 ± 3 µg/mL in Huh-5-2 cells) than 
ribavirin 3 (Figure 1.6, chapter 1) (EC50 = 7 ± 2 µg/mL, CC50 > 21 ± 11 µg/mL in Huh-
5-2 cells), 176 was much less cytotoxic (CC50 > 50 µg/mL in Huh-5-2 cells).14 
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Figure 6.2. Acyclic nucleoside 176 and acyclic nucleoside phosphonates 177 and 178 as  
inhibitors of HCV RNA replication. 
 
Moreover, efforts to target the HCV polymerase led to the development of acyclic 
nucleoside phosphonates, known to be efficient inhibitors of DNA viruses and 
retroviruses.16 Recently, Wyles and co-workers reported the synthesis and biological 
activity of 177 (ODE-(S)-HPMPA, Figure 6.2).17 The latter is not only the first acylic 
nucleoside phosphonate reported to be potent against a RNA virus,17, 18 but is also the 
first of this class to exhibit anti-HCV activity versus genotypes 1b (EC50 = 1.55 ± 0.5 
µM) and 2a (EC50 = 1.65 ± 0.33 µg/mL).19 To address the issue of cytoxicity (CC50 = 
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35.6 ± 6.8 µM) displayed by 177, other related analogues were synthetised.17, 19 
Replacement of the hydroxyl chain by a methoxy group led to 178 (ODE-(S)-MPMPA, 
Figure 6.2) which reduced considerably the cytotoxicity while retaining micromolar 
potency against HCV replication in cells (genotype 1b: EC50 = 1.43 ± 0.38 µM, 
genotype 2a: EC50 = 2.38 ± 1.09 µM, CC50 > 150 µM).19  
 
1.3.  Objectives 
Acyclic pyrimidine12 and purine20 nucleosides (Figure 6.3), based on the features of 
penciclovir (174, Figure 6.1) and the antitumor and antibiotic neplanocin A (179, Figure 
6.3),21 have been reported and tested against herpes simplex viruses (HSV). Only 
guanine derivatives (180 and 181, Figure 6.3) exhibited moderate activity respectively 
against HSV-2 (EC50 = 11.7 µg/mL) and HSV-1 (EC50 = 32.7 µg/mL), without 
displaying cellular toxicity (CC50 > 100 µg/mL).20 The lack of antiviral activity is 
reported to be likely due to poor phosphorylation during nucleoside activation.12  
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Figure 6.3. Antibiotic neplanocin A (179) and acyclic guanine nucleosides (180 and 181). 
 
Taking these facts into considerations and aiming at developing acyclic nucleosides as 
potential inhibitors of HCV RNA replication, acyclic purine nucleosides, sharing 
similar structure with 181, and their phosphoramidate analogues were synthesised. 
Fixing the acyclic chain, only the heterobase moiety was varied, using 6-chloropurine, 
adenine, guanine and 6-O-methyl guanine.  
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2. Synthesis of acyclic purine nucleosides and prodrugs 
2.1. Acyclic purine nucleosides 
Coupling of the heterobase with a carbon substrate22 or formation of the heterobase 
from aminoalkanes23 are common methods for the preparation of acyclic nucleosides, 
which are not efficient in the case of electron-rich purines. Reported methods for 
carbon-base bond formation consist of allylic ester palladium-catalysed displacement, 
nucleophilic displacement of halides or activated alcohols, and Mitsunobu coupling.24 
While the first two methods give moderate yields because of competition at N-7 and N-
9 of the purine base,25, 26 the mild conditions and stereospecificity of the Mitsunobu 
coupling make it an attractive method.27 
 
The synthetic pathway towards acyclic purine nucleoside (Scheme 6.1) analogues of 
181 (Figure 6.3), was reported by Hong and co-workers, via displacement of allylic 
bromide.12, 20 This synthetic route (Scheme 6.1) was first investigated and compared 
with the results obtained from the Mitsunobu coupling.  
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H 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(i. anh. DMF, imidazole (2.5 eq), TBDMSCl (2.2 eq), rt, 36 hrs, 81%; ii. anh. THF, NaH (60% 
dispersion in oil, 1.0 eq), (EtO)2POCH2COOEt (1.2 eq), rt, 1 hr, 51%; iii. anh. DCM, DIBAL-H 
(1.0 M in hexane, 2.0 eq), 0 °C, 2 hrs, rt, 2 hrs, 24%; iv. anh. DCM, PPh3 (1.1 eq), NBS (1.1 
eq), 0 °C to rt, 4 hrs, 38%; v. anh. DMF, adenine (3.2 eq), NaH (60% dispersion in oil, 3.2 eq), 
rt, overnight, 21%; vi. anh. THF, purine (1.0 eq), PPh3 (1.1 eq), DIAD (1.0 eq), rt, overnight; 
vii. anh. THF, TBAF (2.2 eq), 30 min, rt.) 
Scheme 6.1. Synthetic route to acyclic purine nucleosides. 
 
Commercially available hydroxypropan-2-one 182 was protected with tert-butyl-
dimethyl silyl chloride (TBDMSCl) before being subjected to Horner-Emmons 
olefination,28 whose mechanism proceeding via nucleophilic attack is described in 
Scheme 6.2. After deprotonation by sodium hydride, the activated α-carbon of 
triethylphosphonoacetate ((EtO)2POCH2COOEt) attacks onto the carbonyl group of 182 
(Scheme 6.2) to form an intermediate, which then undergoes elimination to afford the 
α,β-unsaturated ester 184. The latter was recovered as a mixture of separable E- and Z-
isomers (E/Z ratio: 22/78) in 51% yield. The mixture was reduced by diisobutyl 
aluminium hydride (DIBAL-H) to its corresponding mixture of unsaturated allylic 
alcohol 185.29, 30 A portion of the major isomer could be easily obtained pure after flash 
chromatography, whereas the other was always obtained as a mixture. However since it 
was not necessary, the isomers were not separated at this stage. !
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Scheme 6.2. Mechanism of Horner-Emmons reaction. 
 
 
The first pathway investigated is reported in the literature,12, 20 and the allylic bromide 
186 was formed with N-bromosuccinimide (NBS). Subsequent displacement of allylic 
bromide 186 by adenine under basic conditions afforded N-9 alkylated 187.a in 21% 
yield, despite the 64% reported.20 The yield over two steps (30%) was only comparable 
to the one reported in the literature (35-72%).20, 29, 30 The low yield is mainly due to the 
poor solubility of the heterobase in dimethylformamide. We can speculate that the use 
of cesium carbonate would have probably enhance the solubility.20, 31 
 
As an attempt to increase the yield, one-pot reaction was performed under Mitsunobu 
conditions. This approach gives good N-9 regioselectivity under mild conditions.32 
Generation of the phosphonium intermediate by action of diisopropylazodicarboxylate 
(DIAD) and triphenylphosphine (PPh3) and activation of the heterobase, are key steps 
for condensation of the latter onto activated allylic phosphonium intermediate (Scheme 
6.3). Despite moderate yields reported in the literature,33, 34 187.a was recovered in 26% 
yield, comparable to the 30% obtained from the two-step synthesis. The poor solubility 
of the heterobase in tetrahydrofuran, best solvent for Mitsunobu reaction, and the 
competing nucleophilicity of the exocyclic amino group at N-6, are presumably the 
main reasons for the poor yield obtained. 
 
While the first route enabled the recovery of a separable mixture of regioisomers (94/6), 
the Mitsunobu coupling of 185 with adenine afforded only one isomer. The latter and 
the major isomer formed during the first reaction shared identical NMR spectra. They 
were they were tentatively assigned with E geometry at the double bond. This 
hypothesis was confirmed by comparing 13C-NMR analysis of both isomers. In fact, the 
characteristic 13C-NMR peaks of unsaturated acyclic nucleoside E-isomers often 
appears at a downfield shifts compared to their Z-isomers.35, 36 The major isomer 
corresponded to the trans-configuration (E-isomer) (141.46 ppm, 116.36 ppm, 67.15 
ppm, 40.79 ppm, 13.66 ppm),20 while the signals of the minor Z-isomer appeared with 
upfield shifts (141.07 ppm, 116.09 ppm, 66.16 ppm, 40.58 ppm, 13.57 ppm). 
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Figure 6.3. Mechanism of Mitsunobu coupling. 
 
 
From these results and because the yield of the one-step Mitsunobu coupling was 
similar to the two-step synthesis via displacement of allylic bromide 186, the latter route 
was abandoned. 185 was then coupled with 6-chloro purine, 6-O-methyl guanine and 
guanine heterobases under Mitsunobu conditions, and results are described in Table 6.1. 
The acyclic 6-chloro purine nucleoside 187.b was recovered in high yield (Table 6.1), 
which is twice the yield reported via the allylic bromide intermediate 186.20 Comparison 
of NMR data with the literature20 confirmed the cis-configuration of the double bond 
(Z-isomer).  
Coupling with 6-O-methyl guanine afforded 187.c, which was recovered as a mixture of 
separable isomers and surprisingly the formation of the sterically hindered Z-isomer was 
favoured.  
 
 187.a 187.b 187.c 
Yield 26% 70% 16% 
E-isomer 100 0 18 
Z-isomer 0 100 87 
Table 6.1. Yields of Mitsunobu coupling and ratio of different isomers  
of acyclic chain of nucleosides. 
 
In contrast, the insolubility of guanine in tetrahydrofuran did not allow the reaction to 
take place under Mitsunobu conditions, and the same happened when using the 
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commercially available N-2-acetylated guanine. A new approach via the formation of 
the 6-chloro guanine intermediate 187.e was then investigated (Scheme 6.4).     
 
N
N
N
NH
O
TBDMSO
NH2
N
N
N
N
Cl
TBDMSO
NH2
TBDMSO
OH
185187.d 187.e  
Scheme 6.4. Retrosynthetic route to guanine acyclic nucleoside 187.d  
via 6-Cl-guanine acyclic intermediate 187.e. 
  
Mistunobu coupling between 6-chloro guanine and 185 allowed the formation of 187.e 
(Scheme 6.4) in 79% yield as a mixture of isomers. Subsequent hydrolytic 
dechlorination treatement using an aqueous solution of formic acid (95-97%) at -78 °C 
for two hours,27 did not suggest formation of the desired 187.d, and total degradation of 
the starting material occured. It was then decided to obtain the guanine derivative after 
deprotection of 187.c (acyclic 6-O-methyl guanine derivative), followed by treatment 
with sodium iodide (NaI) and trimethylsilyl chloride (TMSCl).37 
 
The mixture of isomers 187.a obtained via allylic bromide route and intermediates 
187.b-c were deprotected using tetra-butylammonium fluoride (TBAF, step vii, Scheme 
6.1) as a source of fluoride, and acyclic nucleosides 188,20 189 and 190 were obtained 
in respectively 58%, 31% and 32% yield. E- and Z-isomers of both 188 and 190 were 
separated by flash chromatography and their configurations were assigned by 1H-NMR 
and 13C-NMR (Table 6.2). In both cases, the E-isomer was more apolar than the Z-
isomer. The peak of the vinylic proton appeared as a triplet in the case of the E-isomer, 
whereas a triplet of quadruplet was observed for the Z-isomer. This multiplet 
corresponds to a coupling with the methylene group linked to the heterobase (CHCH2-
base) and an allylic cis coupling with the methyl group in proximity only in the cis-
configuration of the double bond (Z-isomer).  
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 E-isomer (a) Z-isomer (b) 
188 
E/Z ratio 31 69 
1H (MeOD) 5.54 (t, J = 7.30 Hz, CH) 5.74 (tq, J = 7.10 Hz, 1.40 Hz, CH) 
13C (MeOD) 
142.44 (C(CH3)CH2OH), 121.71 (CH), 
61.64 (CH2OH), 42.05 (CHCH2-base), 
13.95 (CH3) 
142.28 (C(CH3)CH2OH), 118.75 (CH),  
67.52 (CH2OH), 42.04 (CHCH2-base),  
13.86 (CH3) 
190 
E/Z ratio 40 60 
1H (CDCl3) 5.63 (t, J = 7.50 Hz, CH) 5.71 (tq, J = 7.00 Hz, 1.50 Hz, CH) 
13C (CDCl3) 
142.22 (C(CH3)CH2OH), 120.16 (CH), 
61.52 (CH2OH), 41.34 (CHCH2-base), 
13.70 (CH3) 
141.23 (C(CH3)CH2OH), 117.43 (CH),  
66.97 (CH2OH), 40.70 (CHCH2-base),  
13.63 (CH3) 
Table 6.2. Ratio of different isomers and 13C chemical shifts (ppm) of acyclic chain of 
nucleosides 188 and 190. 
 
The E-isomer of molecule 190 (190.a) was treated with sodium iodide (NaI) and 
trimethylsilyl chloride (TMSCl)37 to afford its acyclic guanine analogue 191 in 8% 
yield. The triplet peak corresponding to the vinylic proton confirmed the trans-
configuration of the alkene. 
 
After confirmation of purity, acyclic purine nucleosides 188.a (E-isomer), 188.b (Z-
isomer), 189 (Z-isomer), 190.a (E-isomer), 190.b (Z-isomer) and 191 (E-isomer) were 
sent to Inhibitex Inc. for evaluation of their cellular toxicity and potency against HCV 
RNA replication. 
 
2.2. Acyclic purine ProTides 
α-Naphthyl L-alanine ester phosphoramidates of acyclic purine nucleosides 188.b, 189 
and 190.b were synthesised according to the standard Uchiyama procedure, using tert-
butyl magnesium chloride as a base (Scheme 6.5). Starting from the (Z)-isomer of each 
nucleoside, only ProTide endowed with a cis-configuration of the double bond were 
synthesised. The ester was the only moiety varied at the ProTide level, using neopentyl 
(a), cyclohexyl (b) or benzyl (c) esters. Acyclic 6-chloropurine nucleoside 189 was not 
obtained in sufficient quantity to form the α-naphthyl L-alanine benzyl ester ProTide. 
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(i. anh. THF, tBuMgCl (2.0 eq), α-naphthyl L-Alanine ester phosphochloridate (2.0 eq), rt, 
overnight.) 
Scheme 6.5. Synthesis of α-naphthyl L-Alanine ester Protides of acyclic purine nucleosides. 
 
Acyclic guanine Protides were obtained from their corresponding 6-O-methyl 
derivatives by treatment with sodium iodide (NaI) and trimethylsilyl chloride (TMSCl) 
(Scheme 6.6).37   
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(i. anh. ACN, NaI (1.5 eq), TMSCl (1.5 eq), rt, 1-4 hrs). 
Scheme 6.6. Synthesis of naphthyl L-Alanine ester acyclic guanine Protides 195. 
 
All acyclic ProTides were recovered as mixtures of diastereoisomers at the phosphorus 
center. Yields, phosphorus chemical shifts (31P δ) in deuterated chloroform (CDCl3) and 
ratio of diastereoisomers are reported Table 6.3. 
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 192 193 194 195 
a. 
 
Yield 18% 2% 47% 2% 
31P δ (ppm) / ratio 
3.16, 3.81  
(44/56) 
2.82, 2.63  
(36/64) 
4.23, 3.91  
(39/61) 
4.12, 3.93  
(41/59) 
b. 
Yield 47% 20% 44% 2% 
31P δ (ppm) / ratio 
2.89, 2.76  
(50/50) 
2.83, 2.69 
(36/64)  
3.09, 2.90  
(43/57) 
4.19, 3.96  
(46/54) 
c. 
Yield 65% - 44% 10% 
31P δ (ppm) / ratio 
4.11, 3.72 
(50/50)  
- 
4.22, 3.82  
(33/67) 
4.10, 3.71  
(44/56) 
Table 6.3. Yields, 31P -NMR chemical shifts and  
ratio of diastereoisomers of acyclic purine ProTides. 
 
 
The yields were quite variable, and even starting from the same parent acyclic 
nucleoside, poor to moderate yields were obtained (192.a/192.c and 193.a/193.b). 
Formation of acyclic guanine ProTide via demethylation of the 6-position was poor 
yielding (195.a-c), and the reaction time varied depending on the ester moiety.  
The Rp and SP isomers of acyclic adenine ProTides (192.a-c) were formed in a 50/50 
ratio. Only the neopentyl ester (192.a) favours the formation of one diastereoisomer (31P 
δ = 3.81 ppm).  
In the case of acyclic 6-chloro purine (193.a-b), 6-O-methyl guanine (194.a-c) and 
guanine (195.a-b) ProTides, the major diastereoisomer formed always appeared to be 
the one corresponding with an upfield phosphorus peak. Because the diastereoisomers 
have not been separated, it was not possible to assign the configuration of the favoured 
isomer.  
 
α-Naphthyl L-Alanine ester ProTides 192.a-c, 193.a-b, 194.a-c, 195a-c were tested as 
mixture of diastereoisomers against HCV replication. 
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3. Biological evaluation  
Six acyclic purine nucleosides 188.a (E-isomer), 188.b (Z-isomer), 189 (Z-isomer), 
190.a (E-isomer), 190.b (Z-isomer) and 191 (E-isomer) and eleven ProTides (192.a-c, 
193.a-b, 194.a-c, 195a-c) were tested in replicon-based assays by Inhibitex Inc. to 
determine their inhibitory potency (EC50) against HCV replication and their eventual 
cellular toxicity (CC50). The results of these assays are reported Table 6.4. 
!"#$%& '( )*%+!+% ,-./0#&#-12&!+%
!"# $!%&'()*+ !!%&'()*+ !"# $!%&'()*+ !!%&'()*+
345 - 6778) ,-&& ./ - 0 0
395 - 6778: ,-&& ,-&& 67; .123 4%
395 <=>?@2 6;>8) ,'4& 4% 6;(8) /3 %-
395 .=%A 6;>8: ,'4& 4. 6;(8: ,'4& ,-&&
395 @+ 6;>8. ,'4& ,-&& - 0 0
!"#$%& '( ,-BC%DE2)+!+% E2)+!+%
!"# $!%&'()*+ !!%&'()*+ !"# $!%&'()*+ !!%&'()*+
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395 @+ 6;G8. ,'4& .3 6;H8. 52- ,-&&  
Table 6.4. Inhibitory activity (EC50) and cellular toxicity (CC50) of  
acyclic purine nucleosides and ProTides. 
 
According to these data, neither acyclic purine nucleosides, nor their ProTides, are 
efficient in inhibiting HCV replication in replicon-based assays. The cis- or trans-
configuration of the double bond present in the acyclic chain does not have a significant 
impact on the activity, since both isomers are inactive at a nucleoside level (188.a-b and 
190.a-b). While poor efficiency was expected at the nucleoside level due to potential 
poor phosphorylation,20 the ProTide technology may have overcome this issue.  
With the exception of 195.c, exhibiting micromolar potency against HCV RNA 
replication (EC50 = 7.1 µM) and being not cytotoxic (EC50 > 100 µM), other ProTides 
are either inactives, or are moderately active, but only at cytotoxic concentrations.  
The acyclic guanine family (191, 195.a-c) appears somehow more potent than any 
other. The guanine base is probably better accepted by metabolic enzymes or fits better 
in the active site of the NS5B polymerase. It is stricking that the introduction of a 
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methoxy substituent at C-6 of the heterobase (190.a-b, 194.a-c) leads to total loss of 
activity compared to its guanine analogue. Thus, in this case it might be that the acyclic 
6-O-methyl guanine analogues are not substrates of the enzymes responsible for 6-O-
ether hydrolysis.  
 
In conclusion, the lack of anti-HCV activity of these acyclic derivatives is likely to be 
associated with an unfavourable conformation of the double bond, which may prevent 
nucleosides and ProTides to be good substrates for metabolic enzymes responsible for 
phosphorylation and/or hydrolysis of the heterobase. On the other hand, it is also 
possible that the 5’-triphosphate of such acyclic nucleosides is not an inhibitor of HCV 
NS5B polymerase. Work to prepare and assay the 5’-triphosphate directly against the 
viral polymerase would clarify this, but was beyond the scope of our work, given the 
poor antiviral activity of the agents prepared. 
 
4. Conclusion and future work 
Starting from the potent anti-HCV 2’-C-methyl-6-O-methyl guanosine 11, the sugar 
moiety was modified to an acyclic chain containing an unsaturated bond. A different 
method than the one reported in the literature20 was investigated for the formation of 
such acyclic purine nucleosides. Mitsunobu coupling enabled the synthesis of four 
acyclic purine nucleosides, from which two were obtained as a separable mixture of cis- 
and trans-isomers. The former isomer (Z-isomer) appeared to be the preferred 
conformation despite steric hindrance. In order to overcome eventual poor metabolism 
of the acyclic nucleoside, ProTides of the (Z-isomer) of each acyclic nucleoside were 
synthesised, with variation at the ester moiety. 
Due to poor solubility of the guanine nucleobase in tetrahydrofuran, the preferred 
solvent for the Mitsunobu reaction, the acyclic guanine nucleosides and 
phosphoramidates were obtained by demethoxylation of their corresponding 6-O-
methyl derivatives.32 From this method acyclic guanine analogues were more easily 
accessible in comparison with the two-step synthesis reported in the literature.20 
Acyclic purine nucleosides were inactive in HCV replicon assay, and unfortunately the 
ProTide technology did not reinstate the potency without increasing the cytotoxicity. 
These disappointing results are likely to be related to inefficient metabolism resulting 
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from the unfavourable conformation of the alkene, or possibly to poor activity of the 5’-
triphosphate derivative against HCV RNA replication.  
The acyclic guanine family appeared as the most potent in cell-based assays. Moreover, 
taking into consideration the remarkable loss of potency related to the introduction of 
the 6-O-methyl group at the heterobase, it is presumable that such acyclic nucleoside 
are not substrate for metabolic enzymes responsible for base hydrolysis. 
The α-naphthyl L-alanine benzyl ester phosphoramidate (195.c) of acyclic guanine 
nucleoside was the most promising derivative among all acyclic analogues synthesised. 
Further work would concentrate on tuning the acyclic moiety by removing the 
unsaturation of the nucleoside and develop an extensive structure-activity relationship, 
to better understand the mode of action of acyclic derivatives towards inhibition of 
NS5B polymerase. 
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Chapter Seven: Conclusion 
 
 
This thesis reports the design, synthesis and biological evaluation of prodrugs of β-2’-C-
methyl-6-O-methyl guanosine (11), and of several modified analogues as potential back-
up molecules for INX-08189 (BMS-986094) an efficient inhibitor of HCV previously 
discovered in our laboratory. The rationale behind each of these modifications has been 
discussed in this report.  
HCV replicon based assays revealed that modifications at the nucleobase or sugar 
moieties tend to be unfavourable. However, the ProTide technology somehow restored 
the inhibitory potency against HCV replication, at the exception of acyclic nucleosides. 
While the latter were not promising, future investigations should take into consideration 
tuning the prodrug motif and/or applying the phosphorodiamidate prodrug technology on 
the 7-deaza family in order to deliver more efficiently the 5’-monophosphate species 
intracellularly. 
 
Enzymatic hydrolysis of phosphorodiamidates, 2’-O-modified and base modified 
nucleoside prodrugs using carboxypeptidase Y and cell lysates supported the putative 
mechanism of activation and the results obtained in biological assays. Additionally, 
molecular modelling studies were performed using cathepsin A, human hint 
phosphoramidase, inosine monophosphate dehydrogenase and adenosine deaminase-like 
protein-1, to investigate the intracellular mechanism of bioactivation. 
 
Despite the lack of significant inhibitory activity of modified nucleosides against HCV, 
the development of novel synthetic pathways towards varied modifications performed at 
a nucleoside level represents a significant achievement. We believe that the work 
presented herein will be the foundation of future research in the development of novel 
antivirals or anticancer molecules. 
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 Chapter Eight: Experimental Section 
 
 
1. General experimental methods 
Solvent and Reagents: 
All solvents were anhydrous and purchased from Aldrich: chloroform (CHCl3), 
dichloromethane (DCM), diethyl ether (Et2O), acetonitrile (ACN), methanol (MeOH), 
N,N-dimethylformamide (DMF), tetrahydrofuran (THF), pyridine, acetone. All reagents 
bought from Aldrich, Fischer, TCI, Carbosynth, Hande Pharma or CiVentiChem were 
used without purification. All glassware was dried in the oven at 130 °C before use. 
Thin Layer Chromatography (TLC): 
Thin layer chromatography (TLC) was performed on commercially available aluminium 
backed plates from Merck, (60 F264, thickness 0.2 mm), and separated fractions were 
visualised using ultra-violet light (245-366 nm). 
 
Preparative Chromatography: 
Preparative TLC was performed on 20x20 cm, 500 to 2000 µm silica gel plates from 
Merck. 
 
Column Chromatography (CC): 
Column chromatography was peformed using silica gel (60 Å, 35-70 µm) from Fischer 
as stationary phase. Glass column was packed with the appropriate solvent and the 
residues were loaded and pre-absorbed on the silica. Identification of the fractions was 
performed on TLC plates and the solvent was evaporated under reduced pressure. 
 
Nuclear Magnetic Resonance (NMR) Spectroscopy: 
1H, 13C, 19F and 31P spectra were recorded on a Bruker Advance 500 spectrometer at 
25°C with respective frequencies of 500, 125, 470 and 202 MHz. Spectra were 
calibrated to the residual signal of the deuterated solvent used for the experiment. The 
external standard for 31P NMR is 85% of phosphoric acid. Chemical shifts (δ) are given 
in parts per million (ppm) and coupling constants (J) in Hertz (Hz). The NMR signals 
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are assigned for each molecule using the following abbreviations: s (singlet), bs (broad 
singulet), d (doublet), dd (doublet of doublet), t (triplet), m (multiplet). 
 
Mass Spectroscopy (MS): 
Mass spectroscopy experiments were performed by the School of Chemistry, Cardiff 
University. Low resolution mass spectra were run on a Waters GCT Premier 
spectrometer in either positive or negative mode. High resolution mass spectra were run 
using electrospray ionisation source (EI). m/z values are reported in Da. 
 
High Performance Liquid Chromatography (HPLC): 
Analytical High Performance Liquid Chromatography (HPLC) were run either on a 
Varian Prostar LC workstation with a Varian Prostar 335 LC detector, and pro-star 210 
delivery system using an analytical column Varian Polaris C18-A (10 µm) with Galaxie 
Chromatography Data System as software, or on a Thermo-Fischer workstation with a 
Spectra System UV2000 detector, and Spectra System P4000 coupled with a Spectra 
System SCM1000 delivery system using an analytical Thermo-Fischer C18-A (10 µm) 
column (reverse phase) with Chrom Quest 5.0 as software. 
Semi-preparative HPLC was only performed on the first instrument mentioned above. 
Only compounds which purity was ≥ 95% were sent for biological evaluation. 
 
UV Spectroscopy (UV): 
The UV experiments were run on Varian 50 Bio UV-visible spectrophotometer, and 
recordered by the WinUV version 3.1 software.  
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2. Standard procedures 
Standard procedure A: Preparation of protected amino acid ester.1 
To the Boc-protected amino acid (1.0 eq) dissolved in anh. DCM (20 mL/g of amino 
acid) was added the alcohol (1.4 eq), DCC (1.0 eq) and DMAP (0.1 eq) and the solution 
was stirred overnight at room temperature. After removal of solvent under reduced 
pressure, flash chromatography using a gradient of hexane/ethyl acetate was performed 
to afford a white solid. 
 
Standard procedure B1: Preparation of protected amino ester tosylate salt. 
The protected amino acid ester (1.0 eq) and pTSA (1.0 eq) was dissolved in EtOAC and 
the solution was refluxed overnight, then cooled down to room temperature to enable 
precipitation of the desired sulfonate salt. 
 
Standard procedure B2: Preparation of protected amino ester tosylate salt. 
To the amino acid (1.0 eq) dissolved in toluene (20 mL/g of amino acid) was added the 
alcohol (5 to 15 eq) and pTSA (1.1 eq). The solution was heated under reflux overnight 
using Dean-Stark apparatus. After removal of solvent under reduced pressure, the amino 
acid was precipitated from Et2O to afford a white solid. 
 
Standard procedure C: Preparation of amino acid ester α-naphthyl 
phosphochloridates.2 
The amino ester sulfonate salt (1.0 eq) dissolved in anh. DCM (5 mL) was added to the 
α-naphthyl phosphorodichloridate (1.0 eq) and the solution cooled down to -78 °C, at 
which NEt3 (2.0 eq) was added dropwise. After one hour at - 78 °C, the reaction was 
left to warm at room temperature and stirred for further 30 min. The volatiles were 
evaporated under reduced pressure and the residue was purified by flash 
chromatography using Hexane/EtOAc (1:1). 
 
Standard procedure D: Preparation of ProTides via tBuMgCl method.2 
tBuMgCl (1M in THF, 2.0 eq) was added dropwise to 2’-C-Me-6-OMe guanosine (1.0 
eq) in anh. THF (1.5 mL) and the solution was stirred for 20 min, after which the amino 
acid ester α-naphthyl amino acid ester phosphochloridate (2.0 eq) in anh. THF (1.5 mL) 
was added. The solution was stirred overnight at room temperature before the removal 
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of solvent under reduced pressure. The residue was purified on by flash chromatography 
using CHCl3/MeOH as eluents. 
 
Standard procedure E: Preparation of phosphorodiamidates. 
To a suspension of the nucleoside (1.0 eq) in anh. THF was added NEt3 (1.2 eq). After 
stirring for 30 min at room temperature, POCl3 (1.2 eq) is added dropwise at -78 °C and 
the reaction mixture is stirred 30 min at -78 °C, then allowed to warm to room 
temperature over 30 min. Anh. DCM was added, followed by the amino acid ester 
salt/amine (5.0 eq) and NEt3  (10.0 eq.) at -78 °C. After stirring at room temperature 
overnight, water was added and the layers were separated. The aqueous phase was 
extracted with DCM and the organic phase washed with brine. The combined organic 
layers are dried over anh. Na2SO4, filtered and evaporated to dryness. The resulting 
residue is purified by flash chromatography column chromatography using a gradient of 
DCM/MeOH.  
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3. Experimental procedures related to chapter 3 
3.1. Preparation of β-2’-C-methyl-6-O-methyl guanosine phosphoramidates 
3.1.1. Preparation of protected amino acid esters 
Preparation of Boc protected L-Phenylglycine-neopentyl ester  
O
O
N
H
O
O
 
Prepared according to standard procedure A, using N-Boc-L-α-phenylglycine (1.69 g, 
6.72 mmol, 1.0 eq) in anh. DCM (31 mL) was added the neopentyl alcohol (0.83 g, 9.42 
mmol, 1.4 eq), DCC (1.39 g, 6.76 mmol, 1.0 eq) and DMAP (0.08 g, 0.68 mmol, 0.1 
eq). After overnight stirring, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography using Hexane/EtOAc (9:1) to afford a 
white solid (1.88 g, 5.84 mmol, 87%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.42-7.34 (m, 5H, Ph), 5.25 (s, 1H, CH), 3.92 & 
3.76 (AB system, 2H, J = 10.5 Hz, OCH2C(CH3)3), 1.47 (s, 9H, NHCOOC(CH3)3), 0.84 
(s, 9H, OCH2C(CH3)3). 
 
Preparation of Boc protected L-Phenylglycine-benzyl ester  
O
O
N
H
O
O
 
Prepared according to standard procedure A, using N-Boc-L-α-phenylglycine (1.52 g, 
6.06 mmol, 1.0 eq) in anh. DCM (33 mL) was added the benzyl alcohol (0.85 mL, 8.20 
mmol, 1.4 eq), DCC (1.26 g, 6.26 mmol, 1.0 eq) and DMAP (0.07 g, 0.60 mmol, 0.1 
eq). After overnight stirring, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography using Hexane/EtOAc (9:1) to afford a 
white solid (1.35 g, 3.95 mmol, 65%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.36 to 7.34 (m, 5H, Ph), 7.31 (m, 3H, 
OCH2Ph), 7.22 (t, 2H, J = 3.5 Hz, OCH2Ph), 5.56 (m, 1H, NH), 5.40 (d, 1H, J = 7 Hz, 
CH), 5.18-5.15 (m, 2H, OCH2Ph), 1.46 (s, 9H, NHCOOC(CH3)3). 
 
Claire Bourdin  Chapter Eight: Experimental section 
 
162 
3.1.2.  Preparation of amino acid ester salts or free amino acids 
Preparation of L-Phenylglycine-neopentyl ester tosylate salt (12.a) 
O
O
NH3
+
S
O
-O
O
 
Prepared according to standard procedure B1, using Boc protected L-phenylglycine 
neopentyl ester (1.05 g, 3.27 mmol, 1.0 eq), pTSA (0.63 g, 3.31 mmol, 1.0 eq) dissolved 
in EtOAc (37 mL) and refluxed overnight. The solution was then cooled down to RT 
and the product precipitated. After filtration and diethyl ether washes a white solid was 
recovered white product (0.88 g, 2.25 mmol, 68%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.68 (bs, 3H, NH3+), 7.57 (d, J = 8.0 Hz, 2H, 2 x 
CH ortho Ts), 7.49 -7.33 (m, J = 7.5 Hz, 5H, 2 x CH meta Ts, 2 x CH meta Ph, CH para 
Ph), 7.08 (d, J = 7.5 Hz, 2H, 2 x CH ortho Ph), 5.10 (s, 1H, CH), 3.81 & 3.67 (AB 
system, J = 10.3 Hz, 2H, OCH2C(CH3)3), 2.37 (s, 3H, CH3 Ts), 0.72 (s, 9H, 
OCH2C(CH3)3). 
 
Preparation of L-Phenylglycine-benzyl ester tosylate salt (12.b) 
O
O
NH3
+
S
O
-O
O
 
Prepared according to standard procedure B1, using Boc protected L-phenylglycine 
benzyl ester (1.35 g, 3.95 mmol, 1.0 eq), pTSA (0.75 g, 3.91 mmol, 1.0 eq) dissolved in 
EtOAC (44 mL) and refluxed overnight. The solution was then cooled down to RT and 
the product precipitated. After filtration and diethyl ether washes a white solid was 
recovered (1.53 g, 3.71 mmol, 94%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.70 (bs, 3H, NH3+), 7.54 (d, 2H, J = 8.0 Hz, 2 x 
CH ortho Ts), 7.31-7.14 (m, 7H, CH Bn, 2  x CH meta Ts), 7.06 (d, 2H, J = 7.0 Hz, 2 x 
CH ortho Ph), 7.01 (d, 3H, J = 8.0 Hz, 2 x CH meta, CH para Ph), 5.14 (s, 1H, CH), 
5.03 & 4.95 (AB system, 2H, J =12.5 Hz, OCH2Ph), 2.33 (s, 3H, CH3 Ts). 
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3.1.3. Preparation of α-naphthyl phosphorodichloridate (13)2 
O
P
O
Cl
Cl 	  
Phosphorus oxychloride (1.95 mL, 20.9 mmol, 1.0 eq) and α-naphthol (3.01 g, 20.9 
mmol, 1.0 eq) were stirred in anh. Et2O (20 mL) under argon. Anh. NEt3 (2.91 mL, 20.9 
mmol, 1.0 eq) was added at -78 °C and stirred for 30 min, then the solution was allowed 
to warm to room temperature over 45 min. The triethylamine chloride salt was filtered 
under reduced pressure to give bright yellow oil (2.7936 g, 10.7 mmol, 51%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.13 (d, 1H, J = 8.5 Hz, H-8 Ar), 7.93 (d, 1H, J 
= 8.0 Hz, H-6 Ar), 7.84 (d, 1H, J = 8.5 Hz, H-4 Ar), 7.61 (m, 3H, H-9, H-7, H-3 Ar), 
7.49 (t, 1H, J = 7.75 Hz, H-2 Ar). 
31P (202 MHz, CDCl3) δP (ppm): 3.74 (s). 
 
3.1.4. Preparation of α-naphthyl phosphorochloridates 
Preparation of α-naphthyl L-Phenylglycine-neopentyl phosphochloridate (14.a) 
O
P
O
HN
Cl
O
O
 
Prepared according to procedure C, using L-phenylglycine-neopentyl ester tosylate salt 
(12.a) (0.71 g, 1.80 mmol, 1.0 eq) in anh. DCM (10.5 mL), α-naphthyl 
phosphorodichloridate (13) (0.51 g, 1.95 mmol, 1.0 eq) and NEt3 (0.52 mL, 3.73 mmol, 
2.0 eq). The solvent was removed under reduced pressure and the residue purified by 
flash chromatography using Hexane/EtOAc (1:1) to obtain the desired molecule (0.61 g, 
1.38 mmol, 76%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.11-8.01 (m, 1H, H-8 Ar), 7.82 (d, 1H, J = 8.0 
Hz, H-6 Ar), 7.68 (d, 1H, J = 8.0 Hz, H-4 Ar), 7.55-7.46 (m, 3H, H-3, H-9, H-7 Ar), 
7.40-7.08 (m, 6H, 5 x CH Ph, H-2 Ar), 5.31-4.91 (m, 4H, NHCHPhCO, NHCHPhCO, 
OCH2C(CH3)3), 0.81 (s, 9H, OCH2C(CH3)3). 
 31P NMR (202 MHz, CDCl3) δP (ppm): 7.72 (s), 7.44 (s). 
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Preparation of α-naphthyl L-Phenylglycine-benzyl ester phosphochloridate (14.b) 
O P
O
Cl
O
O
NH
 
Prepared according to procedure C, using L-phenylglycine-benzyl ester tosylate salt 
(12.b) (1.11 g, 2.69 mmol, 1.0 eq) in anh. DCM (5 mL), α-naphthyl 
phosphorodichloridate (13) (0.72 g, 2.74 mmol, 1.0 eq) and NEt3 (0.76 mL, 5.45 mmol, 
2.0 eq). The solvent was removed under reduced pressure and the residue purified by 
flash chromatography using Hexane/EtOAc (1:1), to obtain the desired molecule (0.92 
g, 1.98 mmol, 73%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.11-8.01 (m, 1H, H-8 Ar), 7.82 (d, 1H, J = 8.0 
Hz, H-6 Ar), 7.68 (d, 1H, J = 8.0 Hz, H-4 Ar), 7.55-7.46 (m, 3H, H-3, H-9, H-7 Ar), 
7.40-7.08 (m, 11H, 5 x CH Ph, 5 x CH OCH2Ph, H-2 Ar), 5.31-4.91 (m, 4H, 
NHCHPhCO, NHCHPhCO, OCH2Ph). 
 31P NMR (202 MHz, CDCl3) δP (ppm): 7.50 (s), 7.24 (s). 
 
Preparation of α-naphthyl L-Phenylglycine-cyclopropylmethyl ester 
phosphochloridate (14.c) 
Cl
P
O
H
N
O
O
O
 
Prepared according to procedure C, using L-alanine-cyclopropylmethyl ester tosylate 
salt (0.61 g, 1.92 mmol, 1.0 eq) in anh. DCM (11 mL), α-naphthyl 
phosphorodichloridate (13) (0.54 g, 2.06 mmol, 2.0 eq) and anh. NEt3 (0.54 mL, 3.84 
mmol, 2.0 eq). The solvent was removed under reduced pressure and the residue 
purified by flash chromatography using Hexane/EtOAc (1:1) to yield the desired 
molecule (0.65 g, 1.86 mmol, 97%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.10-8.08 (d, 1H, J = 9.0 Hz, H-8 Ar), 7.84 (d, 
1H, J = 6.0 Hz, H-6 Ar), 7.70 (d, 1H, J = 8.0 Hz, H-4 Ar), 7.61 (t, 1H, J = 5.0 Hz, H-3 
Ar), 7.52 (m, 2H, H-7, H-9 Ar), 7.51 (m, 1H, H-2 Ar), 4.93 (m, 1H, NHCH(CH3)CO), 
4.33 (m, 1H, NHCH(CH3)CO), 4.02 (m, 2H, OCH2cProp), 1.15 (d, 3H, J =2.5 Hz, 
Claire Bourdin  Chapter Eight: Experimental section 
 
165 
NHCH(CH3)CO), 0.85 (m, 1H, CH cProp), 0.51 (m, 2H, 2 x CH cProp), 0.45 (m, 2H, 2 
x CH cProp). 
 31P NMR (202 MHz, CDCl3) δP (ppm): 8.38 (s), 8.22 (s). 
 
3.1.5. Preparation of β-2’-C-methyl-6-O-methyl guanosine ProTides 
Synthesis of α-naphthyl L-Phenylglycine-neopentyl ester β-2’-C-methyl-6-O-methyl 
guanosine phosphoramidate (15.a) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H O
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 1.38 mL, 1.38 mmol, 2.0 eq), β-2’-C-Me-6-OMe guanosine (11)  (0.22 g, 0.70 
mmol, 1.0 eq) in anh. THF (1.3 mL) and α-naphthyl L-Phenylglycine neopentyl ester 
phosphochloridate (14.a) (0.61 g, 1.38 mmol, 2 eq) in anh. THF (1.3 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography using CHCl3/MeOH as eluents to yield a 
white solid (0.23 g, 0.32 mmol, 46%). 
HPLC (MeOH/H2O): Rt = 13.37 min, 14.40 min. 
HPLC (ACN/ H2O): Rt = 21.33 min. 
MS (TOF ES+): 721.28 (M + H+), 759.23 (M + K+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.01 (m, 2H, H-8 Ar diastereoisomers), 7.83 (m, 
4H, H-6 Ar, H-8 base diastereoisomers), 7.66 (m, 2H, H-4 Ar diastereoisomers), 7.58-
7.25 (m, 18H, H-2, H-3, H-7, H-9 Ar, 5 x CH Ph diastereoisomers), 6.01 & 5.89 (2s, 
2H, H-1’ diastereoisomers), 5.20-5.12 (m, 6H, OCH2C(CH3)3, NHCHPhCO 
diastereoisomers), 4.70-4.58 (m, 2H, H-5’ diastereoisomers), 4.51-4.45 (m, 2H, H-5’ 
diastereoisomers), 4.45-4.32 (m, 2H, H-4’diastereoisomers), 4.19-4.16 (m, 2H, H-3’ 
diastereoisomers), 4.10 & 4.08 (2s, 6H, 6-O-CH3 base diastereoisomers), 0.91 & 0.90 
(2s, 6H, CH3-2’ diastereoisomers), 0.74 & 0.73 (2s, 18H, OCH2C(CH3)3 
diastereoisomers).  
13C NMR (125 MHz, CDCl3) δC (ppm): 172.89 & 172.21 (2d, J3P-N-C-C = 7.45 Hz, 
NHCHPhCO diastereoisomers), 161.65 (s, C-6 base), 159.41 (s, C-2 base), 152.80 (s, 
C-4 base), 145.02 (s, C-1 Ar), 137.75 & 137.68 (2s, C-8 base diastereoisomers), 137.55 
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(s, C-1 Ph), 134.73 (s, C-5 Ar), 128.79 & 128.65 & 128.51 & 128.37  (4s, C-2, C-3, C-
5, C-6 Ph), 127.78 & 127.67 (2s, C-6 Ar diastereoisomers), 126.90 & 126.71 & 126.61 
& 126.58 & 126.35 & 125.41 & 125.36 & 125.10 (8s, C-3, C-7, C-8, C-10 Ar 
diastereoismers), 124.98 (s, C-9 Ar), 121.41 (s, C-4 Ar), 115.09 (s, C-2 Ar), 115.07 (s, 
C-5 base), 91.65 & 91.57 (2s, C-1’ diastereoisomers), 82.05 & 81.86 (2d, J3 P-O-C-C = 6.3 
Hz, C-4’ diastereoisomers), 80.77 & 80.45 (2s, OCH2C(CH3)3 diastereoisomers), , 79.27 
& 79.17 (2s, C-2’ diastereoisomers), 74.64 & 74.27 (2s, C-3’ diastereoisomers), 66.24 
& 65.76 (2d, J2P-O-C = 5.04 Hz, C-5’ diastereoisomers), 58.45 & 58.27 (2s, NHCHPhCO 
diastereoisomers), 53.89 (s, 6-O-CH3 base), 31.41 (s, OCH2C(CH3)3), 26.03 & 26.01 
(2s, OCH2C(CH3)3 diastereoisomers), 20.37 & 20.32 (2s, CH3-2’ diastereoisomers).  
31P NMR (202 MHz, CDCl3) δP (ppm): 3.97 (s) (62%), 3.60 (s) (38%). 
 
Synthesis of α-naphthyl L-Phenylglycine-benzyl ester β-2’-C-methyl-6-O-methyl 
guanosine phosphoramidate (15.b) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H O
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 1.49 mL, 1.49 mmol, 2.0 eq), β-2’-C-methyl-6-O-methyl guanosine (11) (0.23 
g, 0.75 mmol, 1.0 eq) in anh. THF (1.5 mL), and α-naphthyl L-Phenylglycine benzyl 
ester phosphochloridate (14.b) (0.69 g, 1.49 mmol, 2.0 eq) in anh. THF (1.5 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography using CHCl3/MeOH as eluents to yield a 
white solid (0.16 g, 0.22 mmol, 32%). 
HPLC (MeOH/H2O): Rt = 19.35 min, 19.89 min. 
HPLC (ACN/ H2O): Rt = 23.54 min. 
MS (TOF ES+): 741.25 (M + H+), 763.23 (M + Na+), 779.21 (M + K+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.02-8.00 (m, 2H, H-8 Ar diastereoisomers), 
7.85 (m, 4H, H-6 Ar, H-8 base diastereoisomers), 7.66 & 7.64 (2d, 2H, J = 8.5 Hz, H-4 
Ar diastereoisomers), 7.58-7.13 (m, 28H, H-2, H-3, H-7, H-9 Ar, 5 x CH Ph, 5 x CH 
OCH2Ph diastereoisomers), 5.84 & 5.81 (2s, 1H, H-1’ diastereoisomers), 5.18-5.07 (m, 
6H, OCH2Ph, NHCHPhCO diastereoisomers), 4.53-4.49 (m, 2H, H-5’ 
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diastereoisomers), 4.36-4.34 (m, 1H, H-5’ diastereoisomers), 4.30-4.25 (m, 2H, H-4’ 
diastereoisomers), 4.18-4.16 (m, 2H, H-3’ diastereoisomers), 4.03 & 4.02 (2s, 3H, 6-O-
CH3 base diastereoisomers), 0.90 & 0.89 (2s, 3H, CH3-2’ diastereoisomers).  
13C NMR (125 MHz, CDCl3) δC (ppm): 172.54 & 172.18 (2d, J3P-N-C-C = 7.50 Hz, 
NHCHPhCO diastereoisomers), 161.67 (s, C-6 base), 159.38 (s, C-2 base), 152.80 (s, 
C-4 base), 145.43 (s, C-1 Ar), 137.69 & 137.25 (2s, C-8 base diastereoisomers), 134.68 
(s, C-1 Ph), 132.79 (s, C-5 Ar), 128.90  & 128.76 (2s, C-2, C-6 Ph), 128.46 & 128.33 
(2s, C-3, C-5 OCH2Ph), 127.83 & 127.77 & 127.69 (4s, C-3, C-5 Phe, C-6 Ar), 126.90 
& 126.63 & 126.39 (3s, C-2, C-4, C-6 OCH2Ph, C-4 Ph), 125.67 & 125.36 & 125.12 & 
124.98 (2s, C-3, C-7, C-8, C-10 Ar), 124.70 (s, C-9 Ar), 121.40 (s, C-4 Ar), 115.98 (s, 
C-2 Ar), 114.78 (s, C-5 base), 91.84 & 91.62 (2s, C-1’ diastereoisomers), 81.16 & 81.08 
(2s, C-4’ diastereoisomers), 79.80 & 79.29 (2s, C-2’ diastereoisomers), 74.86 & 74.54 
(2s, C-3’ diastereoisomers), 67.68 & 67.42 (2s, OCH2Ph diastereoisomers), 66.24 & 
65.76 (2s, C-5’ diastereoisomers), 58.55 & 58.28 (2s, NHCHPhCO diastereoisomers), 
53.90 & 53.82 (2s, 6-O-CH3 base diastereoisomers), 20.36 & 20.31 (2s, CH3-2’ 
diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 3.82 (s) (20%), 3.41 (s) (80%). 
 
Synthesis of α-naphthyl L-Alanine-cyclopropylmethyl ester β-2’-C-methyl-6-O-methyl 
guanosine phosphoramidate (15.c) 
N
N
N
O
NH2
N
O
OHOH
O
P
O
O
NH
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 1.90 mL, 1.90 mmol, 2eq), β-2’-C-Me-6-OMe guanosine (11) (0.29 mg, 0.93 
mmol, 1.0 eq) in anh. THF (2.0 mL), and α-naphthyl L-Alanine-cyclopropylmethyl ester 
phosphochloridate (14.c) (0.65 g, 1.86 mmol, 2.0 eq) in anh. THF (2.0 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography using CHCl3/MeOH as eluents to yield a 
white solid (0.19 g, 0.30 mmol, 32%). 
HPLC (MeOH/H2O): Rt = 13.04 min, 13.65 min. 
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HPLC (ACN/H2O): Rt = 22.54 min. 
MS (TOF ES+): 643.25 (M + H+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.13-8.05 (m, 2H, H-8 Ar diastereoisomers), 
7.81-7.75 (m, 4H, H-6 Ar, H-8 base diastereoisomers), 7.63-7.58 (m, 2H, H-4 Ar 
diastereoisomers), 7.53-7.45 (m, 6H, H-2, H-3, H-7 Ar diastereoisomers), 7.37-7.02 (m, 
2H, H-9 Ar diastereoisomers), 5.98 & 5.96 (2s, 2H, H-1’ diastereoisomers), 4.73-4.70 
(m, 2H, H-5’ diastereoisomers), 4.66-4.61 (m, 2H, H-5’ diastereoisomers), 4.52-4.46 
(m, 2H, H-3’ diastereoisomers), 4.23-4.19 (m, 1H, H-4’ diastereoisomers), 4.11-4.07 
(m, 2H, NHCH(CH3)CO diastereoisomers), 4.03 & 4.01 (2s, 6H, 6-OCH3 base 
diastereoisomers), 3.87-3.73 (m, 4H, OCH2-cProp diastereoisomers), 1.36-1.33 (m, 6H, 
NHCH(CH3)CO diastereoisomers), 0.99-0.95 (m, 2H, C-1 cProp diastereoisomers), 
0.92 & 0.89 (2s, 6H, CH3-2’ diastereoisomers),  0.47-0.45 (m, 4H, 4 x CH cProp 
diastereoisomers), 0.18-0.15 (m, 4H, 4 x CH cProp diastereoisomers). 
13C NMR (125 MHz, CDCl3) δc (ppm): 173.85 & 173.53 (2d, J3P-N-C-C = 7.56 Hz, 
NHC(CH3)CO diastereoisomers), 161.59 (s, C-6 base), 159.58 (s, C-2 base), 152.89 (s, 
C-4 base), 146.43 (s, C-1 Ar), 137.65 (s, C-8 base), 134.72 & 134.69 (2s, C-5 Ar 
diastereoisomers), 127.78 & 127.65 (2s, C-6 Ar diastereoisomers), 126.69 & 126.65 & 
126.55 & 126.45 (4s, C-7, C-8 Ar diastereoisomers), 126.37 & 126.32 (2s, C-10 Ar 
diastereoisomers), 125.48 & 125.42 (2s, C-3 Ar diastereoisomers), 124.97 & 124.91 (2s, 
C-9 Ar diastereoisomers), 121.48 & 121,42 (2s, C-4 Ar diastereoisomers), 115.03 (s, C-
2 Ar), 114.91 (s, C-5 base), 91.61 & 91.52 (2s, C-1’ diastereoisomers), 80.96 & 80.79 
(2d, J3P-O-C-C = 7.5 Hz, C-4’ diastereoisomers), 79.16 & 79.12 (2s, C-2’ 
diastereoisomers), 73.95 (s, C-3’), 70.40 & 70.38 (2s, OCH2-cProp diastereoisomers), 
66.14 & 65.78 (2s, C-5’ diastereoisomers), 53.88 (s, 6-OCH3 base), 50.46 & 50.40 (2d, 
J2P-N-C = 7.5 Hz, NHCH(CH3)CO diastereoisomers), 20.92 & 20.74 (2d, J3P-N-C-C = 5.0 
Hz, NHCH(CH3)CO diastereoisomers), 20.51 & 20.21 (2s, CH3-2’ diastereoisomers), 
9.74 & 9.54 (2s , C-1 cProp diastereoisomers), 3.19 & 3.14 (2s, CH2 cProp 
diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 4.07 (s) (43%), 3.90 (s) (57%). 
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3.2. Preparation of β-2’-C-methyl-6-O-methyl guanosine phosphorodiamidates 
3.2.1. Preparation of protected amino acid esters 
Preparation of Boc protected L-Leucine-neopentyl ester  
N
H
OO
O
O
 
Prepared according to standard procedure A, using N-Boc-L-Leucine (4.01 g, 17.3 
mmol, 1.0 eq) in anh. DCM (95 mL) was added the neopentyl alcohol (2.00 g, 22 mmol, 
1.3 eq), DCC (3.57 g, 17.3 mmol, 1.0 eq) and DMAP (1.729 g, 0.21 mmol, 0.1 eq). 
After overnight stirring, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography using Hexane/EtOAc (9:1) to afford a 
white solid (5.16 g, 17.12 mmol, 99%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 4.96 (d, 1H, J = 6.9 Hz, NH), 4.33 (d, 1H, J = 
5.5 Hz, NHCH(CH2CH(CH3)2)CO), 3.82 & 3.77 (AB system, 2H, J = 10.55 Hz, 
OCH2C(CH3)3), 1.73 (m, 1H, NHCH(CH2CH(CH3)2)CO), 1.59 (m, 1H, 
NHCH(CH2CH(CH3)2)CO), 1.48 (m, 1H, NHCH(CH2CH(CH3)2)CO), 1.42 (s, 9H, 
NHCOOC(CH3)3), 0.94 (s, 9H, OCH2C(CH3)3), 0.93 (s, 6H, 
NHCH(CH2CH(CH3)2)CO). 
Preparation of Boc protected L-Leucine-cyclohexyl ester 
NH
O
O
O
O
 
Prepared according to standard procedure A, using N-Boc-L-Leucine (4.73 g, 20.5 
mmol, 1.0 eq) in anh. DCM (95 mL) was added the cylohexanol (4.30 mL, 40.9 mmol, 
2.0 eq), DCC (4.23 g, 20.5 mmol, 1.0 eq) and DMAP (0.25 g, 2.05 mmol, 0.1 eq). After 
overnight stirring, the solvent was removed under reduced pressure and the residue was 
purified by flash chromatography using Hexane/EtOAc (9:1) to afford colourless oil 
(4.24 g, 13.53 mmol, 66%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 4.95 (bs, 1H, NH), 4.79 (m, 1H, CH cHex), 4.24 
(m, 1H, NHCH(CH2CH(CH3)2)CO), 1.81 (m, 4H, 2 x CH2 ortho cHex), 1.70 (m, 6H, 2 
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x CH2 meta cHex & CH2 para cHex), 1.56-1.49 (m, 3H, NHCH(CH2CH(CH3)2)CO), 
1.43 (s, 9H, NHCOOC(CH3)3), 0.93 (s, 6H, NHCH(CH2CH(CH3)2)CO). 
Preparation of Boc protected L-Phenylalanine-neopentyl ester  
N
H
OO
O
O
 
Prepared according to standard procedure A, using N-Boc-L-Phenylalanine (4.00 g, 15.1 
mmol, 1.0 eq) in anh. DCM (83 mL), neopentyl alcohol (1.73 g, 19.6 mmol, 1.3 eq), 
DCC (3.12 g, 15.1 mmol, 1.0 eq) and DMAP (0.19 g, 1.51 mmol, 0.1 eq). After 
overnight stirring, the solvent was removed under reduced pressure and the residue was 
purified by flash chromatography using Hexane/EtOAc (9:1) to afford a white solid 
(5.26 g, 14.68 mmol, 97%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.26 (m, 2H, 2 x CHmeta Ph), 7.20 (m, 1H, CH 
para Ph), 7.13 (m, 2H, 2 x CH ortho Ph), 5.06 (d, 1H, J = 6.95 Hz, NH), 4.59 (d, 1H, J = 
6.8 Hz, CH), 3.82 & 3.68 (AB system, 2H, J = 10.5 Hz, OCH2C(CH3)3), 3.06 (m, 2H, 
CH2Ph), 1.39 (s, 9H, NHCOOC(CH3)3), 0.88 (s, 9H, OCH2C(CH3)3). 
Preparation of Boc protected L-Phenylalanine-cyclohexyl ester  
N
H
OO
O
O
 
Prepared according to standard procedure A, using N-Boc-L-Phenylalanine (4.22 g, 15.9 
mmol, 1.0 eq) in anh. DCM (85 mL), cyclohexanol (3.40 mL, 31.8 mmol, 2.0 eq), DCC 
(3.30 g, 15.9 mmol, 1.0 eq) and DMAP (0.21 g, 1.59 mmol, 0.1 eq). After overnight 
stirring, the solvent was removed under reduced pressure and the residue was purified 
by flash chromatography using Hexane/EtOAc (9:1) to afford a colourless oil (5.19 g, 
4.94 mmol, 94%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.28 (m, 2H, 2 x CH ortho Ph), 7.24 (m, 1H, H 
para Ph), 7.16 (m, 2H, 2 x CH meta Ph), 5.03 (d, 1H, J = 5.0 Hz, NH), 4.79 (m, 1H, CH 
cHex), 1.80 (m, 4H, 2 x CH2 ortho cHex), 1.69 (m, 4H, 2 x CH2 meta cHex), 1.69 (m, 
2H, CH2 para cHex), 1.51 (s, 9H, NHCOOC(CH3)3). 
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Preparation of Boc protected L-Alanine-cyclopentyl ester  
 
Prepared according to standard procedure A, using N-Boc-L-Alanine (7.00 g, 37.0 
mmol, 1.0 eq) in anh. DCM (140 mL) was added the cyclopentyl alcohol (4.40 mL, 48.1 
mmol, 1.3 eq), DCC (7.66 g, 37.0 mmol, 1.0 eq) and DMAP (0.463 g, 3.70 mmol, 0.1 
eq). After overnight stirring, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography using Hexane/EtOAc (9:1) to afford a 
white solid (7.82 g, 30.3 mmol, 82%). 
1H NMR (500 MHz, MeOD) δH (ppm): 5.20 (m, 1H, CH cPent), 4.11-4.05 (m, 1H, 
NHCH(CH3)CO), 1.88 (m, 2H, CH2 cPent), 1.76-1.72 (m, 6H, 3  x CH2 cPent), 1.45 (s, 
9H, NHCOOC(CH3)3), 1.33 (d, 3H, J = 7.30 Hz, NHCH(CH3)CO). 
Preparation of Fmoc-Tyrosine-(tert-butyl)-neopentyl ester  
N
H
OO
O
O
O
 
Prepared according to standard procedure A, using using Fmoc-L-tert-butyl)-OH (3.04 
g, 6.61 mmol, 1.0 eq) in anh. DCM (61 mL) was added the neopentyl alcohol (1.17 g, 
13.2 mmol, 2.0 eq), DCC (1.36 g, 6.61 mmol, 1.0 eq) and DMAP (0.081 g, 0.66 mmol, 
0.1 eq). After overnight stirring, the solvent was removed under reduced pressure and 
the residue was purified by flash chromatography using Hexane/EtOAc (9:1) to afford a 
white solid (3.28 g, 6.19 mmol, 94%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.76 (d, 2H, J = 7.55 Hz, 2 x CH Fmoc), 7.60 (t, 
2H, J = 7.30 Hz, 2 x CH Fmoc), 7.40 (t, 2H, J = 7.45 Hz, 2 x CH Fmoc), 7.32 (m, 2H, 2 
x CH Fmoc), 7.08 (d, 2H, J = 8.15 Hz, 2 x CH ortho Ar), 6.94 (d, 2H, J = 8.20 Hz, 2 x 
CH meta Ar), 5.60 (d, 1H, J = 8.35 Hz, NH), 4.74 (q, 1H, J = 7.85 Hz, 
NHCH(CH2ArOC(CH3)3)CO), 4.45 (m, 1H, CH2 Fmoc), 4.43 (m, 1H, CH2 Fmoc), 4.35 
(t, 1H, J = 7.10 Hz, CH Fmoc), 3.88 & 3.80 (AB system, 2H, J = 10.5 Hz, 
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OCH2C(CH3)3), 3.18-3.07 (m, 2H, NHCH(CH2ArOC(CH3)3)CO), 1.35 (s, 9H, 
NHCH(CH2ArOC(CH3)3)CO), 0.88 (s, 9H, OCH2C(CH3)3). 
 
Preparation of Boc protected L-Tyrosine-(tert-butyl)-cyclohexyl ester  
 
Prepared according to standard procedure A, using N-Boc-L-Tyrosine-O-tert-butyl 
(5.00 g, 14.8 mmol, 1.0 eq) in anh. DCM (100 mL) was added the cyclohexanol (3.09 
mL, 29.6 mmol, 1.3 eq), DCC (3.10 g, 14.8 mmol, 1.0 eq) and DMAP (0.19 g, 1.48 
mmol, 0.1 eq). After overnight stirring, the solvent was removed under reduced pressure 
and the residue was purified by flash chromatography using Hexane/EtOAc (9:1) to 
afford a white solid (6.20 g, 14.78 mmol, 99%). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.14 (d, 2H, J = 8.35 Hz, 2 x CH ortho Ar), 6.92 
(d, 2H, J = 8.25 Hz, 2 x CH meta Ar), 4.76-4.73 (m, 1H, CH cHex), 4.33 (m, 1H, 
NHCH(CH2ArOC(CH3)3)CO), 3.06-3.02 (m,1H, NHCH(CH2ArOC(CH3)3)CO), ), 2.93-
2.89 (m, 1H, NHCH(CH2ArOC(CH3)3)CO), ), 1.92-1.53 (m, 10H, 2 x CH2 meta cHex 
& 2 x CH2 ortho cHex & CH2 para cHex), 1.42 (s, 9H, NHCH(CH2ArOC(CH3)3)CO), ), 
1.36 (s, 9H, NHCOOC(CH3)3). 
 
Preparation of Fmoc-Tyrosine-(tert-butyl)-cyclohexyl ester  
 
Prepared according to standard procedure A, using Fmoc-L-tert-butyl)-OH (3.12 g, 6.80 
mmol, 1.0 eq) in anh. DCM (63 mL) was added the cyclohexanol (1.42 mL, 13.6 mmol, 
2.0 eq), DCC (1.40 g, 6.80 mmol, 1.0 eq) and DMAP (0.083 g, 0.68 mmol, 0.1 eq). 
After overnight stirring, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography using Hexane/EtOAc (9:1) to afford a 
white solid (3.67 g, 6.78 mmol, 99%). 
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1H NMR (500 MHz, CDCl3) δH (ppm): 7.68 (d, 2H, J = 7.55 Hz, 2 x CH Fmoc), 7.56-
7.52 (m, 2H, 2 x CH Fmoc), 7.33-7.30 (m, 2H, 2 x CH Fmoc), 7.25-7.21 (m, 2H, 2 x 
CH Fmoc), 7.04 (d, 2H, J = 8.15 Hz, 2 x CH ortho Ar), 6.87 (d, 2H, J = 8.25 Hz, 2 x 
CH meta Ar), 5.83 (d, 1H, J = 8.25 Hz, NH), 4.76-4.75 (m, 1H, CH cHex), 4.63-4.59 
(m, 1H, NHCH(CH2ArOC(CH3)3)CO), 4.41-4.34 (m, 2H, CH2 Fmoc), 4.29-4.26 (m, 
1H, CH Fmoc), 3.09-2.99 (m, 2H, NHCH(CH2ArOC(CH3)3)CO), 1.84-1.61 (m, 8H, 2 x 
CH2 meta cHex & 2 x CH2 ortho cHex), 1.53-1.36 (m, 2H, CH2 para cHex), 1.27 (s, 9H, 
NHCH(CH2ArOC(CH3)3)CO). 
 
Preparation of Fmoc-Tyrosine-(tert-butyl)-benzyl ester  
N
H
OO
O
O
O
 
Prepared according to standard procedure A, using N-Fmoc-L-Tyrosine(tert-butyl)-OH  
(2.02 g, 4.40 mmol, 1.0 eq) in anh. DCM (41 mL) was added the benzyl alcohol (0.17 
mL, 8.80 mmol, 2.0 eq), DCC (0.91 g, 4.40 mmol, 1.0 eq) and DMAP (0.054 g, 0.44 
mmol, 0.1 eq). After overnight stirring, the solvent was removed under reduced pressure 
and the residue was purified by flash chromatography using Hexane/EtOAc (9:1) to 
afford a white solid (2.28 g, 4.15 mmol, 94%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.79 (d, 2H, J = 7.45 Hz, 2 x CH Fmoc), 7.59 
(d, 2H, J = 7.15 Hz, 2 x CH Fmoc), 7.44-7.32 (m, 9H, 4 x CH Fmoc & 5 x OCH2Ph), 
6.92 (d, 2H, J = 8.10 Hz, 2 x CH ortho Ar), 6.86 (d, 2H, J = 8.30 Hz, 2 x CH meta Ar), 
5.28 (d, 1H, J = 8.00 Hz, NH), 5.20-5.14 (m, 2H, CH2 Fmoc), 4.70-4.68 (m, 1H, 
NHCH(CH2ArOC(CH3)3)CO), 4.59-4.35 (m, 2H, OCH2Ph), 4.32-4.28 (m, 1H, CH 
Fmoc), 3.11-3.0 (m, 2H, NHCH(CH2ArOC(CH3)3)CO), 1.34 (s, 9H, 
NHCH(CH2ArOC(CH3)3)CO).  
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3.2.2. Preparation of amino acid ester salts or free amino acids 
Preparation of L-Leucine-neopentyl ester tosylate salt (12.c) 
+H3N
OO
S
O
O
-O
 
Prepared according to standard procedure B1, using Boc protected L-Leucine neopentyl 
ester (5.16 g, 17.12 mmol, 1.0 eq), pTSA (3.30 g, 17.3 mmol, 1.0 eq) dissolved in 
EtOAc (190 mL) and refluxed overnight. The solution was then cooled down to RT and 
the product crashed down on an ice bath. After filtration and diethyl ether washes a 
white solid was recovered (2.83 g, 7.58 mmol, 44%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.23 (bs, 3H, NH3+), 7.79 (d, 2H, J = 8.1 Hz, 2 x 
CH ortho Ts), 7.15 (d, 2H, J = 8.0 Hz, 2 x CH meta Ts), 3.95 (t, 1H, J = 7.2 Hz, 
NHCH(CH2CH(CH3)2)CO), 3.82 & 3.74 (AB system, 1H, J = 10.5 Hz, OCH2C(CH3)3), 
2.36 (s, 3H, CH3 Ts), 1.71-1.62 (2m, 3H, NHCH(CH2CH(CH3)2)CO), 0.90 (s, 9H, 
OCH2C(CH3)3), 0.80 (d, 6H, NHCH(CH2CH(CH3)2)CO). 
 
Preparation of L-Leucine-cyclohexyl ester tosylate salt (12.d) 
+H3N
OOS
O
O
-O
 
Prepared according to standard procedure B1, using Boc protected L-Leucine-
cyclohexyl ester (4.24 g, 13.5 mmol, 1.0 eq) and pTSA (2.58 g, 13.5 mmol, 1.0 eq) 
dissolved in EtOAc (149 mL) and refluxed overnight (65°C). The solution was then 
cooled down to RT and the product crashed down on an ice bath. After filtration and 
diethyl ether washes a white solid was recovered (4.90 g, 12.7 mmol, 94%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.17 (s broad, 3H, NH3+), 7.79 (d, 2H, J = 7.95 
Hz, 2 x CH ortho Ts), 7.15 (d, 2H, J = 7.80 Hz, 2 x CH meta Ts), 4.78 (m, 1H, CH 
cHex), 3.91 (m, 1H, NHCH(CH2CH(CH3)2)CO), 2.38 (s, 3H, CH3 Ts), 1.77-1.64 (m, 
6H, CH2 ortho cHex, CH2 meta cHex, NHCH(CH2CH(CH3)2)CO), 1.51-1.49 (m, 3H, 
CH2 para cHex, NHCH(CH2CH(CH3)2)CO), 1.41-1.20 (m, 4H, CH2 ortho cHex, CH2 
meta cHex), 0.83 (t, 6H, J = 8.5 Hz, NHCH(CH2CH(CH3)2)CO).  
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Preparation of L-Phenylalanine-neopentyl ester tosylate salt (12.e) 
+H3N
OOS
O
O
-O
 
Prepared according to standard procedure B1, using Boc protected L-Phenylalanine 
neopentyl ester (5.26 g, 14.7 mmol, 1.0 eq), pTSA (3.02 g, 14.7 mmol, 1.01 eq) 
dissolved in EtOAc (174 mL) and refluxed overnight. The solution was then cooled 
down to RT and the product crashed down on an ice bath. After filtration and diethyl 
ether washes a white solid was recovered (1.24 g, 3.04 mmol, 19%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.29 (s broad, 3H, NH3+), 7.77 (d, 2H, J = 8.1 
Hz, 2 x CH ortho Ts), 7.19-7.11 (d, 8H, 2 x CH meta Ts, 5 x CH Ph), 4.34 (q, 1H, J = 
5.2 Hz, NHCH(CH2Ph)CO), 3.64 & 3.58 (AB system, 1H, J = 10.5 Hz, OCH2C(CH3)3), 
3.29 (dd, 1H, J = 5.2 & 14.2 Hz, NHCH(CH2Ph)CO), 3.10 (dd, 1H, J = 8.2 & 14.2 Hz, 
NHCH(CH2Ph)CO), 2.35 (s, 3H, CH3 Ts), 0.72 (s, 9H, OCH2C(CH3)3). 
 
Preparation of L-Phenylalanine-cyclohexyl ester tosylate salt (12.f) 
+H3N
OOS
O
O
-O
 
Prepared according to standard procedure B1, using Boc protected L-Phenylalanine-
cyclohecxyl ester (5.16 g, 14.9 mmol, 1.0 eq), pTSA (2.85 g, 15.0 mmol, 1.0 eq) 
dissolved in EtOAc (182 mL) refluxed overnight. The solution was then cooled down to 
RT and the product crashed down on an ice bath. After filtration and diethyl ether 
washes a white solid was recovered (3.77 g, 8.98 mmol, 60%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.20 (s broad, 3H, NH3+), 7.77 (d, 2H, J = 8.10 
Hz, 2 x CH ortho Ts), 7.19-7.14 (m, 7H, 2 x CH meta Ts, 5 x CH Ph), 4.66 (m, 1H, CH 
cHex), 4.28 (m, 1H, NHCH(CH2Ph)CO), 3.31-3.27 (m, 1H, NHCH(CH2Ph)CO), 3.14-
3.09 (m, 1H, NHCH(CH2Ph)CO), 2.36 (s, 3H, CH3 Ts), 1.62-1.53 (m, 4H, CH2 ortho 
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cHex, CH2 meta cHex), 1.44 (m, 2H, CH2 para cHex), 1.21-1.19 (m, 4H, CH2 ortho 
cHex & CH2 meta cHex).  
 
Preparation of S-methyl-L-Cysteine-neopentyl ester tosylate salt (12.g) 
+H3N
O
O
S
S
O
O
-O
 
Prepared according to standard procedure B2, using commercially available S-methyl-
L-Cysteine (2.56 g, 18.9 mmol, 1.0 eq), pTSA (3.96 g, 20.8 mmol, 1.1 eq) and 
neopentyl alcohol (25.0 g, 284 mmol, 15 eq) dissolved in toluene (28 mL) and refluxed 
overnight. The solution was then cooled down to RT and the product crashed down on 
an ice bath. After filtration and diethyl ether washes a white solid was recovered (6.53 
g, 17.3 mmol, 91%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.36 (bs, 3H, NH3+), 7.79 (d, 2H, J = 6.80 Hz, 2 
x CH ortho Ts), 7.15 (d, 2H, J = 6.80 Hz, 2 x CH meta Ts), 4.35 (m, 1H, 
CH(CH2SCH3)CO), 3.85 & 3.76 (AB system, 2H, J =10.2 Hz, OCH2C(CH3)3), 3.09 (bs, 
2H, CH(CH2SCH3)CO), 2.37 (s, 3H, CH3 Ts), 2.04 (s, 3H, CH(CH2SCH3)CO), 0.91 (s, 
9H, OCH2C(CH3)3).    
 
Preparation of S-methyl-L-Cysteine-cyclohexyl ester tosylate salt (12.h) 
+H3N
O
O
S
S
O
O
-O
 
Prepared according to standard procedure B2, using commercially available S-methyl-
L-Cysteine (2.51 g, 18.6 mmol, 1.0 eq), cyclohexanol (29 mL, 279 mmol, 15 eq) and 
pTSA (3.90 g, 20.4 mmol, 1.1 eq) dissolved in toluene (27 mL) and refluxed overnight. 
The solution was then cooled down to RT and the product crashed down on an ice bath. 
After filtration and diethyl ether washes a white solid was recovered (5.87 g, 15.07 
mmol, 81%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.32 (bs, 3H, NH3+), 7.79 (d, 2H, J = 8.10 Hz, 2 
x CH ortho Ts), 7.15 (d, 2H, J = 7.90 Hz, 2 x CH meta Ts), 4.82-4.77 (m, 1H, CH 
cHex), 4.29-4.27 (m, 1H, CH(CH2SCH3)CO), 3.17-3.04 (m, 2H, CH(CH2SCH3)CO), 
2.36 (s, 3H, CH3 Ts), 2.04 (s, 3H, CH(CH2SCH3)CO), 1.79-1.67 (4H, CH2 meta cHex, 
CH2 ortho cHex), 1.51-1.38 (m, 6H, CH2 meta cHex, CH2 ortho cHex, CH2 para cHex).    
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Preparation of S-methyl-L-Cysteine-benzyl ester tosylate salt (12.i) 
+H3N
O
O
SS
O
O
-O
 
Prepared according to standard procedure B2, using commercially available S-methyl-
L-Cysteine (2.50 g, 18.5 mmol, 1.0 eq), benzyl alcohol (25 mL, 240 mmol, 13 eq) and 
pTSA (3.87 g, 20.3 mmol, 1.0 eq) dissolved in toluene (27 mL) and refluxed overnight. 
The solution was then cooled down to RT and the product crashed down on an ice bath. 
After filtration and diethyl ether washes a white solid was recovered (2.09 g, 5.25 
mmol, 28%). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.74 (d, 2H, J = 8.15 Hz, 2 x CH ortho Ts), 
7.45-7.37 (m, 5H, 5 x CH Ph), 7.26 (d, 2H, J = 7.95 Hz, 2 x CH meta Ts), 5.31 (d, 2H, J 
= 2.50 Hz, OCH2Ph), 4.36-4.34 (m, 1H, CH(CH2SCH3)CO), 3.14 (dd, J = 4.70 Hz & 
14.85 Hz, 1H, CH(CH2SCH3)CO), 2.99 (dd, 1H, J = 7.45 Hz & 14.85 Hz, 
CH(CH2SCH3)CO), 2.39 (s, 3H, CH3 Ts), 2.11 (s, 3H, CH(CH2SCH3)CO).  
 
Preparation of L-Alanine-cyclopentyl ester tosylate salt (12.j) 
 
Prepared according to standard procedure B1, using L-Alanine-cyclopentyl ester (7.82 
g, 30.4 mmol, 1.0 eq), pTSA (5.78 g, 30.4 mmol, 1.0 eq) dissolved in EtOAc (275 mL) 
and refluxed overnight. The solution was then cooled down to RT and the product 
crashed down on an ice bath. After filtration and diethyl ether washes a white solid was 
recovered (7.00 g, 21.3 mmol, 70%). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.73 (d, 2H, J = 8.15 Hz, 2 x CH meta Ts), 7.25 
(d, 2H, J = 7.95 Hz, 2 x CH ortho Ts), 5.31-5.28 (m, 1H, CH cPent), 4.06-4.02 (m, 1H, 
NHCH(CH3)CO), 2.39 (s, 3H, CH3 Ts), 1.96-1.92 (m, 2H, CH2 (2) cPent), 1.79-1.74 
(m, 4H, CH2 (5) cPent, CH2 (3) cPent), 1.69-1.67 (m, 2H, CH2 (4) cPent), 1.52 (d, 3H, J 
= 7.25 Hz, NHCH(CH3)CO). 
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Preparation of L-Tyrosine-(tert-butyl)-neopentyl ester (12.k)  
H2N
O
O
O
 
Fmoc protected L-Tyrosine-(tert-butyl)-neopentyl ester (3.28 g, 6.19 mmol, 1.0 eq) was 
dissolved in  anh. DMF (15 mL) and morpholine (15 mL) was added. The solution was 
left stirring for 30 min at RT. The reaction was quenched by addition of 2-propanol. The 
solvents were evaporated under reduced pressure and the residue was purified by flash 
chromatography using petroleum ether/EtOAc (25%) to afford an oil corresponding to 
the desired material (1.87 g, 6.08 mmol, 98%).  
1H NMR (500 MHz, CDCl3) δH (ppm): 6.87 (d, 2H, J = 6.50 Hz, 2 x CH ortho Ar), 6.71 
(m, 2H, 2 x CH meta Ar), 3.49-3.41 (m, 1H, , NHCH(CH2ArOC(CH3)3)CO), 3.32 & 
3.20 (AB system, 2H, J = 9.50 Hz, OCH2C(CH3)3), 3.10-3.04 (m, 2H, 
NHCH(CH2ArOC(CH3)3)CO), 1.25 (s, 9H, NHCH(CH2ArOC(CH3)3)CO), 0.68 (s, 9H, 
OCH2C(CH3)3). 
 
Preparation of L-Tyrosine-(tert-butyl)-cyclohexyl ester (12.l) 
H2N
O
O
O
 
Route 1: Prepared according to standard procedure B1, using Boc protected L-Tyrosine-
(tert-butyl)-cyclohexyl ester (6.20 g, 14.8 mmol, 1.0 eq), pTSA (2.87 g, 14.8 mmol, 1.0 
eq) dissolved in EtOAc (217 mL) and refluxed overnight. The solution was then cooled 
down to RT and the product crashed down on an ice bath. The residue was filtered and 
washed with diethyl ether and dried to recover a white product (5.02 g, 11.5 mmol, 
78%) corresponding to the tert-butyl deprotected L-Tyrosine- cyclohexyl ester pTSA 
salt, described below. 
1H NMR (500 MHz, MeOD) δH (ppm): 7.73 (d, 2H, J = 8.20 
Hz, 2 x CH ortho Ts), 7.25 (d, 2H, J = 7.95 Hz, 2 x CH meta 
Ts), 7.09 (d, 2H, J = 8.50 Hz, 2 x CH ortho Ar), 6.79 (d, 2H, J 
= 8.55 Hz, 2 x CH meta Ar), 4.78 (m, 1H, CH cHex), 4.19 (t, 
1H, J = 6.90 Hz, NHCH(CH2ArOH)CO), 3.13-3.10 (m, 2H, 
NHCH(CH2ArOH)CO), 2.39 (s, 3H, CH3  Ts), 1.87-1.68 (m, 4H, CH2 meta cHex, CH2 
ortho cHex), 1.58-1.52 (m, 6H,  CH2 meta cHex & CH2 ortho cHex & CH2 para cHex). 
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Route 2: Fmoc protected L-Tyrosine-(tert-butyl)-cyclohexyl ester (3.67 g, 6.78 mmol, 
1.0 eq) was dissolved in  anh. DMF (11 mL) and morpholine (11 mL) was added. The 
solution was left stirring for 30 min at RT. After quenching by addition of 2-propanol. 
The solvents were evaporated under reduced pressure and the residue was purified by 
flash chromatography using petroleum ether/EtOAc (25%) to afford an oil 
corresponding to the desired material (1.96 g, 6.14 mmol, 91%).  
1H NMR (500 MHz, CDCl3) δH (ppm): 6.83 (t, 2H, J = 6.30 Hz, 2 x CH ortho Ar), 6.63 
(m, 2H, 2 x CH meta Ar), 4.49 (m, 1H, CH cHex), 3.38-3.36 (m, 1H, 
NHCH(CH2ArOC(CH3)3)CO), 2.71-2.68 (m, 1H, NHCH(CH2ArOC(CH3)3)CO), 2.60-
2.56 (m, 1H, NHCH(CH2ArOC(CH3)3)CO), 1.54-1.24 (m, 6H, CH2 ortho cHex, CH2 
meta cHex, CH2 para cHex), 1.06 (s, 9H, NHCH(CH2ArOC(CH3)3)CO), 0.98-0.96 (m, 
4H, CH2 ortho cHex, CH2 meta cHex). 
 
Preparation of L-Tyrosine-(tert-butyl)-benzyl ester (12.m) 
H2N
O
O
O
 
Fmoc protected L-Tyrosine-(tert-butyl)-benzyl ester (2.78 g, 5.04 mmol, 1.0 eq) was 
dissolved in  anh. DMF (15 mL) and morpholine (15 mL) was added. The solution was 
left stirring for 30 min at RT. The reaction was quenched by addition of 2-propanol. The 
solvents were evaporated under reduced pressure and the residue was purified by flash 
chromatography using petroleum ether/EtOAc (25%) to afford an oil corresponding to 
the desired material (1.50 g, 4.59 mmol, 91%).  
1H NMR (500 MHz, CDCl3) δH (ppm): 7.38-7.32 (m, 5H, 5 x CH Ph), 7.06 (d, 2H, J = 
8.45 Hz, 2 x CH ortho Ar), 6.91 (d, 2H, J = 8.45 Hz, 2 x CH meta Ar), 5.15 (s, 2H, 
OCH2Ph), 3.78-3.76 (m, 1H, NHCH(CH2ArOC(CH3)3)CO), 3.07-3.03 (m, 1H, 
NHCH(CH2ArOC(CH3)3)CO), 2.88-2.85 (m, 1H, NHCH(CH2ArOC(CH3)3)CO), 1.34 
(s, 9H, NHCH(CH2ArOC(CH3)3)CO). 
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3.2.3. Intermediate from TCE pathway 
Preparation of 2,2,2-trichloroethoxy phosphorodichloridate (16) 3 
P
O
Cl
O
Cl
Cl
ClCl  
To a solution of POCl3 (5.08 mL, 54.5 mmol, 1.0 eq) in anh. Et2O (125 mL) was added 
dropwise, at -80 °C under vigorous stirring, a solution of   2,2,2-trichloroethanol (5.25 
mL,5.45 mmol, 1.0 eq) and NEt3 (7.50 mL, 53.8 mmol, 0.99 eq) in anh. Et2O (100 mL). 
After the completion of addition, the solution was left 2hrs at -78 °C then the mixture 
was allowed to warm to RT while stirring overnight. The mixture was filtered with anh. 
Et2O and the solvent was removed under reduced pressure to yield the 
phosphorodichloridate as an orange oil. The product was purified by distillation (0.80 g, 
3.02 mmol, 6%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 4.81 (d, 1H, J  = 6.50 Hz, OCH2CCl3), 4.51 (d, 
1H, 5.31 (d, 1H, J  = 6.45 Hz, POCH2CCl3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 93.14 (d, J3P-O-C-C = 14.1 Hz, OCH2CCl3), 
78.35 (d, J2P-O-C = 7.5 Hz, OCH2CCl3). 
31P NMR (202 MHz, CDCl3) δP (ppm): 7.70 (s). 
 
Preparation of L-Alanine-methyl ester 2,2,2-trichloroethoxy phosphochloridate (17)4 
P
O
O
ClCl
Cl
Cl
NH
O
O
 
A solution of 2,2,2-trichloroethoxy phosphorodichloridate (16) (0.80 g, 3.02 mmol, 1.0 
eq) in anh. DCM (24 mL) was added to a solution of L-alanine methylester 
hydrochloride (0.47 g, 3.32 mmol, 1.1 eq) in anh. DCM (94 mL), and the solution was 
cooled down to -80 °C. Anh. NEt3 (0.84 mL, 6.04 mmol, 2.0 eq) in anh. DCM (15 mL) 
was added dropwise at -80 °C. After the completion of the addition, the solution was 
allowed to warming at RT, and stirred for a further 1hr 45min. The solvent was then 
removed under reduced pressure to give a yellowish oil (1.11 g, 3.33 mmol) used crude 
for the next step. 
1H NMR (500 MHz, CDCl3) δH (ppm): 5.31 & 4.62 (2d, 2H, J  = 6.50 Hz, 
POCH2CCl3), 4.17 (s, 3H, NHCH(CH3)COOCH3), 3.92 (m, 1H, 
NHCH(CH3)COOCH3), 1.26 (d, 3H, J  = 7.00 Hz, NHCH(CH3)COOCH3). 
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13C NMR (125 MHz, CDCl3) δC (ppm): 169.60 (s, NHCH(CH3)COOCH3), 96.38 (s, 
OCH2CCl3), 76.32 (s, OCH2CCl3), 52.81 (s, NHCH(CH3)COOCH3), 48.96 (s, 
NHCH(CH3)COOCH3), 20.91 (s, NHCH(CH3)COOCH3). 
31P NMR (202 MHz, CDCl3) δP (ppm): 11.73 (s), 11.17 (s). 
 
Preparation of bis(2,2,2-trichloroethoxy) phosphorochloridate (20) 5 
P
O
O
O
Cl
Cl
ClCl
Cl
Cl
Cl
 
To a solution of POCl3 (5.2 mL, 55.8 mmol, 1.0 eq) in anh. Et2O (50 mL) was added 
dropwise, at -80 °C under with vigorous stirring, a solution of   2,2,2-trichloroethanol 
(11 mL, 114 mmol, 2.04 eq), NEt3 (16.0 mL, 115 mmol, 2.06 eq) in anh. Et2O (100 
mL). Then the mixture was allowed to warm to RT and left stirring overnight. The 
reaction mixture was filtered with anh. Et2O and the solvent was removed under 
reduced pressure to yied a yellow solid that was then distillated under reduced pressure. 
The product came out at 120°C as a colourless oil (0.34 g, 0.90 mmol, 2%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 4.77 (m, 4H, OCH2CCl3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 94.30 & 93.62 (2d, J3P-O-C-C = 11.25 & 12.50 
Hz, , OCH2CCl3), 76.90 & 76.18 (2s, OCH2CCl3). 
31P NMR (202 MHz, CDCl3) δP (ppm): 3.10 (s). 
 
Preparation of bis(2,2,2-trichloroethoxy) phosphate (21) 
O
P
O
O
O
Cl
ClCl
Cl
Cl
Cl
N
N
N
O
NH2
N
O
OHOH
 
The bis(2,2,2-trichloroethoxy) phosphorochloridate (20) (0.34 g, 0.90 mmol, 2.0 eq) 
was added to a solution of β-2’-C-me-6-O-Me guanosine (11) (0.14 g, 0.46 mmol, 1.0 
eq) in pyridine (10 mL) and left stirring for 63 hrs at RT. The reaction was monitored 
by phosphorus NMR. The solvent was then removed under reduced pressure and the 
residue was purified by flash chromatography using MeOH/CHCl3 as eluents to yield a 
white solid (0.13 g, 1.20 mmol, 43%). 
HPLC (MeOH/H2O): Rt = 16.64 min 
Claire Bourdin  Chapter Eight: Experimental section 
 
182 
HPLC (ACN/H2O): Rt = 25.63 min. 
MS (TOF ES+): 655.92 (M + H+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.79 (s, 1H, H-8 base), 6.01 (s, 1H, H-1’), 5.32 
(bs, 2H, NH2 base), 4.76-4.75 (m, 1H, H-5’), 4.68 (d, 2H, J = 6.5 Hz, OCH2CCl3), 4.64 
(d, 2H, J = 6.5 Hz, OCH2CCl3), 4.60-4.58 (m, 1H, H-5’), 4.52 (d, 1H, J = 7.0 Hz, H-3’), 
4.32 (m, 1H, H-4’), 4.08 (s, 3H, 6-OCH3 base), 1.04 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 161.65 (s, C-6 base), 159.58 (s, C-2 base), 
152.77 (s, C-4 base), 137.65 (s, C-8 base), 115.52 (s, C-5 base), 91.77 (s, C-1’), 80.74 
(d, J3P-O-C-C = 7.0 Hz, C-4’), 79.07 (s, C-2’), 77.05 & 76.79 (2s, 2 POCH2CCl3), 74.18 
(s, C-3’), 67.89 (d, J2P-O-C = 7.0 Hz, C-5’), 54.07 (s, 6-OCH3 base), 20.30 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): - 4.23 (s). 
 
3.2.4. Preparation of phosphorodiamidates of β-2’-C-methyl-6-O-methyl guanosine 
Synthesis of N-butylamino β-2’-C-methyl-6-O-methyl guanosine phosphorodiamidate 
(19.b) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
O
NH
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (1.04 g, 
3.35 mmol) in anh. THF (17 mL), anh. NEt3 (0.56 mL, 4.02 mmol, 1.2 eq), POCl3 (0.38 
mL, 4.08 mmol, 1.2 eq), commercially available N-butylamine (1.70 mL, 17.20 mmol, 
5.0 eq) in anh. DCM (17 mL), anh. NEt3 (4.70 mL, 33.7 mmol, 10 eq). After overnight 
stirring at RT and flash chromatography using MeOH (3%)/CHCl3, the desired material 
was recovered (0.42 g, 0.83 mmol, 25%). 
HPLC (MeOH/H2O): Rt = 12.31 min 
HPLC (ACN/H2O) : Rt = 12.79 min 
MS (TOF ES+): 502.26 (M + H+), 524.24 (M + Na+), 565.26 (M + MeCN + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.86 (s, 1H, H-8 base), 6.05 (s, 1H, H-1’), 5.68 
(bs, 2H, 2 x NHCH2CH2CH2CH3), 4.44-4.23 (m, 4H, H-5’, H-3’, H4’), 4.04 (s, 3H, 6-
OCH3 base), 2.88-2.85 (m, 4H, 2 x NHCH2CH2CH2CH3), 1.41-1.38 (m, 4H, 2 x 
NHCH2CH2CH2CH3), 1.27-1.23 (m, 4H, 2 x NHCH2CH2CH2CH3), 0.99 (s, 3H, CH3-
2’), 0.82-0.79 (m, 6H, 2 x NHCH2CH2CH2CH3). 
Claire Bourdin  Chapter Eight: Experimental section 
 
183 
13C NMR (125 MHz, CDCl3) δC (ppm): 161.40 (s, C-6 base), 159.69 (s, C-2 base), 
153.07 (s, C-4 base), 137.64 (s, C-8 base), 115.24 (s, C-5 base), 91.36 (s, C-1’), 81.11 
(d, J3P-O-C-C = 6.25 Hz, C4’), 79.36 (s, C-2’), 73.41 (s, C-3’), 64.02 (s, C-5’), 53.75 (s, 6-
OCH3 base), 41.02 & 40.91 (2s, 2 x NHCH2CH2CH2CH3), 33.91 (d, J3P-N-C-C = 6.3 Hz, 
NHCH2CH2CH2CH3), 33.87 (d, J3P-N-C-C = 6.4 Hz, NHCH2CH2CH2CH3), 20.22 (s, CH3-
2’), 19.82 & 19.80 (2s, 2 x NHCH2CH2CH2CH3), 14.07 &13.66 (2s, 2 x 
NHCH2CH2CH2CH3). 
31P NMR (202 MHz, CDCl3) δP (ppm): 17.40 (s). 
 
Synthesis of LAlanine-cyclohexyl ester / L-Alanine-cyclopentyl ester β-2’-C-methyl-6-
O-methyl guanosine phosphorodiamidate (23) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
HN
O
O
O
O
O
 
To a solution of β-2’-C-Me-6-OMe guanosine (11) (0.55 g, 1.76 mmol) in anh. THF (8 
mL), anh. NEt3 (0.30 mL, 2.11 mmol, 1.2 eq) was added and then mixture was left 
stirring at RT for 30 min, after which the solution was cooled to -78 °C and POCl3 (0.20 
mL, 2.11 mmol, 1.2 eq) was added dropwise. The solution was stirred 1 hr at -78 °C and 
then 30 min at RT. The formation of the intermediate was monitored by phosphorus 
NMR. Then L-Alanine-cyclohexyl tosylate salt (provided by Inhibitex Inc.) (0.37 g, 
1.76 mmol, 1.0 eq) in anh. DCM (2 mL) was added, and the reaction was cooled down 
at -78 °C at which anh. NEt3 (0.50 mL, 3.52 mmol, 2.0 eq) was added dropwise. The 
temperature was maintained at -78 °C for 1h, and the solution was then allowed to 
return to RT for 4 hrs. L-Alanine-cyclopentyl tosylate salt (provided by Inhibitex Inc.) 
(2.90 g, 8.80 mmol, 5.0 eq) in anh. DCM (5 mL) was added. The reaction was cooled 
down at -78 °C at which anh. NEt3 (2.50 mL, 17.60 mmol, 10 eq) was added dropwise. 
The solution was left stirring overnight, and after flash chromatography using MeOH 
(3%)/CHCl3, the desired molecule was recovered (0.28 g, 0.41 mmol, 23%). 
HPLC (MeOH/H2O) : Rt = 14.97 min  
HPLC (ACN/H2O) : Rt = 17.37 min 
MS (TOF ES+): 684.32 (M + H+), 706.27 (M + Na+), 722.27 (M + K+). 
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1H NMR (500 MHz, CDCl3) δH (ppm): 7.74 (s, 1H, H-8 base), 5.96 (s, 1H, H-1’), 5.51 
(bs, 2H, NHCH(CH3)COO-cHex, NHCH(CH3)COO-cPent), 5.18-5.13 (m, 1H, H-3’), 
4.76-4.68 (m, 1H, CH cPent), 4.61-4.59 (m, 1H, H-5’), 4.51-4.48 (m, 1H, CH cHex), 
4.32 (m, 1H, H-5’), 4.23-4.20 (m, 1H, H-4’), 4.06 (s, 6-OCH3 guanine), 3.92-3.88 (m, 
2H, NHCH(CH3)COO-cPent, NHCH(CH3)COO-cHex), 1.86-1.57 (m, 18H, 4 x CH2 
cPent, 5 x CH2 cHex), 1.36 (m, 6H, NHCH(CH3)COO-cPent, NHCH(CH3)COO-cHex), 
1.00 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 174.29 (d, J3P-N-C-C = 6.3 Hz, 
NHCH(CH3)COO-cHex), 173.65 (d, , J3P-N-C-C = 6.3 Hz, NHCH(CH3)COO-cPent), 
161.61 (s, C-6 base), 159.61 (s, C-2 base), 152.93 (s, C-4 base), 137.89 (s, C-8 base), 
115.80 (s, C-5 base), 91.84 (s, C-1’), 81.14 (d, J3P-O-C-C = 5.0 Hz, C-4’), 79.44 (s, C-2’), 
78.51 (s, C-3’), 74.60 (s, C-1 cPent), 73.91 (s, C ipso cHex), 65.01 (d, J2P-O-C  = 3.75 
Hz, C-5’), 53.82 (s, 6-OCH3 guanine), 50.97 (d, J2P-N-C = 6.3 Hz, NHCH(CH3)COO-
cHex), 49.95 (d, J2P-N-C = 6.3 Hz, NHCH(CH3)COO-cPent), 32.68 & 32.46 (2s, 2 x C 
cPent (2 & 5)), 31.40 & 31.32 (2s, 2 x C ortho cHex), 25.23 (s, C para cHex), 23.66 & 
23.54 (2s, 2 x C meta cHex, 2 x C cPent (3 & 4)), 21.04 & 20.99 (2s, 
NHCH(CH3)COO-cHex, NHCH(CH3)COO-cPent), 20.36 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.68 (s) (59%), 13.48 (s) (41%). 
 
Synthesis of L-Tyrosine-(tert-butyl)-neopentyl ester β-2’-C-methyl-6-O-methyl 
guanosine phosphorodiamidate (24.a) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
HN
O
O
O
O
O
O
O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.36 g, 
1.17 mmol) in anh. THF (6.25 mL), anh. NEt3 (0.20 mL, 1.40 mmol, 1.2 eq), POCl3 
(0.12 mL, 1.40 mmol, 1.2 eq), L-Tyrosine-(tert-butyl)-neopentyl ester (12.k) (1.80 g, 
5.85 mmol, 5.0 eq) in anh. DCM (7.0 mL), and anh. NEt3 (1.60 mL, 11.7 mmol, 10 eq). 
After overnight stirring at RT and flash chromatography using MeOH (3%)/CHCl3 and 
preparative chromatography, the desired material was recovered (0.35 g, 0.36 mmol, 
31%). 
HPLC (MeOH/H2O) : Rt = 32.05 min 
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HPLC (ACN/H2O) : Rt = 28.53 min 
MS (TOF ES+):  992.49 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.64 (s, 1H, H-8 base), 7.10 (d, 2H, J = 8.4 Hz, 
2 x CH ortho Ar), 6.99 (d, 2H, J = 8.4 Hz, 2 x CH ortho Ar), 6.89-6.85 (m, 4H, 4 x CH 
meta Ar), 5.89 (s, 1H, H-1’), 5.38 (bs, 2H, 2 x NHCH(CH2ArOC(CH3)3)CO), 4.43-4.38 
(m, 2H, H-5’, H-3’), 4.21-4.13 (m, 2H, 2 x NHCH(CH2ArOC(CH3)3)CO), 4.07 (s, 3H, 
6-OCH3 base), 4.05-4.02 (m, 1H, H-4’), 3.93-3.88 (m, 1H, H-5’), 3.79-3.72 (m, 4H, 2 x 
OCH2C(CH3)3), 3.05-2.83 (m, 4H, 2 x NHCH(CH2ArOC(CH3)3)CO), 1.32 & 1.30 (2s, 
18H, 2 x NHCH(CH2ArOC(CH3)3)CO), 0.97 (s, 3H, CH3-2’), 0.92 & 0.88 (m, 18H, 2 x 
COOCH2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.60 (s, NHCH(CH2ArOC(CH3)3)CO), 
173.05 (s, NHCH(CH2ArOC(CH3)3)CO), 161.63 (s, C-6 base), 159.55 (s, C-2 base), 
154.42 & 154.07 (2s, 2 x C para Ar), 152.94 (s, C-4 base), 137.96 (s, C-8 base), 131.46 
& 130.65 (2s, 2 x C-1 Ar), 130.11 &130.07 & 139.89 & 129.86 (4s, 4 x C ortho Ar), 
124.32 & 124.24 & 124.16 & 124.09 (4s, 4 x C meta Ar), 115.83 (s, C-5 base), 91.50 (s, 
C-1’), 80.73  (d, J3P-O-C-C = 6.3 Hz, C-4’), 79.55 (s, C-2’), 78.79 & 78.41 (2s, 2 x 
NHCH(CH2ArOC(CH3)3)CO), 74.90 & 74.79 (2s, 2 x COOCH2C(CH3)3), 74.62 (s, C-
3’), 64.64 (s, C-5’), 55.44 & 55.15 (2s, 2 x NHCH(CH2ArOC(CH3)3)CO), 53.82 (s, 6-
OCH3 base), 39.77 (s, 2 x NHCH(CH2ArOC(CH3)3)CO), 31.26 & 31.21 (2s, 2 x 
OCH2C(CH3)3), 28.81& 28.75 (2s, 6 x NHCH(CH2ArOC(CH3)3)CO), 26.41 & 26.38 
(2s, 6 x OCH2C(CH3)3), 20.32 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.72 (s). 
 
Synthesis of L-Tyrosine-(tert-butyl)-cyclohexyl ester β-2’-C-methyl-6-O-methyl 
guanosine phosphorodiamidate (24.b) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
HN
O
O
O
O
O
O
O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.37 g, 
1.19 mmol) in anh. THF (6.40 mL), anh. NEt3 (0.20 mL, 1.43 mmol, 1.2 eq), POCl3 
(0.12 mL, 1.43 mmol, 1.2 eq), L-Tyrosine-(tert-butyl)-cyclohexyl ester (12.l) (1.90 g, 
5.95 mmol, 5.0 eq) in anh. DCM (7.0 mL), and anh. NEt3 (1.63 mL, 11.90 mmol, 10 
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eq). After overnight stirring at RT and flash chromatography using MeOH 
(2.5%)/CHCl3 and preparative chromatography, the desired material was recovered 
(0.22 g, 0.22 mmol, 18 %). 
HPLC (MeOH/H2O) : Rt = 32.02 min 
HPLC (ACN/H2O) : Rt = 29.10 min 
MS (TOF ES+): 1016.49 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.95 (s, 1H, H-8 base), 7.09-7.04 (m, 4H, 4 c 
CH ortho Ar), 6.88-6.84 (m, 4H, 4 x CH meta Ar), 5.98 (s, 1H, H-1’), 4.66-4.56 (m, 2H, 
CH cHex), 4.25-4.19 (m, 3H, H-5’, H-3’), 4.14-4.11 (m, 1H, H-4’), 4.04 (s, 3H, 6-
OCH3 base), 4.02-3.95 (m, 2H, 2 x NHCH(CH2ArOC(CH3)3)CO), 2.94-2.75 (m, 4H, 2 
x NHCH(CH2ArOC(CH3)3)CO), 1.78-1.62 (m, 10H, 4 x CH2 ortho cHex, CH2 para 
cHex), 1.32 & 1.30 (2s, 18H, 2  x NHCH(CH2ArOC(CH3)3)CO), 1.31-1.18 (m, 10H, 4 
x CH2 meta cHex, 2 x CH2 para cHex), 0.99 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 173.93 (d, J3P-N-C-C = 3.8 Hz, 
NHCH(CH2ArOC(CH3)3)CO), 173.86 (d, J3P-N-C-C = 5.0 Hz, 
NHCH(CH2ArOC(CH3)3)CO), 161.79 (s, C-6 base), 161.94 (s, C-2 base), 155.46 & 
155.35 (2s, 2 x C para Ar), 154.63 (s, C-4 base), 139.39 (s, C-8 base), 133.18 & 133.10 
(2s, 2 x C-1Ar), 131.20 & 130.98 (2s, 4 x C ortho Ar), 125.49 & 125.30 & 125.17 & 
124.98 (4s, 4 x C meta Ar), 115.69 (s, C-5 base), 93.18 (s, C-1’), 82.31 (d, J3P-O-C-C  = 
7.6 Hz, C-4’), 80.03 (s, C-2’), 79.53 & 79.49 (2s, 2 x NHCH(CH2ArOC(CH3)3)CO), 
75.01 (s, C-3’), 74.95 (m, C-1 cHex), 66.56 (d, J2P-O-C = 5.0 Hz, C-5’), 57.00 & 56.91 
(2s, 2 x NHCH(CH2ArOC(CH3)3)CO), 54.30 (s, 6-OCH3 base), 41.00 (d, J3P-N-C-C = 5.0 
Hz, NHCH(CH2ArOC(CH3)3)CO), 40.86 (d, J3P-N-C-C = 7.6 Hz, 
NHCH(CH2ArOC(CH3)3)CO), 32.58 & 32.53 (2s, 4 x C ortho cHex), 29.31 & 29.28 
(2s, 2 x NHCH(CH2ArOC(CH3)3)CO), 26.55 & 26.40 (2s, 2 x C para cHex), 24.73 (s, 4 
x C meta cHex), 20.41 (s, CH3-2’). 
31P NMR (202 MHz, MeOD) δP (ppm): 13.50 (s). 
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Synthesis of L-Tyrosine-(tert-butyl)-benzyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (24.c) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
HN
O
O
O
O
O
O
O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.31 g, 
0.99 mmol) in anh. THF (5.30 mL), anh. NEt3 (0.17 mL, 1.19 mmol, 1.2 eq), POCl3 
(0.10 mL, 1.19 mmol, 1.2 eq), L-Tyrosine-(tert-butyl)-benzyl ester (12.m) (1.62 g, 4.95 
mmol, 5.0 eq) in anh. DCM (5.0 mL), and anh. NEt3 (1.36 mL, 9.90 mmol, 10 eq). 
After overnight stirring at RT and flash chromatography using MeOH (3%)/CHCl3 and 
preparative chromatography, the desired material was recovered (0.16 g, 0.16 mmol, 
16%). 
HPLC (MeOH/H2O) : Rt = 31.10 min 
HPLC (ACN/H2O) : Rt = 27.08 min 
MS (TOF ES+): 1032.42 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.90 (s, 1H, H-8 base), 7.32-7.24 (m, 10H, 2 x 
OCH2Ph), 6.96 (d, 4H, J = 8.4 Hz, 4 x CH ortho Ar), 6.79-6.77 (dd, 4H, J = 2.8 Hz, 8.5 
Hz, 4 x CH meta Ar), 5.95 (s, 1H, H-1’), 5.13-5.02 (m, 4H, 2 x OCH2Ph), 4.22-4.05 (m, 
6H, H-3’, H-5’, H-4’, 2 x NHCH(CH2ArOC(CH3)3)CO), 4.05 (s, 3H, 6-OCH3 base), 
2.89-2.77 (m, 4H, 2 x NHCH(CH2ArOC(CH3)3)CO), 1.29 & 1.27 (2s, 18H, 2 x 
NHCH(CH2ArOC(CH3)3)CO), 0.98 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 174.21 (s, NHCH(CH2ArOC(CH3)3)CO), 
174.12 (d, J3P-N-C-C = 5.0 Hz, NHCH(CH2ArOC(CH3)3)CO), 162.76 (s, C-6 base), 
161.92 (s, C-2 base), 155.47 & 155.37 (2s, 2 x C para Ar), 154.60 (s, C-4 base), 139.35 
(s, C-8 base), 137.02 & 137.00 (2s, 2 x C-1 OCH2Ph), 132.98 & 132.88 (2s, 2 x C-1 
Ar), 131.12 & 131.08 (2s, 4 x C ortho Ar), 129.57 & 129.52 & 129.31 (3s, 4 x C ortho, 
4 x C meta. 2 x C para OCH2Ph), 125.14 & 125.13 (2s, 4 x C meta Ar), 115.63 (s, C-5 
base), 93.14 (s, C-1’), 82.20  (d, J3P-O-C-C = 7.6 Hz, C-4’), 79.96 (s, C-2’), 79.52 (2s, 2 x 
NHCH(CH2ArOC(CH3)3)CO), 74.87 (s, C-3’), 67.99 & 67.94 (2s, 2 x OCH2Ph), 66.36 
(s, C-5’), 57.01 & 56.91 (2s, 2 x NHCH(CH2ArOC(CH3)3)CO), 54.21 (s, 6-OCH3 base), 
40.56 (d, J3P-N-C-C = 6.3 Hz, NHCH(CH2ArOC(CH3)3)CO), 40.39 (s, 
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NHCH(CH2ArOC(CH3)3)CO), 29.25 & 29.23 (2s, 6 x NHCH(CH2ArOC(CH3)3)CO), 
20.31 (s, CH3-2’). 
31P NMR (202 MHz, MeOD) δP (ppm): 13.45 (s). 
 
Synthesis of L-Tyrosine-(tert-butyl)-methyl ester β-2’-C-methyl-6-O-methyl 
guanosine phosphorodiamidate (24.d) 
N
N
N
O
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N
O
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O
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O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11)  (0.26 g, 
0.85 mmol) in anh. THF (4.55 mL), anh. NEt3 (0.14 mL, 1.02 mmol, 1.2 eq), POCl3 
(0.09 mL, 1.02 mmol, 1.2 eq), commercially available L-Tyrosine-(tert-butyl)-methyl 
ester chloridate salt (1.07 g, 4.25 mmol, 5.0 eq) in anh. DCM (3.4 mL), and anh. NEt3 
(1.19 mL, 8.5 mmol, 10 eq). After overnight stirring at RT and flash chromatography 
using MeOH (3%)/CHCl3 and preparative chromatography, the desired material was 
recovered (0.12 g, 0.14 mmol, 16%). 
HPLC (MeOH/H2O) : Rt = 29.01 min 
HPLC (ACN/H2O) : Rt = 20.40 min 
MS (TOF ES+): 858.38 (M + H+), 880.37 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.69 (s, 1H, H-8 base), 7.03 (d, 2H, J = 8.4 Hz, 
2 x CH ortho Ar), 6.98 (d, 2H, J = 8.4 Hz, 2 x CH ortho Ar), 6.87 (dd, 4H, J = 3.0 Hz, 
8.40 Hz, 4 x CH meta Ar), 5.95 (s, 1H, H-1’), 5.45 (bs, 2H, 2 x 
NHCH(CH2ArOC(CH3)3)CO), 4.35-4.30 (m, 2H, H-3’, H-5’), 4.09-4.06 (m, 3H, 2 x 
NHCH(CH2ArOC(CH3)3)CO, H-4’), 4.05 (s, 3H, 6-OCH3 base), 4.01-3.96 (m, 1H, H-
5’), 3.63 & 3.62 (2s, 6H, 2 x COOCH3), 3.31-3.28 (m, 4H, 2 x 
NHCH(CH2ArOC(CH3)3)CO), 1.31 & 1.30 (2s, 18H, 2 x 
NHCH(CH2ArOC(CH3)3)CO), 1.98 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.68 (s, NHCH(CH2ArOC(CH3)3)CO), 
173.36 (d, J3P-N-C-C  = 5.0 Hz, NHCH(CH2ArOC(CH3)3)CO), 161.60 (s, C-6 base), 
159.61 (s, C-2 base), 154.40 & 154.15 (2s, 2 x C para Ar), 153.03 (s, C-4 base), 137.85 
(s, C-8 base), 131.30 & 130.80 (2s, 2 x C-1 Ar), 130.29 & 129.96 & 129.96 & 129.87 
(4s, 4x C ortho Ar), 124.20 & 124.12 (2s, 4 x C meta Ar), 115.70 (s, C-5 base), 91.47 
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(s, C-1’), 80.80  (d, J3P-O-C-C = 6.3 Hz, C-4’), 79.36 (s, C-2’), 78.68 & 78.42 (2s, 2 x 
NHCH(CH2ArOC(CH3)3)CO), 74.39 (s, C-3’), 64.77 (s, C-5’), 55.37 & 55.22 (2s, 2 x 
NHCH(CH2ArOC(CH3)3), 53.81 (s, 6-OCH3 base), 52.24 & 52.18 (2s, 2 x COOCH3), 
39.63 & 30.57 (2s, 2 x NHCH(CH2ArOC(CH3)3)CO), 28.82-22.77 (2s, 6 x 
NHCH(CH2ArOC(CH3)3)CO), 20.29 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.31 (s). 
 
Synthesis of L-Tyrosine-neopentyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (25.a) 
N
N
N
O
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O
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O
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L-Tyrosine-(tert-butyl)-neopentyl ester phosphorodiamidate (24.a, 0.15 g, 0.16 mmol) 
was dissolved in anh. DCM (1.60 mL). Trifluoroacetic acid (0.20 mL) was added and 
the solution was stirred at RT for 30 min. The solvent was removed under reduced 
pressure and the residue was purified by flash chromatography using CHCl3/MeOH 
(6.5%), to recover a white off solid (0.067 g, 0.08 mmol, 49%). 
HPLC (MeOH/H2O) : Rt = 27.20 min 
HPLC (ACN/H2O) : Rt = 17.52 min 
MS (TOF ES+): 858.38 (M + H+), 880.36 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.03 (s, 1H, H-8 base), 7.01-6.95 (dd, 4H, J = 
8.5 Hz, 22 Hz, 4 x CH ortho Ar), 6.72-6.66 (dd, 4H, J = 8.5 Hz, 18.2 Hz, 4 x CH meta 
Ar), 5.97 (s, 1H, H-1’), 4.17-4.06 (m, 4H, H-3’, H-4’, H-5’), 4.04 (s, 3H, 6-OCH3 base), 
4.02-3.95 (m, 2H, 2 x NHCH(CH2ArOH)CO), 3.73-3.62 (m, 4H, 2 COOCH2C(CH3)3), 
2.90-2.77 (m, 4H, 2 x NHCH(CH2ArOH)CO), 0.99 (s, 3H, CH3-2’), 0.87 & 0.84 (2s, 
18H, 2 x COOCH2C(CH3)3). 
13C NMR (125 MHz, MeOD) δC (ppm): 174.77 (s, NHCH(CH2ArOH)CO), 174.70 (d, 
J3P-N-C-C = 5.0 Hz, NHCH(CH2ArOH)CO), 162.65 (s, C-6 base), 161.88 (s, C-2 base), 
157.48 & 157.39 (2s, 2 x C para Ar), 154.56 (s, C-4 base), 139.26 (s, C-8 base), 131.59 
& 131.52 (2s, 4 x C ortho Ar), 128.72 & 128.71 (2s, 2 x C-1 Ar), 116.38 & 116.35 (2s, 
4 x C meta Ar), 115.66 (s, C-5 base), 93.32 (s, C-1’), 82.52  (d, J3P-O-C-C = 7.6 Hz, C-4’), 
79.48 (s, C-2’), 75.56 & 75.52 (2s, 2 x COOCH2C(CH3)3), 74.93 (s, C-3’), 66.54 (d, J2P-
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O-C
 = 3.78 Hz, C-5’), 57.18 & 57.07 (2s, 2 x NHCH(CH2ArOH)CO), 54.42 (s, 6-OCH3 
base), 40.73 (d, J3P-N-C-C = 6.30 Hz, NHCH(CH2ArOH)CO), 40.61 (d, J3P-N-C-C = 6.30 
Hz, NHCH(CH2ArOH)CO), 32.07 & 32.01 (2s, 2 x COOCH2C(CH3)3), 26.82 & 26.79 
(2s, 6 x COOCH2C(CH3)3), 20.36 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.39 (s). 
 
Synthesis of L-Tyrosine-cyclohexyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (25.b) 
N
N
N
O
NH2
N
O
OHOH
O
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N
H
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O
O
O
O
O
OH
HO
 
L-Tyrosine-(tert-butyl)-cyclohexyl ester phosphorodiamidate (24.b, 0.12 g, 0.12 mmol) 
was dissolved in anh. DCM (1.20 mL). Trifluoroacetic acid (0.13 mL) was added and 
the solution was stirred at RT for 30 min. The solvent was removed under reduced 
pressure and the residue was purified by flash chromatography using CHCl3/MeOH 
(6%), to recover a white off solid (0.042 g, 0.05 mmol, 40%). 
HPLC (MeOH/H2O) : Rt = 27.80 min 
HPLC (ACN/H2O: Rt = 17.60 min 
MS (TOF ES+): 882.38 (M + H+), 904.36 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.91 (s, 1H, H-8 base), 7.00-6.96 (m, 4H, 4 x 
CH ortho Ar), 6.71-6.68 (m, 4H, 4 x CH meta Ar), 5.98 (s, 1H, H-1’), 4.66-4.57 (m, 2H, 
2 x CH cHex), 4.21-4.11 (m, 4H, H-3’, H-4’, H-5’), 4.04 (s, 3H, 6-OCH3 base), 3.97-
3.91 (m, 2H, 2 x NHCH(CH2ArOH)CO), 2.85-2.68 (m, 4H, 2 x NHCH(CH2ArOH)CO), 
1.75-1.64 (m, 8H, 2 x CH2 meta cHex, 2 x CH2 ortho cHex), 1.49 (m, CH2 para cHex), 
1.41-1.18 (m, 10H, 2 x CH2 meta cHex, 2 x CH2 ortho cHex, CH2 para cHex), 0.99 (s, 
3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 174.14 (d, J3P-N-C-C = 3.8 Hz, 
NHCH(CH2ArOH)CO), 174.03 (d, J3P-N-C-C = 5.0 Hz, NHCH(CH2ArOH)CO), 162.79 
(s, C-6 base), 161.90 (s, C-2 base), 157.40 & 157.34 (2s, 2 x C para Ar), 154.56 (s, C-4 
base), 139.40 (s, C-8 base), 131.70 & 131.68 & 131.65 & 131.51 (4s, 4 x C ortho Ar), 
128.78 & 128.73 (2s, 2 x C-1 Ar), 116.61 & 116.58 & 116.30 & 116.28 (3s, 4 x C meta 
Ar), 115.66 (s, C-5 base), 93.19 (s, C-1’), 82.36  (d, J3P-O-C-C  = 7.6 Hz, C-4’), 79.99 (s, 
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C-2’), 75.08 (s, C-3’), 75.01 & 74.94 (2s, 2 x C-1 cHex), 66.63 (d, J2P-O-C  = 5.0 Hz, C-
5’), 57.13 (2s, 2 x NHCH(CH2ArOH)CO), 54.31 (s, 6-OCH3 base), 40.71 (d, J3P-N-C-C = 
6.3 Hz, NHCH(CH2ArOH)CO), 40.62 (d, J3P-N-C-C = 6.3 Hz, NHCH(CH2ArOH)CO), 
32.54 & 32.52 & 32.48 & 32.44 (m, 4 x C ortho cHex), 26.41 & 26.38 (2s, 2 x C para 
cHex), 24.66 (s, 4 x C meta cHex), 20.36 (s, CH3-2’). 
31P NMR (202 MHz, MeOD) δP (ppm): 13.48 (s). 
	  
Synthesis of L-Tyrosine-benzyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (25.c) 
N
N
N
O
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N
O
OHOH
O
P
N
H
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O
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O
OH
HO
 
L-Tyrosine-(tert-butyl)-benzyl ester phosphorodiamidate (24.c, 0.099 g, 0.098 mmol) 
was dissolved in anh. DCM (1.00 mL). Trifluoroacetic acid (0.11 mL) was added and 
the solution was stirred at RT for 30 min. The solvent was removed under reduced 
pressure and the residue was purified by flash chromatography using CHCl3/MeOH 
(6%), to recover a white off solid (0.02 g, 0.02 mmol, 24%). 
HPLC (MeOH/H2O) : Rt = 25.75 min 
HPLC (ACN/H2O) : Rt = 16.45 min 
MS (TOF ES+): 898.32 (M + H+), 920.30 (M + Na+), 936.27 (M + K+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.87 (s, 1H, H-8 base), 7.31-7.17 (m, 10H, 2 x 
COOCH2Ph), 6.88-6.85 (m, 4H, 4 x CH ortho Ar), 6.65-6.62 (m, 4H, 4 x CH meta Ar), 
5.96 (s, 1H, H-1’), 5.08-4.94 (m, 4H, 2 x COOCH2Ph), 4.21-4.19 (d, 1H, J = 8.7 Hz, H-
3’), 4.13-4.10 (m, 3H, H-4’, H-5’), 4.02 (s, 3H, 6-OCH3 guanine), 3.97-3.94 (m, 2H, 2 x 
NHCH(CH2ArOH)CO), 2.82-2.73 (m, 4H, 2 x NHCH(CH2ArOH)CO), 0.98 (s, 3H, 
CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 174.39 (d, J3P-N-C-C = 3.8 Hz, 
NHCH(CH2ArOH)CO), 174.28 (d, J3P-N-C-C = 5.0 Hz, NHCH(CH2ArOH)CO), 162.76 
(s, C-6 base), 161.89 (s, C-2 base), 157.41 & 157.34 (2s, 2 x C para Ar), 154.55 (s, C-4 
base), 139.38 (s, C-8 base), 137.03 & 137.00 (2s, 2 x C ipso Ph), 131.64 & 131.61 (2s, 
4 x C ortho Ar), 129.53 & 129.52 & 129.50 & 129.47 & 129.32 & 129.26 (6s, 2 x 
COOCH2Ph), 128.61 & 128.57 (2s, 2 C ipso Ar), 116.34 & 116.32 (2s, 4 x C meta Ar), 
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115.66 (s, C-5 base), 93.18 (s, C-1’), 82.31  (d, J3P-O-C-C  = 7.6 Hz, C-4’), 79.96 (s, C-
2’), 75.00 (s, C-3’), 67.94 & 67.86 (2s, 2 x COOCH2Ph), 66.49 (d, J2P-O-C  = 3.8 Hz, C-
5’), 55.22 & 55.12 (2s, 2 x NHCH(CH2ArOH)CO), 54.24 (s, 6-OCH3 base), 40.49 & 
40.39 (2s, 2 x NHCH(CH2ArOH)CO), 20.34 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.38 (s). 
 
Synthesis of L-Tyrosine-methyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (25.d) 
N
N
N
O
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O
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L-Tyrosine-(tert-butyl)-methyl ester phosphorodiamidate (24.d, 0.49 g, 0.57 mmol) was 
dissolved in anh. DCM (1.90 mL). Trifluoroacetic acid (0.63 mL) was added and the 
solution was stirred at RT for 30 min. The solvent was removed under reduced pressure 
and the residue was purified by flash chromatography using CHCl3/MeOH (6%) and 
preparative TLC to recover a white off solid (0.077 g, 0.11 mmol, 18%). 
HPLC (MeOH/ H2O) : Rt = 19.76 min 
HPLC (ACN/H2O) : Rt = 10.45 min 
MS (TOF ES+): 746.26 (M + H+), 768.24 (M + Na+), 784.20 (M + K+). 
1H NMR (500 Hz, MeOD) δH (ppm): 7.91 (s, 1H, H-8 base), 6.99 (d, 2H, J = 8.5 Hz, 2 
x CH ortho Ar), 6.94 (d, 2H, J = 8.4 Hz, 2 x CH ortho Ar), 6.71-6.66 (dd, 4H, J = 8.1 
Hz, 16.45 Hz, 4 x CH meta Ar), 5.97 (s, 1H, H-1’), 4.20 (d, 1H, J = 8.3 Hz, H-3’), 4.10-
4.05 (m, 3H, H-5’, H4’), 4.00 (s, 3H, 6-OCH3 base), 3.99-3.96 (q, 1H, J = 7.8 Hz, 
NHCH(CH2ArOH)CO), 3.92-3.88 (q, J = 7.0 Hz, 1H, NHCH(CH2ArOH)CO), 3.63 & 
3.61 (2s, 6H, 2 x COOCH3), 2.89-2.86 (m, 2H, NHCH(CH2ArOH)CO), 2.78-2.74 (m, 
2H, NHCH(CH2ArOH)CO), 0.99 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 175.09 (s, NHCH(CH2ArOH)CO), 174.97 (d, 
J3P-N-C-C  = 5.0 Hz, NHCH(CH2ArOH)CO), 162.78 (s, C-6 base), 161.93 (s, C-2 base), 
157.43 & 157.33 (2s, 2 x C para Ar), 154.58 (s, C-4 base), 139.33 (s, C-8 base), 131.62 
& 131.52 (2s, 4 x C ortho Ar), 128.77 & 128.73 (2s, 2 x C ipso Ar), 116.30 & 116.27 
(2s, 4 x C meta Ar), 115.61 (s, C-5 base), 93.14 (s, C-1’), 82.23  (d, J3P-O-C-C  = 7.6 Hz, 
C-4’), 79.95 (s, C-2’), 74.47 (s, C-3’), 66.29 (s, J2P-O-C = 5.0 Hz, C-5’), 57.06 & 56.98 
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(2s, 2 x NHCH(CH2ArOH)CO), 54.24 (s, 6-OCH3 base), 52.58 & 52.52 (2s, 2 x 
COOCH3), 40.44 (d, J3P-N-C-C  = 6.3 Hz, NHCH(CH2ArOH)CO), 40.35 (d, J3P-N-C-C  = 
7.6 Hz, NHCH(CH2ArOH)CO), 20.34 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.42 (s). 
 
Synthesis of L-Alanine-cyclopentyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (27.e) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
O
NH
O
O
O
O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.32 g, 
1.02 mmol) in anh. THF (5 mL), anh. NEt3 (0.17 mL, 1.22 mmol, 1.2 eq), POCl3 (0.12 
mL, 1.22 mmol, 1.2 eq), L-Alanine-cyclopentyl ester tosylate salt (provided by 
Inhibitex Inc.) (1.68 g, 5.10 mmol, 5.0 eq) in anh. DCM (8 mL) and anh. NEt3 (1.42 
mL, 10.2 mmol, 10 eq). After overnight stirring at RT and flash chromatography using 
MeOH (4%)/CHCl3, the desired material was recovered (0.063 g, 0.09 mmol, 9%). 
HPLC (MeOH/ H2O): Rt = 15.35 min 
HPLC (ACN/ H2O): Rt = 10.27 min 
MS (TOF ES+): 670.30 (M + H+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.70 (s, 1H, H-8 base), 5.89 (s, 1H, H-1’), 5.48 
(bs, 2H, 2 x NHCH(CH3)COO-cPent), 5.06 (m, 2H, CH cPent), 4.46-4.42 (m, 1H, H-
5’), 4.37 (d, 1H, J = 8.5 Hz, H-3’), 4.26-4.22 (m, 1H, H-5’), 4.11-4.08 (m, 1H, H-4’), 
3.94 (s, 3H, 6-OCH3 base), 3.83-3.70 (m, 2H, 2 x NHCH(CH3)COO-cPent), 1.73-1.45 
(m, 16H, 8 x CH2 cPent), 1.31 (d, 3H, J = 8.0 Hz, NHCH(CH3)COO-cPent), 1.29 (d, 
3H, J = 8.0 Hz, NHCH(CH3)COO-cPent), 1.02 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 174.00 (d, J3P-N-C-C = 5.0 Hz, 
NHCH(CH3)COO-cPent), 173.90 (d, J3P-N-C-C = 6.3 Hz, NHCH(CH3)COO-cPent), 
161.37 (s, C-6 base), 159.56 (s, C-2 base), 152.99 (s, C-4 base), 137.97 (s, C-8 base), 
115.50 (s, C-5 base), 91.76 (s, C-1’), 81.14  (d, J3P-O-C-C = 6.4 Hz, C-4’), 79.22 (s, C-2’), 
78.18 & 78.10 (2s, 2 x CH cPent), 73.93 (s, C-3’), 64.95 (s, C-5’), 53.70 (s, 6-OCH3 
base), 49.81 & 49.67 (2s, 2 x NHCH(CH3)COO-cPent), 32.56 & 32.34 (2s, 4 x CH2 
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cPent (C-2 & C-5)), 23.55 (s, 4 x CH2 cPent (C-3 & C-4)), 20.75 & 20.71 (2s, 2 x 
NHCH(CH3)COO-cPent), 20.27 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 12.99 (s). 
 
Synthesis of L-Alanine-cyclopropylmethyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (27.f) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
O
NH
O
O
O
O
	  
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.29 g, 
0.93 mmol) in anh. THF (5 mL), anh. NEt3 (0.16 mL, 1.12 mmol, 1.2 eq), POCl3 (0.11 
mL, 1.12 mmol, 1.2 eq), L-Alanine-cyclopropylmethyl ester tosylate salt (provided by 
Inhibitex Inc.) (1.47 g, 4.65 mmol, 5.0 eq) in anh. DCM (8 mL) and anh. NEt3 (1.30 
mL, 9.3 mmol, 10 eq). After overnight stirring at RT and flash chromatography using 
MeOH (6%)/CHCl3 the desired material was recovered (0.034 g,  0.06 mmol, 7%). 
HPLC (MeOH/ H2O): Rt = 13.03 min 
HPLC (ACN/ H2O): Rt = 11.12 min 
MS (TOF ES+): 642.26 (M + H+), 665.25 (M + Na+), 680.22 (M + K+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.77 (s, 1H, H-8 base), 5.99 (s, 1H, H-1’), 5.58 
(bs, 2H, NHCH(CH3)COOCH2), 4.54 (m, 1H, H-5’), 4.43 (m, 1H, H-3’), 4.34-4.31 (m, 
1H, H- 5’), 4.22-4.21 (m, 1H, H-4’), 4.03 (s, 3H, 6-OCH3 base), 3.99-4.86 (m, 6H, 
NHCH(CH3)COOCH2-cProp, NHCH(CH3)COOCH2-cProp), 1.38 (d, 3H, J = 5.0 Hz, 
NHCH(CH3)COOCH2-cProp), 1.35 (d, 3H, J = 7.0 Hz, NHCH(CH3)COOCH2-cProp), 
1.08 (m, 2H, 2 x CH cProp), 0.99 (s, 3H, CH3-2’), 0.52 & 0.23 (2s, 8H, 4 x CH2 cProp). 
13C NMR (125 MHz, CDCl3) δC (ppm): 174.43 (s, NHCH(CH3)COOCH2), 174.30 (d, 
J3P-N-C-C = 5.0 Hz, NHCH(CH3)COOCH2), 161.54 (s, C-6 base), 159.66 (s, C-2 base), 
152.99 (s, C-4 base), 137.87 (s, C-8 base), 115.56 (s, C-5 base), 91.69 (s, C-1’), 81.11 
(d, J3P-O-C-C = 6.3 Hz, C-4’), 79.34 (s, C-2’), 74.21 (s, C-3’), 70.23 & 70.16 (2s, 2 x 
NHCH(CH3)COOCH2-cProp), 64.98 (s, C-5’), 53.80 (s, 6-OCH3 base), 49.91 & 49.78 
(2s, 2 x NHCH(CH3)COOCH2-cProp), 20.94 (d, J3P-N-C-C = 6.4 Hz, 
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NHCH(CH3)COOCH2), 20.84 (s, NHCH(CH3)COOCH2-cProp), 20.27 (s, CH3-2’), 9.63 
& 8.61 (2s, 2 x CH cProp), 3.23 & 3.17 (2s, 4 x CH2 cProp). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.17 (s). 
 
Synthesis of L-Leucine-neopentyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (29.a) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
HN
O
O
O
O
O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.25 g, 
0.80 mmol) in anh. THF (4.3 mL), anh. NEt3 (0.13 mL, 0.96 mmol, 1.2 eq), POCl3 (0.09 
mL, 0.96 mmol, 1.2 eq), L-Leucine-neopentyl ester tosylate salt (12..c) (1.51 g, 4.05 
mmol, 5.0 eq) in anh. DCM (2.3 mL), and anh. NEt3 (1.12 mL, 8.04 mmol, 10 eq). 
After overnight stirring at RT and flash chromatography using MeOH (2.5%))/CHCl3 
the desired material was recovered (0.005 g, 0.008 mmol, 1%). 
HPLC (MeOH/ H2O) : Rt =  32.41 min 
HPLC (ACN/ H2O) : Rt =  25.39 min 
MS (TOF ES+): 758.42 (M + H+), 780.40 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.67 (s, 1H, H-8 base), 5.90 (s, 1H, H-1’), 5.51 
(bs, 2H, 2 x NHCH(CH2CH(CH3)2)CO), 4.74 (m, 1H, H-5’), 4.66 (m, 1H, H-3’), 4.25 
(m, 1H, H-5’), 4.23 (m, 1H, H-4’), 4.06 (s, 3H, 6-OCH3 base), 3.97-3.91 (2m, 2H, 2 x 
NHCH(CH2CH(CH3)2)CO), 3.82-3.75 (m, 4H, 2 x COOCH2C(CH3)3), 1.73-1.68 (m, 
2H, 2 x NHCH(CH2CH(CH3)2)CO), 1.58-1.45 (m, 4H, 2 x NHCH(CH2CH(CH3)2)CO), 
1.00 (s, 3H, CH3-2’), 0.94 & 0.93 (2s, 30H, 2 x NHCH(CH2CH(CH3)2)CO, 2 x 
COOCH2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 175.20 (s, NHCH(CH2CH(CH3)2)CO), 174.58 
(s, NHCH(CH2CH(CH3)2)CO), 161.61 (s, C-6 base), 159.63 (s, C-2 base), 152.86 (s, C-
4 base), 137.05 (s, C-8 base), 115.96 (s, C-5 base), 91.25 (s, C-1’), 81.33  (s, C-4’), 
79.65 (s, C-2’), 75.19 (s, C-3’), 74.77 & 74.65 (2s, 2 x COOCH2C(CH3)3), 65.59 (s, C-
5’), 53.65 (s, 6-OCH3 base), 52.96 & 52.82 (2s, 2 NHCH(CH2CH(CH3)2)CO), 43.77 (s, 
2 x NHCH(CH2CH(CH3)2)CO), 31.34 & 31.24 (2s, 2 x COOCH2C(CH3)3),  26.52 & 
26.49 & 26.43 & 26.40 & 26.38 & 26.32 (6s, 6 COOCH2C(CH3)3), 24.62 & 24.56 (2s, 2 
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x NHCH(CH2CH(CH3)2)CO), 22.68 & 22.45 & 22.31 & 22.01 (2s, 4 x 
NHCH(CH2CH(CH3)2)CO), 20.43 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.76 (s). 
 
Synthesis of L-Leucine-cyclohexyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (29.b) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
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O
O
O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.59 g, 
1.89 mmol) in anh. THF (8 mL), anh. NEt3 (0.32 mL, 2.27 mmol, 1.2 eq), POCl3 (0.21 
mL, 2.27 mmol, 1.2 eq), L-Leucine-cyclohexyl ester tosylate salt (12.d) (3.64 g, 9.45 
mmol, 5.0 eq) in anh. DCM (5.4 mL), and anh. NEt3 (2.67 mL, 18.9 mmol, 10 eq). 
After overnight stirring at RT and flash chromatography using MeOH (3%)/CHCl3, the 
desired material was recovered (0.1 g,  0.13 mmol, 7%). 
HPLC (MeOH/ H2O) : Rt =22.00 min 
HPLC (ACN/ H2O) : Rt =20.11 min 
MS (TOF ES+): 782.42 (M + H+), 804.41 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.71 (s, 1H, H-8 base), 5.95 (s, 1H, H-1’), 5.18 
(bs, 2H, 2 x NHCH(CH2CH(CH3)2)CO), 4.76-4.70 (m, 2H, 2 x CH cHex), 4.60 (m, 1H. 
H-5’), 4.48-4.47 (m, 1H, H-3’), 4.25-4.23 (m, 1H, H-5’), 4.20-4.17 (m, 1H, H-4’), 4.02 
(s, 3H, 6-OCH3 base), 3.89-3.77 (m, 2H, 2 x NHCH(CH2CH(CH3)2)CO), 1.79 (m, 8H, 4 
x CH2 ortho cHex), 1.67-1.65 (m, 4H, 2 x CH2 para cHex), 1.50-1.24 (m, 14H, 4 x CH2 
meta cHex, 2 x NHCH(CH2CH(CH3)2CO, 2 x NHCH(CH2CH(CH3)2)CO), 1.24 (s, 3H, 
CH3-2’), 0.98 & 0.84 (m, 12H, 4 x NHCH(CH2CH(CH3)2)CO). 
13C NMR (125 MHz, CDCl3) δC (ppm): 174.25 (s, NHCH(CH2CH(CH3)2)CO), 173.84 
(d, J3P-N-C-C = 3.4 Hz, NHCH(CH2CH(CH3)2)CO), 161.55 (s, C-6 base), 159.71 (s, C-2 
base), 152.93 (s, C-4 base), 137.87 (s, C-8 base), 115.68 (s, C-5 base), 91.93 (s, C-1’), 
81.12  (d, J3P-O-C-C  = 5.0 Hz, C-4’), 79.41 (s, C-2’), 74.71 (s, C-3’), 73.87 & 73.72 (2s, 
2 x CH cHex), 65.23 (s, C-5’), 53.43 (s, 6-OCH3 base), 52.94 & 52.80 (2s, 2 x 
NHCH(CH2CH(CH3)2)CO), 43.60 (d, J3P-N-C-C = 2.5 Hz, NHCH(CH2CH(CH3)2CO), 
43.54 (s, NHCH(CH2CH(CH3)2CO),  31.46 & 31.37 (2s, 4 x CH2 ortho cHex), 25.28 & 
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25.23 (2s, 2 x CH2 para cHex), 24.56 & 24.51 (2s, 2 x NHCH(CH2CH(CH3)2)CO), 
22.81 & 22.73 & 22.61 & 22.53 (4s, 4 x CH2 meta cHex), 22.05 & 22.03 & 21.99 & 
21.97 (2s, 2 x NHCH(CH2CH(CH3)2)CO), 20.31 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.78 (s). 
 
Synthesis of L-Leucine-benzyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (29.c) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
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O
O
O
O
O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.32 g, 
1.03 mmol) in anh. THF (5.5 mL), anh. NEt3 (0.18 mL, 1.28 mmol, 1.2 eq), POCl3 (0.11 
mL, 1.24 mmol, 1.2 eq), commercially available L-Leucine-benzyl ester tosylate salt 
(2.04 g, 5.15 mmol, 5.0 eq) in anh. DCM (8 mL), and anh. NEt3 (1.55 mL, 10.3 mmol, 
10 eq). After overnight stirring at RT and flash chromatography using MeOH 
(4%)/CHCl3, the desired material was recovered (0.22 g,  0.28 mmol, 27%). 
HPLC (MeOH/ H2O) : Rt = 22.12 min 
HPLC (ACN/ H2O) : Rt = 18.92 min 
MS (TOF ES+): 798.33 (M + H+), 820.31 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.72 (s, 1H, H-8 base), 7.33 (m, 10H, 
COOCH2Ph), 5.92 (s, 1H, H-1’), 5.49 (bs, 2H, 2 x NHCH(CH2CH(CH3)2)CO), 5.15 (m, 
4H, 2 x COOCH2Ph), 4.55 (m, 1H, H-5’), 4.49 (m, 1H, H-3’), 4.22 (m, 1H, H-5’), 4.12 
(m, 1H, H-4’), 4.05 (s, 3H, 6-OCH3 base), 3.57 (t, J = 10.5 Hz, 2H, 2 x 
NHCH(CH2CH(CH3)2)CO), 1.66 (m, 2H, 2 x NHCH(CH2CH(CH3)2)CO), 1.53 (m, 2H, 
NHCH(CH2CH(CH3)2)CO), 1.44 (m, 2H, NHCH(CH2CH(CH3)2)CO), 0.97 (s, 3H, 
CH3-2’), 0.87 (m, 12H, 2 x NHCH(CH2CH(CH3)2)). 
13C NMR (125 MHz, CDCl3) δC (ppm): 174.61 (s, NHCH(CH2CH(CH3)2)CO), 174.22 
(s, NHCH(CH2CH(CH3)2)CO), 161.61 (s, C-6 base), 159.62 (s, C-2 base), 152.86 (s, C-
4 base), 137.94 (s, C-8 base), 135.45 (2s, 2 x C-1 Ph), 128.63 & 128.59 & 128.56 & 
128.45 & 128.42 & 128.38 & 128.31 & 128.25 & 128.19 & 128.10  (m, 10C, 2 x C 
para,  4 x C meta, 4 x C ortho Ph), 115.72 (s, C-5 base), 91.84 (s, C-1’), 81.07 (d, J3P-O-
C-C = 6.3 Hz, C-4’), 79.41 (s, C-2’), 74.40 (s, C-3’), 67.17 & 67.05 (2s, 2 x 
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COOCH2Ph), 65.07 (d, J2P-O-C = 5.0 Hz, C-5’), 53.84 (s, 6-OCH3 guanine), 50.47 & 
50.41 (2s, 2 x NHCH(CH2CH(CH3)2)CO), 43.36 & 43.31 (2s, 2 
NHCH(CH2CH(CH3)2)CO), 24.51 & 24.49 (2s, 2 x NHCH(CH2CH(CH3)2)CO), 22.71 
& 22.62 & 22.53 & 22.42 (4s, 4 x NHCH(CH2CH(CH3)2)CO), 20.32 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.87 (s). 
 
Synthesis of L-Phenylalanine-neopentyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (32.a) 
N
N
N
O
NH2
N
O
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O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.18 g, 
0.57 mmol) in anh. THF (3.1 mL), anh. NEt3 (0.10 mL, 0.69 mmol, 1.2 eq), POCl3 (0.07 
mL, 0.69 mmol, 1.2 eq), L-Phenylalanine-neopentyl ester tosylate salt (12.e) (1.12 g, 
2.87 mmol, 5.0 eq) in anh. DCM (4.4 mL), and anh. NEt3 (0.80 mL, 5.73 mmol, 10 eq). 
After overnight stirring at RT and flash chromatography using MeOH (3%)/CHCl3, the 
desired material was recovered (0.05 g, 0.06 mmol, 11%). 
HPLC (MeOH/ H2O) : Rt = 32.69 min 
HPLC (ACN/ H2O) : Rt =  24.91 min 
MS (TOF ES+): 826.39 (M + H+), 848.50 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.68 (s, 1H, H-8 base), 7.25-7.08 (m, 10H, 2 x 
NHCH(CH2Ph)CO), 5.92 (s, 1H, H-1’), 5.49 (bs, 2H, NHCH(CH2Ph)CO), 4.42 (m, 1H, 
H-3’), 4.35 (m, 1H, H-5’), 4.19 (m, 2H, H-4’, NHCH(CH2Ph)CO), 4.17-4.08 (m, 2H, 
H-5’, NHCH(CH2Ph)CO), 4.04 (s, 3H, 6-OCH3 base), 3.79-3.70 (m, 4H, 2 x 
COOCH2C(CH3)3), 2.98-2.84 (2m, 4H, 2 x NHCH(CH2Ph)CO), 0.97 (s, 3H, CH3-2’), 
0.88 & 0.87 (2s, 18H2 x COOCH2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.50 (s, NHCH(CH2Ph)CO), 173.03 (s, 
NHCH(CH2Ph)CO), 161.60 (s, C-6 base), 159.58 (s, C-2 base), 152.96 (s, C-4 base), 
137.90 (s, C-8 base), 136.16 & 136.03 (2s, 2 C-1 Ph), 129.48 & 129.42 & 129.39 & 
129.35 (4s, 4 x C meta Ph), 128.55 & 128.53 & 128.33 &128.27 (4s, 4 x C ortho Ph), 
127.05 & 127.01 (2s, 2 x C para Ph), 115.77 (s, C-5 base), 91.82 (s, C-1’), 81.09  (s, C-
4’), 79.47 (s, C-2’),  76.83 (s, C-3’), 74.89 & 74.77 (2s, 2 x COOCH2C(CH3)3), 65.20 
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(s, C-5’), 55.22 & 55.19 (2s, 2 x NHCH(CH2Ph)CO), 53.80 (s, 6-OCH3 base), 45.78 (d, 
J3P-N-C-C = 6.3 Hz, NHCH(CH2Ph)CO), 40.40 (2, J3P-N-C-C = 5.0 Hz, NHCH(CH2Ph)CO), 
31.21 & 31.15 (2s, 2 x COOCH2C(CH3)3), 26.73 & 26.37 (2s, 2 x COOCH2C(CH3)3), 
20.36 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.10 (s). 
 
Synthesis of L-Phenylalanine-cyclohexyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (32.b) 
N
N
N
O
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Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.31 g, 
1.01 mmol) in anh. THF (5.43 mL), anh. NEt3 (0.17 mL, 1.21 mmol, 1.2 eq), POCl3 
(0.11 mL, 1.21 mmol, 1.2 eq), L-Phenylalanine-cyclohexyl ester tosylate salt (12.f) 
(2.13 g, 5.05 mmol, 5.0 eq) was added and anh. DCM (4.0 mL), and anh. NEt3 (1.41 
mL, 10.1 mmol, 10 eq). After overnight stirring at RT and flash chromatography using 
MeOH (2%)/CHCl3, the desired material was recovered (0.04 g, 0.05 mmol, 5%). 
HPLC (MeOH/H2O) : Rt =22.09 min 
HPLC (ACN/H2O) : Rt = 20.32 min 
MS (TOF ES+): 850.39 (M + H+), 872.37 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.65 (s, 1H, H-8 base), 7.28-7.11 (m, 10H, 2 x 
NHCH(CH2Ph)CO), 5.91 (s, 1H, H-1’), 5.16 (bs, 2H, NHCH(CH2Ph)CO), 4.48 (m, 1H, 
H-3’), 4.38 (m, 1H, H-5’), 4.13-4.12 (m, 2H, H-4’, H-5’), 4.06 (s, 3H, 6-OCH3 base), 
4.02 (m, 2H, 2 x NHCH(CH2Ph)CO), 3.59-345 (m, 2H, 2 x CH cHex), 2.98-2.85 (m, 
4H, 2 x NHCH(CH2Ph)CO), 1.80-1.67 (m, 8H, 2 x CH2 ortho cHex, 2 x CH2 meta 
cHex), 1.51 (m, 2H, 2 x CH2 para cHex), 1.32-1.23 (m, 8H, 2 CH2 x ortho cHex, 2 x 
CH2 meta cHex), 0.98 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 172.76 (s, NHCH(CH2Ph)CO), 172.28 (s, 
NHCH(CH2Ph)CO), 161.58 (s, C-6 base), 159.65 (s, C-2 base), 152.96 (s, C-4 base), 
137.81 (s, C-8 base), 136.23 & 136.14 (2s, 2 x C-1 Ph), 129.62 & 129.58 & 129.52 & 
129.48 (2s, 4 C x meta Ph), 128.81 & 128.44 & 128.41 & 128.12 (4s, 4 x C ortho Ph), 
126.97 & 126.92 (2s, 2 x C para Ph), 115.72 (s, C-5 base), 91.76 (s, C-1’), 81.06  (s, C-
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4’), 79.46 (s, C-2’), 74.81 (s, C-3’), 74.21 & 74.06 (2s, 2 x C-1 cHex), 65.17 (s, C-5’), 
55.30 & 55.26 (2s, 2 x NHCH(CH2Ph)CO), 53.81 (s, 6-OCH3 base), 40.40 & 40.34 (2s, 
2 x NHCH(CH2Ph)CO),  31.49 & 31.40 (2s, 4 x C ortho cHex), 25.22 (s, 2 x C para 
cHex), 23.67 (s, 4 x C meta cHex), 20.34 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.16 (s). 
 
Synthesis of L-Phenylalanine-benzyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (32.c) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
HN
O
O
O
O
O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.15 g, 
0.47 mmol) in anh. THF (2.5 mL), anh. NEt3 (0.08 mL, 0.56 mmol, 1.2 eq), POCl3 (0.05 
mL, 0.56 mmol, 1.2 eq), commercially available L-Phenylalanine-benzyl ester tosylate 
salt (1.00 g, 2.34 mmol, 5.0 eq) in anh. DCM (3.6 mL), anh. NEt3 (0.65 mL, 4.68 mmol, 
10 eq). After overnight stirring at RT and flash chromatography using MeOH 
(3%)/CHCl3, the desired material was recovered (0.04 g, 0.04 mmol, 9%). 
HPLC (MeOH/H2O) : Rt = 25.97 min 
HPLC (ACN/H2O) : Rt = 21.16 min 
MS (TOF ES+): 866.33 (M + H+), 888.35 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.66 (s, 1H, H-8 base), 7.33-7.26 (m, 10H, 6 x 
CH OCH2Ph, 4 x CH NHCH(CH2Ph)CO), 7.19-1.17 (m, 6H, 6 x CH 
NHCH(CH2Ph)CO), 7.02-7.00 (m, 4H, 4 x CH OCH2Ph), 5.91 (s, 1H, H-1’), 5,1 (bs, 
2H, NHCH(CH2Ph)CO), 5.14-5.02 (m, 4H, 2 x OCH2Ph), 4.45 (m, 1H, H-3’), 4.34 (m, 
1H, H-5’), 4.18-4.09 (m, 3H, 2 x NHCH(CH2Ph)CO, H-4’), 4.05 (s, 3H, 6-OCH3 base), 
2.92-2.84 (m, 4H, 2 x NHCH(CH2Ph)CO), 0.97 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.18 (s, NHCH(CH2Ph)CO), 172.69 (s, 
NHCH(CH2Ph)CO), 161.62 (s, C-6 base), 159.57 (s, C-2 base), 152.90 (s, C-4 base), 
137.94 (s, C-8 base), 135.94 & 135.87 (2s, 2 x C-1 NHCH(CH2Ph)CO), 135.13 & 
135.08 (2s, 2 x C-1 OCH2Ph), 120.53 & 129.50 & 129.46 & 129.42 (4s, 4 x C meta 
NHCH(CH2Ph)CO, 4 x C meta OCH2Ph), 128.59 &  128.52 & 128.49 & 128.45 (4s, 4 
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x C ortho, 2 x C para OCH2Ph, 4 x C ortho NHCH(CH2Ph)CO), 127.04 & 127.02 (2s, 2 
x C para NHCH(CH2Ph)CO), 115.86 (s, C-5 base), 91.82 (s, C-1’), 81.04  (s, C-4’), 
79.51 (s, C-2’), 74.94 (s, C-3’), 67.33 & 67.19 (2s, 2 x OCH2Ph), 65.16 (s, C-5’), 55.30 
& 55.24 (2s, 2 x NHCH(CH2Ph)CO), 53.44 (s, 6-OCH3 base), 40.15 (s, 2 x 
NHCH(CH2Ph)CO), 20.37 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.20 (s). 
 
Synthesis of D-Alanine-neopentyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (34.a) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
HN
O
O
O
O
O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.66 g, 
2.13 mmol) in anh. THF (11 mL), anh. NEt3 (0.35 mL, 2.56 mmol, 1.2 eq), POCl3 (0.24 
mL, 2.56 mmol, 1.2 eq), D-Alanine-neopentyl tosylate salt (provided by M. Aljarah) 
(3.53 g, 10.65 mmol, 5.0 eq) in anh. DCM (8.0 mL), and anh. NEt3 (2.95 mL, 21.3 
mmol, 10 eq). After overnight stirring at RT, flash chromatography using MeOH 
(3%)/CHCl3, and work-up with 0.5N HCl in H2O, the desired material was recovered 
(0.25 g, 0.38 mmol, 18%). 
HPLC (MeOH/H2O) : Rt = 20.16 min 
HPLC (ACN/H2O) : Rt = 18.33 min 
MS (TOF ES+): 674.33 (M + H+), 696.31 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.90 (s, 1H, H-8 base), 6.01 (s, 1H, H-1’), 5.41 
(bs, 2H, NHCH(CH3)CO), 4.55-4.50 (m, 1H, H-3’), 4.32-4.29 (m, 2H, H-4’, H-5’), 4.18 
(m, 1H, H-5’), 4.07 (s, 3H, 6-OCH3 guanine), 4.03-3.88 (m, 4H, 2 x OCH2C(CH3)3), 
3.63-3.50 (m, 2H, 2 x NHCH(CH3)CO), 1.42 (d, 6H, J = 7.9 Hz, 2 x NHCH(CH3)CO), 
0.99 (s, 3H, CH3-2’), 0.90 & 0.85 (2s, 18H, 2 x OCH2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 172.76 (s, NHCH(CH3)CO), 172.28 (s, 
NHCH(CH3)CO), 161.56 (s, C-6 base), 159.65 (s, C-2 base), 152.96 (s, C-4 base), 
137.89 (s, C-8 base), 115.72 (s, C-5 base), 91.18 (s, C-1’), 81.92  (d, J3P-O-C-C  = 6.3 Hz, 
C-4’), 79.45 (s, C-2’), 74.90 & 74.69 (2s, 2 x OCH2C(CH3)3), 73.41 (s, C-3’), 65.84 (s, 
C-5’), 53.85 (s, 6-OCH3 base), 49.88 & 49.58 (2s, 2 x NHCH(CH3)CO), 31.37 (s, 2 x 
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NHCHC(CH)3CO), 26.25 & 26.19 (2s, 2 x OCH2C(CH3)3), 21.29 (d, J3P-N-C-C  = 6.3 Hz, 
NHCH(CH3)CO), 21.07  (d, J3P-N-C-C  = 6.3 Hz, NHCH(CH3)CO), 20.42 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.61 (s). 
 
Synthesis of S-methyl-L-Cysteine-neopentyl ester β-2’-C-methyl-6-O-methyl 
guanosine phosphorodiamidate (35.a) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
HN
O
O
O
O
O S
S
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.33 g, 
1.05 mmol) in anh. THF (5.61 mL), anh. NEt3 (0.18 mL, 1.26 mmol, 1.2 eq), POCl3 
(0.11 mL, 1.26 mmol, 1.2 eq), S-methyl-L-Cysteine-neopentyl tosylate salt (12.g) (1.98 
g, 5.25 mmol, 5.0 eq) in anh. DCM (6.0 mL), and anh. NEt3 (1.44 mL, 10.5 mmol, 10 
eq). After overnight stirring at RT, flash chromatography using MeOH (3%)/CHCl3, 
and preparative chromatography, the desired material was recovered (0.097 g, 0.13 
mmol, 12%). 
HPLC (MeOH/H2O) : Rt = 28.80 min 
HPLC (ACN/H2O) : Rt = 19.89 min 
MS (TOF ES+): 788.28 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.98 (s, 1H, H-8 base), 5.98 (s, 1H, H-1’), 4.47-
4.38 (m, 2H, H-5’), 4.38 (d, 1H, J = 9.0 Hz, H-3’), 4.21-4.14 (m, 2H, 2 x 
NHCH(CH2SCH3)CO), 4.07 (s, 3H, 6-OCH3 base), 3.86-3.73 (m, 5H, H-4’, 2 x 
COOCH2C(CH3)3), 2.89-2.83 (m, 4H, 2 x NHCH(CH2SCH3)CO), 2.13 & 2.09 (2s, 6H, 
2 x NHCH(CH2SCH3)CO), 0.99 (s, 3H, CH3-2’), 0.96 & 0.94 (2s, 18H, 2 x 
COOCH2C(CH3)3). 
13C NMR (125 MHz, MeOD) δC (ppm): 173.72 (s, NHCH(CH2SCH3)CO), 173.68 (d, 
J3P-N-C-C = 6.3 Hz, NHCH(CH2SCH3)CO), 162.76 (s, C-6 base), 161.92 (s, C-2 base), 
154.59 (s, C-4 base), 139.48 (s, C-8 base), 115.60 (s, C-5 base), 93.25 (s, C-1’), 82.43  
(d, J3P-O-C-C = 7.6 Hz, C-4’), 79.99 (s, C-2’), 75.76 & 74.96 (2s, 2 x COOCH2C(CH3)3), 
74.91 (s, C-3’), 66.88 (s, C-5’), 55.32 & 55.00 (2s, 2 x NHCH(CH2SCH3)CO), 54.21 (s, 
6-OCH3 base), 39.43 & 39.35 (2s, 2 x CH2 NHCH(CH2SCH3)CO), 32.25 & 32.20 (2s, 2 
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x COOCH2C(CH3)3), 26.84 & 26.57 (2s, 6 x COOCH2C(CH3)3), 20.26 (s, CH3-2’), 
16.15 & 16.11 (2s, 2 x NHCH(CH2SCH3)CO). 
31P NMR (202 MHz, MeOD) δP (ppm): 13.36 (s). 
 
Synthesis of S-methyl-L-Cysteine-cyclohexyl ester β-2’-C-methyl-6-O-methyl 
guanosine phosphorodiamidate (35.b) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
HN
O
O
O
O
O S
S
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.55 g, 
1.77 mmol) in anh. THF (9.50 mL), anh. NEt3 (0.30 mL, 2.12 mmol, 1.2 eq), POCl3 
(0.20 mL, 2.12 mmol, 1.2 eq), S-methyl-L-Cysteine-cyclohexyl ester tosylate salt (12.h) 
(3.44 g, 8.85 mmol, 5.0 eq) in anh. DCM (10 mL), and anh. NEt3 (2.43 mL, 17.7 mmol, 
10 eq). After overnight stirring at RT, flash chromatography using MeOH (3%)/CHCl3, 
and preparative chromatography, the desired material was recovered (0.11 g, 0.14 
mmol, 8%). 
HPLC (MeOH/H2O) : Rt = 29.15 min 
HPLC (ACN/H2O) : Rt = 20.10 min 
MS (TOF ES+): 790.30 (M + H+), 812.29 (M + Na+), 828.27 (M + K+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.78 (s, 1H, H-8 base), 5.96 (s, 1H, H-1’), 5.52 
(bs, 2H, 2 x NHCH(CH2SCH3)CO), 4.78-4.73 (m, 2H, 2 x CH cHex), 4.57-4.54 (m, 2H, 
H-5’), 4.43 (m, H-3’), 4.33-4.11 (m, 3H, 2 x NHCH(CH2SCH3)CO, H-4’), 4.03 (s, 3H, 
6-OCH3 base), 2.86-2.06 (m, 4H, 2 x NHCH(CH2SCH3)CO), 2.10 & 2.06 (2s, 6H, 2 x 
NHCH(CH2SCH3)CO), 1.79 (m, 4H, 2 x CH2 ortho cHex), 1.67 (m, 4H, 2 x CH2 meta 
cHex), 1.49 (m, 2H, CH2 para cHex), 1.40-1.19 (m, 10H, 2 x CH2 ortho cHex , 2 x CH2 
meta cHex, CH2 para cHex), 0.97 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 171.77 (d, J3P-N-C-C = 5.0 Hz, 
NHCH(CH2SCH3)CO), 171.60 (d, J3P-N-C-C = 5.0 Hz, NHCH(CH2SCH3)CO), 161.56 (s, 
C-6 base), 159.62 (s, C-2 base), 152.90 (s, C-4 base), 137.90 (s, C-8 base), 115.51 (s, C-
5 base), 91.68 (s, C-1’), 80.98  (s, J3P-O-C-C = 6.3 Hz, C-4’), 79.33 (s, C-2’), 74.54 (s, C-
3’), 74.48 & 74.23 (2s, 2 x C ipso cHex), 65.19 (d, J2P-O-C  = 5.04 Hz, C-5’), 55.86 & 
53.80 (2s, 2 x NHCH(CH2SCH3)CO), 53.73 (s, 6-OCH3 base), 38.86 (d, J3P-N-C-C = 5.0 
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Hz, NHCH(CH2SCH3)CO), 38.78 (s, NHCH(CH2SCH3)CO), 31.41 & 31.37 (2s, 4 x 
CH2 ortho cHex), 25.19 (s, 2 x CH2 para cHex), 23.59 & 23.53 (2s, 4 x CH2 meta 
cHex), 20.25 (s, CH3-2’), 16.17 & 15.98 (2s, 2 x NHCH(CH2SCH3)CO). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.31 (s). 
 
Synthesis of S-methyl-L-Cysteine-benzyl ester β-2’-C-methyl-6-O-methyl guanosine 
phosphorodiamidate (35.c) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
H
HN
O
O
O
O
O S
S
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.31 g, 
1.00 mmol, 1.0 eq) in anh. THF (5.35 mL), anh. NEt3 (0.17 mL, 1.20 mmol, 1.2 eq), 
POCl3 (0.11 mL, 0.11 mmol, 1.2 eq), S-methyl-L-Cysteine-benzyl ester tosylate salt 
(12.i) (1.99 g, 5.00 mmol, 5.0 eq) in anh. DCM (8.0 mL), and anh. NEt3 (1.39 mL, 10.0 
mmol, 10 eq). After overnight stirring at RT, flash chromatography using MeOH 
(3%)/CHCl3, and preparative chromatography, the desired material was recovered 
(0.053g, 0.07 mmol, 6.6 %). 
HPLC (MeOH/H2O) : Rt = 27.18 min 
HPLC (ACN/H2O) : Rt = 17.86 min 
MS (TOF ES+): 806.24 (M + H+), 828.22 (M + Na+), 844.20 (M + K+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.74 (s, 1H, H-8 base), 7.34-7.30  (m, 10H, 2 x 
COOCH2Ph), 5.91 (s, 1H, H-1’), 5.37 (bs, 2H, 2 x NHCH(CH2SCH3)CO), 5.20-5.10 
(m, 4H, 2 x COOCH2Ph), 4.59-4.52 (m, 2H, H5’, H3’), 4.25-4.21 (m, 2H, 2 x 
NHCH(CH2SCH3)CO), 4.16-4.11 (m, 2H, H5’, H4’), 4.05 (s, 3H, 6-OCH3 base), 2.87-
2.83 (m, 4H, 2 x NHCH(CH2SCH3)CO), 2.03 (s, 3H, NHCH(CH2SCH3)CO), 2.01 (s, 
3H, NHCH(CH2SCH3)CO), 0.98 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 172.27 (s, NHCH(CH2SCH3)CO), 172.07 (s, 
NHCH(CH2SCH3)CO), 161.62 (s, C-6 base), 159.51 (s, C-2 base), 152.83 (s, C-4 base), 
138.01 (s, C-8 base), 135.02 (s, 2 x C ipso Ph), 128.62 & 128.56 & 128.46 & 128.44 
(4s, 4 x C meta Ph, 4 x CH ortho Ph, 2 x C para Ph), 115.57 (s, C-5 base), 91.77 (s, C-
1’), 80.96  (s, J3P-O-C-C  = 6.3 Hz, C-4’), 79.43 (s, C-2’), 74.42 (s, C-3’), 67.60 & 67.55 
(2s, 2 x OCH2Ph), 65.06 (s, C-5’), 55.87 & 53.79 & 53.62 (3s, 2 x 
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NHCH(CH2SCH3)CO, 6-OCH3 base), 38.68 & 38.63 (2s, 2 x NHCH(CH2SCH3)CO), 
20.35 (s, CH3-2’), 16.03 & 16.00 (s, 2 x NHCH(CH2SCH3)CO). 
31P NMR (202 MHz, CDCl3) δP (ppm): 13.34 (s). 
 
Synthesis of morpholino β-2’-C-methyl-6-O-methyl guanosine phosphorodiamidate 
(36) 
N
N
N
O
NH2
N
O
OHOH
O
P
N
N
O
O
O
 
Prepared according to procedure E, using β-2’-C-Me-6-OMe guanosine (11) (0.91 g, 
2.92 mmol) in anh. THF (14 mL), anh. NEt3 (0.49 mL, 3.50 mmol, 1.2 eq), POCl3 (0.33 
mL, 3.50 mmol, 1.2 eq), commercially available morpholine  (1.26 mL, 14.6 mmol, 5.0 
eq) in anh. DCM (10 mL), and anh. NEt3 (4.10 mL, 29.2 mmol, 10 eq). After overnight 
stirring at RT, flash chromatography using MeOH (6%)/CHCl3, and preparative 
chromatography, the desired material was recovered (0.034 g, 0.063 mmol, 3%). 
HPLC (MeOH/H2O): Rt = 13.48 min 
HPLC (ACN/H2O): Rt = 12.47 min 
MS (TOF ES+): 530.21 (M + H+). 
1H NMR (500 MHz, CDCl3): 7.75 (s, 1H, H-8 base), 6.00 (s, 1H, H-1’), 5.51-4.48 (m, 
1H, H-5’), 4.41-4.35 (m, 2H, H-5’, H-3’), 4.28-4.26 (m, 1H, H-4’), 4.07 (s, 3H, 6-OCH3 
base), 3.66-3.62 (m, 8H, 4 x O(CH2CH2)2N), 3.19-3.12 (m, 8H, 4 x O(CH2CH2)2N), 
1.03 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3): 160.84 (s, C-6 base), 159.56 (s, C-2 base), 152.59 (s, C-4 
base), 137.35 (s, C-8 base), 114.40 (s, C-5 base), 91.33 (s, C-1’), 80.62 (d, J3P-O-C-C = 
8.8 Hz, C-4’), 78.51 (s, C-2’), 77.98 (s, C-3’), 67.74 & 66.45 & 66.41 & 66.37 (4s, 4 x 
O(CH2CH2)2N), 64.63 (d, J2P-O-C = 3.75 Hz, C-5’), 53.96 (s, 6-OCH3 base), 44.87 & 
44.72 & 44.69 & 44.56 (4s, 4 x O(CH2CH2)2N), 19.50 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 14.85 (s). 
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4. Experimental procedures related to chapter 4 
4.1. 8-modified nucleosides and phosphoramidates 
4.1.1. 8-modified nucleosides 
Synthesis of 8-bromo β-2’-C-methyl-6-O-methyl guanosine (46) 
N
N
N
O
NH2
N
O
OHOH
HO
Br
 
To β-2’-C-Me-6-OMe guanosine (11) (2.52 g, 8.11 mmol, 1.0 eq) dissolved in anh. 
MeOH (125 m) was added N-bromo succinimide (2.43 g, 12.17 mmol, 1.5 eq), the 
solution was left stirring for 1 hr at RT. After purification by flash chromatography 
using MeOH (4%)/CH2Cl2, the desired material was recovered (3.05 g, 7.82 mmol, 
96%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 6.16 (s, 1H, H-1’), 5.10 (bs, 2H, NH2 base), 4.66 
(dd, 1H, J = 6.2 Hz, 8.6 Hz, H-4’), 4.37 (d, 1H, J = 6.2 Hz, H-3’), 4.24 (d, 1H, J =1.5 
Hz, H-5’), 4.22 (d, 1H, J =1.5 Hz, H-5’), 4.06 (s, 3H, 6-OCH3 base), 1.04 (s, 3H, CH3-
2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 161.00 (s, C-6 base), 158.78 (s, C-2 base), 
152.71 (s, C-4 base), 124.16 (s, C-8 base), 116.40 (s, C-5 base), 95.15 (s, C-1’), 82.85 
(s, C-4’), 79.64 (s, C-2’), 71.91 (s, C-3’), 60.38 (s. C-5’), 54.23 (s, 6-OCH3 base), 21.53 
(s, CH3-2’). 
 
Synthesis of 8-iodo β-2’-C-methyl-6-O-methyl guanosine (47) 
N
N
N
O
NH2
N
O
OHOH
HO
I
 
To β-2’-C-Me-6-OMe guanosine (11) (1.51 g, 4.82 mmol, 1.0 eq) dissolved in anh. 
THF (57 mL) was added N-iodo succinamide (2.90 g, 12.62 mmol, 2.6 eq), and the 
solution was left stirring for 72 hrs at 35 °C in the dark. After purification by flash 
chromatography using MeOH (2%)/CH2Cl2, the desired material was recovered (0.53 g, 
1.21 mmol, 25%). 
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1H NMR (500 MHz, MeOD) δH (ppm): 6.01 (s, 1H, H-1’), 4.62 (m, 1H, H-4’), 4.16 (d, 
1H, J = 6.0 Hz, H-3’), 4.09 (s, 3H, 6-OCH3 base), 4.08-3.96 (m, 2H, H-5’), 1.05 (s, 3H, 
CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 162.70 (s, C-6 base), 161.20 (s, C-2 base), 
154.15 (s, C-4 base), 119.29 (s, C-5 base), 99.22 (s, C-8 base), 98.71 (s, C-1’), 84.32 (s, 
C-3’), 79.52 (s, C-2’), 74.52 (s, C-4’), 62.30 (s, C5’), 54.93 (s, 6-OCH3 base), 21.49 (s, 
CH3-2’). 
 
Synthesis of 8-chloro β-2’-C-methyl-6-O-methyl guanosine (48) 
N
N
N
O
NH2
N
O
OHOH
HO
Cl
 
To β-2’-C-Me-6-OMe guanosine (11) (1.51 g, 4.82 mmol, 1.0 eq) dissolved in anh. 
THF (56 mL) was added N-chloro succinamide (0.78 g, 5.83 mmol, 1.21 eq), and the 
solution was left stirring for 64 hrs at RT in the dark. After purification by flash 
chromatography using MeOH (4%)/CH2Cl2, the desired material was recovered (1.10 g, 
3.19 mmol, 66%). 
1H NMR (500 MHz, MeOD) δH (ppm): 6.01 (s, 1H, H-1’), 4.58 (d, 1H, J = 6.2 Hz, 
H3’), 4.11-4.06 (m, 2H, H4’, H5’), 4.07 (s, 3H, 6-OCH3 base), 3.97-3.92 (m, 1H, H-5’), 
1.03 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 162.03 (s, C-6 base), 161.22 (s, C-2 base), 
154.28 (s, C-4 base), 136.59 (s, C-8 base), 114.59 (s, C-5 base), 95.60 (s, C-1’), 84.41 
(s, C-4’), 80.37 (s, C-2’), 74.33 (s, C-3’), 62.27 (s. C-5’), 54.68 (s, 6-OCH3 base), 21.13 
(s, CH3-2’). 
 
Synthesis of 8-benzylamino β-2’-C-methyl-6-O-methyl guanosine (49) 
N
N
N
O
NH2
N
O
OHOH
HO
HN
 
To a solution of 8-bromo-6-O-methyl-2’-C-methyl guanosine (46) (0.51 g, 1.30 mmol, 
1.0 eq) dissolved in anh. MeOH (3 mL), was added benzylamine (0.18 mL, 1.69 mmol, 
1.3 eq). The mixture was stirred overnight at 115 °C in a sealed vessel. The solvent was 
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evaporated under reduced pressure and the residue was purified by flash 
chromatography using MeOH (6%)/CHCl3 and preparative chromatography to recover 
the desired material (0.04 mg, 0.09 mmol, 6.6%). 
HPLC (MeOH/H2O): Rt = 18.52 min 
HPLC (ACN/H2O): Rt = 10.04 min 
MS (TOF ES+): 417.19 (M + H+), 739.17 (M + Na+), 480.19 (M + MeCNNa+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7,36-7.22 (m, 5H, Ph), 6.09 (s, 1H, H-1’), 4.63 
& 4.44 (AB system, 2H, J = 15.1 Hz, CH2Ph), 4.21 (m, 1H, H-3’), 4.01 (s, 3H, 6-OCH3 
base), 3.99 (m, 1H, 1H H-5’), 3.93 (m, 1H, H-4’), 3.84 (m, 1H, H-5’), 0.94 (s, 3H, CH3-
2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 159.48 (s, C-6 base), 159.34 (s, C-2 base), 
152.71 (s, C-8 base), 148.65 (s, C-4 base), 140.84 (s, C ipso Ph), 128.78 & 128.64 & 
128.24 & 128.17 & 128.01 & 127.60 (6s, 2 x C Ph, C-5 base), 93.69 (s, C-1’), 82.88 (s, 
C-4’), 79.85 (s, C-2’), 73.94 (s, C-3’), 53.89 (s, 6-OCH3 base), 46.89 (s, CH2Ph), 20.99 
(s, CH3-2’).  
 
Synthesis of 8-dimethylamino β-2’-C-methyl-6-O-methyl guanosine (50) 
N
N
N
O
NH2
N
O
OHOH
HO
N
	  
8-bromo-6-O-methyl-2’-C-methyl guanosine (46) (0.63 g, 1.62 mmol) was dissolved in 
anh. DMF (3.30 mL), and dimethylamine (0.97 mL, 1.94 mmol, 1.2 eq) was added. 
Then anh. NEt3 (0.59 mL, 4.21 mmol, 2.6 eq) was added and the solution was stirred 
over 72 hrs in a sealed tube at 115 °C. The solvent was evaporated. The residue was 
purified by flash chromatography using CHCl3/MeOH (5 %) as eluents, and preparative 
chromatography (EtOAc) allowed the recovery of the desired material (0.29 g, 0.83 
mmol, 51%). 
HPLC (MeOH/H2O) : Rt = 12.20 min 
HPLC (ACN/H2O) : Rt = 3.25 min 
MS (TOF ES+): 355.17 (M + H+). 
1H NMR (500 MHz, MeOD) δH (ppm): 5.91 (s, 1H, H-1’), 4.74 (d, 1H, J = 8.7 Hz, H-
3’), 4.04 (s, 3H, 6-OCH3 base), 4.02-3.99 (m, 2H, H-5’ & H-4’), 3.94-3.91 (m, 1H, H-
5’), 2.89 (2s, 6H, N(CH3)2), 1.12 (s, 3H, CH3-2’). 
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13C NMR (125 MHz, MeOD) δC (ppm): 161.18 (s, C-6 base), 160.25 (s, C-2 base), 
157.04 (s, C-4 base), 154.51 (s, C-8 base), 112.94 (s, C-5 base), 96.65 (s, C-1’), 83.75 
(s, C-4’), 80.23 (s, C-2’), 74.87 (s, C-3’), 62.36 (s, C-5’), 54.26 (s, 6-OCH3 base), 43.61 
(s, N(CH3)2), 21.58 (s, CH3-2’). 
 
Synthesis of 8-pyrrolidino β-2’-C-methyl-6-O-methyl guanosine (51) 
N
N
N
O
NH2
N
O
OHOH
HO
N
 
8-bromo-6-O-methyl-2’-C-methyl guanosine (46) (0.68 g, 1.75 mmol) was dissolved in 
anh. DMF (15 mL), and pyrrolidine (0.17 mL, 2.10 mmol, 1.2 eq) was added. Then anh. 
NEt3 (0.64 mL, 4.55 mmol, 2.6 eq) was added, and the solution was stirred over the 
weekend in a sealed tube at 155 °C. The solvent was evaporated. The residue was 
purified by flash chromatography using CHCl3/MeOH (5 %) as eluent, and a 
preparative chromatography (EtOAc) allowed the recovery of the desired material (0.06 
g, 0.16 mmol, 9%). 
HPLC (MeOH/H2O) : Rt = 4.60 min 
HPLC (ACN/H2O) : Rt = 2.61 min 
MS (TOF ES+): 381.19 (M + H+). 
1H NMR (500 MHz, MeOD) δH (ppm): 5.98 (s, 1H, H-1’), 4.71 (d, 1H, J = 8.8 Hz, H-
3’), 4.02 (s, 3H, 6-OCH3 base), 3.98-3.96 (m, 2H, H-5’, H4’), 3.91-3.90 (m, 1H, H-5’), 
3.58-3.55 (m, 2H, N(CH2CH2)2), 3.43-3.39 (m, 2H, N(CH2CH2)2), 2.08-1.98 (m, 4H, 
N(CH2CH2)2), 1.15 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 161.17 (s, C-6 base), 159.70 (s, C-2 base), 
157.01 (s, C-4 base), 154.65 (s, C-8 base), 113.28 (s, C-5 base), 94.47 (s, C-1’), 83.81 
(s, C-4’), 80.22 (s, C-2’), 74.79 (s, C-3’), 62.72 (s, C-5’), 54.11 (s, 6-OCH3 base), 53.15 
& 53.09 (2s, N(CH2CH2)2), 26.56 & 26.23 (2s, N(CH2CH2)2), 21.71 (s, CH3-2’). 
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Synthesis of 8-methylamino β-2’-C-methyl-6-O-methyl guanosine (57) 
N
N
N
O
NH2
N
O
OHOH
HO
HN
 
To a solution of 8-chloro-6-O-methyl-2’-C-methyl guanosine (48) (0.44 g, 1.27 mmol, 
1.0 eq) is anh. MeOH (12 mL), was added anh. methylamine (2.0M in sol. MeOH, 1.28 
mL, 2.54 mmol, 2.0 eq). The reaction was left stirring in a sealed vessel for 72 hrs at 
115 °C. The solvent was evaporated under reduced pressure and the residue was 
purified by flash chromatography using MeOH (6%)/CHCl3 to recovered the desired 
molecule (0.160 g, 0.47 mmol, 37%). 
HPLC (MeOH/H2O): Rt = 5.69 min 
HPLC (ACN/H2O): Rt = 4.23 min 
MS (TOF ES+): 341.16 (M + H+). 
1H NMR (500 MHz, MeOD) δH (ppm): 6.06 (s, 1H, H-1’), 4.18 (d, 1H, J = 8.9 Hz, H-
3’), 4.03 (m, 1H, H-5’), 4.02 (s, 3H, 6-OCH3 base), 3.92-3.86 (m, 2H, H-4’, H-5’), 2.89 
(s, 3H, NHCH3), 0.96 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 159.48 (s, C-6 base), 159.31 (s, C-2 base), 
153.31 (s, C-4 base), 153.72 (s, C-8 base), 112.29 (s, C-5 base), 93.58 (s, C-1’), 82.85 
(s, C-4’), 79.85.37 (s, C-2’), 73.88 (s, C-3’), 59.37 (s, C-5’), 53.88 (s, 6-OCH3 base), 
29.29 (s, NHCH3), 20.95 (s, CH3-2’). 
 
Synthesis of 8-phenylamino β-2’-C-methyl-6-O-methyl guanosine (58) 
N
N
N
O
NH2
N
O
OHOH
HO
HN
 
8-chloro-6-O-methyl-2’-C-methyl guanosine (48) (0.52 g, 1.50 mmol) was dissolved in 
anh. MeOH (15 mL), and aniline (0.27 mL, 3.00 mmol, 2.0 eq) was added. The solution 
was stirred over the weekend in a sealed tube at 115 °C. The solvent was evaporated 
and the residue was purified by flash chromatography using CHCl3/MeOH (4.5 %) as 
eluents, and preparative chromatography allowed the recovery of the desired material 
(0.19 g, 0.47 mmol, 32%). 
HPLC (MeOH/H2O) : Rt = 18.04 min 
HPLC (ACN/H2O) : Rt = 13.93 min 
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MS (TOF ES+): 403.17 (M + H+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.50 (m, 2H, 2 x CH ortho Ph), 7.28 (m, 2H, 2 x 
CH meta Ph), 6.97 (m, 1H, CH para Ph), 6.22 (s, 1H, H-1’), 4.21 (m, 1H, H-3’), 4.11-
4.08 (dd, 1H, J = 2.0 Hz, 11.9 Hz, H-5’), 4.02 (s, 3H, 6-OCH3 base), 3.97-3.91 (m, 2H, 
H-5’, H-4’), 1.03 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 160.33 (s, C-6 base), 160.27 (s, C-2 base), 
154.83 (s, C-4 base), 153.12 (s, C-8 base), 141.37 (s, C ipso Ph), 130.13 & 129.92 (2s, 2 
x C meta Ph), 123.54 (s, C para Ph), 120.67 &120.37 (2s, 2 x C ortho Ph), 111.99 (s, C-
5 base), 93.49 (s, C-1’), 82.69 (s, C-4’), 79.68 (s, C-2’), 74.04 (s, C-3’), 59.49 (s, C-5’), 
54.23 (s, 6-OCH3 base), 19.57 (s, CH3-2’). 
 
Synthesis of 8-butylamino β-2’-C-methyl-6-O-methyl guanosine (59) 
N
N
N
O
NH2
N
O
OHOH
HO
HN
 
8-chloro-6-O-methyl-2’-C-methyl guanosine (48) (0.17 g, 0.49 mmol) was dissolved in 
anh. MeOH (5.0 mL) and N-butylamine (0.97 mL, 0.98 mmol, 2.0 eq) was added. The 
solution was stirred over the weekend in a sealed tube at 115 °C. The solvent was 
evaporated and the residue was purified by flash chromatography using CHCl3/MeOH 
(3-4%) and preparative chromatography was performed to recover the desired material 
(0.050 g, 0.13 mmol, 27%). 
HPLC (MeOH/H2O) : Rt =  8.53 min 
HPLC (ACN/H2O) : Rt = 12.45 min 
MS (TOF ES+): 383.41 (M + H+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 6.08 (s, 1H, H-1’), 5.80 (bs, 1H, 
NHCH2CH2CH2CH3), 4.21 (d, 1H, J = 8.5 Hz, H-3’), 4.02 (s, 3H, 6-OCH3 base), 3.94-
3.88 (m, 1H, H-4’), 3.75-3.54 (m, 2H, H-5’), 3.33-3.32 (m, 2H, NHCH2CH2CH2CH3), 
1.64-1.60 (m, 2H, NHCH2CH2CH2CH3), 1.45-1.40 (m, 2H, NHCH2CH2CH2CH3), 1.26 
(s, 3H, CH3-2’), 0.98 (t, 3H, J = 4.4 Hz, NHCH2CH2CH2CH3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 159.41 (s, C-6 base), 159.23  (s, C-2 base), 
154.55 (s, C-4 base), 154.09 (s, C-8 base), 110.78 (s, C-5 base), 93.57 (s, C-1’), 84.57  
(s, C-4’), 79.77 (s, C-2’), 71.98 (s, C-3’), 60.35 (s, C-5’), 53.42 (s, 6-OCH3 base), 40.10 
Claire Bourdin  Chapter Eight: Experimental section 
 
212 
(s, NHCH2CH2CH2CH3), 31.55 (s, NHCH2CH2CH2CH3), 21.13 (s, 
NHCH2CH2CH2CH3), 19.98 (s, CH3-2’), 13.73 (s, NHCH2CH2CH2CH3). 
 
Synthesis of 8-oxo β-2’-C-methyl guanosine (63) 
NH
N
N
O
NH2
N
O
OHOH
HO
HO
 
8-bromo-6-O-methyl-2’-C-methyl guanosine (46) (0.45 g, 1.15 mmol, 1.0 eq) was 
suspended in anh. pyridine (14 mL) and sodium acetate (0.95 g, 11.6 mmol, 10 eq), and 
mixed with silver acetate (0.20 g, 1.17 mmol, 1.0 eq). A solution of 1-methylimidazole 
(0.035 mL, 0.44 mmol, 0.38 eq) in acetic anhydride (1.15 mL, 12.19 mmol, 10.6 eq) 
was added dropwise at 0 °C and refluxed overnight. The excess of acetic anhydride was 
evaporated under high reduced pressure, followed by hydrolysis with ammonium 
bicarbonate ((NH4)HCO3) at 0 °C. The solution was then evaporated to dryness and the 
residue was extracted with DCM. The organic layer was washed several times and after 
evaporation of the solvent, the residue was loaded on Sephadex G-10 for purification 
(ACN/H2O). The residue was purified by preparative TLC to recover the desired 
material (0.016 g, 0.052 mmol, 5%) 
HPLC (MeOH/H2O) : Rt = 2.31 min 
MS (TOF ES+): 336.27 (M + Na+). 
1H NMR (500 MHz, DMSO) δH (ppm): 10.66 (bs, 1H, NH base), 6.47 (bs, 2H, NH2 
base), 5.69 (s, 1H, H-1’), 4.99 (m, 2H, 3’-OH. 8-OH base), 4.79 (s, 1H, 2’-OH), 4.55 
(m, 5’-OH), 4.29 (t, 1H, J = 7.4 Hz, H-3’), 3.76 (m, 2H, H-5’), 3.73 (m, 1H, H-4’), 1.02 
(s, 3H, CH3-2’).  
13C NMR (125 MHz, DMSO) δC (ppm): 155.3 (s, C-6 base), 153.6 (s, C-2 base), 149.6 
(s, C-8 base), 148.1 (s, C-4 base), 115.2 (s, C-5 base), 91.32 (s, C-1’), 84.33 (s, C-4’), 
79.93 (s, C-2’), 75.09 (s, C-3’), 63.23 (s, C-5’), 20.67 (s, CH3-2’). 
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Synthesis of 8-oxo β-2’-C-methyl-6-O-methyl-N-2-acetate guanosine (64) 
N
N
H
N
O
N
H
N
O
OHOH
HO
O
O
 
Prepared as 63. The residue was purified by preparative TLC to recover the desired 
material (0.009 g, 0.025 mmol, 2%) 
HPLC (MeOH/H2O) : Rt = 2.43 min 
MS (TOF ES+): 392.12 (M + Na+). 
1H NMR (500 MHz, DMSO) δH (ppm): 11.43 (bs, 1H, NH-7 base), 10.28 (s, 1H, 
NHCOCH3 base), 5.80 (s, 1H, H-1’), 4.92 (bs, 1H, 3’-OH), 4.87 (s, 1H, 2’-OH), 4.50 
(bs, 1H, 5’-OH), 4.43 (m, 1H, H-3’), 3.99 (s, 3H, 6-OCH3 base), 3.80-3.77 (m, 1H, H-
4’), 3.71-3.61 (m, 2H, H-5’), 2.18 (s, 3H, NHCOCH3 base), 1.01 (s, 3H, CH3-2’).  
13C NMR (125 MHz, DMSO) δC (ppm): 166.6 (s, NHCOCH3 base), 158.4  (s, C-6 
base), 152.0 (s, C-2 base), 149.9 (s, C-8 base), 135.2 (s, C-4 base), 102.2 (s, C-5 base), 
89.01 (s, C-1’), 83.38 (s, C-4’), 77.77 (s, C-2’), 73.54 (s, C-3’), 62.10 (s, C-5’), 55.87 
(s, 6-OCH3 base), 24.35 (s, NHCOCH3 base), 20.16 (s, CH3-2’). 
 
4.1.2. Preparation of phosphorochloridates 
Preparation of α-naphthyl L-Alanine-neopentyl ester phosphochloridate (14.d) 
O P
O
Cl
O
O
NH
 
Prepared according to procedure C, using L-Alanine-neopentyl tosylate salt (provided 
by M. Aljarah) (0.66 g, 2.00 mmol, 1.0 eq) in anh. DCM (11 mL), α-naphthyl 
phosphorodichloridate (12) (0.57 g, 2.18 mmol, 1.1 eq), NEt3 (0.57 mL, 4.00 mmol, 2.0 
eq). The solvent was removed under reduced pressure and the residue purified by flash 
chromatography using Hexane/EtOAc (1:1) to yield the desired molecule (0.60 g, 1.55 
mmol, 78%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.08 (m, 1H, H-9 Ar), 7.82 (m, 1H, H-6 Ar), 
7.70 (m, 1H, H-4 Ar), 7.61 (m, 1H, H-3 Ar), 7.50 (m, 2H, H-7, H-8 Ar), 7.39 (m, 1H, 
H-2 Ar), 4.11 (m, 1H, NHCH(CH3)CO), 3.91 (m, 2H, COOCH2C(CH3)3), 1.56 (d, 3H, J 
= 2.5 Hz, NHCH(CH3)CO), 0.95 (2s, 9H, COOCH2C(CH3)3). 
31P NMR (202 MHz, CDCl3) δP (ppm): 8.41 (s), 8.25 (s). 
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4.1.3. Preparation of 8-modified ProTides 
Synthesis of α-naphthyl L-Alanine-neopentyl ester 8-methylamino β-2’-C-methyl-6-
O-methyl guanosine (68) 
O
P
O
HN
O
O
O
N
N
N
O
NH2
N
O
OHOH
HN
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl 
(1.16 mL, 2.0 eq), 8-methylamino-2’-C-Me-6-OMe-guanosine (57) (0.198 g, 0.58 
mmol) in anh. THF (1.70 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.472 g, 1.17 mmol, 2.0 eq) in anh. THF (1.1 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure, and the 
residue was purified by flash chromatography, using CHCl3/MeOH (4%) as eluents, and 
preparative chromatography to yield the starting material (57) and the desired ProTide 
(0.011 g, 0.015 mmol, 3%). 
HPLC (MeOH/H2O): Rt = 28.29 min, 28.39 min 
HPLC (ACN/ H2O): Rt = 18.20 min 
MS (TOF ES+): 688.28 (M + H+), 710.26 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.13 (d, 2H, J = 7.5 Hz, H-9 Ar 
diastereoisomers), 7.86 (d, 2H, J = 7.0 Hz, H-6 Ar diastereoisomers), 7.68 (d, 2H, J = 
6.7 Hz, H-4 Ar diastereoisomers), 7.55 (m, 6H, H-7, H-8, H-3 Ar diastereoisomers), 
7.43-7.39 (m, 2H, H-2 Ar diastereoisomers), 5.88 & 5.85 (2s, 1H, H-1’ 
diastereoisomers), 4.74-4.69 (m, 4H, COOCH2C(CH3)3 diastereoisomers), 4.64-4.62 
(m, 2H, H-3’ diastereoisomers), 4.54-4.42 (m, 2H, H-5’ diastereoisomers), 4.19-4.15 
(m, 4H, H-4’, H-5’ diastereoisomers), 4.04 (s, 6H, 6-OMe base diastereoisomers), 3.89-
3.858 (m, 4H, NHCH(CH3)CO, NHCH3 base diastereoisomers), 2.97 (d, 3H, J = 2.3 
Hz, NHCH3 base),  2.93 (d, 3H, J = 2.0 Hz, NHCH3 base), 1.61 (bs, 2H, 
NHCH(CH3)CO diastereoisomers), 1.44 (d, J = 7.0 Hz, NHCH(CH3)CO), 1.34 (d, J = 
7.0 Hz, NHCH(CH3)CO), 1.05 & 0.98 (2s, 6H, CH3-2’ diastereoisomers), 0.93 & 0.90 
(2s, 18H, COOCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.38 & 173. 21 (2s, NHCH(CH3)CO 
diastereoisomers), 158.12 (s, C-6 base), 157.19 (s, C-2 base), 156.64 (s, C-8 base), 
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154.10 & 152.30  (2s, C-4 base, C-1 Ar), 134.83 (s, C-5 Ar), 127.95 (s, C-6 Ar), 126.78 
& 126.61 & 126.58 & 126.35 (4s, C-8, C-7 Ar diastereoisomers), 125.48 & 125.25 & 
125.19 (3s, C-10, C-2, C-3 Ar), 121.20 (s, C-9 Ar), 115.24 & 115.12 (2s, C-4 Ar 
diastereoisomers), 112.9 (s, C-5 base), 92.43 & 92.03 (2s, C-1’ diastereoisomers), 82.47 
& 82.36 (2s, C-4’ diastereoisomers), 81.93 & 81.89 (s, C-2’ diastereoisomers), 81.58 & 
81.50 (2s, C-3’ diastereoisomers), 74.98 & 74.17 (2s, COOCH2C(CH3)3 
diastereoisomers), 65.24 & 65.19 (2s, C-5’ diastereoisomers), 53.53 & 53.49 (2s, 6-
OMe base diastereoisomers), 50.59 & 50.47 (2s, NHCH(CH3)CO diastereoisomers), 
31.41 & 31.35 (2s, COOCH2C(CH3)3 diastereoisomers), 29.78 & 29.62 (s, NHCH3 base 
diastereoisomers), 26.28 (s, COOCH2C(CH3)3), 21.19 & 21.11 (s, CH3-2’ 
diastereoisomers), 20.97 & 20.89 (s, NHCH(CH3)CO diastereoisomers).  
31P NMR (202 MHz, CDCl3) δP (ppm): 3.99 (s, 46%), 3.30 (s, 54%). 
 
Synthesis of α-naphthyl L-Alanine-neopentyl ester 8-dimethylamino β-2’-C-methyl-6-
O-methyl guanosine (69) 
O
P
O
HN
O
O
O
N
N
N
O
NH2
N
O
OHOH
N
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.70 mL, 2.0 eq), 8-dimethylamino-2’-C-Me-6-OMe-guanosine (50) (0.12 g, 
0.35 mmol, 1.0 eq) in anh. THF (1.02 mL). α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.33 g, 0.85 mmol, 2.4 eq) in anh. THF (1.00 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure, and the 
residue was purified by flash chromatography, using CHCl3/MeOH (2%) as eluents, and 
preparative chromatography to yield the starting material (0.037 g, 0.05 mmol, 15%). 
HPLC (MeOH/H2O): 28.49 min, 29.13 min 
HPLC (ACN/H2O): 18.25 min, 18.81 min 
MS (TOF ES+): 702.21 (M + H+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.15-8.13 (2m, 2H, H-9 Ar diastereoisomers), 
7.84-7.82 (m, 2H, H-6 Ar diastereoisomers), 7.66-7.63 (m, 2H, H-4 Ar 
diastereoisomers), 7.54-7.34 (m, 8H, H-2, H-3, H-7, H8 Ar diastereoisomers), 5.95 & 
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5.92 (2s, 2H, H-1’ diastereoisomers), 5.19 (bs, 2H, NHCH(CH3)CO diastereoisomers), 
4.24-4.19 (m, 2H, H-3’ diastereoisomers), 4.17-4.07 (m, 4H, NHCH(CH3)CO, H-4’ 
diastereoisomers), 4.0 & 3.98 (2s, 6H, 6-OMe base diastereoisomers), 3.81-3.64 (m, 8H, 
H-5’, COOCH2C(CH3)3 diastereoisomers), 2.88 & 2.87 (m, 12H, N(CH3)2 
diastereoisomers), 1.33 & 1.32 (2d, 6H, J = 3.5 Hz, NHCH(CH3)CO diastereoisomers), 
1.12 & 1.08 (2s, 6H, CH3-2’ diastereoisomers), 0.87  & 0.86 (2s, 18H, 
COOCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, CDCl3) δC (ppm): 174.53 (d, J3P-N-C-C  = 6.3 Hz, NHCH(CH3)CO), 
173.41 (d, J3P-N-C-C  = 7.6 Hz, NHCH(CH3)CO), 159.58 & 159.57 (2s, C-6 base 
diastereoisomers), 158.28 & 158.15 (2s, C-2 base diastereoisomers), 155.63 & 155.53 
(2s, C-4 base diastereoisomers), 153.32 & 153.29 (2s, C-8 base diastereoisomers), 
146.60 & 146.48 (2s, C-1 Ar diastereoisomers), 134.73 (s, C-5 Ar), 127.79 (s, C-6 Ar), 
126.68 & 126.65 & 126.46 & 126.39 (4s, C-7, C-8, C-3, C-10 Ar), 124.56 & 124.88 
(2s, C-4 n Ar diastereoisomers), 121.56 & 121.47 (2s, C-9 Ar diastereoisomers), 115.11 
(d, J3P-O-C-C  = 2.5 Hz, C-2 Ar), 114.94 (d, J3P-O-C-C  = 2.5 Hz, C-2 Ar), 112.81 & 112.62 
(2s, C-5 base diastereoisomers), 91.63 & 91.58 (2, C-1’ diastereoisomers), 80.55 (d, J3P-
O-C-C 
 = 6.3 Hz, C-4’), 80.23 (d, J3P-O-C-C  =  6.3 Hz, C-4’), 79.94 & 79.76 (2s, C-2’ 
diastereoisomers), 76.19 & 75.94 (2s, C-3’ diastereoisomers), 74.94 & 74.71 (2s, 
COOCH2C(CH3)3 diastereoisomers), 67.22 & 67.18 (2s, C-5’ diastereoisomers), 53.44 
& 53.40 (2s, 6-OMe base diastereoisomers), 50.61 & 50.26 (2s, NHCH(CH3)CO 
diastereoisomers), 43.24 & 43.23 (2s,  N(CH3)2 diastereoisomers), 31.43 & 31.39 (s, 
COOCH2C(CH3)3 diastereoisomers), 26.38 & 26.25 (2s, COOCH2C(CH3)3 
diastereoisomers), 21.10 & 21.01 (2s, CH3-2’ diastereoisomers), 20.68 & 20.64 (2s, 
NHCH(CH3)CO diastereoisomers).  
31P NMR (202 MHz, CDCl3) δP (ppm): 4.32 (s, 55%), 4.07 (s, 45%). 
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Synthesis of α-naphthyl L-Alanine-neopentyl ester 8-butylamino β-2’-C-methyl-6-O-
methyl guanosine (70) 
O
P
O
HN
O
O
O
N
N
N
O
NH2
N
O
OHOH
HN
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl 
(0.68 mL, 2.0 eq), 8-butylamino-2’-C-Me-6-OMe-guanosine (59) (0.130 g, 0.34 mmol) 
in anh. THF (1.00 mL), and α-naphthyl L-Alanine-neopentyl ester phosphochloridate 
(14.d) (0.261 g, 0.68 mmol, 2.0 eq) in anh. THF (0.8 mL). After overnight stirring at 
RT, the solvent was removed under reduced pressure, and the residue was purified by 
flash chromatography, using CHCl3/MeOH (4%) as eluents, and preparative 
chromatography to yield the starting material (0.008 g, 0.011 mmol, 4%). 
HPLC (MeOH/H2O): 28.90 min, 29.15 min 
HPLC (ACN/H2O): 20.72 min, 20.75 min. 
MS (TOF ES+): 730.34 (M + H+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.13-8.10 (m, 2H, H-9 Ar diastereoisomers), 
7.86-7.84 (m, 2H, H-6 Ar diastereoisomers), 7.68 (m, 2H, H-7 Ar diastereoisomers), 
7.54-7.51 (m, 6H, H-4, H-2, H-3 Ar diastereoisomers), 7.42-7.38 (m, 2H, H-8 Ar 
diastereoisomers), 5.89 & 5.86 (2s, 2H, H-1’ diastereoisomers), 4.86 (bs, 1H, 
NHCH2CH2CH2CH3), 4.64 (bs, 1H, NHCH2CH2CH2CH3), 4.22-4.12 (m, 6H, H-3’, H-
4’, NHCH(CH3)CO diastereoisomers), 4.03 & 4.02 (2s, 6H, 6-OMe base 
diastereoisomers), 3.86-3.67 (m, 8H, COOCH2C(CH3)3, H-5’ diastereoisomers), 3.40-
3.38 (m, 4H, NHCH2CH2CH2CH3 diastereoisomers), 1.60-1.54 (m, 6H, 
NHCH2CH2CH2CH3, NHCH(CH3)CO diastereoisomers), 1.41 (d, 3H, J = 7.0 Hz, 
NHCH(CH3)CO), 1.31 (d, 3H, J = 7.1 Hz, NHCH(CH3)CO), 1.28-1.26 (m, 4H, 
NHCH2CH2CH2CH3 diastereoisomers), 1.07 & 1.01 (s, 6H, CH3-2’ diastereoisomers), 
0.89 & 0.85 (2s, 18H, COOCH2C(CH3)3 diastereoisomers), 0.82 & 0.80 (2t, 3H, J = 7.3 
Hz, NHCH2CH2CH2CH3 diastereoisomers). 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.88 (s, NHCH(CH3)CO), 173.45 (d, J3P-O-C-C  
= 7.6 Hz, NHCH(CH3)CO), 158.14 & 158.06 (s, C-6 base diastereoisomers), 156.80 & 
156.64 (2s, C-2 base diastereoisomers), 153.52 & 153.23 (2s, C-8 base 
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diastereoisomers), 151.32 & 151.10 (2s, C-4 base diastereoisomers), 146.39 & 146.25 
(2d, J2P-O-C = 7.6 Hz, 6.30 Hz, C-1 Ar diastereoisomers), 134.80 & 134.78 (2s, C-5 Ar 
diastereoisomers), 127.91 & 127.8 (2s, C-6 Ar diastereoisomers), 126.74 & 126.54 & 
126.40 & 126.35 & 126.30 & 126.24 (6s, C-8, C-7, C-10 Ar diastereoisomers), 125.47 
& 125. 23 & 125.14 & 125.08 (4s, C-4, C-3 Ar diastereoisomers), 121.27 & 121.23 (2s, 
C-9 Ar diastereoisomers), 115.15 & 115.01 (2s, C-2 Ar, Ar diastereoisomers), 112.55 & 
112.23 (2s, C-5 base diastereoisomers), 92.13 & 91.93 (2s, C-1’ diastereoisomers), 
81.71 & 81.03 (2s, C-4’ diastereoisomers), 80.25 & 70.98 (2s, C-2’ diastereoisomers), 
79.06 & 78.95 (2s, C-3’ diastereoisomers), 74.95 & 74.90 (2s, COOCH2C(CH3)3 
diastereoisomers), 67.90 (d, J2P-O-C = 5.1 Hz, C-5’), 67.84 (d, J2P-O-C = 5.2 Hz, C-5’), 
53.56 & 53.52 (2s, 6-OMe base diastereoisomers), 50.57 & 50.39 (2s, NHCH(CH3)CO 
diastereoisomers), 42.81 & 42.78 (s, NHCH2CH2CH2CH3 diastereoisomers), 31.73 & 
31.37 (2s, COOCH2C(CH3)3 diastereoisomers), 31.36 & 30.90 (2s, NHCH2CH2CH2CH3 
diastereoisomers), 26.25 & 26.24 (2s, COOCH2C(CH3)3 diastereoisomers), 21.18 & 
21.03 (2s, CH3-2’ diastereoisomers), 21.00 & 20.97 (2s, NHCH(CH3)CO 
diastereoisomers), 20.15 & 20.09 (2s, NHCH2CH2CH2CH3 diastereoisomers), 13.80 & 
13.74 (2s, NHCH2CH2CH2CH3 diastereoisomers).  
31P NMR (202 MHz, CDCl3) δP (ppm): 4.18 (s, 67%), 3.75 (s, 33 %). 
 
Synthesis of α-naphthyl L-Alanine-neopentyl ester 8-phenylamino β-2’-C-methyl-6-
O-methyl guanosine (71) 
O
P
O
HN
O
O
O
N
N
N
O
NH2
N
O
OHOH
HN
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl 
(0.84 mL, 2.0 eq), 8-aniline-2’-C-Me-6-OMe-guanosine (58) (0.170 g, 0.42 mmol, 1.0 
eq) in anh. THF (1.23 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.32 g, 0.84 mmol, 2.0 eq) in anh. THF (0.80 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure, and the 
residue was purified by flash chromatography, using CHCl3/MeOH (2.5%) as eluents, 
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and preparative chromatography to yield the starting material (0.005 g, 0.007 mmol, 
2%). 
HPLC (MeOH/H2O): Rt = 30.93 min, 31.93 min 
HPLC (ACN/H2O): Rt = 21.40 min, 21.71 min 
MS (TOF ES+): 750.30 (M + H+), 772.28 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.13 (m, 2H, H-9 Ar diastereoisomers), 8.04 (d, 
2H, J = 8.4 Hz, H-6 Ar diastereoisomers), 7.84-7.82 (m, 2H, H-4 Ar diastereoisomers), 
7.65-7.60 (m, 6H, CH para Ph, H-7 Ar, H-8 Ar diastereoisomers), 7.54-7.45 (m, 6H, H-
2 Ar, H-3 Ar, CH ortho Ph diastereoisomers), 7.36-7.32(m, 2H, CH ortho Ph 
diastereoisomers), 7.26-7.7.18 (m, 2H, CH meta Ph diastereoisomers), 6.97-6.90 (m, 
2H, CH meta Ph diastereoisomers), 6.03 & 5.99 (2s, 1H, H-1’ diastereoisomers), 4.94 
(bs, 2H, NHPh diastereoisomers), 4.27-4.25 (m, 2H, H-3’ diastereoisomers), 4.17-4.11 
(m, 4H, NHCH(CH3)CO, H-4’ diastereoisomers), 4.09 & 4.07 (s, 6H, 6-OCH3 base 
diastereoisomers), 3.81-3.64 (m, 8H, H-5’, COOCH2C(CH3)3 diastereoisomers), 1.82 
(bs, 2H, NHCH(CH3)CO diastereoisomers), 1.30-1.27 (m, 6H, NHCH(CH3)CO 
diastereoisomers), 1.04 & 0.99 (2s, 6H, CH3-2’ diastereoisomers), 0.89 & 0.87 (2s, 9H, 
COOCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.36 & 173.30 (2s, NHCH(CH3)CO 
diastereoisomers), 159.03 (s, C-6 base), 157.70 (s, C-2 base), 152.92 (s, C-4 base), 
146.87 (s, C-8 base), 146.30 (s, C-1 Ar), 134.76 & 134.68 (2s, C ipso Ph 
diastereoisomers), 129.85 & 129.07 (2s, C meta Ph diastereoisomers), 127.85 & 127.77 
(2s, C-6 Ar diastereoisomers), 126.64 & 126.51 & 126.33 & 126.28 (4s, C-7 Ar, C-8 Ar 
diastereoisomers), 125.47 & 125.40 & 125.04 & 124.99 (4s, C-3, C-10 Ar 
diastereoisomers), 122.41 & 122.25 (2s, C para Ph diastereoisomers), 118.96 & 118.74 
(2s, C ortho Ph diastereoisomers), 115.14 & 114.96 (2s, C-2 Ar  diastereoisomers), 
112.09 (s, C-5 base), 92.41 & 91.29 (2s, C-1’ diastereoisomers), 81.37 (d, J3P-O-C-C = 6.3 
Hz, C-4’), 81.12 (s, C-4’), 80.45 & 80.20 (2s, C-2’ diastereoisomers), 79.45 & 79.17 
(2s, C-3’ diastereoisomers), 74.81 & 74.73 (2s, C5’), 74.32 & 73.87 (2s, 
COOCH2C(CH3)3 diastereoisomers), 54.12 & 53.87 (2s, 6-OMe base), 50.53 (d, J2P-N-C 
= 7.6 Hz, NHCH(CH3)CO), 50.30 (d, J2P-N-C = 7.7 Hz, NHCH(CH3)CO), 31.46 & 31.29 
(2s, COOCH2C(CH3)3 diastereoisomers), 26.36 & 26.22 (2s, COOCH2C(CH3)3 
diastereoisomers), 20.92 & 20.88 (2s, CH3-2’ diastereoisomers), 20.28 & 20.09 (2s, 
NHCH(CH3)CO).  
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31P NMR (202 MHz, CDCl3) δP (ppm): 4.37 (s, 36%), 4.30 (s, 64%). 
 
Synthesis of α-naphthyl L-Alanine-neopentyl ester 8-benzylamino β-2’-C-methyl-6-O-
methyl guanosine (72) 
O
P
O
HN
O
O
O
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N
N
O
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N
O
OHOH
HN
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl 
(0.80 mL, 2.0 eq), 8-benzylamino-2’-C-Me-6-OMe-guanosine (49) (0.165 g, 0.40 
mmol) in anh. THF (1.17 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.304 g, 0.80 mmol, 2.0 eq) in anh. THF (1.1 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure, and the 
residue was purified by flash chromatography, using CHCl3/MeOH (4%) as eluents, and 
preparative chromatography to yield the starting material (11.7 g, 0.015 mmol, 4%). 
HPLC (MeOH/H2O): 30.57 min, 30.85 min 
HPLC (ACN/H2O): 22.55 min 
MS (TOF ES+): 764.32 (M + H+), 786.30 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.07-8.01 (m, 2H, H-9 Ar diastereoisomers), 
7.82-7.78 (m, 2H, H-6 Ar diastereoisomers), 7.65-7.63 (m, 4H, H-4 Ar, CH para Ph 
diastereoisomers), 7.51-7.41 (m, 10H, CH ortho Ph, H-7, H-8, H-3, H-2 Ar 
diastereoisomers), 7.36-7.15 (m, 6H, CH ortho Ph, CH meta Ph), 5.94 & 5.92 (2s, 2H, 
H-1’ diastereoisomers), 4.94 (bs, 2H, NHCH2Ph diastereoisomers), 4.65-4.62 (m, 4H, 
NHCH2Ph diastereoisomers), 4.43-4.35 (m, 4H, COOCH2C(CH3)3 diastereoisomers), 
4.16-4.13 (m, 2H, H-3’ diastereoisomers), 4.02 & 4.01 (2s, 6H, 6-OMe 
diastereoisomers), 3.89-3.58 (m, 8H, H-4’, H-5’, NHCH(CH3)CO diastereoisomers), 
2.19 (bs, 2H, NHCH(CH3)CO diastereoisomers), 1.41 (d, 3H, J = 3.5 Hz, 
NHCH(CH3)CO), 1.32 (d, 3H, J = 3.3 Hz, NHCH(CH3)CO), 1.07 & 1.02 (2s, 6H, CH3-
2’ diastereoisomers), 0.96 & 0.88 (2s, 9H, COOCH2C(CH3)3 diastereoisomers) 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.31 & 173.15 (2s, NHCH(CH3)CO 
diastereoisomers), 158.35 (s, C-6 base), 157.02 & 156.94 (2s, C-2 base 
diastereoisomers), 153.64 (s, C-8 base), 151.01 (s, C-4 base), 147.2 (s, C-1 Ar), 139.12 
Claire Bourdin  Chapter Eight: Experimental section 
 
221 
(s, C-5 Ar), 134.76 & 134.74 (2s, C ipso Ph diastereoisomers), 128.49-125.26 (18s, C-
10, C-8, C-3, C-7, C-6 Ar, Ph diastereoisomers), 125.04 & 125.00 (2s, C-9 Ar 
diastereoisomers), 121.35 & 121.30 (2s, C-4 Ar diastereoisomers), 115.07 & 114.96 (2s, 
C-2 Ar diastereoisomers), 112.45 (s, C-5 base), 92.09 & 91.87 (2s, C-1’ 
diastereoisomers), 81.52 & 81.47 (2s, C-4’ diastereoisomers), 81.25 & 81.17 (2s, C-2’ 
diastereoisomers), 81.06 & 81.01 (2s, C-3’ diastereoisomers), 74.82 & 74.78 (2s, 
COOCH2C(CH3)3 diastereoisomers), 74.19 & 74.02 (2s, C-5’ diastereoisomers), 53.62 
& 53.59 (2s, 6-OCH3 base diastereoisomers), 50.60 & 50.45 (2s, NHCH(CH3)CO 
diastereoisomers), 46.75 & 46.42 (2s, NHCH2Ph diastereoisomers), 31.34 & 30.89 (2s, 
COOCH2C(CH3)3 diastereoisomers), 26.38 & 26.25 (2s, COOCH2C(CH3)3 
diastereoisomers), 21.07 & 21.03 (2s, CH3-2’ diastereoisomers), 20.98 (d, J3P-N-C-C = 5.0 
Hz, NHCH(CH3)CO), 20.83 (d, J3P-N-C-C = 5.1 Hz, NHCH(CH3)CO).  
31P NMR (202 MHz, CDCl3) δP (ppm): 4.09 (s, 60%), 3.86 (s, 40%). 
 
Synthesis of α-naphthyl L-Alanine-neopentyl ester 8-pyrrolidino β-2’-C-methyl-6-O-
methyl guanosine (73) 
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This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 1.28 mL, 2.0 eq), 8-pyrrolidine-2’-C-Me-6-OMe-guanosine (51) (0.24 g, 0.64 
mmol, 1.0 eq) in anh. THF (1.87 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.55 g, 1.43 mmol, 2.2 eq) in anh. THF (1.10 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure, and the 
residue was purified by flash chromatography, using CHCl3/MeOH (2%) as eluents, and 
preparative chromatography to yield the starting material (0.058 g, 0.08 mmol, 12%). 
HPLC (MeOH/H2O): Rt = 22.57 min 
HPLC (ACN/H2O): Rt = 19.41 min, 20.01 min 
MS (TOF ES+): 728.32 (M + H+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.16-8.12 (m, 2H, H-9 Ar diastereoisomers), 
7.89-7.86 (m, 2H, H-6 Ar diastereoisomers), 7.71-7.68 (t, 2H, J = 8.4 Hz, H-4 Ar 
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diastereoisomers), 7.58-7.40 (m, 8H, H-2, H-3, H-7, H-8 Ar diastereoisomers), 6.00 & 
5.95 (2s, 1H, H-1’ diastereoisomers), 5.21-5.14 (m, 2H, NHCH(CH3)CO 
diastereoisomers), 4.90-4.86 (m, 4H, COOCH2C(CH3)3 diastereoisomers), 4.34-4.29 
(m, 4H, H-5’ diastereoisomers), 4.24-4.21 (m, 1H, NHCH(CH3)CO), 4.13-4.10 (m, 1H, 
NHCH(CH3)CO), 4.02 & 3.99 (2s, 6H, 6-OMe base diastereoisomers), 3.87-3.73 (m, 
4H, H-3’, H-4’ diastereoisomers), 3.61-3.58 (m, 4H, NH(CH2CH2)2 diastereoisomers), 
3.48-3.41 (m, 4H, NH(CH2CH2)2 diastereoisomers), 1.98-1.95 (m, 8H, NH(CH2CH2)2 
diastereoisomers), 1.42 & 1.34 (2d, 3H, J = 7.1 Hz, 7.1 Hz, NHCH(CH3)CO 
diastereoisomers), 1.20 & 1.14 (2s, 6H, CH3-2’ diastereoisomers), 0.92 & 0.91 (s, 18H, 
COOCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, CDCl3) δC (ppm): 174.89 (s, NHCH(CH3)CO), 173.40 (d, J3P-N-C-C 
= 7.6 Hz, NHCH(CH3)CO), 159.06 (s, C-6 base), 157.83 & 157.65 (2s, C-2 base 
diastereoisomers), 154.08 & 153.40 (2s, C-4 base diastereoisomers), 146.87 & 146.52 
(2s, C-8 base diastereoisomers), 146.30 (s, C-1 Ar), 134.80 (s, C-5 Ar), 127.90 & 
127.87 (2s, C-6 Ar diastereoisomers), 126.79 & 126.72 & 127.42 & 126.60 & 126.49 & 
126.45 (6s, C-7, C-8, C-10 Ar diastereoisomers), 125.51 & 125.48 & 125.18 & 125.02 
(4s, C-3, C-4 Ar diastereoisomers), 121.48 & 121.44 (2s, C-9 Ar diastereoisomers), 
115.19 & 115.02 (2d, J3P-O-C-C = 2.5 Hz, 2.5 Hz, C-2 Ar diastereoisomers), 113.16 & 
112.93 (2s, C-5 base diastereoisomers), 91.63 & 91.61 (2s, C-1’ diastereoisomers), 
80.24 & 79.99 (2d, J3P-O-C-C = 5.0 Hz, 6.3 Hz, C-4’ diastereoisomers), 79.99 & 79.94 
(2s, C-2’ diastereoisomers), 76.75 & 76.53 (2s, C-3’ diastereoisomers), 75.17 & 74.88 
(2s, COOCH2C(CH3)3 diastereoisomers), 67.19 & 67.99 (2d, J2P-O-C = 5.0 Hz, 5.0 Hz, 
C-5’ diastereoisomers), 53.39 & 53.34 (2s, 6-OMe base diastereoisomers), 51.73 & 
51.71  (2s, NH(CH2CH2)2 diastereoisomers), 50.75 & 50.38 (2s, NHCH(CH3)CO 
diastereoisomers), 31.45 & 31.40 (2s, COOCH2C(CH3)3 diastereoisomers), 26.28 & 
26.12 (2s, COOCH2C(CH3)3 diastereoisomers), 25.34 & 25.12 (2s, NH(CH2CH2)2 
diastereoisomers), 21.38 & 21.22 (2d, J3P-N-C-C = 3.8 Hz, 3.6 Hz, NHCH(CH3)CO 
diastereoisomers), 20.65 & 20.60 (2s, CH3-2’ diastereoisomers).  
31P NMR (202 MHz, CDCl3) δP (ppm): 4.55 (s, 54%), 4.33 (s, 46%). 
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4.2. 7-deaza modified nucleosides and phosphoramidates 
4.2.1. Preparation of the 7-deaza-6-O-methyl guanine 
Synthesis of 7-deaza guanine (79) 6 
 
       
HN
NH2N
O
N
H  
 
2,4-diamino-6-hydroxypyrimidine (78) (3.02 g, 23.6 mmol) was dissolved in H2O (60 
mL) containing NaOAc (1.97 g, 24.0 mmol). The solution was heated to 80 °C until a 
clear solution was obtained. Then 50% aq. α-chloroacetaldehyde (2.52 mL, 39.0 mmol) 
was introduced and the solution was left stirring at 80 °C overnight. A brown precipitate 
was recovered, dried and purified by flash chromatography using CHCl3/MeOH (0.80 g, 
5.33 mmol, 23%). 
1H NMR (500 MHz, DMSO) δH (ppm): 10.94 (s, 1H, NH-9), 10.19 (s, 1H, NH-1), 6.61 
(d, 1H, J = 2.2 Hz, H-8), 6.19 (d, 1H, J = 2.1 Hz, H-7), 6.01 (s, 2H, NH2-2).  
13C NMR (125 MHz, DMSO) δC (ppm): 158.83 (s, C-6), 152.17 (s, C-2), 151.12 (s, C-
4), 116.55 (s, C-8), 101.55 (s, C-7), 99.84 (s, C-5). 
 
Synthesis of 7-deaza-6-chloro guanine (80) 7 
     
N
NH2N
Cl
N
H  
 
POCl3 (32 mL) and 7-deazaguanine (79) (0.80 g, 5.33 mmol) were heated under reflux 
for 1 hr 30 min. After cooling the mixture was concentrated under reduced pressure. 
Later some ice was cautiously added and then some water. The mixture was then 
neutralized with NaHCO3. The precipitated solid was filtered off and dried to yield the 
desired material (0.57 g, 3.4 mmol, 64%).  
1H NMR (500 MHz, CDCl3) δH (ppm): 8.30 (bs, 1H, NH-9), 7.00 (s, 1H, H-8), 6.45 (s, 
1H, H-7), 4.95 (broad s, 2H, NH2-2).  
13C NMR (125 MHz, CDCl3) δC (ppm): 153.19 (s, C-2), 151.78 (s, C-4), 150.68 (s, C-
6), 122.09 (s, C-8), 111.98 (s, C-5), 100.78 (s, C-7).  
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Synthesis of 7-deaza-6-O-methyl guanine (81) 
     
N
NN
H
O
NH2  
 
7-deaza-6-chloro-guanine (80) (0.350 g, 2.08 mmol) in anh. MeOH (59 mL) with 
NaOMe (0.337 g, 6.24 mmol, 1.0 eq) was heated under reflux for 5 days. The residue 
was purified by flash  chromatography using MeOH/CHCl3 (15%) to afford the desired 
material (0.0084, 0.05 mmol, 3%).  
1H NMR (500 MHz, MeOD) δH (ppm): 6.82 (d, 1H, J = 3.5 Hz, H-8), 6.31 (d, 1H, J = 
3.5 Hz, H-7), 4.02 (s, 3H, 6-OCH3). 
13C NMR (125 MHz, MeOD) δC (ppm): 163.32 (s, C-6), 153.09 (s, C-2), 151.56 (s, C-
4), 120.60 (s, C-8), 112.21 (s, C-5), 99.82 (s, C-7), 54.80 (s, 6-OCH3).  
 
4.2.2. Glycosylation via fully protected 2’-C-methyl ribofuranose  
Preparation	  of	  2’,3’-­‐isopropylidene-­‐2’-­‐C-­‐methyl-­‐D-­‐ribono-­‐1,4-­‐lactone	  (83)	  
O
OO
HO
O
	  
Commercially available 2’-C-methyl-ribono lactone (82) (3.67 g, 22.7 mmol) was 
suspended in anh. acetone (90 mL) and perchloric acid (60%, 2.20 mL) was added 
dropwise at RT. After 1 hr 30 min, the reaction was neutralized with NaOH and the 
solvent was removed under reduced pressure. The residue was purified by flash 
chromatography using hexane/ethyl acetate (9:1) as eluents to yield the 2’,3’-
isopropylidene protected lactone (3.46 g, 17.1 mmol, 76%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 4.52-4.49 (m, 1H, H-3’), 3.96-3.95 (m, 1H, H-
5’), 3.81-3.78 (m, 1H, H-5’), 3.19-3.16 (m, 1H, H-4’), 1.64 (s, 3H, CH3-2’), 1.43 & 1.41 
(2s, 6H, 2 x CH3).  
13C NMR (125 Hz, CDCl3) δC (ppm): 177.2 (s, C-1’), 112.9 (s, C(CH3)2), 84.04 (s, C-
3’), 83.72 (s, C-2’), 82.55 (s, C-4’), 61.95 (s, C-5’), 26.94 & 26.38 (2s, C(CH3)2), 19.75 
(s, CH3-2’). 
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Preparation	  of	  2’,3’-­‐isopropylidene-­‐5’-­‐TBDMS-­‐2’-­‐C-­‐methyl-­‐D-­‐ribono-­‐1,4-­‐lactone	  (84)	  
O
OO
O
O
Si
	  
	  
The 2’,3’-isopropylidene-2’-C-Me-ribono-lactone (83) (0.77 g, 3.78 mmol) was 
dissolved in anh. DMF (10 mL), then imidazole (0.54 g, 7.96 mmol, 2.1 eq) and 
TBDMSCl (1.25 g, 8.28 mmol, 2.2 eq) were added, and the reaction was left stirring 
overnight. The solvent was evaporated under reduced pressure and the residue was 
purified by flash chromatography using CHCl3/MeOH (9:1) to yield a white solid (0.39 
g, 1.04 mmol, 28%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 4.41-4.39 (m, 2H, H-3’, H-4’), 3.81-3.76 (m, 
2H, H-5’), 1.53 (s, 3H, CH3-2’), 1.34 & 1.32 (2s, 6H, C(CH3)2), 0.81 & 0.80 (2s, 9H, 
OSi(CH3)2C(CH3)3), 0.009 (s, 6H, OSi(CH3)2C(CH3)3).  
13C NMR (d-CDCl3) δC (ppm): 175.95 (s, C-1’), 112.63 (s, C(CH3)2), 83.29 (s, C-3’), 
82.96 (s, C-4’), 63.59 (s, C-5’), 27.07 & 26.74 (2s, C(CH3)2), 26.15 & 25.83 & 25.69 
(3s, OSi(CH3)2C(CH3)3), 19.87  (s, CH3-2’), 18.49 (s, OSi(CH3)2C(CH3)3), -5.29 & -
5.52 (2s, OSi(CH3)2C(CH3)3). 
 
Preparation	  of	  2’,3’-­‐isopropylidene-­‐5’-­‐TBDMS-­‐2’-­‐C-­‐methyl-­‐furanose	  	  (85)	  
O
OO
O
OH
Si
 
2’,3’-isoproylidene-5’-TBDMS protected ribonolactone (84) (0.33 g, 1.04 mmol) was 
dissolved in anh. THF (8.0 mL) and DIBAL-H (1M in hexanes, 3.10 mL, 3.12 mmol, 
3.0 eq) was added dropwise at -78 °C and the reaction was stirred for 1 hr and then 3-4 
hrs at -15 °C. The reaction was quenched with 8% HCl, diluted with EtOAc and brine. 
After extraction with EtOAc, the residue was purified by flash chromatography using 
hexane/EtOAc (9:1) to yield a colorless oil (0.09 g, 0.29 mmol, 28%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 5.11 (d, 1H, J = 10.5 Hz, H-1’, β-anomer), 5.02 
(bs, 1H, H-1’, α-anomer), 4.49 (d, 1H, J = 11.0 Hz, OH, β-anomer), 4.42 (d, 1H, J = 1.0 
Hz, H-3’, β-anomer), 4.32 (bs, 1H, H-3’, α-anomer), 4.18 (m, 1H, H-4’ β-anomer), 4.05 
(m, 1H, H-4’, α-anomer), 3.74-3.66 (m, 5H, OH α-anomer & H-5’), 1.49 (s, 3H, CH3-
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2’), 1.45 (s, 3H, CH3-2’), 1.42 & 1.41 & 1.40 & 1.38 (4s, 12H, 2 x C(CH3)2), 0.90 & 
0.86 (2s, 18H, 2 x OSi(CH3)2C(CH3)3), 0.10 & 0.09 (s, 12H, 2 x OSi(CH3)2C(CH3)3).  
13C NMR (125 MHz, CDCl3) δC (ppm): 113.2 & 112.43 (2s, C(CH3)2 anomers), 104.57 
& 102.20  (2s, C-1’ anomers), 92.54 & 87.95 (2s, C-2’ anomers), 87.50 & 87.05 (2s, C-
3’ anomers), 86.71 & 82.33 (2s, C-4’ anomers), 65.10 & 64.85 (2s, C-5’ anomers), 
29.62 & 29.28 & 29.08 & 28.45 (4s, C(CH3)2 anomers), 26.54 & 26.25 & 26.17 & 
25.93 & 25.84 & 25.72 (6s, OSi(CH3)2C(CH3)3 anomers), 21.45 & 20.06 (s, CH3-2’ 
anomers), 18.42 & 18.40 (2s, OSi(CH3)2C(CH3)3 anomers), -5.41 & -5.58 & -5.73 & -
5.76 (4s, OSi(CH3)2C(CH3)3 anomers). 
 
4.2.3. Glycosylation with 3,5-bis-O-(2,4-dichlorophenylmethyl)-2’-C-methyl-1-O-
methyl-α-D-ribofuranose 
Preparation of 3’,5’-O-[2,4-dichlorophenyl)methyl]-2’-C-methyl-6-chloro-7-deaza 
guanosine (90) 8 
 
     
N
N
Cl
NH2
N
O
OHO
O
ClCl
Cl
Cl  
 
To a precooled solution (0 °C) of commercially available 3,5-bis-O-(2,4-
dichlorophenylmethyl)-2’-C-methyl-1-O-methyl-α-D-ribofuranose (89) (1.53 g, 3.08 
mmol, 1.0 eq) in anh. DCM (36 mL), was added dropwise HBr (33% in acetic acid, 
3.72 mL, 20.5 mmol, 6.7 eq). The reaction was left stirring for 2 hrs at RT and the 
solvent was evaporated under reduced pressure by coevaporation with toluene. The 
resulting residue was dissolved in anh. ACN (18 mL) and added dropwise into a well-
stirred solution of 7-deaza-6-chloro guanine (80) (0.52 g, 3.02 mmol, 1.0 eq), KOH 
(85% powdered, 0.62 g, 9.24 mmol, 3.0 eq) and tris[2-(2-methoxyethoxy)-ethyl]amine 
(TDA-1, 0.20 mL, 0.62 mmol, 0.2 eq) in anh. ACN (36 mL). The solution was stirred 
for 1bhr at RT, filtered and evaporated under reduced pressure. The residue was purified 
by flash chromatography using Petroleum ether/EtOAc (5:1, 3:1, 2:1 et 1.5:1) to recover 
the desired material (0.60 g, 0.96 mmol, 31%).  
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1H NMR (500 MHz, CDCl3) δH (ppm): 7.44-7.39 (m, 4H, 2 x H-6 & 2 x H-5 DCB), 
7.36 (d, 1H, J = 3.8 Hz, H-8 base), 7.29-7.25 (m, 2H, 2 x H-3 DCB), 6.34 (d, 1H, J = 
3.8 Hz, H-7 base), 6.23 (s, 1H, H-1’), 4.82-4.63 (m, 4H, 2 x CH2 DCB), 4.27-4.24 (m, 
1H, H-4’), 4.20 (d, 1H, J = 8.2 Hz, H-3’), 3.99-3.97 (m, 1H, H-5’), 3.78-3.76  (m, 1H, 
H-5’), 1.00 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.05 (s, C-2 base), 156.72 (s, C-4 base), 
155.89 (s, C-6 base), 138.03 & 137.73 & 137.40 & 137.29 & 137.26 & 137.09 (6s, 2 x 
C-1, 2 x C-4, 2 x C-2 DCB), 134.11 & 133.96 (2s, 2 x C-6 DCB), 132.74 & 134.68 (2s, 
2 x C-3 DCB), 131.05 & 130.61 (2s, 2 x C-5 DCB), 126.50 (s, C-8 base), 114.03 (s, C-5 
base), 104.04 (s, C-7 base), 93.91 (s, C-1’), 83.09  (s, C-4’), 83.26 (s, C-3’), 82.49 (s, C-
2’), 73.69 & 73.44 (2s, 2 x CH2 DCB), 72.11 (s, C-5’), 21.97 (s, CH3-2’). 
 
Preparation of 7-deaza-6-chloro-2’-C-methyl guanosine (91) 8 
      
N
N
Cl
NH2
N
O
OHOH
HO
 
To a solution of 3’,5’-O-[(2,4-dichlorophenyl)methyl]-2’-C-methyl-6-chloro-7-deaza-
guanosine (90) (0.27 g, 0.42 mmol, 1.0 eq) in anh. DCM (8.40 mL) at -78 °C, was 
added dropwise BCl3 (1M in DCM, 4.2 mL, 4.2 mmol, 10 eq). The reaction was left 
stirring for 2 hrs at -78 °C and then for 2 hrs 30 min at -20 °C. The reaction was 
quenched with DCM/MeOH (1:1) (4.2/4.2 mL), and left stirring at -20 °C for 30 min, 
then neutralized at 0 °C with aq. NH3. The solid formed was filtered and the filtrate was 
evaporated under reduced pressure. The residue was purified by flash chromatography 
using CHCl3/MeOH (50:1 and 20:1) to give the desired material (0.088 g, 0.28 mmol, 
66%). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.45 (d, 1H, J = 3.6 Hz, H-8 base), 6.41 (d, 1H, 
J = 3.5 Hz, H-7 base), 6.18 (s, 1H, H-1’), 4.11 (d, 1H, J = 9.0 Hz, H-3’), 4.02-3.99 (m, 
2H, H-4’, H-5’), 3.85-3.83 (m, 1H, H-5’), 0.89 (s, 3H, CH3-2’).  
13C NMR (125 MHz, MeOD) δC (ppm): 161.05 (s, C-2 base), 154.90 (s, C-4 base), 
153.41 (s, C-6 base), 124.99 (s, C-8 base), 113.43 (s, C-5 base), 101.06 (s, C-7 base), 
92.53 (s, C-1’), 83.70  (s, C-4’), 80.31 (s, C-2’), 74.04 (s, C-3’), 61.47 (s, C-5’), 20.05 
(s, CH3-2’). 
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Synthesis of 7-deaza-6-O-methyl-2’-C-methyl guanosine (88) 
      
N
N
O
NH2
N
O
OHOH
HO
 
To a solution of 7-deaza-6-chloro-2’-C-methyl guanosine (91) (0.88 g, 0.28 mmol, 1.0 
eq) in anh. MeOH (9 mL) was added NaOMe (0.05 mmol, 0.84 mmol, 3.0 eq) at 0 °C. 
The reaction was left stirring overnight under reflux at 65 °C. After neutralization of the 
reaction with amberlite, the solvent was evaporated under reduced pressure and the 
residue was purified by flash chromatography using CHCl3/MeOH (50:1 and 20:1) to 
give the desired material (0.043 g, 0.14 mmol, 49%).  
HPLC (MeOH/H2O): Rt = 15.3 min 
HPLC (ACN/H2O): Rt = 6.58 min 
MS (TOF ES+): 311.13 (M + H+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.10 (d, 1H, J = 3.6 Hz, H-8 base), 6.34 (d, 1H, 
J = 3.6 Hz, H-7 base), 6.08 (s, 1H, H-1’), 4.15 (d, 1H, J = 9.2 Hz, H-3’), 4.03 (m, 2H, 
H-5’, H-4’), 4.02 (s, 3H, 6-OCH3 base), 3.86 (dd, 1H, J =3.3 Hz, 12.3 Hz, H-5’), 0.86 
(s, 3H, CH3-2’).  
13C NMR (125 MHz, MeOD) δC (ppm): 165.34 (s, C-6 base), 160.92 (s, C-2 base), 
154.81 (s, C-4 base), 121.54 (s, C-8 base), 100.53 (s, C-7 base), 100.08 (s, C-5 base), 
93.47  (s, C-1’), 83.54 (s, C-4’), 80.50 (s, C-2’), 74.22 (s, C-3’), 61.73 (s, C-5’), 54.00 
(s, 6-OCH3 guanine), 20.31 (s, CH3-2’). 
 
Synthesis of 7-deaza-2’-C-methyl guanosine (95) 8, 9 
O
OHOH
HO
N
N
NH
O
NH2
 
To a solution of 7-deaza-6-O-methyl-2’-C-methyl guanosine (88) (8.0 mg, 0.026 mmol, 
1.0 eq) in anh. ACN (1.0 mL) was added NaI  (0.006g, 0.04 mmol, 1.5 eq) and TMSCl 
(5 µL, 0.04mmol, 1.5 eq). The solvent was evaporated under reduced pressure and the 
residue was purified by flash chromatography using CH2Cl2/MeOH as eluants, to 
recover the desired molecule (0.0016 g, 0.0054 mmol, 21%). 
HPLC (MeOH/H2O): Rt = 7.44 min 
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HPLC (ACN/H2O): Rt = 2.22 min 
MS (TOF ES-): 295.08 (M - H+), 331.08 (M + Cl-). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.09 (d, 1H, J = 3.6 Hz, H-8 base), 6.42 (d, 1H, 
J = 3.6 Hz, H-7 base), 6.09 (s, 1H, H-1’), 4.07 (d, 1H, J = 9.2, H-3’), 4.01-3.96 (m, 2H, 
H-4’, H-5’), 3.84-3.81 (dd, 1H, J = 3.6, 12.70 Hz, H-5’), 0.90 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 162.05 (s, C-2 base), 154.87 (s, C-4 base), 
153.19 (s, C-6 base), 118.98 (s, C-8 base), 102.43 (s, C-7 base), 91.82 (s, C-1’), 82.76  
(s, C-4’), 82.51 (s, C-2’), 73.35 (s, C-3’), 60.91 (s, C-5’), 19.30 (s, CH3-2’). 
 
Synthesis of 3’,5’-O-[2,4-dichlorophenyl)methyl]-7-deaza-6-chloro-2’-C-methyl 
purine (105) 8 
N
N
Cl
N
O
OHO
O
ClCl
Cl
Cl  
Prepared following the procedure for (90), using commercially available 5-bis-O-(2,4-
dichlorophenylmethyl)-2’-C-methyl-1-O-methyl-α-D-ribofuranose (89) (1.08 g, 2.17 
mmol, 1.0 eq) in anh. DCM (35 mL), HBr (33% in acetic acid, 2.36 mL, 13.02 mmol, 
6.0 eq). The resulting residue was dissolved in anh. ACN (6 mL) and added dropwise 
into a solution of commercially available 6-chloro-7-deaza purine (104) (1.00 g, 6.51 
mmol, 3.0 eq) and NaH (60% dispersion in oil, 0.26 g, 6.51 mmol, 3.0 eq) in anh. ACN 
(12 mL). After suspension in water (29 mL) and extraction with EtOAc (57 mL), the 
organic layer was washed with brine (34 mL) and evaporated under reduced pressure. 
Purification by flash chromatography using Petroleum ether/EtOAc (3:1, 2:1) afforded 
the desired material (0.60 g, 0.96 mmol, 44%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.49 (s, 1H, H-2 base), 7.66 (d, 1H, J = 3.5 Hz, 
H-8 base), 7.30-7.22 (m, 4H, 2 x H-3, 2 x H-6 DCB), 7.16-7.14 (dd, 1H, J = 2.0 Hz, 8.3 
Hz, H-5 DCB), 7.09-7.07 (dd, 1H, J = 2.0 Hz, 8.3 Hz, H-5 DCB), 6.42 (d, 1H, J = 3.5 
Hz, H-7 base), 6.34 (s, 1H, H-1’), 4.70-4.52 (m, 4H, 2 x CH2 DCB), 4.25-4.22 (dt, 1H, J 
= 2.5 Hz, 8.5 Hz, H-4’), 4.16 (d, 1H, J = 8.5 Hz, H-3’), 3.92-3.89 (dd, 1H, J = 2.5 Hz, 
11.0 Hz, H-5’), 3.72-3.69  (dd, 1H, J = 2.5 Hz, 11.0 Hz, H5’), 0.85 (s, 3H, CH3-2’). 
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13C NMR (125 MHz, CDCl3) δC (ppm): 151.96 (s, C-6 base), 150.76 (s, C-4 base), 
150.57 (s, C2 base), 134.64 & 134.48 & 134.24 & 133.90 & 133.37 & 133.54 (6s, 2 x 
C-1, 2 x C-2, 2 x C-4 DCB), 130.84 & 130.23 (2s, 2 x C-6 DCB), 129.57 & 129.12 (2s, 
2 x C-3 DCB), 127.40 & 127.07 (2s, 2 x C-5 DCB), 126.83 (s, C-8 base), 117.76 (s, C-5 
base), 104.04 (s, C-7 base), 90.88 (s, C-1’), 80.65 (s, C-4’), 80.05 (s, C-3’), 79.29 (s, C-
2’), 70.56 & 70.24 (2s, 2 x CH2 DCB), 68.95 (s, C-5’), 20.77 (s, CH3-2’). 
 
Preparation of 7-deaza-6-chloro-2’-C-methyl purine (106) 8, 9 
N
N
Cl
N
O
OHOH
HO
 
To a solution of 3’,5’-O-[2,4-dichlorophenyl)methyl]-7-deaza-6-chloro-2’-C-methyl 
purine (105) in anh. DCM (23 mL) at -78 °C was added BCl3 (1M in DCM, 11.2 mL, 
11.2 mmol, 10 eq). The mixture was stirred at -78 °C for 2 hrs 30 min, then at -30 °C to 
-20 °C fror 3 hrs. The reaction was quenched with MeOH/DCM (13 mL : 13 mL) and 
stirred at -15 °C for 30 min, then neutralized with aq. NH3 at 0 °C and stirred at RT for 
15 min. The solvent was evaporated under reduced pressure and the residue was 
purified by flash chromatography using DCM/MeOH (99:1, 98:2, 95:5 and 90:10) to 
recover the desire molecule (0.12 g, 0.41 mmol, 37 %). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.61 (s, 1H, H-2 base), 8.06 (d, 1H, J = 3.8 Hz, 
H-8 base), 6.72 (d, 1H, J = 3.8 Hz, H-7 base), 6.43 (s, 1H, H-1’), 4.16 (d, 1H, J = 9.2 
Hz, H-3’), 4.08-4.03 (m, 2H, H-4’, H5’), 3.90-3.87 (dd, 1H, J = 3.3 Hz, 12.6 Hz, H-5’), 
0.83 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 151.68 (s, C-6 base), 151.50 (s, C-4 base), 
150.48 (s, C-2 base), 129.41 (s, C-8 base), 117.54 (s, C-5 base), 100.94 (s, C-7 base), 
92.93 (s, C-1’), 84.06  (s, C-4’), 81.52 (s, C-2’), 73.71 (s, C-3’), 61.21 (s, C-5’), 19.89 
(s, CH3-2’). 
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Preparation of 7-deaza-2’-C-methyl inosine (107) 
NH
N
O
N
O
OHOH
HO
 
To 7-deaza-6-chloro-2’-C-methyl purine (106) (1.07 g, 3.56 mmol, 1.0 eq) was added 
sodium hydroxide (20 g in 500 mL H2O, 1M, 20 mL). The mixture was heated under 
reflux for 1 hr, cooled and neutralized with aqueous HCl (2M (2.7 mL) in 50 mL H2O). 
The solvent was evaporated under reduced pressure and the residue was purified by 
flash chromatography using MeOH/CHCl3 (1:4) as eluant to afford the desired material 
(0.080 g, 0.28 mmol, 8%). 
HPLC (MeOH/H2O): Rt = 7.56 min 
HPLC (ACN/H2O): Rt = 2.34 min 
MS (TOF ES-): 280.08 (M - H+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.94 (s, 1H, H-2 base), 7.53 (d, 1H, J = 3.6 Hz, 
H-8 base), 6.68 (d, 1H, J = 3.6 Hz, H-7 base), 6.28 (s, 1H, H-1’), 4.11 (d, 1H, J = 8.8 
Hz, H-3’), 4.05-4.01 (m, 2H, H-4’, H-5’), 3.88-3.84 (dd, 1H, J = 3.8 Hz, 12.9 Hz, H-5’), 
0.84 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 161.60 (s, C-6 base), 149.12 (s, C-4 base), 
144.12 (s, C-2 base), 123.01 (s, C-8 base), 109.67 (s, C-5 base), 100.59 (s, C-7 base), 
92.99 (s, C-1’), 83.82  (s, C-4’), 80.57 (s, C-2’), 73.82 (s, C-3’), 61.45 (s, C-5’), 19.98 
(s, CH3-2’). 
 
4.2.4. Preparation of phosphorochloridates 
Preparation of α-naphthyl L-Alanine-cyclohexyl ester phosphochloridate (14.e) 
P
O
N
H
O
O
O
Cl
 
Prepared according to procedure C, using L-Alanine-cyclohexyl tosylate salt (provided 
by Inhibitex Inc.) (3.69 g, 17.77 mmol, 1.0 eq) in anh. DCM (93 mL), α-naphthyl 
phosphorodichloridate (12)  (4.6387 g, 17.77 mmol, 1.1 eq), and NEt3 (4.95 mL, 35.54 
mmol, 2.0 eq). The solvent was removed under reduced pressure and the residue 
purified by flash chromatography using Hexane/EtOAc (1:1) to yield the desired 
molecule (4.90 g, 12.28 mmol, 69%). 
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1H NMR (500 MHz, CDCl3) δH (ppm): 8.25-8.21 (m, 2H, H-9 Ar diastereoisomers), 
8.09-7.92 (m, 2H, H-6 Ar diastereoisomers), 7.72-7.70 (m, 2H, H-4 Ar 
diastereoisomers), 7.61-7.56 (m, 2H, H3 Ar diastereoisomers), 7.50-7.51 (m, 4H, H-7, 
H-8 Ar diastereoisomers), 7.39-7.01 (m, 2H, H-2 Ar diastereoisomers), 4.15-4.10 (m, 
2H, CH cHex diastereoisomers), 4.06-3.99 (m, 2H, NHCH(CH3)CO diastereoisomers), 
1.99-1.87 (m, 4H, 2 x CH2 ortho diastereoisomers), 1.76-1.61 (m, 16 H, 4 x CH2 meta, 2 
x CH2 para, 2 x CH2 ortho diastereoisomers), 1.51 & 1.48 (2d, 3H, J = 2.5 Hz, 2.5 Hz, 
CH3 L-Ala),. 
31P NMR (202 MHz, CDCl3) δP (ppm): 8.28 (s), 8.13 (s). 
 
Preparation of α-naphthyl L-Alanine-benzyl ester phosphochloridate (14.f) 10 
P
O
N
H
O
O
O
Cl
 
Prepared according to procedure C, using L-Alanine-benzyl tosylate salt (provided by 
Inhibitex Inc.) (3.15 g, 8.98 mmol, 1.0 eq) in anh. DCM (52 mL), α-naphthyl 
phosphorodichloridate (12) (2.34 g, 8.98 mmol, 1.1 eq), and NEt3 (17.96 mL, 2.50 
mmol, 2.0 eq). The solvent was removed under reduced pressure and the residue 
purified by flash chromatography using Hexane/EtOAc (1:1) to yield the desired 
molecule (0.58 g, 1.44 mmol, 16%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.19-8.18 (m, 2H, H-4 Ar diastereoisomers), 
7.83-7.82 (m, 2H, H-7 Ar diastereoisomers), 7.69-7.67 (m, 4H, H-2, H-9 Ar 
diastereoisomers), 7.52-7.47 (m, 4H, H-3, H-8 Ar diastereoisomers), 7.39-7.28 (m, 12H, 
H-6 Ar, 5 x CH Ph diastereoisomers), 5.22-5.25 (m, 4H, OCH2Ph diastereoisomers), 
4.47-4.37 (m, 2H, NHCH(CH3)CO diastereoisomers), 1.58 & 1.56 (2d, 6H, J = 6.5 Hz, 
6.5 Hz, NHCH(CH3)CO). 
31P NMR (202 MHz, CDCl3) δP (ppm): 8.72 (s), 8.63 (s). 
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4.2.5. Preparation of α-naphthyl L-Alanine-ester ProTides 
Preparation of α-naphthyl L-Alanine-cyclohexyl-ester 2’-C-methyl-6-O-methyl-7-
deaza-guanosine ProTide (92) 
     
O
OHOH
O
N
N
N
O
NH2
P
O
HN
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.25 mL, 0.25 mmol, 2eq), 7-deaza-6-OMe-2’-C-Me guanosine (88) (0.039 g, 
0.13 mmol, 1.0 eq) in anh. THF (0.37 mL). and α-naphthyl L-Alanine-cyclohexyl ester 
phosphochloridate (14.e)  (0.100 g, 0.25 mmol, 2.0 eq) in anh. THF (0.37 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (4%) as eluents, and 
preparative chromatography to yield the desired molecule (0.010 g, 0.015 mmol, 12%). 
HPLC (MeOH/H2O): Rt = 24.31 min, 24.52 min 
HPLC (ACN/H2O): Rt = 17.64, 18.05 min 
MS (TOF ES+): 670.259 (M + H+).   
92.a (fast eluting isomer):  
1H NMR (500 MHz, CDCl3) δH (ppm): 8.16 (d, 1H, J = 7.0 Hz, H-9 Ar), 7.88 (1H, d, J 
= 7.5 Hz, H-6 Ar), 7.70 (d, 1H, J = 7.5 Hz, H-4 Ar), 7.59-7.54 (m, 3H, H-2, H-7, H-8 
Ar), 7.44 (t, 1H, J = 8.0 Hz, H-3 Ar), 6.80 (d, 1H, J = 3.6 Hz, H-8 base), 6.30 (d, 1H, J 
= 3.6 Hz, H-7 base), 6.00 (s, 1H, H-1’), 4.89 (s, 2H, NH2 base), 4.77 (m, 1H, 
NHCH(CH3)CO), 4.63 (m, 1H, H-3’), 4.22 (m, 1H, H-4’), 4.13-4.08 (m, 1H, CH cHex), 
4.02 (s, 3H, 6-OCH3 base), 3.83-3.79 (m, 2H, H-5’), 3.63 (m, 1H, NHCH(CH3)CO), 
1.79-1.76 (m, 2H, CH2 ortho cHex), 1.72-1.70 (m, 2H, CH2 ortho cHex), 1.69-1.50 (m, 
4H, CH2 meta, CH2 para cHex), 1.40 (d, 3H, J = 7.0 Hz, NHCH(CH3)CO), 1.38-1.37 
(m, 2H, CH2 meta), 0.91 (s, 3H, CH3-2’).  
13C NMR (125 MHz, CDCl3) δc (ppm): 174.24 (s, NHCH(CH3)CO), 166.35 (s, C-6 
base), 160.65 (s, C-2 base), 155.78 (s, C-4 base), 148.53 (s, C-1 Ar), 136.49 (s, C-5 Ar), 
128.67 (s, C-6 Ar), 127.96 (s, C-7 Ar), 127.37 (s, C-8 Ar), 126.56 (s, C-10 Ar), 125.80 
(s, C-3 Ar), 122.24 (s, C-9 Ar), 121.56 (s, C-8 base), 120.89 (s, C-4 Ar), 116.32 (s, C-2 
Ar), 100.98 (s, C-5 base), 100.17 (s, C-7 base), 93.84 (s, C-1’), 84.09 (d, J3P-O-C-C = 7.5 
Hz, C-4’), 80.46 (s, C-2’), 74.98 (s, C-3’), 74.36 (s, C ipso cHex), 66.34 (d, J2P-O-C = 5.1 
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Hz, C-5’), 53.78 (s, 6-OMe base), 51.64 (s, NHCH(CH3)CO),  32.67 & 30.97 (2s, 2 x C 
ortho cHex), 26.23 (s, C para cHex), 20.67 & 20.34 (s, 2 x C meta cHex), 20.76 (d, J3P-
O-C-C = 6.8 Hz, NHCH(CH3)CO), 19.73 (s, CH3-2’). 
31P NMR (202 MHz, CDCl3) δP (ppm): 3.86 (s). 
92.b (slow eluting isomer containing 13% of fast isomer).  
1H NMR (500 MHz, CDCl3) δH (ppm): 8.09 (m, 2H, H-9 Ar diastereoisomers), 7.80 
(2H, m, H-6 Ar diastereoisomers), 7.70 (d, 2H, J = 8.0 Hz, H-4 Ar diastereoisomers), 
7.51 & 7.50 & 7.49 & 7.48 & 7.46 & 7.44 (6s, 6H, H-2, H-7, H-8 Ar diastereoisomers), 
7.34 (t, 2H, J = 8.0 Hz, H-3 Ar diastereoisomers), 6.70 (d, 1H, J = 3.5 Hz, H-8 base), 
6.39 (d, 1H, J =3.5 Hz, H-8 base), 6.21 (d, 1H, J = 3.5 Hz, H-7 base), 6.07 (d, 1H, J = 
3.5 Hz, H-7 base), 5.93 (bs, 2H, H-1’ diastereoisomers), 4.85 & 4.81 (s, 2H, NH2 base 
diastereoisomers), 4.66-4.58 (m, 2H, H-3’ diastereoisomers), 4.40-4.36 (m, 2H, H-4’ 
diastereoisomers), 4.11 (m, 2H, NHCH(CH3)CO diastereoisomers), 4.07-4.00 (m, 2H, 
CH cHex diastereoisomers),  3.93 (s, 3H, 6-OCH3 base), 3.91 (s, 3H, 6-OCH3 base), 
3.87-3.86 (m, 2H, H-5’), 3.83-3.80 (m, 2H, H-5’), 3.70-3.66 (m, 2H, NHCH(CH3)CO 
diastereoisomers), 1.70-1.65 (m, 4H, 2 x CH2 ortho cHex diastereoisomers), 1.59-1.57 
(m, 4H, 2 x CH2 ortho cHex diastereoisomers), 1.53 (m, 8H, 2 x CH2 meta, 2 X CH2 
para cHex diastereoisomers), 1.42 (m, 2H, CH2 meta cHex), 1.29 (d, 3H, J = 7.0 Hz, 
NHCH(CH3)CO), 1.25 (d, 3H, J = 7.0 Hz, NHCH(CH3)CO), 1.23-1.15 (m, 2H, CH2 
meta cHex), 0.81 (s, 3H, CH3-2’), 0.74 (s, 3H, CH3-2’).  
13C NMR (125 MHz, CDCl3) δc (ppm): 174.24 & 174.10 (2s, NHCH(CH3)CO 
diastereoisomers), 166.83 & 166.35 (2s, C-6 base diastereoisomers), 160.98 & 160.65 
(2s, C-2 base diastereoisomers), 156.78 & 156.19 (2s, C-4 base diastereoisomers), 
147.65 & 147.53  (2s, C-1 Ar diastereoisomers), 136.63 & 136.49 (2s, C-5 Ar 
diastereoisomers), 128.93 & 128.67 (2s, C-6 Ar), 127.96 & 127.86 (2s, C-7 Ar 
diastereoisomers), 127.37 & 127.12 (2s, C-8 Ar diastereoisomers), 126.89 & 126.56 (2s, 
C-10 Ar diastereoisomers), 126.54 & 125.80 (2s, C-3 Ar diastereoisomers), 122.89 & 
122.24 (2s, C-9 Ar diastereoisomers), 121.75 & 121.56 (2s, C-8 base diastereoisomers), 
120.89 & 119.67 (2s, C-4 Ar diastereoisomers), 116.87 & 116.32 (2s, C-2 Ar 
diastereoisomers), 101.21 & 100.98 (2s, C-5 base diastereoisomers), 100.17 & 99.04 
(2s, C-7 base diastereoisomers), 94.34 & 93.84 (2s, C-1’ diastereoisomers), 84.56 & 
84.09 (2d, J3P-O-C-C = 7.4 Hz, 8.1 Hz, C-4’ diastereoisomers), 80.78 & 80.46 (2s, C-2’ 
diastereoisomers), 74.98 & 74.56 (2s, C-3’ diastereoisomers), 74.36 & 74.18 (2s, C ipso 
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cHex diastereoisomers), 66.34 & 66.18 (2d, J2P-O-C =5.1 Hz, 5.0 Hz, C-5’ 
diastereoisomers), 53.78 & 53.53 (2s, 6-OMe base diastereoisomers), 51.87 & 51.64 
(2s, NHCH(CH3)CO diastereoisomers),  33.13 & 32.67 & 31.75 & 30.97 (4s, C ortho 
cHex diastereoisomers), 26.52 & 26.23 (2s, C para cHex diastereoisomers), 20.80 & 
20.78 & 20.67 & 20.34 (4s, C meta cHex  diastereoisomers), 20.81 & 20.76 (2d, J3P-O-C-
C = 6.8 Hz, 6.8 Hz, NHCH(CH3)CO diastereoisomers), 19.75 & 19.73 (2s, CH3-2’ 
diastereoisomers). 
31P NMR (202 MHz, d-CDCl3) δP (ppm): 3.86 (s, 13%), 4.62 (s, 87%). 
 
Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-C-methyl-6-O-methyl-7-
deaza-guanosine ProTide (93) 
O
OHOH
O N N
N
O
NH2
PO
HN
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.28 mL, 0.28 mmol, 2eq), 7-deaza-6-OMe-2’-C-Me guanosine (88) (0.04 mg, 
0.14 mmol, 1.0 eq) in anh. THF (0.41 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.11 g, 0.28 mmol, 2.0 eq) in anh. THF(0.41 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (4%) as eluents, and 
preparative chromatography to yield the desired molecule (0.0115 g, 0.017 mmol, 
12%). 
HPLC (MeOH/H2O): Rt = 28.36 min 
HPLC (ACN/H2O): Rt = 20.29 min, 20.64 min 
MS (TOF ES+): 658.26 (M + H+), 680.25 (M + Na+).  
1H NMR (500 MHz, MeOD) δH (ppm): 8.22-8.20 (m, 2H, H-9 Ar diastereoisomers), 
7.93-7.90 (m, 2H, H-6 Ar diastereoisomers), 7.74-7.71 (m, 2H, H-4 Ar 
diastereoisomers), 7.59-7.54 (m, 6H, H-2, H-7, H-8 Ar diastereoisomers), 7.45-7.41 (m, 
2H, H-3 Ar diastereoisomers), 6.79 (d, 1H, J = 4.0 Hz, H-8 base), 6.74 (d, 1H, J = 3.5 
Hz, H-8 base), 6.18 (s, 1H, H-1’), 6.17 (d, 1H, J = 3.5 Hz, H-7 base), 6.15 (s, 1H, H-1’), 
5.97 (d, 1H, J = 3.5 Hz, H-7 base), 4.50-4.47 (m, 2H, H-3’ diastereoisomers), 4.18-4.16 
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(m, 2H, H-5’ diastereoisomers), 4.09-4.04 (m, 4H, H-5’, H-4’ diastereoisomers), 4.00 & 
3.99 (2s, 6H, 6-OCH3 base diastereoisomers), 3.80-3.75 (m, 2H, OCH2C(CH3)3), 3.77-
3.75 (m, 2H, NHCH(CH3)CO diastereoisomers), 3.65-3.62 (m, 2H, OCH2C(CH3)3), 
1.35 (d, 3H, J = 7.5 Hz, NHCH(CH3)CO), 1.31 (d, 3H, J = 7.0 Hz, NHCH(CH3)CO), 
0.93 & 0.91 (2s, 6H, CH3-2’ diastereoisomers), 0.87 & 0.85 (2s, 18H, OCH2C(CH3)3 
diastereoisomers).  
13C NMR (1265 MHz, MeOD) δc (ppm): 174.93 & 174.89 (2s, NHCH(CH3)CO 
diastereoisomers), 165.26 & 165.23 (2s, C-6 base diastereoisomers), 161.16 & 160.07 
(2s, C-2 base diastereoisomers), 155.32 & 155.22 (2s, C-4 base diastereoisomers), 
148.06 & 147.99  (2s, C-1 Ar diastereoisomers), 136.39 & 136.36 (2s, C-5 Ar 
diastereoisomers), 128.97 & 128.91 (2s, C-6 Ar diastereoisomers), 127.90 & 127.81 (2s, 
C-7 Ar diastereoisomers), 127.51 & 127.45 (2s, C-8 Ar diastereoisomers), 126.58 & 
126.49 (2s, C-10 Ar diastereoisomers), 125.96 & 125.89 (2s, C-3 Ar diastereoisomers), 
122.75 & 122.58 (2s, C-9 Ar diastereoisomers), 120.78 & 120.74 (2s, C-8 base 
diastereoisomers), 120.33 & 120.27 (2s, C-4 Ar diastereoisomers), 116.15 & 115.74 
(2d, J3P-O-C-C= 3.5 Hz, 2.9 Hz, C-2 Ar diastereoisomers), 100.99 & 100.88 (2s, C-7 base 
diastereoisomers), 99.64 & 99.41 (2s, C-5 base diastereoisomers), 92.66 & 92.24 (2s, C-
1’ diastereoisomers), 81.36 & 81.22 (2d, J3P-O-C-C = 11.3 Hz, 8.9 Hz, C-4’ 
diastereoisomers), 80.17 & 80.06 (2s, C-2’ diastereoisomers), 74.63 & 74.59 (2s, 
OCH2C(CH3)3 diastereoisomers),  74.03 & 74.01 (2s, C-3’ diastereoisomers), 67.46 & 
66.21 (2d, J2P-O-C = 6.2 Hz, 5.7 Hz, C-5’ diastereoisomers), 53.85 & 53.77 (2s, 6-OCH3 
base diastereoisomers), 51.69 & 51.64 (2s, NHCH(CH3)CO diastereoisomers), 32.25 & 
32.21 (2s, OCH2C(CH3)3 diastereoisomers), 26.72 & 26.69 (2s, OCH2C(CH3)3 
diastereoisomers), 20.83 & 20.72 (2d, J3P-N-C-C= 6.5 Hz, 6.9 Hz, NHCH(CH3)CO 
diastereoisomers), 19.99 & 19.94 (2s, CH3-2’ diastereoisomers).  
31P NMR (202 MHz, MeOD) δP (ppm): 4.13 (s, 24%), 4.09 (s, 76%).  
 
 
 
 
 
 
 
 
Claire Bourdin  Chapter Eight: Experimental section 
 
237 
Preparation of α-naphthyl L-Alanine-benzyl-ester 2’-C-methyl-6-O-methyl-7-deaza-
guanosine ProTide (94) 
O
OHOH
O N N
N
O
NH2
PO
HN
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.35 mL, 0.35 mmol, 2eq), 7-deaza-6-OMe-2’-C-Me guanosine (88) (0.054 g, 
0.17 mmol, 1.0 eq) in anh. THF (1.00 mL), α-naphthyl L-Alanine-benzyl ester 
phosphochloridate (14.f) (0.141 g, 0.35 mmol, 2.0 eq) in anh. THF (0.51 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (3.5%) as eluents, 
and preparative chromatography to yield the desired molecule (0.0149 g, 0.022 mmol, 
13%). 
HPLC (MeOH/H2O): Rt = 23.41 min.  
HPLC (ACN/H2O): Rt = 16.67 & 16.93 min.  
MS (TOF ES+): 678.23 (M + H+).  
1H NMR (500 MHz, MeOD) δH (ppm): 8.21 (2d, 2H, J = 8.5 Hz, H-9 Ar 
diastereoisomers), 7.91-7.89 (m, 4H, OCH2Ph diastereoisomers), 7.72-7.70 (m, 2H, H-6 
Ar diastereoisomers), 7.68 (d, 2H, J = 8.2 Hz, H-4 Ar diastereoisomers), 7.56-7.49 (m, 
6H, H-2, H-7, H-8 Ar diastereoisomers), 7.43-7.37 (m, 2H, H-3 Ar diastereoisomers), 
7.27-7.25 (m, 6H, OCH2Ph diastereoisomers), 6.80 (d, 1H, J = 3.5 Hz, H-8 base), 6.73 
(d, 1H, J = 4.0 Hz, H-8 base), 6.17 (s, 1H, H-1’), 6.16 (d, 1H, J = 3.5 Hz, H7 base), 6.15 
(s, 1H, H-1’), 5.94 (d, 1H, J = 4.0 Hz, H-7 base), 5.07-4.98 (m, 2H, COOCH2Ph), 4.58-
4.55 (m, 2H, COOCH2Ph), 4.48-4.45 (m, 2H, H-3’ diastereoisomers), 4.15-4.04 (m, 4H, 
H-4’, H-5’ diastereoisomers), 4.04 & 3.98 (2s, 6H, 6-OCH3 base diastereoisomers), 
3.33-3.32 (m, 4H, H-5’, NHCH(CH3)CO diastereoisomers), 1.32-1.29 (m, 6H, 
NHCH(CH3)CO diastereoisomers), 0.85 & 0.79 (2s, 6H, CH3-2’ diastereoisomers).  
13C NMR (125 MHz, MeOD) δc (ppm): 174.31 & 174.20 (2s, NHCH(CH3)CO 
diastereoisomers), 166.75 & 166.12 (2s, C-6 base diastereoisomers), 161.35 & 161.02 
(2s, C-2 base diastereoisomers), 156.63 & 156.47 (2s, C-4 base diastereoisomers), 
147.42 & 147.18 (2s, C-1 Ar diastereoisomers), 138.65 & 138.18 (2s, C-5 Ar 
Claire Bourdin  Chapter Eight: Experimental section 
 
238 
diastereoisomers), 136.53 & 136.09 (2s, C ipso Ph diastereoisomers), 129.51 & 129.47 
& 129.40 & 129.31 & 129.27 & 129.18 & 128.89 & 128.67 (8s, C meta Ph, C para Ph, 
C-6 Ar diastereoisomers), 127.85 & 127.81 & 127.79 & 127.61 & 127.54 & 127.50 (6s, 
C ortho Ph, C-7 Ar diastereoisomers), 126.58 & 126.34 (2s, C-8 Ar diastereoisomers), 
126.02 & 125.93 (2s, C-10 Ar diastereoisomers), 125.43 & 125.09 (2s, C-3 Ar 
diastereoisomers), 122.75 & 122.23 (2s, C-9 Ar diastereoisomers), 121.97 & 121.76 (2s, 
C-8 base diastereoisomers), 120.48 & 120.12 (2s, C-4 Ar  diastereoisomers), 115.19 & 
115.01 (2s, C-2 Ar diastereoisomers), 101.93 & 100.84 (2s, C-7 base diastereoisomers), 
99.45 & 99.16 (2s, C-5 base diastereoisomers), 92.68 & 92.15 (2s, C-1’ 
diastereoisomers), 84.56 & 84.34 (2d, J3P-O-C-C =7.4 Hz, 8.2 Hz, C-4’ diastereoisomers), 
81.26 & 80.87 (2s, C-2’ diastereoisomers), 74.63 & 74.29 (2s, C-3’ diastereoisomers), 
73.98 & 73.17 (2s, OCH2Phe diastereoisomers), 67.94 & 67.87 (2d, J2P-O-C = 5.9 Hz, 
5.5 Hz, C-5’ diastereoisomers), 54.02 & 53.78 (2s, 6-OCH3 base diastereoisomers), 
51.71 & 51.31 (2s, NHCH(CH3)CO diastereoisomers), 20.78 & 20.45 (2s, CH3-2’ 
diastereoisomers), 19.97 & 19.23 (2d, J3P-N-C-C = 6.5 Hz, 6.8 Hz, NHCH(CH3)CO 
diastereoisomers).  
31P NMR (202 MHz, MeOD-d4) δP (ppm): 4.28 (s, 47%), 4.18 (s, 53%).  
 
Preparation of α-naphthyl L-Alanine-cyclohexyl-ester 2’-C-methyl-7-deaza-
guanosine ProTide (98) 
      
O
OHOH
O N N
NH
O
NH2
PO
HN
O
O
O
 
To a solution of α-naphthyl L-Alanine-cyclohexyl-ester 2’-C-methyl-6-O-methyl-7-
deaza-guanosine ProTide (92) (4.5 mg, 0.007 mmol, 1.0 eq) in anh. ACN (1.0 mL) was 
added NaI  (0.0016 g, 0.011 mmol, 1.5 eq) and TMSCl (1.5 µL, 0.011 mmol, 1.5 eq). 
The reaction was stirred at RT for 1 hr, then the solvent was evaporated under reduced 
pressure and the residue was purified by preparative chromatography using 
CH2Cl2/MeOH as eluants, to recover the desired molecule (0.0016 g, 0.002 mmol, 
34%). 
HPLC (MeOH/H2O): Rt = 25.82 min, 26.55 min 
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HPLC (ACN/H2O): Rt = 15.32 min, 15.84 min 
MS (TOF ES+): 656.23 (M + H+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.23-8.21 (m, 2H, H-9 Ar diastereoisomers), 
7.93-7.90 (m, 2H, H-6 Ar diastereoisomers), 7.74-7.71 (m, 2H, H-4 Ar 
diastereoisomers), 7.59-7.54 (m, 6H, H-2, H-7, H-8 Ar diastereoisomers), 7.45 (t, 2H, J 
= 8.0 Hz, H-3 Ar diastereoisomers), 6.75 (d, 1H, J = 3.7 Hz, H-8 base), 6.71 ((d, 1H, J 
= 3.7 Hz, H-8 base), 6.31 (d, 1H, J = 3.7 Hz, H-7 base), 6.19 (d, 1H, J = 3.7 Hz, H-7 
base), 6.11 (s, 1H, H-1’), 6.10 (s, 1H, H-1’), 4.64-4.51 (m, 8H, H-3’, H-5’, H-4’ 
diastereoisomers), 4.28-4.24 (m, 2H, CH cHex diastereoisomers), 3.99-3.95 (m, 2H, 
NHCH(CH3)CO diastereoisomers), 1.74-1.66 (m, 8H, 4 x CH2 ortho cHex 
diastereoisomers), 1.51-1.37 (m, 8H, 2 x CH2 para, 2 x CH2 meta cHex 
diastereoisomers), 1.35-1.29 (m, 6H, NHCH(CH3)CO diastereoisomers), 1.14-1.11 (m, 
4H, CH2 meta diastereoisomers), 0.89 (s, 3H, CH3-2’), 0.84 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δc (ppm): 170.05 & 169.86 (s, NHCH(CH3)CO 
diastereoisomers), 159.87 & 159,35 (s, C-6 base diastereoisomers), 153.67 & 153.40 (s, 
C-2 base diastereoisomers), 150.10 & 150.02 (s, C-4 base diastereoisomers), 139.86 & 
139.72 (s, C-1 Ar diastereoisomers), 136.61 & 136.43 (2s, C-5 Ar diastereoisomers), 
128.94 & 128.91 (2s, C-6 Ar diastereoisomers), 127.90 & 127.80 (2s, C-7 Ar 
diastereoisomers), 127.67 & 127.58 (2s, C-8 Ar diastereoisomers),127.53 & 127.35 (s, 
C-10 Ar diastereoisomers), 126.53 & 125.81 (2s, C-3 Ar diastereoisomers), 122.98 & 
122.54 (2s, C-9 Ar diastereoisomers), 120.76 & 119.55 (2s, C-4 Ar diastereoisomers), 
118.99 & 118.54 (2s, C-8 base diastereoisomers), 115.65 & 115.32 (2s, C-2 Ar 
diastereoisomers), 103.79 & 103.66 (2s, C-7 base diastereoisomers), 99.36 & 99.21 (s, 
C-5 base diastereoisomers), 92.31 & 92.18 (2s, C-1’ diastereoisomers), 81.20 & 81.02 
(2s, C-4’ diastereoisomers), 78.56 & 78.43 (2s, C-2’ diastereoisomers), 73.92 & 73.83 
(2s, C-3’ diastereoisomers), 73.91 & 73.56 (2s, C ipso cHex diastereoisomers), 66.13 & 
66.01 (2s, C-5’ diastereoisomers), 51.76 & 51.63 (2s, NHCH(CH3)CO 
diastereoisomers), 32.30 & 32.18 (2s, C ortho cHex diastereoisomers), 26.35 & 26.11 
(1s, C para cHex diastereoisomers), 25.56 & 25.44 (2s, C meta cHex diastereoisomers), 
20.62 & 20.55 (2s, CH3-2’ diastereoisomers), 20.01 & 19.98 (2s, NHCH(CH3)CO 
diastereoisomers). 
31P NMR (202 MHz, MeOD) δP (ppm): 4.18 (s, 68%), 4.14 (s, 32%). 
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Preparation of α-naphthyl L-Alanine-cyclohexyl-ester 2’-C-methyl-7-deaza-inosine 
ProTide (108) 
O
OHOH
O N N
NH
O
PO
HN
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.19 mL, 0.19 mmol, 2eq), 7-deaza-2’-C-methyl inosine (107) (0.027 g, 0.10 
mmol, 1.0 eq) in anh. THF (1.00 mL), and α-naphthyl L-Alanine-cyclohexyl ester 
phosphochloridate (14.e) (0.075 g, 0.19 mmol, 2.0 eq) in anh. THF (0.51 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (3.0%) as eluents, 
and preparative chromatography to yield the desired molecule (0.001 g, 0.0016 mmol, 
2%). 
HPLC (MeOH/H2O): Rt = 26.30 min, 27.04 min 
HPLC (ACN/H2O): Rt = 15.87 min, 16.39 min 
MS (TOF ES+): 641.24 (M + H+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.23-8.22 (m, 2H, H-2 base diastereoisomers), 
7.93-7.91 (m, 4H, H-4, H-9 Ar diastereoisomers), 7.75-7.71 (m, 2H, H-6 Ar 
diastereoisomers), 7.67-7.64 (m, 2H, H-4 Ar diastereoisomers), 7.59-7.54 (m, 6H, H-3, 
H-7, H-8 Ar diastereoisomers), 7.45-7.32 (2t, 2H, J = 8.0 Hz, 7.5 Hz, H-2 Ar 
diastereoisomers), 7.11 (d, 1H, J = 3.5 Hz, H-8 base), 7.063 (d, 1H, J = 3.5 Hz, H-8 
base), 6.51 (d, 1H, J = 3.5 Hz, H-7 base), 6.35 (d, 1H, J = 3.0 Hz, H-7 base), 6.29 & 
6.28 (2s, H-1’ diastereoisomers), 4.66-4.63 (m, 4H, H-5’, H-3’ diastereoisomers), 4.55-
4.50 (m, 4H, H-5’, H-4’ diastereoisomers), 4.23-4.20 (m, 2H, NHCH(CH3)CO 
diastereoisomers), 4.08 (dd, 2H, J = 1.5 Hz, 8.5 Hz, CH cHex diastereoisomers), 1.77-
1.65 (m, 12H,  2 x CH2 para, 4 x CH2 meta cHex diastereoisomers), 1.52-1.49 (m, 2H, 2 
x CH2 ortho cHex), 1.37-1.29 (m, 12H, 2 x CH2 ortho cHex, CH3-2’ diastereoisomers), 
0.83 (d, 3H, J = 3.5 Hz, NHCH(CH3)CO), 0.78 (d, 3H, J = 3.5 Hz, NHCH(CH3)CO). 
13C NMR (125 MHz, MeOD) δc (ppm): 171.53 & 171.23 (2s, NHCH(CH3)CO 
diastereoisomers), 161.42 & 161.37 (2s, C-6 base diastereoisomers), 149.35 & 149.28 
(2s, C-4 base diastereoisomers), 148.12 & 147.96 (s, C-1 Ar diastereoisomers), 144.24 
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& 144.21 (2s, C-2 base diastereoisomers), 136.39 & 136.37 (2s, C-5 Ar 
diastereoisomers), 128.98 & 128.95 (2s, C-6 Ar diastereoisomers), 127.93  & 127.83 & 
127.54 & 127.52 (4s, C-7, C-8 Ar diastereoisomers), 126.58 & 126.55 (2s, C-10 Ar 
diastereoisomers), 125.98 & 125.88 (2s, C-3 Ar diastereoisomers), 122.70 & 122.58 (2s, 
C-9 Ar diastereoisomers), 122.20 & 122.13 (s, C-4 Ar diastereoisomers), 116.12 & 
116.10 (2s, C-8 base diastereoisomers), 115.69 & 115.66 (2s, C-2 Ar diastereoisomers), 
109.65 & 109.53 (2s, C-5 base diastereoisomers), 104.05 & 103.97 (2s, C-7 base 
diastereoisomers), 93.15 & 92.84 (2s, C-1’ diastereoisomers), 81.60 & 81.47 (2s, J3P-O-
C-C = 7.9 Hz, C-4’ diastereoisomers), 80.23 & 80.15 (2s, C-2’ diastereoisomers), 74.98 
& 74.94 (2s, C-3’ diastereoisomers), 74.25 & 73.74 (2s, C ipso cHex diastereoisomers), 
67.16 & 66.12 (2d, J2P-O-C = 5.1 Hz, C-5’ diastereoisomers), 51.80 & 51.20 (2s, 
NHCH(CH3)CO diastereoisomers), 32.38 & 32.32 &  30.76 & 30.70 (4s, C ortho cHex 
diastereoisomers), 26.36 & 24.28  (2s, C para cHex diastereoisomers), 20.80 & 20.78 & 
20.75 & 20.70 (4s, C meta cHex diastereoisomers), 20.61 & 20.55 (2s, NHCH(CH3)CO 
diastereoisomers), 19.84 & 19.82 (2s, CH3-2’ diastereoisomers). 
31P NMR (202 MHz, MeOD) δP (ppm): 4.17 (s, 55%), 4.15 (s, 45%). 
 
Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-C-methyl-7-deaza-inosine 
ProTide (109) 
O
OHOH
O N N
NH
O
PO
HN
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.38 mL, 0.38 mmol, 2eq), 7-deaza-2’-C-methyl inosine (107) (0.053 g, 0.19 
mmol, 1.0 eq) in anh. THF (1.00 mL). and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.15 g, 0.38 mmol, 2.0 eq) in anh. THF (0.50 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (5%) as eluents, and 
preparative chromatography to yield the desired molecule (0.0007 g, 0.0011 mmol, 
1%). 
HPLC (MeOH/H2O): Rt = 23.07 min, 23.29 min 
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HPLC (ACN/H2O): Rt = 15.75 min, 16.20 min 
MS (TOF ES+): 629.22 (M + H+), 652.46 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.23-8.22 (m, 2H, H-2 base diastereoisomers), 
7.93-7.91 (m, 4H, H-4, H-9 Ar diastereoisomers), 7.75-7.71 (m, 2H, H-3 Ar 
diastereoisomers), 7.60-7.54 (m, 6H, H-6, H-7, H-8 Ar diastereoisomers), 7.45-7.43 (m, 
2H, H-2 Ar diastereoisomers), 7.09 (d, 1H, J =3.5 Hz, H-8 base), 7.05 (d, 1H, J =3.5 
Hz, H-8 base), 6.50 (d, 1H, J =3.0 Hz, H-7 base), 6.35 (d, 1H, J =3.5 Hz, H-7 base), 
6.29 & 6.27 (2s, H-1’ diastereoisomers), 4.60-4.50 (m, 2H, H-5’ diastereoisomers), 
4.23-4.51 (m, 3H, H-3’ diastereoisomers, H-5’), 4.08-4.03 (m, 4H, H-4’, 
NHCH(CH3)CO diastereoisomers), 3.90-3.86 (m, 1H, H-5’), 3.82-3.77 (AB system, 2H, 
JAB = 10.5 Hz, COOCH2C(CH3)3), 3.69-3.65 (AB system, 2H, JAB = 10.5 Hz, 
OCH2C(CH3)3), 1.38 & 1.34 (2s, 6H, CH3-2’ diastereoisomers), 0/90 & 0.88 (2s, 18H, 
OCH2C(CH3)3), 0.83 (d, 3H, J = 1.5 Hz, NHCH(CH3)CO), 0.78 (d, 3H, J = 1.5 Hz, 
NHCH(CH3)CO). 
13C NMR (125 MHz, MeOD) δc (ppm): 170.32 & 170.03 (2s, NHCH(CH3)CO 
diastereoisomers), 160.70 & 160.67 (2s, C-6 base diastereoisomers), 151.49 & 151.41 
(2s, C-4 base diastereoisomers), 148.66 & 148.63 (2s, C-1 Ar diastereoisomers), 144.22 
& 144.16 (2s, C-2 base diastereoisomers), 134.46 & 134.43 (2s, C-5 Ar 
diastereoisomers), 129.39 & 129.35 (2s, C-6 Ar diastereoisomers), 128.05 & 127.96  & 
127.94 & 127.85 (2s, C-7, C-8 Ar diastereoisomers), 126.58 & 126.54 (2s, C-10 Ar 
diastereoisomers), 125.92 & 125.90 (2s, C-3 Ar diastereoisomers), 122.69 & 122.65 (2s, 
C-9 Ar diastereoisomers), 122.22 & 122.19 (2s, C-4 Ar diastereoisomers), 116.10 & 
116.05 (2s, C-8 base diastereoisomers), 115.74 & 115.69 (2s, C-2 Ar diastereoisomers), 
110.12 & 110.09 (2s, C-5 base diastereoisomers), 104.05 & 103.99 (2s, C-7 base 
diastereoisomers), 92.93 & 92.86 (2s, C-1’ diastereoisomers), 84.07 & 84.05 (2s, C-4’ 
diastereoisomers), 75.45 & 75.38 (2s, C-2’ diastereoisomers), 74.60 & 74.58 (2s, 
COOCH2C(CH3)3 diastereoisomers), 73.76 & 73.72 (2s, C-3’ diastereoisomers), 61.21 
& 61.20 (2s, C-5’ diastereoisomers), 50.23 & 50.20 (2s, NHCH(CH3)CO 
diastereoisomers), 30.75 & 30.71 (2s, COOCH2C(CH3)3), 26.72 & 26.59 (2s, 
COOCH2C(CH3)3 diastereoisomers), 19.87 & 19.85 (2s, NHCH(CH3)CO 
diastereoisomers), 18.70 & 18.40 (CH3-2’ diastereoisomers). 
31P NMR (202 MHz, MeOD) δP (ppm): 4.18 (s, 65%), 4.12 (s, 35%). 
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Preparation of α-naphthyl L-Alanine-benzyl-ester 2’-C-methyl-7-deaza-inosine 
ProTide (110) 
O
OHOH
O N N
NH
O
PO
HN
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.36 mL, 0.36 mmol, 2eq), 7-deaza-2’-C-methyl inosine (107) (0.050 g, 0.18 
mmol, 1.0 eq) in anh. THF (1.00 mL), and α-naphthyl L-Alanine-benzyl ester 
phosphochloridate (14.f) in anh. THF (1.50 mL). After overnight stirring at RT, the 
solvent was removed under reduced pressure and the residue was purified by flash 
chromatography, using CHCl3/MeOH (5%) as eluents, and preparative chromatography 
to yield the desired molecule (0.0022 g, 0.0034 mmol, 2%). 
HPLC (MeOH/H2O): Rt = 25.05 min, 25.80 min 
HPLC (ACN/H2O): Rt = 14.88 min, 15.35 min 
MS (TOF ES-): 683.11 (M + Cl-). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.21-8.20 (m, 2H, H-2 base diastereoisomers), 
7.92-7.90(m, 4H, H-4, H-9 Ar diastereoisomers), 7.73-7.71 (m, 2H, H-3 Ar 
diastereoisomers), 7.57-7.53 (m, 6H, H-6, H-7, H-8 Ar diastereoisomers), 7.44-7.39 (m, 
2H, H-2 Ar diastereoisomers), 7.30-7.26 (m, 10H, OCH2Ph diastereoisomers), 7.08 (d, 
1H, J = 3.5 Hz, H-8 base), 7.065(d, 1H, J = 4.0 Hz, H-8 base), 6.48 (d, 1H, J = 3.5 Hz, 
H-7 base), 6.34 (d, 1H, J = 4.0 Hz, H-7 base), 6.28 & 6.27 (2s, H-1’ diastereoisomers), 
5.10-5.50 (m, 4H, COCH2Ph diastereoisomers), 4.51-4.48 (m, 2H, H-5’ 
diastereoisomers), 4.21-4.04 (m, 8H, H-5’, H-3’, H-4’, NHCH(CH3)CO 
diastereoisomers), 1.31 & 1.30 (2s, 6H, CH3-2’ diastereoisomers), 0.83 (d, 3H, J = 3.5 
Hz, NHCH(CH3)CO), 0.78 (d, 3H, J = 3.5 Hz, NHCH(CH3)CO). 
13C NMR (125 MHz, MeOD) δc (ppm): 171.19 & 171.12 (2s, NHCH(CH3)CO 
diastereoisomers), 161.38 & 161.37 (2s, C-6 base diastereoisomers), 149.33 & 149.27 
(2s, C-4 base diastereoisomers), 148.12 & 148.09 (s, C-1 Ar diastereoisomers), 144.24 
& 144.11 (2s, C-2 base diastereoisomers), 137.13 & 137.10 (2s, C ipso Ph 
diastereoisomers), 136.37 & 136.35 (2s, C-5 Ar diastereoisomers), 129.55 & 129.54 & 
129.53 & 129.52 (4s, C meta Ph diastereoisomers), 129.32 & 129.28 (2s, C para Ph 
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diastereoisomers), 129.24 & 129.22 & 129.17 & 129.15 (4s, C ortho Ph 
diastereoisomers), 128.96 & 128.94 (2s, C-6 Ar diastereoisomers), 127.93  & 127.84 
(2s, C-7 Ar diastereoisomers), 127.59 & 127.55 (2s, C-8 Ar diastereoisomers), 126.59 
& 126.53 (2s, C-10 Ar diastereoisomers), 126.01 & 125.93 (2s, C-3 Ar 
diastereoisomers), 122.69 & 122.56 (2s, C-9 Ar diastereoisomers), 122.22 & 122.20 (2s, 
C-4 Ar diastereoisomers), 116.17 & 116.14 (2s, C-8 base diastereoisomers), 115.80 & 
115.77 (2s, C-2 Ar diastereoisomers), 109.53 & 109.50 (2s, C-5 base diastereoisomers), 
104.01 & 103.97 (2s, C-7 base diastereoisomers), 93.12 & 92.82 (2s, C-1’ 
diastereoisomers), 81.51 & 81.44 (2d, J3P-O-C-C = 6.4 Hz, 6.45 Hz, C-4’ 
diastereoisomers), 80.22 & 80.17 (2s, C-2’ diastereoisomers), 74.69 & 73.69 (2s, C-3’ 
diastereoisomers), 67.96 & 67.93 (2s, COCH2Phe), 67.15 & 66.09 (2d, J2P-O-C = 8.4 Hz, 
4.7 Hz, C-5’ diastereoisomers), 51.78 & 51.73 (2s, NHCH(CH3)CO diastereoisomers), 
20.54 & 20.37 (2d, J3P-N-C-C = 6.4 Hz, 7.7 Hz, NHCH(CH3)CO diastereoisomers), 19.87 
& 19.83 (2s, CH3-2’ diastereoisomers). 
31P NMR (202 MHz, MeOD) δP (ppm): 4.21 (s, 61%), 4.08 (s, 39%). 
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5. Experimental procedures related to chapter 5 
5.1. 2’-O-modifications of 2’-C-methyl-6-O-methyl guanosine 
5.1.1.  Intermediates prepared with the use of Markiewicz’s reagent 
Preparation of 3’,5’-protected 2’-C-methyl-6-O-methyl guanosine (118) 
N
NN
N
O
O
OHO
O
NH2Si
Si
O 	  
To 2’-C-methyl-6-O-methyl guanosine (11, provided by Inhibitex Inc.) (0.81 g, 2.60 
mmol) in anh. pyridine (20.0 mL) was added TPDSCl2 (1.2 eq, 3.12 mmol, 1.0 mL). 
The solution was left stirring 30 min at 0 °C, then overnight at RT. The solvents were 
evaporated under reduced pressure and the residue was purified by flash 
chromatography, using CHCl3/MeOH as eluents, to recover a white solid (0.63 g, 1.17 
mmol, 45%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.91 (s, 1H, H-8 base), 6.05 (s, 1H, H-1’), 4.28 
(d, 1H, J = 9.0 Hz, H-3’), 4.23 (d, 1H, J = 1.5 Hz, H-5’), 4.20 (d, 1H, J = 1.5 Hz, H-5’), 
4.12 (d, 1H, J = 9.0 Hz, H-4’), 4.01 (s, 3H, 6-OCH3 base), 1.12 (m, 4H, 4 x CH), 1.03 
(m, 27H, 8 x CH3, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 161.59 (s, C-6 base), 159.85 (s, C-2 base), 
153.14 (s, C-4 base), 136.18 (s, C-8 base), 115.46 (s, C-5 base), 89.99 (s, C-1’), 81.43 
(s, C-4’), 79.39 (s, C-2’), 73.44 (s, C-3’), 60.45 (s. C-5’), 53.70 (s, 6-OCH3 base), 20.72 
(s, CH3-2’), 17.45-16.30 (12s, 4 x CH, 8 x CH3). 
 
Preparation of 3’,5’-protected 2’-C-methyl-2’-O-methyl-6-O-methyl guanosine 
(119.a) 
      
N
NN
N
O
O
OO
O
NH2Si
Si
O
 
3’,5’-protected 2’-C-methyl-6-O-methyl guanosine (118) (1.15 g, 2.14 mmol) was 
dissolved in anh. DMF (15 mL) and molecular sieves 3Å were added. At 0 °C, NaH 
(60% in dispersion oil, 0.10 g, 2.35 mmol, 1.1 eq) and methyliodide (MeI) (0.42 mL, 
6.42 mmol, 3.0 eq) were added and the solution was stirred for 1 hr. Then NaH (60% in 
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dispersion oil, 0.10 g, 2.35 mmol, 1.1 eq) was added, and the solution was stirred for 30 
min at 0 °C. Absolute EtOH (61 mL) and ice cold EtOAc were added, and the solution 
was washed with NH4Cl, dried over Na2SO4, the solvents were evaporated under 
reduced pressure and the residue was purified by flash chromatography, using EtOAc 
(25-30%)/petroleum ether, to yield the desired unpure material (0.057 g, 0.10 mmol, 
5%).   
 
Preparation of 3’,5’-protected 2’-C-methyl-2’-O-ethyl-6-O-methyl guanosine (119.b) 
     
N
NN
N
O
O
OO
O
NH2Si
Si
O
 
Similar to procedure for 119.a, using 3’,5’-protected 2’-C-methyl-6-O-methyl 
guanosine (118) (0.2092 g, 0.39 mmol) in anh. DMF (4 mL), molecular sieves 3Å, NaH 
(60% in dispersion oil, 0.0198 g, 0.50 mmol, 1.3 eq), 2-iodoethanol (0.07 mL, 1.18 
mmol, 3 eq) and NaH (60% in dispersion oil, 0.0226 g, 0.57 mmol). The solution was 
stirred for 1 hr at 0 °C. Asbsolute EtOH (11 mL) and ice cold EtOAc (56 mL) were 
added, and the solution was washed with NH4Cl, dried over Na2SO4, and the solvents 
were evaporated under reduced pressure. The purification by flash chromatography with 
EtOAc/Hexane allowed the recovery of the desired material (0.100 g, 0.17 mmol, 44%).  
1H NMR (500 MHZ, CDCl3) δH (ppm): 8.46 (s, 1H, H-8 base), 6.19 (s, 1H, H-1’), 4.8 
(bs, 2H, NH2 base), 4.27 (m, 2H, H-4’, H-3’), 4.15 (dd, 1H, J = 1.5 Hz, 12 Hz, H-5’), 
4.09 (s, 3H, 6-OCH3 base), 4.03 (dd, 1H, J = 2.0 Hz, 12.0 Hz, H5’), 3.93 (m, 1H, 
OCH2CH3), 3.76 (m, 1H, OCH2CH3), 1.33 (t, 3H, J = 7.0 Hz, OCH2CH3), 1.07 (d, 24 H, 
J = 2.0 Hz, 8 x CH3), 1.05 (m, 4H, 4 x CH), 1.00 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δc (ppm): 161.55 (s, C-6 base), 159.27 (s, C-2 base), 
153.29 (s, C-4 base), 138.02 (s, C-8 base), 115.38 (s, C-5 base), 86.32 (s, C-1’), 83.66 
(s, C-2’), 83.16 (s, C-4’), 72.77 (s, C-3’), 60.16 (s, C-5’), 59.19 (s, OCH2CH3), 53.91 (s, 
6-OCH3 base), 17.40-17.13 (13s, 8 x CH3, 4 x CH, CH3-2’), 15.44 (s, CH3 OCH2CH3 ). 
 
 
 
 
Claire Bourdin  Chapter Eight: Experimental section 
 
247 
Preparation of 3’,5’-protected 2’-C-methyl-2’-O-propyl-6-O-methyl guanosine (119.c) 
N
NN
N
O
O
OO
O
NH2Si
Si
O 	  
Similar to procedure for 119.a, using 3’,5’-protected 2’-C-methyl-6-O-methyl 
guanosine (118) (0.05 g, 0.09 mmol) in anh. DMF (1 mL), molecular sieves 3Å, 1-
iodopropane (0.04 mL, 0.40 mmol, 4.3 eq), NaH (60% dispersion in mineral oil, 0.03 g, 
1.11 mmol, 1.2 eq). The solution was stirred for 1 hr at 0 °C. Asbsolute EtOH (3.0 mL) 
and ice cold EtOAc (30 mL) were added, and the solution was washed with NH4Cl, 
dried over Na2SO4, and the solvents were evaporated under reduced pressure. The 
purification by flash chromatography with EtOAc/Hexane allowed the recovery of the 
desired material (0.03 g, 0.06 mmol, 62%).  
1H NMR (500 MHz, CDCl3) δH (ppm): 8.47 (s, 1H, H-8 base), 6.19 (s, 1H, H-1’), 4.82 
(bs, 2H, NH2 base), 4.28 (d, 1H, J = 1.5, H-3’), 4.16 (m, 2H, OCH2CH2CH3), 4.09 (s, 
3H, 6-OCH3 base), 4.02 (d, 1H, H-4’), 3.83 (m, 1H, H-5’), 3.78 (m, 1H, H-5’), 1.29 (m, 
2H, OCH2CH2CH3), 1.09 (s, 24H, 8 x CH3), 1.07-1.03 (m, 7H, 4 x CH, OCH2CH2CH3), 
0.99 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 161.55 (s, C-6 base), 159.29 (s, C-2 base), 
153.28 (s, C-4 base), 138.06 (s, C-8 base), 115.36 (s, C-5 base), 86.24 (s, C-1’), 83.22 
(s, C-4’), 83.51 (s, C-2’), 72.87 (s, C-3’), 65.07 (s, C-5’), 60.18 (s, OCH2CH2CH3), 
53.93 (s, 6-OCH3 base), 23.36 (s, OCH2CH2CH3), 17.3-17.13 (10s, 8 x CH3, 4 x CH), 
15.41 (s, CH3-2’), 10.71 (s, OCH2CH2CH3). 
 
5.1.2. Intermediates prepared with the use of tert-butyl-dimethyl-silyl protecting group 
Preparation of 3’,5’-protected 2’-C-methyl-6-O-methyl guanosine (124.a) 
     
N
NN
N
O
O
OHO
O
NH2
Si
Si
 
2’-C-methyl-6-O-methyl guanosine (11, provided by Inhibitex Inc.) (3.19 g, 10.3 mmol, 
1.0 eq) was dissolved in anh. DMF (16 mL). TBDMSCl (6.64 g, 44.1 mmol, 4.3 eq) and 
imidazole (5.65 g, 83.0 mmol, 8.1 eq) were added and the solution was left stirring 
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overnight at RT. A purification using EtOAc/petroleum ether was performed to 
recovered the desired material (2.49 g, 4.61 mmol, 45%).  
1H NMR (500 MHz, MeOD) δH (ppm): 8.16 (s, 1H, H-8 base), 6.03 (s, 1H, H-1’), 4.31 
(d, 1H, J = 8.5 Hz, H-3’), 4.12-4.07 (m, 2H, H-5’, H4’), 4.05 (s, 6-OCH3 base), 3.91-
3.88 (dd, 1H, J = 2.0 Hz, 11.95 Hz, H-5’), 1.01 (s, 3H, CH3-2’) 0.98 & 0.94 (2s, 18H, 2 
x Si(CH3)2C(CH3)3), 0.19 (m, 12H, 2 x Si(CH3)2C(CH3)3). 
13C NMR (125 MHz, MeOD) δC (ppm): 162.78 (s, C-6 base), 161.92 (s, C-2 base), 
154.74 (s, C-4 base), 138.45 (s, C-8 base), 115.38 (s, C-5 base), 91.72 (s, C-1’), 83.88  
(s, C-4’), 80.49 (s, C-2’), 74.64 (s, C-3’), 62.25 (s, C-5’), 54.34 (s, 6-OCH3 base), 28.89 
& 28.04 (2s, 4 x Si(CH3)2C(CH3)3), 27.17-26.64 (m, 6 x Si(CH3)2C(CH3)3), 20.53 (s, 
CH3-2’), -5.43 & -5.67 (2s, 4 x Si(CH3)2C(CH3)3). 
 
Preparation of 3’,5’-protected-N-2-protected 2’-C-methyl-6-O-methyl guanosine 
(124.b) 
     
N
NN
N
O
O
OO
O
N
H
Si
Si
Si
 
Recovered preparing 124.a after purification by flash chromatography (3.68	   g,	   5.63	  mmol,	  55%). 
1H NMR (400 MHz, CDCl3) δH (ppm): 7.94 (s, 1H, H-8 base), 5.89 (s, 1H, H-1’), 4.67 
(bs, 1H, NH base), 4.12 (d, 1H, J = 8.5 Hz, H-3’), 4.12-4.07 (m, 2H, H-5’, H4’), 3.90 (s, 
6-OCH3 base), 3.86-3.82 (dd, 1H, J = 2.5 Hz, 11.9 Hz, H-5’), 1.01 (s, 3H, CH3-2’) 0.98 
& 0.94 (2s, 18H, 2 x Si(CH3)2C(CH3)3), 0.19 (m, 12H, 2 x Si(CH3)2C(CH3)3), 0.16 (2s, 
NHSi(CH3)2C(CH3)3). 
 
Preparation of 3’,5’-protected 2’-C-methyl-2’-O-propyl-6-O-methyl guanosine (125.b) 
N
NN
N
O
O
OO
O
NH2
Si
Si
 
Similar to procedure for 119.a, using 3’,5’-protected 2’-C-methyl-6-O-methyl 
guanosine (124.a) (0.80 g, 1.48 mmol, 1.0 eq) in anh. DMF (11.0 mL), molecular sieves 
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3Å and NaH (60% in dispersion oil, 0.066 g, 1.63 mmol, 1.1 eq), propyl iodide (0.43 
mL, 4.44 mmol, 3.0 eq). NaH (60% in dispersion oil, 0.066 g, 1.63 mmol, 1.1 eq). The 
solution was stirred for 30 min at 0 °C. Absolute EtOH (12 mL) and ice cold EtOAc (36 
mL) were added and the solution was washed with NH4Cl, dried over Na2SO4, the 
solvents were evaporated under reduced pressure. The purification was undertaken on 
flash chromatography with EtOAc (16%)/Hexane to recover only the desired material 
(0.300 g, 0.57 mmol, 38%).  
1H NMR (500 MHz, MeOD) δH (ppm): 8.04 (s, 1H, H-8 base), 5.88 (s, 1H, H-1’), 4.12 
(d, 1H, J = 9.5 Hz, H-3’), 3.93-3.91 (m, 3H, H-4’, H-5’), 3.87 (s, 3H, 6-OCH3 base), 
3.14 (t, 2H, J =1.5 Hz, OCH2CH2CH3), 1.47 (m, 2H, OCH2CH2CH3), 1.17 (s, 3H, CH3-
2’), 0.84 (s, 9H, Si(CH3)2C(CH3)3), 0.78 (s, 9H, Si(CH3)2C(CH3)3), 0.76 (m, 3H, 
OCH2CH2CH3), 0.03 (m, 12H, 2 x Si(CH3)2C(CH3)3). 
 
Preparation of 3’,5’-protected 2’-C-methyl-2’-O-isopropyl-6-O-methyl guanosine 
(125.c) 
     
N
NN
N
O
O
OO
O
NH2
Si
Si
 
Similar to procedure for 119.a, using 3’,5’-protected 2’-C-methyl-6-O-methyl 
guanosine (124.a) (1.00 g, 1.85 mmol, 1.0 eq) in anh. DMF (13.5 mL), molecular sieves 
3Å, NaH (60% in dispersion oil, 0.081 g, 2.04 mmol, 1.1 eq), isopropyl iodide (0.55 
mL, 5.55 mmol, 3.0 eq), and NaH (60% in dispersion oil, 0.081 g, 2.04 mmol, 1.1 eq). 
The solution was stirred for 30 min at 0 °C. Absolute EtOH (15 mL) and ice cold 
EtOAc (45 mL) were added and the solution was washed with NH4Cl, dried over 
Na2SO4. The solvents were evaporated under reduced pressure and the residue was 
purified by flash chromatography using EtOAc (12 to 25%)/petroleum ether to recover 
the desired material (0.043 g, 0.07 mmol, 4%).  
1H NMR (500 MHz, CDCl3) δH (ppm): 8.14 (s, 1H, H-8 base), 5.98 (s, 1H, H-1’), 4.61 
(s, 2H, NH2 base), 4.00-3.98 (m, 1H, H-4’), 3.96 (d, 1H, J = 2.0 Hz, H-3’), 3.90  (s, 3H, 
6-OCH3 base), 3.88 (m, 1H, OCH(CH3)2), 3.71 (dd, J = 1.5 Hz, 12.0 Hz, H-5’), 1.10 (s, 
3H, CH3-2’), 0.82 (s, 9H, Si(CH3)2C(CH3)3), 0.79 (d, 6H, J = 3.0 Hz, OCH(CH3)2), 0.75 
(s, 9H, Si(CH3)2C(CH3)3), 0.02 (m, 12H, 2 x Si(CH3)2C(CH3)3). 
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Preparation of 3’,5’-protected 2’-C-methyl-2’-O-methyl-N-2-methyl-6-O-methyl 
guanosine (125.d) 
      
N
NN
N
O
O
OO
O
N
H
Si
Si
 
Similar to procedure for 119.a, using 3’,5’-protected 2’-C-methyl-6-O-methyl 
guanosine (124.a) (1.00 g, 1.85 mmol, 1.0 eq) in anh. DMF (13.5 mL), molecular sieves 
3Å and NaH (60% in dispersion oil, 0.081 g, 2.04 mmol, 1.1 eq), methyl iodide (0.36 
mL, 5.55 mmol, 3.0 eq), and NaH (60% in dispersion oil, 0.081 g, 2.04 mmol, 1.1 eq). 
The solution was stirred for 30 min at 0 °C. Absolute EtOH (15 mL) and ice cold 
EtOAc (75 mL) were added and the solution was washed with NH4Cl, dried over 
Na2SO4. The solvents were evaporated under reduced pressure and the residue was 
purified by flash chromatography using EtOAc/Hexane to recover the bis-methylated 
material (0.380 g, 0.69 mmol, 37%).  
1H NMR (500 MHz, CDCl3) δH (ppm): 7.99 (s, 1H, H-8 base), 5.98 (s, 1H, H-1’), 4.86 
(s, 1H, NH base), 4.10 (d, 1H, J = 9.5 Hz, H-3’), 3.98-3.91 (m, 2H, H-4’, H5’), 3.88 (s, 
3H, 6-OCH3 base), 3.69-3.67 (m, 1H, H-5’), 3.38 (s, 3H, OCH3), 2.82 (d, 3H, J = 5.0 
Hz, NHCH3), 1.10 (s, 3H, CH3-2’), 0.81 (s, 9H, Si(CH3)C(CH3)3), 0.75 (s, 9H, 
Si(CH3)2C(CH3)3), 0.02 (m, 12H,  2x Si(CH3)2C(CH3)3). 
 
Preparation of 3’,5’-protected-N-2-protected 2’-C-methyl-2’-O-methyl-N-2-methyl-6-
O-methyl guanosine (125.e) 
N
NN
N
O
O
OO
O
NSi
Si
Si
 
Similar to procedure for 119.a, using 3’,5’-protected-N-2-protected 2’-C-methyl-6-O-
methyl guanosine (124.b) (3.68 g, 5.63 mmol, 1.0 eq) in anh. DMF (40 mL), molecular 
sieves 3Å, NaH (60% in dispersion oil, 0.248 g, 6.20 mmol, 1.1 eq), methyl iodide (1.05 
mL, 16.89  mmol, 3.0 eq), and NaH (60% in dispersion oil, 0.248 g, 6.20 mmol, 1.1 eq). 
The solution was stirred for 30 min at 0 °C. Absolute EtOH (161 mL) and ice cold 
EtOAc (800 mL) were added and the solution was washed with NH4Cl, dried over 
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Na2SO4. The solvents were evaporated under reduced pressure and the residue was 
purified by flash chromatography using EtOAc/Hexane to recover the bis-methylated 
material (0.180 g, 0.26 mmol, 5%).  
1H NMR (500 MHz, CDCl3) δH (ppm): 8.10 (s, 1H, H-8 base), 5.82 (s, 1H, H-1’), 3.97 
(dd, 1H, J = 1.5 Hz, 12 Hz, H-4’), 3.92 (m, 1H, H-3’), 3.90 (s, 3H, 6-OCH3 base), 3.73-
3.70 (m, 2H, H-5’), 3.33 (s, 3H, OCH3), 2.85 (s, 3H, NCH3Si(CH3)C(CH3)3), 0.93 (s, 
3H, CH3-2’), 0.81, 0.79, 0.76 (3s, 27H, 2 x OSi(CH3)C(CH3)3, NCH3Si(CH3)C(CH3)3), 
0.24 (m, 6H, NCH3(CH3)2C(CH3)3), 0.05 (m, 12H, OSi(CH3)2C(CH3)3). 
 
Preparation of 2’-C-methyl-2’-O-methyl-N-2-dimethylformamide-6-O-methyl 
guanosine (127) 
      
N
NN
N
O
O
OHOH
HO
N N
 
To 2’-C-methyl-6-O-methyl guanosine (11) (1.04 g, 3.33 mmol, 1.0 eq) in anh. DMF 
(15 mL), was added N,N-dimethylformamide dimethylacetal (2.22 mL, 16.65 mmol, 5.0 
eq) and the reaction was left stirring overnight at RT. Purification by flash 
chromatography afforded the desired material (0.17 g, 0.46 mmol, 14%). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.50 (s, 1H, H-8 base), 8.26 (s, 1H, 
NCHN(CH3)2), 5.99 (s, 1H, H-1’), 4.24 (d, 1H, J = 9.0 Hz, H-3’), 4.12 (m, 1H, H-5’), 
4.06 (s, 3H, 6-OCH3 base)), 4.05-4.02 (m, 1H, H-4’), 3.89-3.86 (dd, 1H, J = 2.5 Hz, 
12.0 Hz, H-5’), 3.22 (s, 3H, NCHN(CH3)2), 3.15 (s, 3H, NCHN(CH3)2), 0.96 (s, 3H, 
CH3-2’). 
 
5.1.3. Intermediates prepared with the use of di-tert-butyl-silyl and 
dimethylformamide protecting group 
Preparation of 3’,5’-protected 2’-C-methyl-6-O-methyl guanosine (130) 
     
N
NN
N
O
O
OHO
O
NH2Si
 
To a suspension of 2’-C-methyl-6-O-methyl guanosine (11) (0.555 g, 1.78 mmol, 1.0 
eq) in anh. DMF (9 mL) was added di-tert-bytyl-silyl-triflate (0.64 mL, 1.96 mmol, 1.1 
eq) at 0 °C. The solution was stirred 2 hrs 30 min at 0 °C, and the reaction was 
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quenched with cold EtOH and neutralised with NEt3. The solvent was removed under 
reduced pressure and the remaining oil was dissolved in MeOH. A white precipitate 
crashed out by addition of H2O. After filtration and drying under Buchner, the desired 
molecule was recovered (0.203 g, 0.45 mmol, 25%). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.88 (s, 1H, H-8 base), 5.96 (s, 1H, H-1’), 4.47-
4.43 (m, 1H, H-5’), 4.26-4.17 (m, 3H, H-5’, H-3’, H-4’), 4.07 (s, 3H, 6-OCH3 base), 
1.13 & 1.09 (2s, 18H, 2 x SiC(CH3)3), 1.04 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 162.76 (s, C-6 base), 162.11 (s, C-2 base), 
154.61 (s, C-4 base), 139.40 (s, C-8 base), 115.29 (s, C-5 base), 94.19 (s, C-1’), 81.58 
(s, C-4’), 79.97 (s, C-2’), 75.16 (s, C-3’), 68.52 (s, C-5’), 54.26 (s, 6-OCH3 base), 32.64 
& 34.54 (2s, 2 x SiC(CH3)3), 28.06 & 27.71 (2s, 2 x SiC(CH3)3), 20.19 (s, CH3-2’). 
 
Preparation of 3’,5’-protected-N-2-protected 2’-C-methyl-6-O-methyl guanosine 
(131) 
N
NN
N
O
O
OHO
O
NSi N
 
To a solution of 3’,5’-protected 2’-C-methyl-6-O-methyl guanosine (130) (0.20 g, 0.45 
mmol, 1.0 eq) in anh. DMF (3.42 mL) was added N,N-dimethylformamide 
dimethylacetate (0.26 mL, 1.80 mmol, 4.0 eq). The reaction mixture was stirred 
overnight at RT, and the solvent was evaporated. The residue was dissolved in EtOAc 
and washed with NaHCO3, H2O and brine. Evaporation of the organic layer afforded the 
desired material (0.22 g, 0.43 mmol, 95%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.62 (s, 1H, NCHN(CH3)2), 7.69 (s, 1H, H-8 
base), 6.18 (s, 1H, H-1’), 4.49 (d, 1H, J = 3.5 Hz, H-5’), 4.14 (s, 3H, 6-OCH3 base), 
4.11-4.08 (m, 3H, H-5’, H-3’, H-4’), 3.14 & 3.13 (2s, 6H, NCHN(CH3)2), 1.05 & 1.02 
(2s, 18H, SiC(CH3)3), 1.00 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.74 (s, C-6 base), 161.10 (s, C-2 base), 
158.45 (s, NCHN(CH3)2), 153.15 (s, C-4 base), 138.23 (s, C-8 base), 118.04 (s, C-5 
base), 94.93 (s, C-1’), 80.06 (s, C-4’), 78.12 (s, C-2’), 74.82 (s, C-3’), 67.73 (s, C-5’), 
53.84 (s, 6-OCH3 base), 41.15 (s, NCHN(CH3)2), 35.17 (s, NCHN(CH3)2), 27.73 & 
27.40 (2s, 2 x SiC(CH3)3), 22.81 & 22.71 (2s, 2 x SiC(CH3)3), 20.29 (s, CH3-2’). 
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Preparation of 3’,5’-protected-N-2-protected 2’-C-methyl-2’-O-methyl-6-O-methyl 
guanosine (132) 
N
NN
N
O
O
OO
O
NSi N
 
To a solution of 3’,5’-protected-N-2-protected 2’-C-methyl-6-O-methyl guanosine (131) 
(0.22 g, 0.43 mmol, 1.0 eq) in anh. DMF (6.5 mL) was added molecular sieves 3Å, 
methylidodide (0.16 mL, 2.58 mmol, 6.0 eq) at 0 °C. The reaction was left stirring at 0 
°C for 15 min, and then NaH (60% dispersion in oil, 0.02 g, 0.52 mmol, 1.2 eq) was 
added. The mixture was left stirring for 1 hr at 0 °C, and quenched with sodium 
dihydrogen phosphate (0.5 M) and dissolved in EtOAc. The organic layer was washed 
with sodium dihydrogen phosphate, H2O and brine, and the solvent was evaporated 
under reduced pressure to yield the desired material without further purification needed 
(0.16 g, 0.30 mmol, 70%). 
1H NMR (500 MHZ, CDCl3) δH (ppm): 8.60 (s, 1H, NCHN(CH3)2), 7.64 (s, 1H, H-8 
base), 6.10 (s, 1H, H-1’), 4.48-4.44 (m, 1H, H-5’), 4.24-4.19 (m, 1H H-4’), 4.10 (s, 3H, 
6-OCH3 base), 4.07-4.03 (m, 2H, H-5’, H-3’), 3.52 (s, 3H, OCH3), 3.12 & 3.09 (2s, 6H, 
NCHN(CH3)2), 1.02 (s, 3H, CH3-2’), 1.01 & 0.99 (2s, 18H, 2 x SiC(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.72 (s, C-6 base), 161.07 (s, C-2 base), 
158.47 (s, NCHN(CH3)2), 153.23 (s, C-4 base), 137.91 (s, C-8 base), 117.95 (s, C-5 
base), 82.12 (s, C-1’), 80.01 (s, C-2’), 74.79 (s, C-4’), 74.04 (s, C-3’), 67.82 (s, C-5’), 
53.76 (s, 6-OCH3 base), 52.67 (s, OCH3), 41.12 (s, NCHN(CH3)2), 35.15 (s, 
NCHN(CH3)2), 28.08 & 27.92 (2s, 2 x SiC(CH3)3), 22.73 & 22.66 (2s, 2 x SiC(CH3)3), 
20.92 (s, CH3-2’). 
 
Preparation of N-2-formamide 2’-C-methyl-2’-O-methyl-6-O-methyl guanosine 
(133.a) 
N
NN
N
O
O
OOH
HO
N
H
O
 
To 3’,5’-protected-N-2-protected 2’-C-methyl-2’-O-methyl-6-O-methyl guanosine 
(132) (0.33 g, 0.63 mmol, 1.0 eq) in anh. THF (16 mL) was added anh. NEt3 (0.15 mL, 
1.13 mmol, 1.8 eq) and NEt3.H3F (0.35 mL, 2.21 mmol, 3.5 eq). The solution was 
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stirred at RT for 1 hr. The solvent was evaporated under reduced pressure and the 
residue purified by flash chromatography followed by preparative chromatography to 
recover the partially hydrolysed formamidine (0.12 g, 0.37 mmol, 59%). 
HPLC (MeOH/H2O): Rt = 15.28 min 
HPLC (ACN/H2O): Rt = 5.87 min 
MS (TOF ES+): 376.12 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 9.41 (d, 1H, J = 11.0 Hz, NHCHO), 8.76 (d, 1H, 
J = 10.5 Hz, NHCHO), 8.43 (s, 1H, H-8 base), 6.25 (s, 1H, H-1’), 4.28 (d, 1H, J = 9.5 
Hz, H-3’), 4.20 (dd, 1H, J = 2.0 Hz, 13.0 Hz, H-5’), 4.10 (s, 3H, 6-OCH3 base), 4.06 
(dd, 1H, J = 2.0 Hz, 9.5 Hz, H-4’), 3.97 (m, 1H, H-5’), 3.53 (s, 3H, OCH3), 0.97 (s, 3H, 
CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 163.40 (s, NHCHO), 161.32 (s, C-6 base), 
153.43 (s, C-2 base), 151.87 (s, C-4 base), 139.94 (s, C-8 base), 118.25 (s, C-5 base), 
86.93 (s, C-1’), 83.65 (s, C-2’), 83.11 (s, C-4’), 73.43 (s, C-3’), 59.67 (s, C-5’), 54.58 
(s, 6-OCH3 base), 51.32 (s, OCH3), 14.79 (s, CH3-2’). 
 
5.1.4. Preparation of 2’-O-modified 2’-C-methyl-6-O-methyl guanosine nucleosides 
Preparation of 2’-C-methyl-2’-O-methyl-6-O-methyl guanosine (120) 
      
N
NN
N
O
O
OOH
HO
NH2
 
Route 1: To 3’,5’-protected 2’-C-methyl-2’-O-methyl-6-O-methyl guanosine (119.a) 
(0.057 g, 0.10 mmol) dissolved in anh. THF (5.96 mL). TBAF (0.069 mL, 0.22 mmol, 
2.2 eq) was added and the mixture was stirred for 3 hrs 30 min at RT. The purification 
was performed by flash chromatography using CH2Cl2/MeOH to recover the desired 
unpure material (0.007 g, 0.02 mmol, 20%). 
Route 2: N-2-formamide 2’-C-methyl-2’-O-methyl-6-O-methyl guanosine (133.a) 
 (0.12 g, 0.37 mmol) was dissolved in isopropanol (5 mL) and stirred under reflux 
overnight. The solvent was evaporated under reduced pressure and the material was 
recovered after preparative chromatography (0.005 g, 0.015 mmol, 4%). 
HPLC (MeOH/H2O): Rt = 12.23 min 
HPLC (ACN/H2O): Rt = 12.09 min 
MS (TOF ES+): 326.14 (M + H+). 
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1H NMR (500 MHz, MeOD) δH (ppm): 8.29 (s, 1H, H-8 base), 6.17 (s, 1H, H-1’), 4.22 
(d, 1H, J = 9.5 Hz, H-3’), 4.07 (s, 3H, 6-OCH3 base), 4.04-4.01 (m, 2H, H-4’, H-5’), 
3.87-3.84 (dd, 1H, J = 3.0 Hz, 12.5 Hz, H-5’), 3.56 (s, 3H, OCH3), 1.01 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 163.63 (s, C-6 base), 162.70 (s. C-2 base), 
154.58 (s, C-4 base), 139.10 (s, C-8 base), 112.83 (s, C-5 base), 88.62 (s, C-1’), 84.95 
(s, C-2’), 83.76 (s, C-4’), 74.77 (s, C-3’), 61.95 (s, C-5’), 54.25 (s, 6-OCH3 base), 51.83 
(s, OCH3), 15.20 (s, CH3-2’). 
 
Preparation of 2’-C-methyl-2’-O-ethyl-6-O-methyl guanosine (121) 
N
NN
N
O
O
OOH
HO
NH2 	  
Route 1: Prepared following the procedure to 120, using 3’,5’-protected 2’-C-methyl-
2’-O-ethyl-6-O-methyl guanosine (119.b) (0.10 g, 0.17 mmol) in anh. THF (10 mL), 
and TBAF (0.11 mL, 0.38 mmol). The reaction was left stirring for 2 hrs at RT. The 
solvent was evaporated under reduced pressure, and purified by flash chromatography 
using MeOH/CHCl3 to yield the desired material (0.15 g, 0.05 mmol, 87%). 
HPLC (MeOH/H2O): Rt = 1.29 min 
HPLC (ACN/H2O): Rt = 2.68 min 
MS (TOF ES+): 340.16 (M + H+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.64 (s, 1H, H-8 base), 5.84 (s, 1H, H-1’), 4.97 
(bs, 2H, NH2 base), 4.47 (d, 1H, J = 8.5 Hz, H-3’), 4.22 (dd, 1H, J = 1.5 Hz, 11.0 Hz, 
H-5’), 4.15 (dd, 1H, J = 2.0 Hz, 10.0 Hz, H-5’), 4.09 (s, 3H, 6-OCH3 base), 3.88-3.82 
(m, 3H, OCH2CH3, H4’), 1.31 (t, 3H, J = 7.0 Hz, OCH2CH3), 1.02 (s, 3H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.75 (s, C-6 base), 161.84 (s, C-2 base), 
154.49 (s, C-4 base), 139.35 (s, C-8 base), 115.36 (s, C-5 base), 92.99 (s, C-1’), 84.15 
(s, C-4’), 80.36 (s, C-2’), 73.58 (s, C-3’), 61.18 (s, C-5’), 54.61 (s, 6-OCH3 base), 34.18 
(s, OCH2CH3), 20.38 (s, CH3-2’), 13.98 (s, OCH2CH3). 
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Preparation of 2’-C-methyl-2’-O-propyl-6-O-methyl guanosine (122) 
N
NN
N
O
O
OOH
HO
NH2
 
Route 1: Prepared following the procedure to 120, using 3’,5’-protected 2’-C-methyl-
2’-O-propyl-6-O-methyl guanosine (119.c) (0.03 g, 0.06 mmol) in anh. THF (2 mL), 
TBAF (0.03 g, 0.12 mmol, 2.1 eq). The reaction was left stirring for 2 hrs 30 min at RT. 
The solvent was evaporated under reduced pressure, and was purified by flash 
chromatography to yield (0.02 g, 0.04 mmol, 82%). 
Route 2: To a solution of 3’,5’-protected 2’-C-methyl-2’-O-propyl-6-O-methyl 
guanosine (125.b) (0.300 g, 0.57 mmol, 1.0 eq) in anh. THF (7.0 mL) was added TBAF 
(1M in THF, 1.71 mL, 1.71 mmol, 3.0 eq) at 0 °C. The reaction was left stirring at RT 
for 2 hrs, and solvents were evaporated under reduced pressure. The crude residue was 
purified by flash chromatography using petroleum ether/methanol (2 to 4%) to recover 
the desire molecule (0.121 g, 0.34 mmol, 60%). 
HPLC (MeOH/H2O): Rt = 18.46 min 
HPLC (ACN/H2O): Rt = 2.43 min 
MS (TOF ES+): 353.20 (M), 376.15 (M + Na+), 392.13 (M + K+). 
 1H NMR (500 MHz, CDCl3) δH (ppm): 7.80 (s, 1H, H-8 base), 5.98 (s, 1H, H-1’), 5.03 
(bs, 2H, NH2 base), 4.51 (d, 1H, J = 9.0 Hz, H-3’), 4.18 (dd, 1H, J = 2.5 Hz, 12.5 Hz, 
H-5’), 4.09 (s, 3H, 6-OCH3 base), 4.06 (m, 1H, H-4’), 3.99 (dd, 1H, J = 2.0 Hz, 12.0 
Hz, H-5’), 3.62 (t, 2H, J = 6.5 Hz, OCH2CH2CH3), 1.74 (m, 2H, OCH2CH2CH3), 1.05 
(s, 3H, CH3-2’), 1.04 (t, 3H, J = 7.5 Hz, OCH2CH2CH3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 161.96 (s, C-6 base), 159.26 (s, C-2 base), 
154.51 (s, C-4 base), 137.86 (s, C-8 base), 115.46 (s, C-5 base), 89.43 (s, C-1’) 83.54 (s, 
C-4’), 83.36 (s, C-2’), 73.81 (s, C-3’), 64.95 (s, C-5’), 60.41 (s, OCH2CH2CH3), 54.07 
(s, 6-OCH3 base), 23.31 (s, OCH2CH2CH3), 15.81 (s, CH3-2’), 10.70 (s, 
OCH2CH2CH3). 
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Preparation of 2’-C-methyl-2’-O-isopropyl-6-O-methyl guanosine (123) 
     
N
NN
N
O
O
OOH
HO
NH2
 
Route 2: To a solution of 3’,5’-protected 2’-C-methyl-2’-O-isopropyl-6-O-methyl 
guanosine (125.c) (0.111 g, 0.19 mmol, 1.0 eq) in anh. THF (3.0 mL) was added TBAF 
(1M in THF, 0.57 mL, 0.57 mmol, 3.0 eq) at 0 °C. The reaction was left stirring at RT 
for 2 hrs, and solvents were evaporated under reduced pressure. The crude residue was 
purified by flash chromatography using petroleum ether/MeOH (2 to 4%) to recover the 
desired molecule (0.025 g, 0.071 mmol, 37%). 
HPLC (MeOH/H2O): Rt = 19.95 min  
HPLC (ACN/H2O): Rt = 9.32 min 
MS (TOF ES+): 354.18 (M + H+); MS (TOF ES-): 388.14 (M + Cl-). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.24 (s, 1H, H-8 base), 6.00 (s, 1H, H-1’), 4.26 
(d, 1H, J = 8.5 Hz, H-3’), 4.23-4.17 (m, 2H, H-5’, OCH(CH3)2), 4.06 (s, 3H, 6-OCH3 
base), 4.03-4.00 (m, 1H, H-4’), 3.88 (dd, 1H, J = 3.5 Hz, 12.5 Hz, H-5’), 1.27 & 1.26 
(2s, 6H, OCH(CH3)2), 0.99 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 162.53 (s, C-6 base), 161.75 (s. C-2 base), 
154.33 (s, C-4 base), 138.23 (s, C-8 base), 114.71 (s, C-5 base), 91.85 (s, C-1’), 85.86 
(s, C-2’), 84.83 (s, C-4’), 74.68 (s, C-3’), 72.57 (s, OCH(CH3)2), 59.73 (s, C-5’), 54.21 
(s, 6-OCH3 base), 21.87 (s, OCH(CH3)2), 19.22 (s, CH3-2’). 
 
Preparation of 2’-C-methyl-2’-O-methyl-N-2-methyl-6-O-methyl guanosine (126) 
N
NN
N
O
O
OOH
HO
N
H
 
To a solution of 3’,5’-protected 2’-C-methyl-2’-O-methyl-N-2-methyl-6-O-methyl 
guanosine (125.d) and 3’,5’-protected-N-2-protected 2’-C-methyl-2’-O-methyl-N-2-
methyl-6-O-methyl guanosine (125.e) (0.380 g, 0.69 mmol, 1.0 eq) in anh. THF (8.5 
mL) was added TBAF (1M in THF, 2.07 mL, 2.07 mmol, 3.0 eq) at 0 °C. The reaction 
was left stirring at RT for 2 hrs, and solvents were evaporated under reduced pressure. 
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The crude residue was purified by flash chromatography using petroleum 
ether/methanol (2 to 4%) to recover the desire molecule (0.090 g, 0.265 mmol, 38%). 
HPLC (MeOH/H2O): Rt = 17.08 min 
HPLC (ACN/H2O): Rt = 8.35 min 
MS (TOF ES+): 340.16 (M + H=), 362.13 (M + Na+), 701.28 (2M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.25 (s, 1H, H-8 base), 6.23 (s, 1H, H-1’), 4.21 
(d, 1H, J = 9.0 Hz, H-3’), 4.13 (m, 1H, H-4’), 4.06 (s, 3H, 6-OCH3 base), 4.04-4.03 (m, 
1H, H-5’), 3.88-3.84 (m, 1H, J = 3.5 Hz, 12.5 Hz, H-5’), 3.58 (s, 3H, OCH3), 2.96 (s, 
3H, NHCH3), 1.02 (s, 3H, CH3-2’). 
13C NMR (125 MHz, MeOD) δC (ppm): 162.33 (s, C-6 base), 161.71 (s. C-2 base), 
154.68 (s, C-4 base), 138.51 (s, C-8 base), 114.81 (s, C-5 base), 88.33 (s, C-1’), 85.02 
(s, C-2’), 84.63 (s, C-4’), 74.87 (s, C-3’), 61.09 (s, C-5’), 54.00 (s, 6-OCH3 base), 51.63 
(s, OCH3), 28.79 (s, NHCH3), 15.23 (s, CH3-2’). 
 
5.1.5. Preparation of 2’-O-modified 2’-C-methyl-6-O-methyl guanosine ProTides 
Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-C-methyl-2’-O-methyl-6-O-
methyl guanosine ProTide (146) 
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OOH
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This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.50 mL, 0.50 mmol, 2.0 eq), 2’-C-methyl-2’-O-methyl-6-O-methyl guanosine 
(120) (0.080 g, 0.25 mmol, 1.0 eq) in anh. THF (1.00 mL), α-naphthyl L-Alanine-
neopentyl ester phosphochloridate (14.d) (0.192 g, 0.50 mmol, 2.0 eq) in anh. THF (0.5 
mL). After overnight stirring at RT, the solvent was removed under reduced pressure 
and the residue was purified by flash chromatography, using CHCl3/MeOH as eluents, 
and preparative chromatography to yield the desired molecule (0.005 g, 0.007 mmol, 
3%). 
HPLC (MeOH/H2O): Rt = 27.43 min, 27.85 min. 
HPLC (ACN/H2O): Rt = 19.01 min, 19.31 min 
MS (TOF ES+): 673.27 (M + H+), 695.25 (M + Na+). 
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1H NMR (500 MHz, MeOD) δH (ppm): 8.37 & 8.24 (2s, 2H, H-8 base 
diastereoisomers), 8.18-8.13 (m, 2H, H-9 Ar diastereoisomers), 7.89-7.84 (m, 2H, H-6 
Ar diastereoisomers), 7.69-7.66 (m, 2H, H-4 Ar diastereoisomers), 7.53-7.45 (m, 6H, H-
3, H-7, H-8 Ar diastereoisomers), 7.40-4.35 (m, 2H, H-2 Ar diastereoisomers), 6.27 & 
6.26 (2s, 2H, H-1’ diastereoisomers), 4.67-4.65 (dd, 2H, J = 2.0 Hz, 5.5 Hz, H-5’), 
4.60-4.53 (m, 2H, H-5’), 4.29-4.22 (m, 4H, H-3’, H-4’ diastereoisomers), 4.14 & 4.13 
(2s, 6H, 6-OCH3 base diastereoisomers), 4.10-4.03 (m, 2H, NHCH(CH3)CO 
diastereoisomers), 3.77 & 3.74 (AB system, 2H, JAB = 10.5 Hz, OCH2C(CH3)3), 3.67 & 
3.61 (AB system, 2H, JAB = 10.5 Hz, OCH2C(CH3)3 ), 3.56 & 3.55 (2s, 6H, OCH3 
diastereoisomers), 1.37 (d, 3H, J = 7.0 Hz, NHCH(CH3)CO), 1.34 (d, 3H, J =  7.0 Hz, 
NHCH(CH3)CO), 1.03 & 1.00 (2s, 6H, CH3-2’ diastereoisomers), 0.88 & 0.87 (2s, 18H, 
OCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, MeOD) δC (ppm): 174.87 & 174.10 (2s, NHCH(CH3)CO 
diastereoisomers), 161.72 & 172.57 (2s, C-6 base diastereoisomers), 159.43 & 159.23 
(2s, C-2 base diastereoisomers), 155.28 & 155.11 (2s, C-4 base diastereoisomers), 
153.43 & 153.09 (2s, C-1 Ar diastereoisomers), 140.27 & 140.12 (2s, C-8 base 
diastereoisomers), 138.56 & 138.43 (2s, C-5 Ar diastereoisomers), 128.87 & 128.78 (2s, 
C-6 Ar diastereoisomers), 127.91 & 127.81  (2s, C-10 Ar diastereoisomers), 127.76 & 
127.68 (2s, C-7 Ar diastereoisomers), 127.43 & 127.36 (2s, C-4 Ar diastereoisomers), 
126.50 & 126.47 (2s, C-8 Ar diastereoisomers), 125.91 & 125.84 (2s, C-9 Ar 
diastereoisomers), 122.74 & 122.68 (2s, C-3 Ar diastereoisomers), 117.38 & 117.11 (2s, 
C-5 base diastereoisomers), 116.18 & 116.14 (2s, C-2 Ar diastereoisomers), 89.34 & 
89.32 (2s, C-1’ diastereoisomers), 84.54 & 84.32 (2s, C-2’ diastereoisomers), 81.88 & 
81.80 (2d, J3P-O-C-C = 6.4 Hz, 6.4 Hz, C-4’ diastereoisomers), 75.70 & 75.65 (2s, C-3’ 
diastereoisomers), 75.38 & 75.33 (2s, OCH2C(CH3)3), 67.34 & 67.30 (2s, C-5’ 
diastereoisomers), 55.05 & 55.03 (2s, 6-OCH3 base diastereoisomers), 51.84 & 50.81 
(2s, OCH3 diastereoisomers), 50.01 & 49.54 (2s, NHCH(CH3)CO diastereoisomers), 
29.89 & 29.79 (s, OCH2C(CH3)3 diastereoisomers), 26.69 & 26.68  (2s, OCH2C(CH3)3 
diastereoisomers), 20.58 & 20.52 (2s, NHCH(CH3)CO diastereoisomers), 15.16 & 
15.12 (s, CH3-2’ diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm):  4.19 (s, 48%), 4.18 (s, 52%). 
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Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-C-methyl-2’-O-ethyl-6-O-
methyl guanosine ProTide (147) 
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This ProTide was prepared according to the Standard Procedure D, using tBuMgCl 
(0.94 mL, 4.7 eq), 2’-C-methyl-2’-O-ethyl-6-O-methyl guanosine (121) (0.069 g, 0.20 
mmol) in anh. THF (2.0 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.360 g, 0.94 mmol, 4.7 eq) anh. THF (1.5 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (3.5%) as eluents, 
and preparative chromatography to yield the desired molecule (0.002 g, 0.003 mmol, 
1.4%). 
HPLC (MeOH/H2O): Rt = 25.24 min, 25.67 min 
HPLC (ACN/H2O): Rt = 20.81 min, 20.96 min 
MS (TOF ES+): 687.70 (M + H+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.87-7.81 (m, 2H, H-9 Ar diastereoisomers), 
7.69-7.64 (m, 4H, H-6 Ar, H-8 base diastereoisomers), 7.58-7.36 (m, 10H, H-2, H-3, H-
4, H-7, H-8 Ar diastereoisomers diastereoisomers), 5.90 & 5.83 (s, 2H, H-1’ 
diastereoisomers), 4.78 (m, 2H, H-4’ diastereoisomers), 4.46 (m, 4H, H-5’ 
diastereoisomers), 4.01 (m, 2H, H-3’ diastereoisomers), 4.09 & 4.07 (2s, 6H, 6-OCH3 
diastereoisomers), 3.85 (m, 8H, OCH2CH3, COOCH2C(CH3)3 diastereoisomers), 3.69 
(m, 2H, NHCH(CH3)CO diastereoisomers), 1.39 & 1.32 (2t, 6H, J = 7.3 Hz, 7.3 Hz, 
OCH2CH3 diastereoisomers), 1.19 & 1.16 (2d, 6H, J = 5.6 Hz, 5.7 Hz, NHCH(CH3)CO 
diastereoisomers), 0.92 & 0.90 (s, 18H, 2 x COOCH2C(CH3)3 diastereoisomers), 0.87 & 
0.85 (s, 6H, CH3-2’ diastereoisomers). 
13C NMR (125 MHz, CDCl3) δC (ppm): 172.83 & 172.65 (2s, NHCH(CH3)CO 
diastereoisomers), 164.26 & 164.18 (2s, C-6 base diastereoisomers), 160.96 & 160.07 
(2s, C-2 base diastereoisomers), 155.52 & 155.22 (2s, C-4 base diastereoisomers), 
148.09 & 147.96  (2s, C-1 Ar diastereoisomers), 141.03 & 142.87 (2s, C-8 base 
diastereoisomers), 138.60 & 138.56 (2s, C-5 Ar diastereoisomers), 128.79 & 128.56 (2s, 
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C-6 Ar diastereoisomers), 127.78 & 127.21 (2s, C-7 Ar diastereoisomers), 126.67 & 
126.43  & 126. 12 (3s, C-8, C-7, C-10 Ar diastereoisomers), 125.01 & 124.95 (4s, C-4, 
C-3 Ar diastereoisomers), 121.27 & 121.23 (2s, C-9 Ar diastereoisomers), 115.01 & 
114.92 (2s, C-2 Ar, Ar diastereoisomers), 112.85 & 112.30 (2s, C-5 base 
diastereoisomers), 94.41 & 94.23 (2s, C-1’ diastereoisomers), 82.49 & 82.23 (2s, C-4’ 
diastereoisomers), 80.27 & 80.02 (2s, C-2’ diastereoisomers), 79.63 & 79.14 (2s, C-3’ 
diastereoisomers), 74.77 & 74.56 (2s, COOCH2C(CH3)3 diastereoisomers), 67.87 & 
67.56 (2s, C-5’ diastereoisomers), 61.07  & 60.87 (2s, OCH2CH3 diastereoisomers), 
54.04 & 53.86 (2s, 6-OMe diastereoisomers), 50.80 & 50.65 (2s, NHCH(CH3)CO 
diastereoisomers), 26.27 & 26.08 (s, 2 x COOCH2C(CH3)3 diastereoisomers), 25.41 & 
25.18 (2s, OCH2C(CH3)3 diastereoisomers), 21.98 & 21.67 (2s, CH3-2’ 
diastereoisomers), 21.46 & 21.33 (2s, NHCH(CH3)CO diastereoisomers), 15.71 & 
15.68 (2s, OCH2CH3 diastereoisomers).  
31P NMR (202 MHz, CDCl3) δP (ppm): 3.60 (s, 60%), 3.41 (s, 40%). 
 
Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-C-methyl-2’-O-propyl-6-O-
methyl guanosine ProTide (148) 
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This ProTide was prepared according to the Standard Procedure D, using tBuMgCl 
(0.28 mL, 0.29 mmol, 2.0 eq), 2’-C-methyl-2’-O-propyl-6-O-methyl guanosine (122) 
(0.050 g, 0.14 mmol, 1.0 eq) in anh. THF (0.81 mL), and α-naphthyl L-Alanine-
neopentyl ester phosphochloridate (14.d) (0.108 g, 0.28 mmol, 2.0 eq) in anh. THF (0.5 
mL). After overnight stirring at RT, the solvent was removed under reduced pressure 
and the residue was purified by flash chromatography, using CHCl3/MeOH (3.5%) as 
eluents, and preparative chromatography followed by preparative HPLC to yield the 
desired molecule (0.0006 g, 0.0009 mmol, 6 %). 
HPLC (MeOH/H2O): Rt = 28.48 min, 28.97 min 
HPLC (ACN/H2O): Rt = 21.80 min, 22.14 min 
MS (TOF ES+): 723.28 (M + Na+). 
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1H NMR (500 MHz, CDCl3) δH (ppm): 8.18-8.01 (m, 2H, H-9 Ar diastereoisomers), 
7.86-7.85 (m, 2H, H-6 Ar diastereoisomers), 7.73-7.65 (m, 2H, H-8 base 
diastereoisomers), 7.72-7.66 (m, 2H, H-4 Ar diastereoisomers), 7.59-7.57 (m, 2H, H-8 
Ar diastereoisomers), 7.54-7.51 (m, 4H, H-7, H-3 Ar diastereoisomers), 7.43-7.39 (m, 
2H, H-2 Ar diastereoisomers), 6.06 & 6.04 (2s, 2H, H-1’ diastereoisomers), 4.96 (bs, 
4H, NH2 base diastereoisomers), 4.70-4.66 (m, 2H, H-5’ diastereoisomers), 4.53-4.48 
(m, 2H, H-5’ diastereoisomers), 4.27-4.23 (m, 2H, H-3’ diastereoisomers), 4.19-4.14 
(m, 4H, H-4’, NHCH(CH3)CO diastereoisomers), 4.09 & 4.08 (2s, 6H, 6-OCH3 base 
diastereoisomers), 3.84-3.75 (m, 4H, OCH2CH2CH3 diastereoisomers), 3.72-3.59 (2m, 
4H, COOCH2C(CH3)3 diastereoisomers), 1.89-1.86 (m, 2H, OCH2CH2CH3), 1.72-1.65 
(m, 2H, OCH2CH2CH3), 1.39 & 1.36 (2d, 6H, J = 7.0 Hz, 7.0 Hz, NHCH(CH3)CO 
diastereoisomers), 1.04-1.03 (m, 6H, OCH2CH2CH3 diastereoisomers), 0.95-0.92 (2s, 
18H, OCH2C(CH3)3 diastereoisomers), 0.89 & 0.86 (2s, 6H, CH3-2’). 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.15 & 17.10 (2s, NHCH(CH3)3CO 
diastereoisomers), 161.36 & 161.19 (2s, C-6 base diastereoisomers), 159.84 & 159.45 
(2s, C-2 base), 156.18 & 156.02 (2s, C-4 base diastereoisomers), 153.28 & 153.01 (2s, 
C-1 Ar diastereoisomers), 134.73 & 134.23 (2s, C-5 Ar diastereoisomers), 127.77 & 
127.43 (2s, C-6 Ar diastereoisomers), 126.55 & 126.37 (2s, C-7 Ar diastereoisomers), 
126.37 & 126.18 (2s, C-8 base diastereoisomers), 125.87 & 125.42 & 125.57 (3s, C-10, 
C-8, C-3 Ar diastereoisomers), 124.80 & 124.66 (2s, C-4 Ar diastereoisomers), 121.60 
& 121.55 (2s, C-9 Ar diastereoisomers), 115.20 & 115.12 (2s, C-5 base), 115.02 & 
114.96 (2s, C-2 Ar diastereoisomers), 87.76 & 87.34 (2s, C-1’ diastereoisomers), 83.11 
& 83.01 (2s, C-2’ diastereoisomers), 81.03 & 79.86 (2s, C-4’ diastereoisomers), 75.28 
& 75.12 (2s, C-3’ diastereoisomers), 74.71 & 74.53 (2s, OCH2C(CH3)3 
diastereoisomers), 65.09 & 64.95 (2s, OCH2CH2CH3 diastereoisomers), 53.87 & 53.41 
(2s, 6-OCH3 base diastereoisomers), 50.89  50.43 (2s, NHCH(CH3)CO 
diastereoisomers), 26.26 & 26.12 (2s, OCH2C(CH3)3 diastereoisomers), 23.33 & 23.04 
(2s, OCH2C(CH3)3 diastereoisomers), 21.40 & 21.32 (2s, OCH2CH2CH3 
diastereoisomers), 21.40 & 41.23 (2s, NHCH(CH3)CO diastereoisomers), 15.56 & 
15.12 (2s, CH3-2’ diastereoisomers), 10.73 & 10.21 (2s, OCH2CH2CH3 
diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 3.45 (s, 17%), 3.40 (s, 83%). 
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Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-C-methyl-2’-O-isopropyl-6-
O-methyl guanosine ProTide (149) 
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This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.14 mL, 0.14 mmol, 2.0 eq), 2’-C-methyl-2’-O-isopropyl-6-O-methyl 
guanosine (123) (0.025 g, 0.071 mmol, 1.0 eq) in anh. THF (1.00 mL), and α-naphthyl 
L-Alanine-neopentyl ester phosphochloridate (14.d) (0.055 g, 0.14 mmol, 2.0 eq) in 
anh. THF (0.5 mL). After overnight stirring at RT, the solvent was removed under 
reduced pressure and the residue was purified by flash chromatography, using 
CHCl3/MeOH as eluents, and preparative chromatography followed by preparative 
HPLC to yield the desired molecule (0.001 g, 0.0014 mmol, 2 %). 
HPLC (MeOH/H2O): Rt = 28.95 min, 29.31 min 
HPLC (ACN/H2O): Rt = 21.89 min, 22.22 min 
MS (TOF ES+): 701.30 (M + H+), 723.28 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.23 & 8.21 (2s, 2H, H-8 base 
diastereoisomers), 8.18-8.16 (m, 2H, H-9 Ar diastereoisomers), 8.12 (m, 1H, H-8 Ar 
diastereoisomers), 7.93-7.84 (m, 2H, H-6 Ar diastereoisomers), 7.71-7.66 (m, 2H, H-2 
Ar diastereoisomers), 7.54-7.35 (m, 6H, H-4, H-3, H-7 Ar diastereoisomers), 5.99 & 
5.97 (2s, 2H, H-1’ diastereoisomers), 4.40-4.36 (m, 2H, H-3’ diastereoisomers), 4.28-
4.11 (2m, 4H, OCH(CH3)2, H-5’ diastereoisomers), 4.04 & 4.03 (2s, 6H, 6-OCH3 base 
diastereoisomers), 3.99-3.93 (m, 2H, H-4’ diastereoisomers), 3.93-3.86 (m, 2H, 
NHCH(CH3)CO diastereoisomers), 3.76-3.63 (m, 4H, OCH2C(CH3)3 diastereoisomers), 
1.50 (d, 3H, J = 7.1 Hz, NHCH(CH3)CO), 1.32 (d, 3H, J = 6.8 Hz, NHCH(CH3)CO), 
1.27-1.25 (m, 3H, OCH(CH3)2), 1.21-1.19 (m, 3H, OCH(CH3)2), 1.01 & 0.99 (2s, 6H, 
CH3-2’ diastereoisomers), 0.86 & 0.85 (2s, 18H, OCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, MeOD) δC (ppm): 173.67 & 174.10 (2s, NHCH(CH3)3CO   
diastereoisomers), 168.10 & 167.89 (2s, C-6 base diastereoisomers), 159.32 & 159.11 
(2s, C-2 base diastereoisomers), 155.48 & 155.13 (s, C-4 base diastereoisomers), 153.43 
& 153.09 (2s, C-1 Ar diastereoisomers), 140.67 & 140.11 (2s, C-8 base 
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diastereoisomers), 138.67 & 138.32 (2s, C-5 Ar diastereoisomers), 128.97 & 128.54 (2s, 
C-6 Ar diastereoisomers), 127.43 & 127.19  (2s, C-10 Ar diastereoisomers), 127.98 & 
127.76 (2s, C-7 Ar diastereoisomers), 127.44 & 127.36 (2s, C-4 Ar diastereoisomers), 
126.62 & 126.44 (2s, C-3 Ar diastereoisomers), 125.90 & 125.87 (2s, C-9 Ar 
diastereoisomers), 122.76 & 122.64 (2s, C-8 Ar diastereoisomers), 117.42 & 117.28 (2s, 
C-5 base diastereoisomers), 116.58 & 116.23 (2s, C-2 Ar diastereoisomers), 89.14 & 
89.02 (2s, C-1’ diastereoisomers), 84.54 & 84.32 (2s, C-2’ diastereoisomers), 80.16 & 
79.46 (2d, J3P-O-C-C = 6.3 Hz, 6.5 Hz, C-4’ diastereoisomers), 75.31 & 75.20 (2s, C-3’ 
diastereoisomers), 75.35 & 75.31 (2s, OCH2C(CH3)3 diastereoisomers), 71.37& 71.29 
(2s, OCH(CH3)2 diastereoisomers), 67.73 & 67.60 (2s, C-5’ diastereoisomers), 53.97 & 
53.30 (s, 6-OCH3 base diastereoisomers), 50.20 & 50.19 (2s, NHCH(CH3)CO 
diastereoisomers), 30.76 & 30.69 (s, OCH2C(CH3)3 diastereoisomers), 26.65 & 26.21 
(2s, OCH2C(CH3)3 diastereoisomers), 23.58 & 23.35 (2s, OCH(CH3)2 diastereoisomers), 
21.53 & 21.37 (2s, NHCH(CH3)CO diastereoisomers), 18.98 & 18.56 (s, CH3-2’ 
diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 4.14 (s, 60%), 4.00 (s, 40%). 
 
Preparation of α-naphthyl L-Alanine-neopentyl-ester N-2-methyl-2’-C-methyl-2’-O-
methyl-6-O-methyl guanosine ProTide (150) 
     
O
OOH
O
N
N
N
N
O
N
H
P
O
HN
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl 
(0.20 mL, 0.20 mmol, 2.0 eq), 2’-C-methyl-2’-O-methyl-N-2-methyl-6-O-methyl 
guanosine (126) (0.033 g, 0.098 mmol, 1.0 eq) in anh. THF (1.00 mL), and α-naphthyl 
L-Alanine-neopentyl ester phosphochloridate (14.d) (0.075 g, 0.20 mmol, 2.0 eq) in 
anh. THF (0.5 mL). After overnight stirring at RT, the solvent was removed under 
reduced pressure and the residue was purified by flash chromatography, using 
CHCl3/MeOH (1.5%) as eluents, and preparative chromatography followed by 
preparative HPLC to yield the desired molecule (0.0014 g, 0.002 mmol, 20%). 
HPLC (MeOH/H2O): Rt = 28.36 min, 28.85 min 
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HPLC (ACN/H2O): Rt = 21.17 min, 21.58 min 
MS (TOF ES+): 709.27 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.18-8.16 (m, 2H, H-9 Ar diastereoisomers), 
7.86-7.84 (m, 2H, H-6 Ar diastereoisomers), 7.71-7.65 (m, 4H, H-4, H-8 Ar 
diastereoisomers), 7.57-7.49 (m, 6H, H-8 base, H-2, H-7 Ar diastereoisomers), 7.43-
4.39 (m, 2H, H-3 Ar diastereoisomers), 6.14 (s, 2H, H-1’ diastereoisomers), 5.02 (bs, 
2H, NHCH3 base diastereoisomers), 4.70-4.60 (m, 2H, H-5’ diastereoisomers), 4.53-
4.49 (m, 2H, H-5’ diastereoisomers), 4.19-4.14 (m, 4H, H-3’, H-4’ diastereoisomers), 
4.08 & 4.07 (2s, 6H, 6-OCH3 base diastereoisomers), 3.82 & 3.80 (AB system, 2H, JAB 
= 10.5 Hz, OCH2C(CH3)3), 3.69 & 3.64 (AB system, 2H, J = 10.5 Hz, OCH2C(CH3)3), 
3.57 & 3.56 (2s, 6H, OCH3 diastereoisomers), 3.00 (d, 3H, J = 5.0 Hz, NHCH3), 2.96 
(d, 3H, J = 5.0 Hz, NHCH3), 2.92 & 2.90 (2d, 2H, J = 5.0 Hz, NHCH3 
diastereoisomers), 1.39 & 1.36 (2d, 6H, J = 7.0 Hz, 7.2 Hz, NHCH(CH3)CO 
diastereoisomers), 1.02 & 1.01 (2s, 6H, CH3-2’ diastereoisomers), 0.89 & 0.88 (2s, 
18H, OCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.15 & 17.10 (2s, NHCH(CH3)3CO  
diastereoisomers), 161.36 (s, C-6 base), 159.84 (s, C-2 base), 156.18 (s, C-4 base), 
153.28 (C-1 Ar), 136.44 & 136.34 (2s, C-5 Ar diastereoisomers), 127.75 (s, C-6 Ar), 
126.62-125.59 (6s, C-3, C-7, C-10 Ar, C-8 base diastereoisomers), 125.57 & 125.51 
(2s, C-8 Ar diastereoisomers), 124.87 & 124.81 (2s, C-4 Ar diastereoisomers), 121.59 
& 121.55 (2s, C-9 Ar diastereoisomers), 115.20 & 115.17 (2s, C-5 base 
diastereoisomers), 115.06 & 115.04 (2s, C-2 Ar diastereoisomers), 87.17 & 87.10 (2s, 
C-1’ diastereoisomers), 83.21 (s, C-2’), 80.73 & 80.54 (2d, J3P-O-C-C = 6.4 Hz, 6.4 Hz, 
C-4’ diastereoisomers), 75.10 & 74.87 (2s, C-3’ diastereoisomers), 74.73 (s, 
OCH2C(CH3)3), 65.98 & 65.42 (2s, C-5’ diastereoisomers), 53.64 & 53.32 (s, 6-OCH3 
base), 51.16 & 50.87 (2s, OCH3 diastereoisomers), 50.43 & 50.38 (2s, NHCH(CH3)CO 
diastereoisomers), 29.70 (s, OCH2C(CH3)3), 28.78 & 28.72 (2s, NHCH3 
diastereoisomers), 26.27 (s, OCH2C(CH3)3), 21.30 & 21.20 (2d, J3P-N-C-C =  3.8 Hz, 5.12 
Hz, NHCH(CH3)CO diastereoisomers), 14.88 & 14.80 (2s, CH3-2’ diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 3.68 (s, 47%), 3.43 (s, 53%). 
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5.2. 2’-O-modifications of 6-O-methyl guanosine 
5.2.1. Preparation of 2’-O-modified-6-O-methyl guanosine nucleosides 
Preparation acetylated guanosine (135) 
     
NH
NN
N
O
O
OO
O
NH2
O
O O
 
To a supension of guanosine (2.52 g, 8.90 mmol) and DMAP (0.11 g, 0.89 mmol, 0.17 
eq) in anh. ACN (95 mL) was added anh. NEt3 (4.90 mL, 35.2 mmol, 4.0 eq). Acetic 
anhydride was added dropwise (3.03 mL, 32.1 mmol, 3.6 eq) and the reaction was left 
stirring at RT overnight. MeOH (30 mL) was added to quench the reaction, a and a 
white product precipitated (2.25 g, 5.51 mol, 62%). by addition of Et2O (300 mL). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.87 (s, 1H, H-8 base), 6.08 (d, 1H, J = 4.9 Hz, 
H-1’), 5.95 (t, 1H, J = 5.4 Hz, H-3’), 5.70 (t, 1H, J = 5.3 Hz, H-4’), 4.47 (m, 3H, H-5’, 
H-2’), 2.15 (s, 3H, OCOCH3), 2.09 & 2.08 (2s, 6H, 2 x OCOCH3). 
13C NMR (125 MHz, MeOD) δC (ppm): 172.33 (s, OCOCH3), 171.50 (s, OCOCH3), 
171.22 (s, OCOCH3), 159.29 (s, C-6 base), 155.42 (s, C-2 base), 138.25 (s, C-8 base), 
118.27 (s. C-5 base), 87.84 (s, C-1’), 81.38 (s, C-2’), 74.31 (s. C-3’), 72.05 (s, C-4’), 
64.24 (s, C-5’), 20.62 (s, OCOCH3), 20.45  (s, OCOCH3), 20.29 (s, OCOCH3). 
 
Preparation acetylated 6-chloroguanosine (136) 
     
N
NN
N
Cl
O
OO
O
NH2
O
O O
 
Acetyl guanosine (135) (0.59 g, 1.44 mmol), BTEA-Cl (0.66 g, 2.88 mmol, 2eq), N,N-
dimethylaniline (0.20 mL, 1.58 mmol, 1.1 eq) and POCl3 (0.67 mL, 7.20 mmol, 5 eq) in 
anh. ACN (20 mL) were heated under reflux at 85 °C for 2 hrs. Volatiles were 
evaporated immediately and the yellow oil recovered was dissolved in CHCl3 and 
stirred for 30 min at RT with crushed ice. The 2 layers were separated and the aqueous 
layer was extracted 3 times with CHCl3. Then crushed ice was added to the combined 
organic layers and washed 3 times with cold H2O and once with NaHCO3 (5%) in water 
to reach neutral pH. The organic layer was dried over MgSO4. The solvent was 
evaporated to give a green yellow oil (0.57 g, 1.33 mmol, 92%). 
Claire Bourdin  Chapter Eight: Experimental section 
 
267 
1H NMR (500 MHz, CDCl3) δH (ppm); 7.89 (s, 1H, H-8 base), 6.01 (d, 1H, J = 4.9 Hz, 
H-1’), 5.94 (t, 1H, J = 5.1 Hz, H-3’), 5.72 (t, 1H, J = 5.0 Hz, H-4’), 5.51 (bs, 2H, NH2 
base), 4.42 (m, 3H, H-5’, H-2’), 2.12 (s, 3H, OCOCH3), 2.07 (s, OCOCH3), 2.05 (s, 6H, 
OCOCH3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 170.45 (s, OCOCH3), 169.58 (s, OCOCH3), 
169.38 (s, OCOCH3), 159.28 (s, C-6 base), 153.15 (s, C-2 base), 151.66 (s, C-4 base), 
140.75 (s, C-8 base), 125.59 (s. C-5 base), 87.29 (s, C-1’), 79.96 (s, C-2’), 72.74 (s. C-
3’), 71.45 (s, C-4’), 62.73 (s, C-5’), 20.97 (s, OCOCH3), 20.65  (s, OCOCH3), 20.49 (s, 
OCOCH3). 
 
Preparation 6-O-methyl guanosine (137) 12 
      
N
NN
N
O
O
OHOH
HO
NH2
 
Acetylated 6-chloro-guanosine (136) (0.58 g, 1.33 mmol) was dissolved in anh. MeOH 
(50 mL) and NaOMe (0.48 g, 8.78 mmol, 6.6 eq) was added at 0 °C. The solution was 
stirred overnight at RT. The solvent was evaporated under reduced pressure after 
neutralisation with amberlite and filtration. The residue was purified by flash 
chromatography to yield the desired material (0.2125 g, 0.72 mmol, 54%). 
1H NMR (500 MHz, DMSO) δH (ppm): 8.10 (s, 1H, H-8 base), 6.43 (s, 2H, NH2 base), 
5.79 (d, 1H, J = 6.0 Hz, H-1’), 5.38 (d, 1H, J = 5.5 Hz, H-2’), 5.09 (m, 2H, H-4’, H-3’), 
4.47 (d, 1H, J = 5.5 Hz, OH-5’), 4.11 (d, 1H, J = 3.5 Hz, OH-4’), 3.97 (s, 3H, 6-OCH3 
base), 3.91 (d, 1H, J = 3.5, OH-3’), 3.65 (m, 1H, H-5’), 3.55 (m, 1H, H-5’). 
13C NMR (125 MHz, DMSO) δC (ppm): 160.67 (s, C-6 base), 159.76 (s, C-2 base), 
154.09 (s, C-4 base), 137.95 (s, C-8 base), 113.56 (s, C-5 base), 86.54 (s, C-1’), 85.23 
(s, C-4’), 73.44 (s, C-2’), 70.37 (s, C-3’), 61.41 (s, C-5’), 53.16 (s, 6-OCH3 base). 
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Preparation 3’,5’-DTBS-protected 6-O-methyl guanosine (138) 13 
     
N
NN
N
O
O
OHO
O
NH2Si
 
To a suspension of 6-O-methyl guanosine (137) (0.23 g, 0.77 mmol, 1.0 eq) in anh. 
DMF (4.5 mL) was added di-tert-butyl-silyl-triflate (0.28 mL, 0.85 mmol, 1.1 eq) at 0 
°C. The solution was stirred 30 min at 0 °C, and the reaction was quenched with cold 
EtOH and neutralised with NEt3. The solvent was removed under reduced pressure and 
the remaining oil was dissolved in MeOH. A white solid precipitated by addition of 
H2O. After filtration and drying under Buchner, the desired molecule was recovered 
(0.27 g, 0.61 mmol, 80%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.65 (s, 1H, H-8 base), 5.99 (s, 1H, H-1’), 4.64-
4.61 (m, 1H, H-4’), 4.57 (m, 1H, H-2’), 4.53-4.48 (m, 1H, H-5’), 4.22-4.17 (m, 1H, H-
3’), 4.11-4.09 (m, 1H, H-5’), 4.07 (s, 3H, 6-OCH3 base), 1.13 & 1.07 (2s, 18H, 
Si(C(CH3)3)2). 
13C NMR (125 MHz, CDCl3) δC (ppm): 161.77 (s, C-6 base), 159.38 (s, C-2 base), 
152.51 (s, C-4 base), 137.47 (s, C-8 base), 116.20 (s, C-5 base), 90.58 (s, C-1’), 75.53 
(s, C-4’), 74.82 (s, C-2’), 73.76 (s, C-3’), 67.60 (s, C-5’), 53.99 (s, 6-OCH3 base), 32.24 
& 32.18 (2s, Si(C(CH3)3)2), 27.80 & 27.78 & 27.50 & 27.41 & 27.37 & 27.26 (6s, 
Si(C(CH3)3)2). 
 
Preparation 3’,5’-DTBS-protected-N-2-formamidine 6-O-methyl guanosine (139) 
N
NN
N
O
O
OHO
O
N
Si
N
 
To a solution of 3’,5’-protected 6-O-methyl guanosine (138) (0.19 g, 0.43 mmol, 1.0 eq) 
in anh. DMF (3.10 mL) was added N,N-dimethylformamide dimethylacetate (0.24 mL, 
1.72 mmol, 4.0 eq). The reaction mixture was stirred overnight at RT, and the solvent 
was evaporated. The residue was dissolved in EtOAc and washed with NaHCO3, H2O 
and brine. Evaporation of the organic layer afforded the desired material (0.21 g, 0.42 
mmol, 97%). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.44 (s, 1H, NCHN(CH3)2), 7.65 (s, 1H, H-8 
base), 5.93 (s, 1H, H-1’), 4.59 (d, 1H, J = 5.0 Hz, H-3’), 4.35-3.30 (m, 2H, H-4’, H-5’), 
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4.07-4.01 (s, 1H, H-2’), 3.97 (s, 3H, 6-OMe base), 3.96 & 3.86 (m, 1H, H-5’), 2.97 & 
2.96 (2s, 6H, NCHN(CH3)2), 0.93 & 0.89 (2s, 18H, Si(C(CH3)3)2). 
13C NMR (125 MHz, MeOD) δC (ppm): 162.32 (s, C-6 base), 160.79 (s, C-2 base), 
158.26 (s, NCHN(CH3)2), 152.51 (s, C-4 base), 138.53 (s, C-8 base), 117.86 (s, C-5 
base), 90.66 (s, C-1’), 77.56 (s, C-4’), 76.23 (s, C-2’), 74.43 (s, C-3’), 67.52 (s, C-5’), 
53.67 (s, 6-OMe base), 41.09 (s, NCHN(CH3)2), 35.09 (s, NCHN(CH3)2), 27.67 & 
27.56 & 27.42 & 27.37& 27.28 & 27.05 (6s, Si(C(CH3)3)2), 22.61 & 22.56 (2s,  
Si(C(CH3)3)2). 
 
Preparation 3’,5’-DTBS-protected-N-2-formamidine 2’-O-methyl-6-O-methyl 
guanosine (140.a) 
N
NN
N
O
O
OO
O
N
Si
N
 
To a solution of 3’,5’-DTBS-protected-N-2-formamidine 6-O-methyl guanosine (139) 
 (0.21 g, 0.42 mmol, 1.0 eq) in anh. DMF (5.9 mL) was added molecular sieves 3Å, 
methylidodide (0.16 mL, 2.52 mmol, 6.0 eq) at 0 °C. The reaction was left stirring at 0 
°C for 15 min, and then NaH (60% dispersion in oil, 0.02 g, 0.50 mmol, 1.2 eq) was 
added. The mixture was left stirring for 1 hr at 0 °C, and quenched with sodium 
dihydrogen phosphate (0.5 M) and dissolved in ethyl acetate. The organic layer was 
washed with sodium dihydrogen phosphate, H2O and brine, and the solvents were 
evaporated under reduced pressure to yield the desired material without further 
purification needed (0.2064 g, 0.40 mmol, 97 %). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.64 (s, 1H, NCHN(CH3)2), 7.72 (s, 1H, H-8 
base), 6.02 (s, 1H, H-1’), 4.53-4.27 (m, 2H, H-5’, H-4’), 4.22-4.19 (m, 1H H-2’), 4.15 
(s, 3H, 6-OCH3 base), 4.01-3.97 (m, 2H, H-5’, H-3’), 3.64 (s, 3H, OCH3), 3.18 & 3.16 
(2s, 6H, NCHN(CH3)2), 1.07 & 1.05 (2s, 18H, Si(C(CH3)3)2). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.74 (s, C-6 base), 161.18 (s, C-2 base), 
158.39 (s, NCHN(CH3)2), 152.81 (s, C-4 base), 140.94 (s, C-8 base), 118.16 (s, C-5 
base), 88.82 (s, C-1’), 82.35 (s, C-2’), 77.80 (s, C-4’), 74.34 (s, C-3’), 67.58 (s, C-5’), 
53.87 (s, 6-OMe base), 52.04 (s, OCH3), 40.94 (2s, NCHN(CH3)2), 35.12 (s, 
NCHN(CH3)2), 28.70 & 27.85 (2s, Si(C(CH3)3)2), 22.74 & 22.66 (2s, Si(C(CH3)3)2). 
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Preparation 3’,5’-DTBS-protected-N-2-formamidine 2’-O-methyl-6-O-methyl 
guanosine (140.b) 
N
NN
N
O
O
OO
O
N
Si
N
 
Prepared similarly to 140.a, using 3’,5’-DTBS-protected-N-2-formamidine 6-O-methyl 
guanosine (139) (0.25 g, 0.51 mmol, 1.0 eq) in anh. DMF (7.5 mL), molecular sieves 
3Å, ethyl idodide (0.19 mL, 3.06 mmol, 6.0 eq), and NaH (60% dispersion in oil, 0.025 
g, 0.61 mmol, 1.2 eq). The mixture was left stirring for 2 hrs at 0 °C, and quenched with 
sodium dihydrogen phosphate (0.5 M) and dissolved in EtOAc. The organic layer was 
washed with sodium dihydrogen phosphate, H2O and brine, and the solvents were 
evaporated under reduced pressure to yield the desired material without further 
purification needed (0.18 g, 0.34 mmol, 67%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.64 (s, 1H, NCHN(CH3)2), 7.72 (s, 1H, H-8 
base), 6.03 (d, 1H, J = 7.5 Hz, H-1’), 4.46-4.39 (m, 1H, , H-5’), 4.32-4.30 (m, 1H, H-
2’), 4.20-4.16 (m, 1H, H-4’), 4.15 (s, 3H, 6-OCH3 base), 4.13-4.08 (m, 1H, H-3’), 4.01-
3.97 (m, 1H, H-5’), 3.74-3.58 (m, 2H, OCH2CH3), 3.16 & 3.13 (2s, 6H, NCHN(CH3)2), 
1.25-1.23 (m, 3H, 2OCH2CH3), 1.06 & 1.03 (2s, 18H, 2 x Si(C(CH3)3)2).. 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.73 (s, C-6 base), 161.17 (s, C-2 base), 
158.38 (s, NCHN(CH3)2), 152.83 (s, C-4 base), 138.43 (s, C-8 base), 118.20 (s, C-5 
base), 89.18 (s, C-1’), 80.71 (s, C-4’), 77.47 (s, C-2’), 74.30 (s, C-3’), 67.51 (s, 
OCH2CH3), 62.79 (s, C-5’), 53.75 (s, 6-OCH3 base), 41.09 & 35.18 (2s, NCHN(CH3)2), 
29.65 & 29.31 (2s, 2 x Si(C(CH3)3)2), 27.90 & 27.85 & 27.79 & 27.69 & 27.49 & 27.37 
(6s, 2 x Si(C(CH3)3), 15.37 (s, OCH2CH3). 
 
Preparation 3’,5’-DTBS-protected-N-2-formamidine 2’-O-propyl-6-O-methyl 
guanosine (140.c) 
N
NN
N
O
O
OO
O
N
Si
N
 
Prepared similarly to 140.a, using 3’,5’-DTBS-protected-N-2-formamidine 6-O-methyl 
guanosine (139) (0.60 g, 1.22 mmol, 1.0 eq) in anh. DMF (17 mL), molecular sieves 
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3Å, propyl idodide (0.71 mL, 7.32 mmol, 6.0 eq), and NaH (60% dispersion in oil, 
0.059 g, 1.47 mmol, 1.2 eq). The mixture was left stirring for 5 hrs at 0 °C, and 
quenched with sodium dihydrogen phosphate (0.5 M) and dissolved in EtOAc. The 
organic layer was washed with sodium dihydrogen phosphate, H2O and brine, and the 
solvents were evaporated under reduced pressure to yield the desired material without 
further purification needed (0.52 g, 0.97 mmol, 80%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.50 (s, 1H, NCHN(CH3)2), 7.65 (s, 1H, H-8 
base), 5.90 (d, 1H, J = 6.0 Hz, H-1’), 4.32-4.28 (m, 2H, H-2’, H3’), 4.18 (m, 1H, H-4’), 
3.99 (s, 3H, 6-OCH3 base), 3.91-3.84 (m, 1H, H-5’), 3.77-3.72 (m, 1H, H-5’), 3.53-3.51 
(m, 2H, OCH2CH2CH3), 3.02 & 3.00 (2s, 6H, NCHN(CH3)2), 1.54-1.47 (m, 2H, 
OCH2CH2CH3), 0.85 & 0.81 (2s, 18H, Si(C(CH3)3)2), 0.79-0.73 (m, 3H, 
OCH2CH2CH3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.52 (s, C-6 base), 160.93 (s, C-2 base), 
158.19 (s, NCHN(CH3)2), 152.64 (s, C-4 base), 138.45 (s, C-8 base), 117.93 (s, C-5 
base), 89.01 (s, C-1’), 86.42 (s, C-4’), 80.83 (s, C-2’), 72.86 (s, CH2CH2CH3), 69.32 (s, 
C-3’), 63.04 (s, C-5’), 54.09 (s, 6-OCH3 base), 36.18 & 34.72 (2s, NCHN(CH3)2), 29.44 
& 29.15 (2s, Si(C(CH3)3)2), 26.64 & 26.58 & 26.55 & 26.50 & 24.44 & 26.41 (6s, 
Si(C(CH3)3)2), 22.89 (s, OCH2CH2CH3), 11.18 (s, OCH2CH2CH3). 
 
Preparation 3’,5’-DTBS-protected-N-2-formamidine 2’-O-isopropyl-6-O-methyl 
guanosine (140.d) 
N
NN
N
O
O
OO
O
N
Si
N
 
Prepared similarly to 140.a, using 3’,5’-DTBS-protected-N-2-formamidine 6-O-methyl 
guanosine (139) (0.60 g, 1.22 mmol, 1.0 eq) in anh. DMF (17 mL), molecular sieves 
3Å, isopropyl idodide (0.73 mL, 7.32 mmol, 6.0 eq), and NaH (60% dispersion in oil, 
0.059 g, 1.46 mmol, 1.2 eq). The mixture was left stirring for 5 hrs at 0 °C, and 
quenched with sodium dihydrogen phosphate (0.5 M) and dissolved in EtOAc. The 
organic layer was washed with sodium dihydrogen phosphate, H2O and brine, and the 
solvents were evaporated under reduced pressure to yield the desired material without 
further purification needed (0.40 g, 0.75 mmol, 61%). 
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1H NMR (500 MHz, CDCl3) δH (ppm): 8.57 (s, 1H, NCHN(CH3)2), 7.93 (s, 1H, H-8 
base), 5.87 (d, 1H, J = 6.0 Hz, H-1’), 4.32-4.27 (m, 1H, H-2’), 4.10-4.08 (m, 2H, H-3’), 
4.08 (s, 3H, 6-OCH3 base), 4.05-3.98 (m, 1H, H-4’), 3.99-3.94 (m, 1H, H-5’), 3.59-3.55 
(m, 1H, H-5’), 3.11-3.04 (m, 1H, CH(CH3)2), 2.89 & 2.81 (2s, 6H, NCHN(CH3)2), 1.49-
1.44 (m, 6H, OCH(CH3)2), 0.99 & 0.96 (2s, 18H, Si(C(CH3)3)2). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.61 (s, C-6 base), 160.04 (s, C-2 base), 
158.83 (s, NCHN(CH3)2), 152.64 (s, C-4 base), 140.32 (s, C-8 base), 118.46 (s, C-5 
base), 89.47 (s, C-1’), 85.46 (s, C-4’), 78.40 (s, C-2’), 73.82 (s, OCH(CH3)2), 71.49 (s, 
C-3’), 63.14 (s, C-5’), 53.84 (s, 6-OCH3 base), 35.55 & 35.18 (2s, NCHN(CH3)2), 29.64 
& 29.28 (2s, Si(C(CH3)3)2), 27.64 & 27.58 & 27.55 & 27.50 & 27.43 & 27.40 (6s, 
Si(C(CH3)3)2), 20.93 & 19.86 (s, OCH(CH3)2). 
 
Preparation N-2-formamide 2’-O-methyl-6-O-methyl guanosine (141.a) 
N
NN
N
O
O
OOH
HO
N
H
O
 
To a solution of 3’,5’-DTBS-protected-N-2-formamidine 2’-O-methyl-6-O-methyl 
guanosine (140.a) (0.26 g, 0.51 mmol, 1.0 eq) in anh. THF (11 mL) was added anh. 
NEt3 (0.13 mL, 0.92 mmol, 1.8 eq) and NEt3.H3F (0.29 mL, 1.79 mmol, 3.5 eq). The 
solution was stirred at rrom temperature for 1 hr. The solvent was evaporated under 
reduced pressure and the residue purified by flash chromatography using MeOH/CHCl3 
to recover the partially DMF cleaved molecules A (0.0066 g, 0.19 mmol, 38 %). 
HPLC (MeOH/H2O): Rt = 1.52 min 
HPLC (ACN/H2O): Rt = 5.59 min 
MS (TOF ES+): 339.34 (M + H+). 
1H NMR (500 MHz, MeOD) δH (ppm): 9.49 (bs, 1H, NHCHO), 8.45 (s, H-8 base), 6.14 
(d, 1H, J = 4.5 Hz, H-1’), 4.50 (m, 1H, H-3’), 4.33 (t, 1H, J = 4.7 Hz, H-2’), 4.16 (s, 
3H, 6-OCH3 base), 4.11-4.09 (m, 1H, H-4’), 3.92 (dd, 1H, J = 2.9 Hz, 12.3 Hz, H-5’), 
3.81 (dd, 1H, J = 3.5 Hz, 12.2 Hz, H-5’), 3.52 (s, 3H, OCH3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 165.58 (s, NHCHO), 162.59 (s, C-6 base), 
154.23 (s, C-2 base), 153.51 (s, C-4 base), 142.09 (s, C-8 base), 119.31 (s, C-5 base), 
88.12 (s, C-1’), 86.96 (s, C-4’), 85.06 (s, C-2’), 70.34 (s, C-3’), 62.32 (s, C-5’), 58.96 
(s, OCH3), 55.05 (s, 6-OCH3 base). 
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Preparation N-2-formamide 2’-O-ethyl-6-O-methyl guanosine (141.b) 
N
NN
N
O
O
OOH
HO
N
H
O
 
To as solution of 3’,5’-DTBS-protected-N-2-formamidine 2’-O-ethyl-6-O-methyl 
guanosine (140.b) (0.18 g, 0.34 mmol, 1.0 eq) in anh. THF (9 mL), anh. NEt3 (0.086 
mL, 0.61 mmol, 1.8 eq) and NEt3.H3F (0.19 mL, 1.19 mmol, 3.5 eq) were added. The 
solution was stirred at RT for 1 hr. The solvent was evaporated under reduced pressure 
and the residue purified by flash chromatography using CHCl3/MeOH (3-4%) to afford 
the desired molecule (0.044 g, 0.12 mmol, 35 %). 
1H NMR (500 MHz, CDCl3) δH (ppm): 9.51 (d, 1H, J = 9.5 Hz, NHCHO), 8.51 (d, 1H, 
J = 9.5 Hz, NHCHO), 7.99 (s, 1H, H-8 base), 5.94 (d, 1H, J = 6.5 Hz, H-1’), 4.62 (dd, 
1H, J = 5.0 Hz, 6.5 Hz, H-2’), 4.55 (m, 1H, H-3’), 4.32 (m, 1H, H-4’), 4.16 (s, 3H, 6-
OCH3 base), 3.99-3.96 (m, 1H, H-5’), 3.84-3.79 (m, 1H, H-5’), 3.64-3.57 (m, 1H, 
OCH2CH3), 3.55-3.50 (m, 1H, OCH2CH3), 1.814 (t, 3H, J = 7.0 Hz, OCH2CH3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 163.02 (s, NHCHO), 161.75 (s, C-6 base), 
151.91 (s, C-2 base), 151.51 (s, C-4 base), 141.37 (s, C-8 base), 119.98 (s, C-5 base), 
88.86 (s, C-1’), 86.96 (s, C-4’), 81.02 (s, C-2’), 70.53 (s, C-3’), 67.00 (s, CH2CH3), 
62.68 (s, C-5’), 54.70 (s, 6-OCH3 base), 15.23 (s, OCH2CH3). 
 
Preparation N-2-formamide 2’-O-propyl-6-O-methyl guanosine (141.c) 
N
NN
N
O
O
OOH
HO
N
H
O
 
To a solution of 3’,5’-DTBS-protected-N-2-formamidine 2’-O-propyl-6-O-methyl 
guanosine (140.c) (0.52 g, 0.97 mmol, 1.0 eq) in THF (25 mL), anh. NEt3 (0.24 mL, 
1.75 mmol, 1.8 eq) and NEt3.H3F (0.55 mL, 3.40 mmol, 3.5 eq) were added. The 
solution was stirred at RT for 1 hr. The solvent was evaporated under reduced pressure 
and the residue purified by flash chromatography using CHCl3/MeOH (2%) to afford 
the desired molecule (0.13 g, 0.36 mmol, 37 %). 
1H NMR (500 MHz, CDCl3) δH (ppm): 9.49 (d, 1H, J = 10.0 Hz, NHCHO), 8.67 (d, 1H, 
J = 10.0 Hz, NHCHO), 8.03 (s, 1H, H-8 base), 5.96 (d, 1H, J = 5.5 Hz, H-1’), 4.58-4.56 
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(m, 2H, H-2’, H-3’), 4.30 (m, 1H, H-4’), 4.14 (s, 3H, 6-OCH3 base), 3.98-3.96 (m, 1H, 
H-5’), 3.84-3.79 (m, 1H, H-5’), 3.52-3.38 (m, 2H, OCH2CH2CH3), 1.53-1.46 (m, 2H, 
OCH2CH2CH3), 0.82 (t, 3H, J = 7.0 Hz, OCH2CH2CH3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 163.17 (s, NHCHO), 161.64 (s, C-6 base), 
151.94 (s, C-2 base), 151.56 (s, C-4 base), 141.27 (s, C-8 base), 119.19 (s, C-5 base), 
88.61 (s, C-1’), 86.84 (s, C-4’), 81.31 (s, C-2’), 73.08 (s, OCH2CH2CH3), 70.41 (s, C-
3’), 62.49 (s, C-5’), 54.65 (s, 6-OCH3 base), 22.82 (s, OCH2CH2CH3), 10.19 (s, 
OCH2CH2CH3). 
 
Preparation N-2-formamide 2’-O-isopropyl-6-O-methyl guanosine (141.d) 
N
NN
N
O
O
OOH
HO
N
H
O
 
To a solution of 3’,5’-DTBS-protected-N-2-formamidine 2’-O-isopropyl-6-O-methyl 
guanosine (140.d) (0.40 g, 0.75 mmol, 1.0 eq) in anh. THF (19 mL). (0.043 g, 0.76 
mmol, 4.0 eq), anh. NEt3 (0.19 mL, 1.35 mmol, 1.8 eq) and NEt3.H3F (0.43 mL, 2.63 
mmol, 3.5 eq) were added. The solution was stirred at RT for 1 hr. The solvent was 
evaporated under reduced pressure and the residue purified by flash chromatography 
using CHCl3/MeOH (2%) to afford the desired molecule (0.070 g, 0.19 mmol, 25 %). 
1H NMR (500 MHz, CDCl3) δH (ppm): 9.51 (d, 1H, J = 9.8 Hz, NHCHO), 8.39 (d, 1H, 
J = 9.8 Hz, NHCHO), 7.94 (s, 1H, H-8 base), 5.85 (d, 1H, J = 6.9 Hz, H-1’), 4.70 (dd, 
1H, J = 5.0 Hz, 6.8 Hz, H-2’), 4.42 (m, 1H, H-3’), 4.33 (m, 1H, H-4’), 4.18 (s, 3H, 6-
OCH3 base), 3.98 (dd, 1H, J = 1.5 Hz, 12.4 Hz, H-5’), 3.82 (d, 1H, J = 12.4 Hz, H-5’), 
3.67-3.62 (m, 1H, OCH(CH3)2), 1.16 (d, 3H,  J = 6.2 Hz, OCH(CH3)2), 0.94 (d, 3H, J = 
6.1 Hz, OCH(CH3)2). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.88 (s, NHCHO), 161.82 (s, C-6 base), 
151.89 (s, C-2 base), 151.40 (s, C-4 base), 141.50 (s, C-8 base), 120.09 (s, C-5 base), 
89.42 (s, C-1’), 87.10 (s, C-4’), 78.97 (s, C-2’), 73.47 (s, OCH(CH3)2), 71.07 (s, C-3’), 
62.91 (s, C-5’), 50.69 (s, 6-OCH3 base), 22.59 & 22.25 (s, OCH(CH3)2). 
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Preparation 2’-O-methyl-6-O-methyl guanosine (142) 
N
NN
N
O
O
OOH
HO
NH2
	  
N-2-formamide 2’-O-methyl-6-O-methyl guanosine (141.a) (0.050 g, 0.13 mmol, 1.0 
eq) was dissolved in THF/H2O (10/5 mL) and KOH (0.030 g, 0.53 mmol, 4.0 eq) was 
added. The reaction was left stirring for 6 hrs at RT. The solvent was evaporated under 
reduced pressure to give a yellow residue that was purified by preparative 
chromatography using CHCl3/MeOH (10%) to yield the desired material (0.040 g, 0.13 
mmol, 96%). 
HPLC (MeOH/H2O): Rt = 12.62 min 
HPLC (ACN/H2O): Rt = 5.11 min 
MS (TOF ES+): 312.13 (M + H+); MS (TOF ES-): 346.09 (M + Cl-). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.64 (s, 1H, H-8 base), 5.78 (d, 1H, J = 7.5 Hz, 
H-1’), 4.89(bs, 2H, NH2 base), 4.69 (dd, 1H, J = 5.0 Hz, 7.5 Hz, H-2’), 4.57 (dd, 1H, J 
= 5.0 Hz, 5.8 Hz, H-3’), 4.35 (m, 1H, H-4’), 4.10 (s, 3H, 6-OCH3 base), 4.00 (m, 1H, H-
5’), 3.79 (m, 1H, H-5’), 3.36 (m, 1H, OCH3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.23 (s, C-6 base), 158.75 (s, C-2 base), 
151.95 (s, C-4 base), 139.47 (s, C-8 base), 115.76 (s, C-5 base), 89.40 (s, C-1’), 87.86 
(s, C-4’), 80.01 (s, C-2’), 70.78 (s, C-3’), 63.41 (s, C 5’), 58.84 (s, OCH3), 54.08 (s, 6-
OCH3 base). 
 
Preparation 2’-O-ethyl-6-O-methyl guanosine (143) 
N
NN
N
O
O
OOH
HO
NH2
 
N-2-formamide 2’-O-methyl-6-O-methyl guanosine (141.b) (0.050 g, 0.13 mmol, 1.0 
eq) was dissolved in THF/H2O (10/5 mL) and KOH (0.029 g, 0.52 mmol, 4.0 eq) was 
added. The reaction was left stirring for 6 hrs at RT. The solvent was evaporated under 
reduced pressure to give a yellow residue that was purified by preparative 
chromatography using CHCl3/MeOH (10%) to yield the desired material (0.039 g, 0.12 
mmol, 92%). 
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HPLC (MeOH/H2O): Rt = 14.13 min 
HPLC (ACN/H2O): Rt = 3.04 min 
MS (TOF ES+): 325.20 (M); MS (TOF ES-): 360.11 (M + Cl-). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.66 (s, 1H, H-8 base), 5.77 (d, 1H, J = 7.5 Hz, 
H-1’), 4.74 (dd, 1H, J = 7.5 Hz, 4.3 Hz, H2’), 5.51 (dd, 1H, J = 4.5 Hz, 6.5 Hz, H-3’), 
4.35 (m, 1H, H-4’), 4.09 (s, 3H, 6-OCH3 base), 3.99 (dd, 1H, J = 1.0 Hz, 12.5 Hz, H-
5’), 3.77 (d, 1H, J = 12.0 Hz, H-5’), 3.59 (m, 1H, OCH2CH3), 3.47 (m, 1H, OCH2CH3), 
1.11 (t, 3H, J = 7.0 Hz, OCH2CH3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.23 (s, C-6 base), 158.69 (s, C-2 base), 
149.15 (s, C-4 base), 115.23 (s, C-5 base), 139.54 (s, C-8 base), 89.57 (s, C-1’), 87.76 
(s, C-2’), 80.44 (s, C-4’), 71.17 (s, C-3’), 67.00 (s, OCH2CH3), 63.39 (s, C-5’), 54.13 (s, 
6-OCH3 base), 15.25 (s, 3H, OCH2CH3). 
 
Preparation 2’-O-propyl-6-O-methyl guanosine (144) 
N
NN
N
O
O
OOH
HO
NH2
 
N-2-formamide 2’-O-propyl-6-O-methyl guanosine (141.c) (0.060 g, 0.16 mmol, 1.0 eq) 
was dissolved in THF/H2O (3/1.5 mL) and KOH (0.041 g, 0.64 mmol, 4.0 eq) was 
added. The reaction was left stirring for 4 hrs at RT. The solvent was evaporated under 
reduced pressure to give a yellow residue that was purified by preparative 
chromatography using CHCl3/MeOH (10%) to yield the desired material (0.056 g, 0.15 
mmol, 95%). 
HPLC (MeOH/H2O): Rt = 16.51 min 
HPLC (ACN/H2O): Rt = 7.10 min 
MS (TOF ES+): 340.17 (M + H+); MS (TOF ES-): 374.12 (M + Cl-). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.65 (s, 1H, H-8 base), 5.76 (d, 1H, J = 7.5 Hz, 
H-1’), 5.20 (bs, 2H, NH2 base), 4.70 (dd, 1H, J = 4.5 Hz, 3.0 Hz, H-2’), 4.49 (dd, 1H, J 
= 4.5 Hz, 5.5 Hz, H-3’), 4.32 (m, 1H, H-4’), 4.06 (s, 3H, 6-OCH3 base), 3.97 (dd, 1H, J 
= 2.0 Hz, 13.0 Hz, H-5’), 3.75 (d, 1H, J = 13.0 Hz, H-5’), 3.44-3.28 (2m, 2H, 
OCH2CH2CH3), 1.49-1.42 (m, 2H, OCH2CH2CH3), 0.88 (t, 3H, J = 7.5 Hz, 
OCH2CH2CH3). 
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13C NMR (125 MHz, CDCl3) δC (ppm): 162.11 (s, C-6 base), 158.92 (s, C-2 base), 
151.93 (s, C-4 base), 139.49 (s, C-8 base), 115.99 (s, C-5 base), 89.49 (s, C-1’), 87.67 
(s, C-4’), 80.52 (s, C-2’), 73.10 (s, OCH2CH2CH3), 71.06 (s, C-3’), 63.34 (s, C-5’), 
54.06 (s, 6-OCH3 base), 22.83 (s, OCH2CH2CH3), 10.12 (s, OCH2CH2CH3). 
 
Preparation 2’-O-isopropyl-6-O-methyl guanosine (145) 
N
NN
N
O
O
OOH
HO
NH2
 
N-2-formamide 2’-O-isopropyl-6-O-methyl guanosine (141.d) (0.070 g, 0.19 mmol, 1.0 
eq) was dissolved in THF/H2O (3/1.5 mL) and KOH (0.043 g, 0.76 mmol, 4.0 eq) was 
added. The reaction was left stirring for 5 hrs at RT. The solvent was evaporated under 
reduced pressure to give a yellow residue that was purified by preparative 
chromatography using CHCl3/MeOH (10%) to yield the desired material (0.039 g, 0.11 
mmol, 60%). 
HPLC (MeOH/H2O): Rt = 15.67 min 
HPLC (ACN/H2O): Rt = 7.22 min 
MS (TOF ES+): 340.12 (M + H+), 362.10 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.64 (s, 1H, H-8 base), 5.71 (d, 1H, J = 7.5 Hz, 
H-1’), 5.03 (bs, 2H, NH2 base), 4.81 (dd, 1H, J = 5.0 Hz, 2.5 Hz, H-2’), 4.42 (m, 1H, H-
3’), 4.35 (m, 1H, H-4’), 4.10 (s, 3H, 6-OCH3 base), 3.99 (dd, 1H, J = 1.5 Hz, 12.5 Hz, 
H-5’), 3.76 (d, 1H, J = 12.5 Hz, H-5’), 3.63-3.57 (m, 1H, OCH(CH3)2), 1.15 (d, 3H,  J = 
6.0 Hz, OCH(CH3)2), 0.88 (d, 3H, J = 6.5 Hz, OCH(CH3)2). 
13C NMR (125 MHz, CDCl3) δC (ppm): 162.19 (s, C-6 base), 158.81 (s, C-2 base), 
151.90 (s, C-4 base), 139.60 (s, C-8 base), 115.38 (s, C-5 base), 89.81 (s, C-1’), 87.69 
(s, C-4’), 78.51 (s, C-2’), 73.42 (s, OCH(CH3)2), 71.67 (s, C-3’), 63.50 (s, C-5’), 54.07 
(s, 6-OCH3 base), 22.69 & 22.16 (s, OCH(CH3)2). 
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5.2.2. Preparation of 2’-O-modified-6-O-methyl guanosine ProTides 
Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-O-methyl-6-O-methyl 
guanosine ProTide (151) 
O
OOH
O
N
N
N
N
O
NH2
P
O
HN
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.27 mL, 0.27 mmol, 2 eq), 2’-O-methyl-6-O-methyl guanosine (142) (0.042 g, 
0.134 mmol, 1 eq) in anh. THF (1.50 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.11 g, 0.27 mmol, 2 eq) in anh. THF (1.0 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH as eluents, and 
preparative chromatography to yield the desired molecule (0.2 mg, 0.0003 mmol, 
0.2%).  
HPLC (MeOH/H2O): Rt = 26.66 min, 26.88 min 
HPLC (ACN/H2O): Rt = 18.02 min, 18.28 min 
MS (TOF ES+): 659.32 (M + H+), 681.34 (M + Na+), 697.21 (M + K+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.17-8.16  (m, 2H, H-9 Ar diastereoisomers), 
7.93 & 7.91 (2s, 2H, H-8 base diastereoisomers), 7.73-7.69 (m, 4H, H-7, H-4 Ar 
diastereoisomers), 7.55-7.49 (m, 6H, H-8, H-6, H-2 Ar diastereoisomers), 7.43-7.40 (m, 
2H, H-3 Ar diastereoisomers), 5.99 & 5.98 (2d, 2H, J = 5.5 Hz, 5.6 Hz, H-1’ 
diastereoisomers), 4.59-4.56 (m, 2H, H-2’ diastereoisomers), 4.51-4.49 (m, 6H, 
OCH2C(CH3)3 diastereoisomers, H-3’), 4.42-4.37 (m, 1H, H-3’), 4.31-4.26 (2m, 2H, H-
4’ diastereoisomers), 4.10-4.08 (m, 1H, NHCH(CH3)CO), 4.05 & 4.04 (2s, 6H, 6-OCH3 
base diastereoisomers), 4.03-4.00 (m, 1H, NHCH(CH3)CO), 3.81 (2dd, 2H, J = 2.5 Hz, 
12.5 Hz, H-5’ diastereoisomers), 3.71 (2d, 2H, J = 1.5 Hz, 1.6 Hz H-5’ 
diastereoisomers), 2.18 & 2.17 (2s, 6H, OCH3 diastereoisomers), 1.34 & 1.31 (2d, 6H, J 
= 3.0 Hz, 3.0 Hz, NHCH(CH3)CO diastereoisomers), 0.92 & 0.90 (2s, 18H, 
OCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, MeOD) δC (ppm): 174.63 & 174.12 (2s, NHCH(CH3)CO 
diastereoisomers), 161.42 & 172.17 (2s, C-6 base diastereoisomers), 159.23 & 159.10 
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(2s, C-2 base diastereoisomers), 155.38 & 155.10 (2s, C-4 base diastereoisomers), 
153.41 & 153.10 (2s, C-1 Ar diastereoisomers), 140.24 & 140.08 (2s, C-8 base 
diastereoisomers), 138.54 & 138.40 (2s, C-5 Ar diastereoisomers), 128.83 & 128.65 (2s, 
C-6 Ar diastereoisomers), 127.95 & 127.84  (2s, C-10 Ar diastereoisomers), 127.86 & 
127.75 (2s, C-7 Ar diastereoisomers), 127.42 & 127.21 (2s, C-4 Ar diastereoisomers), 
126.70 & 126.57 (2s, C-8 Ar diastereoisomers), 125.82 & 125.75 (2s, C-9 Ar 
diastereoisomers), 122.72 & 122.61 (2s, C-3 Ar diastereoisomers), 117.45 & 117.16 (2s, 
C-5 base diastereoisomers), 116.24 & 116.11 (2s, C-2 Ar diastereoisomers), 89.34 & 
89.23 (2s, C-1’ diastereoisomers), 84.45 & 84.22 (2s, C-2’ diastereoisomers), 81.97 & 
81.84 (2d, J3P-O-C-C = 6.5 Hz, 6.5 Hz, C-4’ diastereoisomers), 75.76 & 75.13 (2s, C-3’ 
diastereoisomers), 75.38 & 75.12 (2s, OCH2C(CH3)3), 67.56 & 67.22 (2s, C-5’ 
diastereoisomers), 55.10 & 55.01 (2s, 6-OCH3 base diastereoisomers), 51.96 & 50.78 
(2s, OCH3 diastereoisomers), 50.04 & 49.82 (2s, NHCH(CH3)CO diastereoisomers), 
29.97 & 29.74 (s, OCH2C(CH3)3 diastereoisomers), 26.70 & 26.55  (2s, OCH2C(CH3)3 
diastereoisomers), 20.56 & 20.48 (2s, NHCH(CH3)CO diastereoisomers). 
31P NMR (202 MHz, MeOD) δP (ppm): 4.24 (s, 78%), 4.22 (s, 22%). 
 
Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-O-ethyl-6-O-methyl 
guanosine ProTide (152) 
O
OOH
O
N
N
N
N
O
NH2
P
O
HN
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.13 mL, 0.13 mmol, 2 eq), 2’-O-ethyl-6-O-methyl guanosine (143) (0.022 g, 
0.066 mmol, 1 eq) in anh. THF (0.75 mL). and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.053 g, 0.13 mmol, 2 eq) in anh. THF (1.0 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH as eluents, and 
preparative chromatography to yield the desired molecule (1.9 mg, 0.0028 mmol, 4%).  
HPLC (MeOH/H2O): Rt = 27.26 min, 26.48 min 
HPLC (ACN/H2O): Rt = 18.95 min, 19.25 min 
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MS (TOF ES+): 673.12 (M + H+), 695.31 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.15-8.13 (m, 2H, H-9 Ar diastereoisomers), 
7.87-7.82 (m, 4H, H-7 Ar, H-8 base diastereoisomers), 7.69-7.63 (m, H-4 Ar 
diastereoisomers), 7.57-7.49 (m, 6H, H-8, H-6, H-2 Ar diastereoisomers), 7.43-7.33 (m, 
2H, H-3 Ar diastereoisomers), 5.88 (bs, 2H, H-1’ diastereoisomers), 4.67-4.65 (m, 2H, 
H-2’ diastereoisomers), 4.61-4.58 (m, 2H, OCH2C(CH3)3), 4.49-4.46 (m, 2H, H-3’ 
diastereoisomers), 4.44-4.40 (m, 2H, OCH2C(CH3)3), 4.30-4.28 (m, 2H, H-4’ 
diastereoisomers), 4.16-4.14 (m, 2H, NHCH(CH3)CO diastereoisomers), 4.08 & 4.06 
(2s, 6H, 6-OCH3 base diastereoisomers), 3.85-3.83 (m, 2H, H- 5’ diastereoisomers), 
3.72-3.70 (m, 2H, H-5’ diastereoisomers), 3.58-3.54 (m, 2H, OCH2CH3), 3.48-3.46 (m, 
2H, OCH2CH3), 1.37 & 1.35 (2d, 6H, J = 3.2 Hz, 3.3 Hz, NHCH(CH3)CO 
diastereoisomers), 1.19-1.52 (m, 6H, OCH2CH3 diastereoisomers), 0.91 & 0.90 (2s, 
18H, OCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, CDCl3) δC (ppm): 168.54 & 168.45 (2d, J3P-N-C-C = 2.9 Hz, 5.4 
Hz, NHCH(CH3)CO diastereoisomers), 161.76 & 161.73 (2s, C-6 base 
diastereoisomers), 161.03 & 161.01 (2s, C-2 base diastereoisomers), 149.52 & 149.51 
(2s, C-4 base diastereoisomers), 147.33 & 147.29 (2s, C-1 Ar diastereoisomers), 141.06 
& 141.03 (2s, C-8 base diastereoisomers), 134.82 & 134.79 (2s, C-5 Ar 
diastereoisomers), 128.85 & 128.83 (2s, C-6 Ar diastereoisomers), 127.71 & 127.69 (2s, 
C-7 Ar diastereoisomers), 126.65 & 127.63 (2s, C-8 Ar diastereoisomers), 126.47 & 
126.42 (2s, C-10 Ar diastereoisomers), 125.57 & 125.45 (2s, C-3 Ar diastereoisomers), 
124.88 & 124.85 (2s, C-9 Ar diastereoisomers), 121.35 & 121.33 (2s, C-4 Ar 
diastereoisomers), 116.42 & 116.10 (2s, C-2 Ar diastereoisomers), 115.35 & 115.11 (2s, 
C-5 base diastereoisomers), 87.69 & 87.67 (2s, C-1’ diastereoisomers), 87.27 & 87.21 
(2s, C-2’ diastereoisomers), 82.93 & 82.89 (2d, J3P-O-C-C = 2.0 Hz, 2.9 Hz, C-4’ 
diastereoisomers), 74.75 & 74.73 (2s, COCH2C(CH3)3 diastereoisomers), 69.85 & 
69.782 (2s, C-3’ diastereoisomers), 66.95 & 66.94 (2s, 2’-OCH2CH3 diastereoisomers), 
66.15 & 66.05 (2d, J2P-O-C = 2.0 Hz, 2.7 Hz, C-5’ diastereoisomers), 53.83 & 53.81 (2s, 
6-OCH3 base diastereoisomers), 50.45 & 50.39 (2d, J2P-N-C = 1.8 Hz, 2.2 Hz, 
NHCH(CH3)CO diastereoisomers), 29.71 & 29.69 (2s, COCH2C(CH3)3 
diastereoisomers), 26.30 & 26.28 (2s, COCH2C(CH3)3 diastereoisomers), 21.18 & 21.13 
(2s, NHCH(CH3)CO diastereoisomers) 15.24 & 15.21 (2s, OCH2CH3 diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 3.70 (s, 45%), 3.35 (s, 55%). 
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Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-O-propyl-6-O-methyl 
guanosine ProTide (153) 
O
OOH
O
N
N
N
N
O
NH2
P
O
HN
O
O
O
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.31 mL, 0.31 mmol, 2 eq), 2’-O-propyl-6-O-methyl guanosine (144)  (0.053 g, 
0.15 mmol, 1 eq) in anh. THF (1.60 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.13 g, 0.31 mmol, 2 eq) in anh. THF (1.0 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH as eluents, and 
preparative chromatography to yield the desired molecule (3.8 mg, 0.0055 mmol, 4%).  
HPLC (MeOH/H2O): Rt = 28.01 min, 28.05 min 
HPLC (ACN/H2O): Rt = 20.14 min, 20.45 min 
MS (TOF ES+): 687.25 (M + H+), 709.24 (M + Na+); MS (TOF ES-): 721.26 (M + Cl-). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.17-8.13 (m, 2H, H-9 Ar diastereoisomers), 
7.94-7.91 (m, 4H, H-7 Ar, H-8 base diastereoisomers), 7.72-7.67 (m, H-4 Ar 
diastereoisomers), 7.54-7.48 (m, 6H, H-8, H-6, H-2 Ar diastereoisomers), 7.42-7.36 (m, 
2H, H-3 Ar diastereoisomers), 5.96 & 5.95 (2d, 2H, J = 8.5 Hz, 6.5 Hz, H-1’ 
diastereoisomers), 4.54-4.52 (m, 2H, H-2’ diastereoisomers), 4.50-4.48 (m, 2H, 
OCH2C(CH3)3), 4.45-4.44 (m, 2H, H-3’ diastereoisomers), 4.41-4.37 (m, 2H, 
OCH2C(CH3)3), 4.24-4.22 (m, 1H, NHCH(CH3)CO diastereoisomers), 4.17-4.16 (m, 
2H, H-4’ diastereoisomers), 4.12-4.09 (m, 1H, NHCH(CH3)CO diastereoisomers), 4.08 
& 4.07 (2s, 6H, 6-OCH3 base diastereoisomers), 4.04 (d, 2H, J = 2.0 Hz, 
NHCH(CH3)CO diastereoisomers), 3.91-3.39 (m, 2H, H-5’), 3.78-3.76 (m, 2H, H-5’), 
3.62-3.60 (m, 2H, OCH2CH2CH3), 3.43-3.39 (m, 2H, OCH2CH2CH3), 1.71-1.65 (m, 
2H, OCH2CH2CH3), 1.56-1.49 (m, 2H, OCH2CH2CH3), 1.35 & 1.33 (2d, J = 3.5 Hz, 3.0 
Hz, NHCH(CH3)CO diastereoisomers), 0.90 & 0.89 (2s, 18H, OCH2C(CH3)3 
diastereoisomers), 0.84 & 0.83 (2t, 6H, J = 6.5 Hz, 6.5 Hz, OCH2CH2CH3 
diastereoisomers). 
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13C NMR (125 MHz, MeOD) δC (ppm): 168.30 & 168.17 (2s, NHCH(CH3)CO 
diastereoisomers), 162.93 & 162.90 (2s, C-6 base diastereoisomers), 161.60 & 161.58 
(2s, C-2 base diastereoisomers), 154.14 & 154.10 (2s, C-4 base diastereoisomers), 
147.23 & 147.10 (2s, C-1 Ar diastereoisomers), 140.36 & 140.33 (2s, C-8 base 
diastereoisomers), 134.96 & 134.90 (2s, C-5 Ar diastereoisomers), 128.93 & 128.86 (2s, 
C-6 Ar diastereoisomers), 127.83 & 127.81 (2s, C-7 Ar diastereoisomers), 127.55 & 
127.52 (2s, C-8 Ar diastereoisomers), 127.13 & 127.06 (2s, C-10 Ar diastereoisomers), 
126.59 & 126.50 (2s, C-3 Ar diastereoisomers), 126.04 & 125.99 (2s, C-9 Ar 
diastereoisomers), 122.71 & 122.66 (2s, C-4 Ar diastereoisomers), 116.72 & 116.54 (2s, 
C-2 Ar diastereoisomers), 116.19 & 116.15 (2s, C-5 base diastereoisomers), 89.26 & 
88.36 (2s, C-1’ diastereoisomers), 82.57 & 82.55 (2s, C4’ diastereoisomers), 79.49 & 
79.46 (2s, C-2’ diastereoisomers), 75.46 & 75.44 (2s, COCH2C(CH3)3 
diastereoisomers), 73.64 & 73.62 (2s, OCH2CH2CH3 diastereoisomers), 71.29 & 71.27 
(2s, C-3’ diastereoisomers), 63.53 & 63.46 (2d, J2P-O-C = 1.8 Hz, 2.2 Hz, C-5’ 
diastereoisomers), 54.35 & 54.33 (2s, 6-OCH3 base diastereoisomers), 49.91 & 49.89 
(2s, NHCH(CH3)CO diastereoisomers), 30.76 & 30.74 (2s, COCH2C(CH3)3 
diastereoisomers), 26.75 & 26.73 (2s, COCH2C(CH3)3 diastereoisomers), 23.87 & 23.84 
(2s, OCH2CH2CH3 diastereoisomers), 20.73 & 20.68 (2s, NHCH(CH3)CO 
diastereoisomers), 10.67 & 10.60 (2s, OCH2CH2CH3 diastereoisomers). 
 
Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-O-isopropyl-6-O-methyl 
guanosine ProTide (154) 
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This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.22 mL, 0.22 mmol, 2 eq), 2’-O-isopropyl-6-O-methyl guanosine (145)  
(0.039 g, 0.11 mmol, 1 eq) in anh. THF (1.20 mL), and α-naphthyl L-Alanine-neopentyl 
ester phosphochloridate (14.d) (0.22 g, 0.22 mmol, 2 eq) in anh. THF (1.2 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
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residue was purified by flash chromatography, using CHCl3/MeOH as eluents, 
preparative chromatography to yield the desired unpure material.  
MS (TOF ES+): 687.21 (M + H+), 709.32 (M + Na+). 
 
Preparation of α-naphthyl L-Alanine-neopentyl-ester 6-O-methyl guanosine ProTide 
(155) 
      
O
OHOH
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This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.42 mL, 0.42 mmol, 2 eq), 6-O-methyl guanosine (137)  (0.061 g, 0.21 mmol, 
1 eq) in anh. THF (2.30 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.17 g, 0.42 mmol, 2 eq) in anh. THF (2.0 mL) anh anh. 
pyridine (0.30 mL). After overnight stirring at RT, the solvent was removed under 
reduced pressure and the residue was purified by flash chromatography, using 
CHCl3/MeOH as eluents, preparative chromatography to yield the desired material (1.4 
mg, 0.002 mmol, 1%).  
HPLC (MeOH/H2O): Rt = 26.23 min, 26.51 min 
HPLC (ACN/H2O): Rt = 16.79 min, 17.05 min 
MS (TOF ES+): 645.22 (M + H+), 667.34 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.16-8.10 (m, 2H, H-9 Ar diastereoisomers), 
7.93 (bs, 2H, H-8 base diastereoisomers), 7.89-7.85 (m, 2H, H-7 Ar diastereoisomers), 
7.71-7.67 (m, H-4 Ar diastereoisomers), 7.54-7.45 (m, 6H, H-8, H-6, H-2 Ar 
diastereoisomers), 7,40-7,34 (m, 2H, H-3 Ar diastereoisomers), 5.90-5.89 (2d, 2H, J = 
5.5 Hz, H-1’ diastereoisomers), 4.65-4.36 (m, 2H, H-2’ diastereoisomers), 4.59-4.54 (m, 
4H, OCH2C(CH3)3 diastereoisomers), 4.51-4.46 (m, 1H, H-3’), 4.42-4.37 (m, 1H, H-3’), 
4.29-4.24 (2m, 2H, H-4’ diastereoisomers), 4.07-4.06 (m, 1H, NHCH(CH3)CO), 4.05 & 
4.04 (2s, 6H, 6-OCH3 base diastereoisomers), 4.02-4.00 (m, 1H, NHCH(CH3)CO), 
3.80-3.78 (m, 2H, H-5’), 3.70-3.68 (m, 2H, H-5’), 1.33 & 1.31 (2d, J = 3.0 Hz, 3.0 Hz, 
NHCH(CH3)CO diastereoisomers), 0.90 & 0.89 (2s, 18H, OCH2C(CH3)3 
diastereoisomers). 
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13C NMR (125 MHz, MeOD) δC (ppm): 169.74 & 169.68 (2d, J3P-N-C-C = 1.9 Hz, 3.7 
Hz, NHCH(CH3)CO diastereoisomers), 161.43 & 161.17 (2s, C-6 base 
diastereoisomers), 160.59 & 160.57 (2s, C-2 base diastereoisomers), 149.45 & 149.38 
(2s, C-4 base diastereoisomers), 145.31 & 145.22 (2s, C-1 Ar diastereoisomers), 143.95 
& 143.93 (2s, C-8 base diastereoisomers), 134.44 & 134.38 (2s, C-5 Ar 
diastereoisomers), 128.87 & 128.81 (2s, C-6 Ar diastereoisomers), 127.76 & 127.75 (2s, 
C-7 Ar diastereoisomers), 127.48 & 127. 46 (2s, C-8 Ar diastereoisomers), 126.71 & 
126.65 (2s, C-10 Ar diastereoisomers), 126.50 & 126.45 (2s, C-3 Ar diastereoisomers), 
125.98 & 125.79 (2s, C-9 Ar diastereoisomers), 122.70 & 122.66 (2s, C-4 Ar 
diastereoisomers), 116.82 & 116..63 (2s, C-2 Ar diastereoisomers), 116.26 & 116.22 
(2s, C-5 base diastereoisomers), 89.96 & 89.87 (2s, C-1’ diastereoisomers), 84.41 & 
84.33 (2d, J3P-O-C-C = 1.7 Hz, 2.6 Hz, C-4’ diastereoisomers), 75.42 & 75.39 (2s, 
COCH2C(CH3)3 diastereoisomers), 74.75 & 74.71 (2s, C-2’ diastereoisomers), 71.85 & 
71.76 (2s, C-3’ diastereoisomers), 67.91 & 67.77 (2d, J2P-O-C = 5.9 Hz, 5.9 Hz, C-5’ 
diastereoisomers), 54.17 & 54.15 (2s, 6-OCH3 base diastereoisomers), 49.88 & 49.84 
(2s, NHCH(CH3)CO diastereoisomers), 30.69 & 30.67 (2s, COCH2C(CH3)3 
diastereoisomers), 26.70 (s, COCH2C(CH3)3 diastereoisomers), 20.69 & 20.55 (2s, 
NHCH(CH3)CO diastereoisomers). 
31P NMR (202 MHz, MeOD) δP (ppm): 4.32 (s, 49%), 4.21 (s, 51%). 
	  
Preparation of α-naphthyl L-Alanine-neopentyl-ester 2’-O-methyl-6-O-methyl-N-2-
formamide guanosine ProTide (156) 
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This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.32 mL, 0.32 mmol, 2 eq), 2’-O-methyl-6-O-methyl-N-2-formamide 
guanosine (141.a) (0.059 g, 0.16 mmol, 1 eq) in anh. THF (1.80 mL), and α-naphthyl L-
Alanine-neopentyl ester phosphochloridate (14.d)  (0.13 g, 0.32 mmol, 2 eq) in anh. 
THF (1.0 mL). After overnight stirring at RT, the solvent was removed under reduced 
pressure and the residue was purified by flash chromatography, using CHCl3/MeOH 
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(8%) as eluents, preparative chromatography to yield the desired material (2.9 mg, 
0.0042 mmol, 3%).  
HPLC (MeOH/H2O): Rt = 26.69 min, 27.02 min 
HPLC (ACN/H2O): Rt = 17.72 min, 18.18 min 
MS (TOF ES+): 687.11 (M + H+), 709.32 (M + Na+), 725.24 (M + K+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 9.51 & 9.33 (2d, J = 10.5 Hz, 10.0 Hz, 
NHCHO), 8.70 & 8.60 (2d, J = 10.5 Hz, 10.0 Hz, NHCHO), 8.13-8.11 (m, 1H, H-9 Ar), 
8.05-8.03 (m, 1H, H-9 Ar), 7.94 & 7.89 (2m, 2H, H-8 base diastereoisomers), 7.87-7.85 
(m, 1H, H-7 Ar), 7.80-7.79 (m, 1H, H-7 Ar), 7.68-7.66 (m, H-4 Ar), 7.60-7.59-7.57 (m, 
H-4 Ar), 7.56-7.46 (m, 6H, H-8, H-6, H-2 Ar diastereoisomers), 7.41-7.37 (m, 1H, H-3 
Ar), 7.32-7.31 (m, 1H, H-3 Ar), 5.96 & 5.95 (2d, 2H, J = 4.0 Hz, H-1’ 
diastereoisomers), 4.68-4.63 (m, 2H, H-3’ diastereoisomers), 4.54-4.51 (m, 4H, 
NHCH(CH3)CO diastereoisomers, H-5’), 4.39-4.34 (m, 4H, H-2’, H-4’ 
diastereoisomers), 4.28-4.26 (m, 2H, H-5’), 4.37-4.15 (m, 2H, NHCH(CH3)CO 
diastereoisomers), 4.14 & 4.08 (2s, 6H, 6-OCH3 base diastereoisomers), 3.87 & 3.85 
(m, 2H, OCH2C(CH3)3), 3.75-3.73 (m, 2H, OCH2C(CH3)3), 3.43 & 3.35 (2s, 6H, OCH3 
diastereoisomers), 1.40 & 1.38 (2d, J = 3.0 Hz, 3.1 Hz, NHCH(CH3)CO 
diastereoisomers), 0.92 & 0.91 (2s, 18H, OCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, CDCl3) δC (ppm): 173.38 & 173.13 (2s, NHCH(CH3)CO 
diastereoisomers), 163.03 & 162.80 (2s, NHCHO diastereoisomers), 162.39 & 162.32 
(2s, C-6 base diastereoisomers), 161.49 & 161.44 (2s, C-2 base diastereoisomers), 
152.14 & 151.96 (2s, C-4 base diastereoisomers), 150.75 & 150.65 (2s, C-1 Ar 
diastereoisomers), 140.33 & 140.28 (2s, C-8 base diastereoisomers), 134.75 & 134.71 
(2s, C-5 Ar diastereoisomers), 127.87 & 127.84 (2s, C-6 Ar diastereoisomers), 127.66 
& 127.62 (2s, C-7 Ar diastereoisomers), 126.67 & 126.64 (2s, C-8 Ar 
diastereoisomers), 126.47 & 126.41 (2s, C-10 Ar diastereoisomers), 125.54 & 125.37 
(2s, C-3 Ar diastereoisomers), 124.95 & 124.88 (2s, C-9 Ar diastereoisomers), 121.37 
& 121.33 (2s, C-4 Ar diastereoisomers), 115.97 & 155.74 (2s, C-5 base 
diastereoisomers), 115.38 & 115.10 (2s, J3P-O-C-C = 3.2 Hz, 2.8 Hz, C-2 Ar 
diastereoisomers), 87.28 & 87.15 (2s, C-1’ diastereoisomers), 82.78 & 82.72 (2d, J3P-O-
C-C = 2.8 Hz, 2.43 Hz, C-4’ diastereoisomers), 87.35 & 87.29 (2s, C-2’ 
diastereoisomers), 74.85 & 74.82 (2s, COCH2C(CH3)3 diastereoisomers), 69.58 & 69.35 
(2s, C-3’ diastereoisomers), 65.87 & 65.61 (2d, J2P-O-C = 5.5 Hz, 5.4 Hz, C-5’ 
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diastereoisomers), 58.84 & 58.77 (2s, OCH3 diastereoisomers), 54.51 & 54.41 (2s, 6-
OCH3 base diastereoisomers), 50.47 & 50.39 (2d, J2P-N-C = 3.8 Hz, 5.4 Hz, 
NHCH(CH3)CO diastereoisomers), 29.70 & 29.66 (2s, COCH2C(CH3)3 
diastereoisomers), 26.28 & 26.23 (s, COCH2C(CH3)3 diastereoisomers), 21.18 & 21.12 
(2s, NHCH(CH3)CO diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 3.47 (s, 38%), 3.31 (s, 62%). 
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5.3. 5’-C-modifications of 2’-C-methyl guanosine 
Preparation of 2’, 3’-isopropylidene protected 2’-C-methyl-guanosine (158) 14 
NH
NN
N
O
O
OO
HO
NH2
	  
To a solution of 2’-C-methyl guanosine (10, provided by Inhibitex Inc.) (1.03 g, 3.45 
mmol, 1 eq) in anh. acetone (50 mL), perchloric acid (60 % in aq. solution, 0.58 mL) 
was added dropwise at RT and stirred overnight. Ammonium hydroxide was then added 
dropwise until reaching a neutral pH. The solvent was removed under reduced pressure 
and the residue was purified by flash chromatography using CHCl3/MeOH (9:1) as 
eluents to yield a white product (0.37 g, 1.09 mmol, 32%). 
1H NMR (500 MHz, DMSO) δH (ppm): 10.68 (bs, 1H, OH-5’), 7.95 (s, 1H, H-8 base), 
6.50 (bs, 2H, NH2 base), 6.01 (s, 1H, H-1’), 5.27 (d, 1H, J = 4.6 Hz, H-3’), 4.58 (d, 1H, 
J = 2.5 Hz, H-5’), 4.17  (dd, 1H, J = 4.0 Hz, 2.5 Hz, H5’), 3.68 (m, 1H, H-4’), 1.53 (s, 
3H, CH3-2’), 1.36 (s, 3H, C(CH3)2), 1.15 (s, 3H, C(CH3)2). 
13 C NMR (125 MHz, DMSO) δC (ppm): 156.68 (s, C-6 base), 153.63 (s, C-2 base), 
150.81 (s, C-4 base), 135.52 (s, C-8 base), 116.29 (s, C(CH3)2), 112.81 (s, C-5 base), 
91.63 (s, C-1’), 89.56 (s, C-2’), 85.67 (s, C-3’), 84.08 (s, C-4’), 61.35 (s, C-5’), 28.09 
(s, C(CH3)2), 26.61 (C(CH3)2), 19.39 (CH3-2’). 
 
Preparation of 2’,3’-isopropylidene-5’-C-diphenylimidazolidin-2’-C-methyl-
guanosine (166) 
NH
NN
N
O
O
OO
NH2
NPhPhN
 
A solution of 2’,3’-isopropylidene-2’-C-methyl guanosine (158) (0.30 g, 0.89 mmol) 
and DCC (0.55 g, 2.67 mmol, 3.0 eq), in anh. DMSO (2.00 mL) was stirred with ice 
cooling while dichloroacetic acd (0.04 mL, 0.5 eq) was added dropwise. The mixture 
was then stirred at RT for 1 hr 30 min and then a solution of oxalic acid dihydrate (0.23 
g, 1.78 mmol, 2.0 eq) in anh. MeOH (0.89 mL) was slowly. The mixture was left 30 
min at RT, then filtered and wash with cold MeOH. N,N’-diphenylethylenediamine 
(0.21 g, 1.02 mmol, 1.1 eq) was added to the combined filtrate and the resulting solution 
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was stirred for 1 hr at RT. H2O was added to slight turbidity and filtration was 
performed. The organic layer was extracted with CHCl3, and the solvent was evaporated 
under reduced pressure to give a brown solid (0.29 g, 0.55 mmol, 62%). 
1H NMR (500 MHz, DMSO) δH (ppm): 8.32 (s, 1H, H-8 base), 7.21 (t, 4H, J = 7.8 Hz, 
4 x CH meta Ph), 6.86 (d, 4H, J = 8.0 Hz, 4 x CH ortho Ph), 6.82 (t, 2H, J =7.5 Hz, 2 x 
CH para Ph), 6.01 (s, 1H, H-1’), 4.59 (m, 2H, H-4’, H-3’), 3.72-3.68 (m, 4H, 
PhNCH2CH2NPh), 3.35 (d, 1H, J = 6.5 Hz, H-5’), 1.53 (s, 3H, CH3-2’), 1.36 (s, 3H, 
C(CH3)2), 1.16 (s, 3H, C(CH3)2). 
13C NMR (125 MHz, DMSO) δC (ppm): 165.69 & 164.08 (2s, 2 x C ipso Ph), 155.72 (s, 
C-6 base), 154.23 (s, C-2 base), 150.32 (s, C-4 base), 135.43 (s, C-8 base), 129.65 & 
129.24 (2s, 4 x C meta Ph), 119.24 & 199.10 (2s, 4 x C ortho Ph), 115.32 & 115.28 (s, 2 
x C para Ph), 113.32 (s, C(CH3)2), 112.92 (C-5 base), 92.43 (s, C-1’), 89.77 (s, C-2’), 
85.83 (s, C-3’), 84.69 (s, C-4’), 65.70 (s, C-5’), 43.39 (s, PhNCH2CH2NPh), 25.16 & 
25.11 (2s, 2 x C(CH3)2), 19.22 (s, CH3-2’). 
	  
Preparation of 2’,3’-isopropylidene-5’-C-dihydroxy-hydrate-2’-C-methyl-guanosine 
(167) 
NH
NN
N
O
O
OO
NH2
OHHO
	  
The 2’,3’-isopropylidene-5’-C-diphenylimidazolidin-2’-C-methyl-guanosine (166) 
(0.08 g, 0.15 mmol) was mixed with Dowex 50WX4-50 (0.15 g) in H2O/THF (1:1 ) and 
stirred for 1 hr 30 min at RT. Then the solvent was evaporated under reduced pressure 
to recover a brown solution. The purification was undertaken by flash chromatography 
using CHCl2/MeOH to recover of the desired material (9.8 mg, 0.03 mmol, 18%). 
1H NMR (500 MHz, DMSO) δH (ppm): 10.66 (bs, 1H NH base), 7.94 (s, 1H, H-8 base), 
6.51 (s, 2H, NH2 base), 6.03 (s, 1H, H-1’), 4.77 (m, 2H, OH-5’), 4.60 (d, 1H, J = 3.0 
Hz, H-3’), 4.33 (m, 1H, H-5’), 3.78 (m, 1H, H-4’), 1.54 (s, 3H, C(CH3)2), 1.38 (s, 3H, 
C(CH3)2), 1.17 (s, 3H, CH3-2’). 
13C NMR (125 MHz, DMSO) δC (ppm): 156.67 (s, C-6 base), 153.76 (s, C-2 base), 
150.82 (s, C-4 base), 135.45 (s, C-8 base), 116.36 (s, C(CH3)2), 112.82 (s, C-5 base), 
91.68 (s, C-1’), 89.64 (s, C-2’), 85.76 (s, C-3’), 84.17 (s. C-4’), 48.56 (s, C-5’), 28.13 
(s, C(CH3)2), 27.00 (s, C(CH3)2), 19.43 (s, CH3-2’). 
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Preparation of 2’,3’-isopropylidene-5’-C-carboxylic acid 2’-C-methyl-guanosine 
(168) 
NH
NN
N
O
O
OO
HO
NH2
O
	  
2’,3’-isopropylidene-2’-C-methyl guanosine (158) (0.84 g, 2.49 mmol), TEMPO (0.63 
mmol, 0.0978 g, 0.25 eq) and BAIB (5.58 mmol, 1.7978 g, 2.2 eq) was dissolved in 
MeCN/H2O (16 mL/16 mL) and the solution was stirred overnight at RT. Acetone (16 
mL) and Et2O (80 mL) were added and the solution was stirred for another 2 hrs 30 min 
at RT, and the material precipitated (0.83 g, 2.36 mmol, 95%). 
1H NMR (500 MHz, DMSO) δH (ppm):  10.67 (bs, 1H, OH-5’), 7.92 (s, 1H, H-8 base), 
6.51 (s, 2H, NH2 base), 6.02 (s, 1H, H-1’), 4.37 (m, 1H, H-3’), 3.71 (m, 1H, H-4’), 1.44 
(s, 3H, CH3-2’), 1.16 (s, 3H, C(CH3)2), 1.08 (s, 3H, C(CH3)2). 
13C NMR (125 MHz, DMSO) δC (ppm): 171.96 (s, C-5’), 156.49 (s, C-6 base), 153.22 
(s, C-2 base), 150.65 (s, C-4 base), 135.48 (s, C-8 base), 116.67 (s, C(CH3)2), 112.14 (s, 
C-5 base), 91.54 (s, C-1’), 90.11 (s, C-2’), 85.75 (s, C-3’), 84.15 (s, C-4’), 25.33 (s, 2 x 
C(CH3)2), 21.02 (s, CH3-2’). 
 
Preparation of 2’,3’-isopropylidene-5’-C-methylester-2’-C-methyl-guanosine (169) 
NH
NN
N
O
O
OO
O
NH2
O
 
2’,3’-isopropylidene-5’-C-carboxylic-acid-2’-C-methyl-guanosine (168) (0.83 g, 2.36 
mmol) was dissolved in anh. MeOH (80 mL) and the solution was stirred at 0 °C for 30 
min. SOCl2 (8.95 mmol, 0.65 mL, 3.8 eq) was added dropwise at 0 °C, and the solution 
was left stirring overnight while allowing return to RT. NaHCO3 sat. (4 mL) were 
cautiously added, then NaHCO3 was added until suspended particles were visible in the 
solution. Silica was added to the mixture and the solvent was evaporated under reduced 
pressure. The residue was purified by flash chromatography using CH2Cl2/MeOH (7%) 
to yield the desired material (0.16 g, 0.43 mmol, 18%). 
1H NMR (500 MHz, DMSO) δH (ppm): 10.66 (bs, 1H, NH base), 7.85 (s 1H, H-8 base), 
6.32 (bs, 2H, NH2 base), 6.15 (s, 1H, H-1’), 5.35 (d, 1H, J = 2.5 Hz, H-3’), 4.77 (d, 1H, 
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J = 2.5 Hz, H-4’), 3.63 (s, 3H, COOCH3), 1.33 (s, 6H, 2 x C(CH3)2), 1.21 (s, 3H, CH3-
2’). 
13C NMR (125 MHz, DMSO) δC (ppm): 170.25 (s, C-5’), 156.60 (s, C-6 base), 153.32 
(s, C-2 base), 150.22 (s, C-4 base), 137.00 (s, C-8 base), 116.95 (s, C(CH3)2), 112.61 (s, 
C-5 base), 91.85 (s, C-1’), 90.31 (s, C-2’), 87.73 (s, C-3’), 83.84 (s, C-4’), 51.94 (s, 
COOCH3), 26.84 (2, 2 x C(CH3)2), 19.48 (s, CH3-2’). 
 
Preparation of 2’,3’-isopropylidene-5’-C-weinreb amide 2’-C-methyl-guanosine (171) 
NH
NN
N
O
O
OO
NH2
ON
O
	  
2’,3’-isopropylidene-5’-C-carboxylic-acid-2’-C-methyl-guanosine (168) (0.74 g, 2.11 
mmol, 1.0 eq) was dissolved in anh. DMF (4.22 mL), and DIPEA (0.92 mL, 5.28 mmol, 
2.5 eq) was added. PyBroP (1.08 g, 2.32 mmol, 1.1 eq) and HOBt.H2O (0.31 g, 2.32 
mmol, 1.1 eq) were added, and after 1 min, subsequent addition of CH3ONHCH3.HCl 
(0.41 g, 4.22 mmol, 2.0 eq). After overnight stirring at RT, the solvent was evaporated 
under reduced pressure, and the residue was washed with HCl (5%) and NaHCO3. 
Purification by flash chromatography allowed the recovery of the desired material (0.55 
g, 1.39 mmol, 66%). 
1H NMR (500 MHz, CDCl3) δH (ppm):  9.32 (bs, 1H, NH base), 8.15 (s, 1H, H-8 base), 
7.89 (s, 2H, NH2 base), 6.03 (s, 1H, H-1’), 4.37 (dd, 1H, J = 5.5 Hz, H-3’), 3.75 (d, 1H, 
J = 5.5 Hz, H-4’), 3.81 (s, CON(CH3)OCH3), 3.45 (s, 3H, CON(CH3)OCH3), 1.54 (s, 
3H, CH3-2’), 1.31 (s, 3H, C(CH3)2), 1.22 (s, 3H, C(CH3)2). 
13C NMR (125 MHz, CDCl3) δC (ppm): 169.75 (s, C-5’), 152.28 (s, C-6 base), 152.11 
(s, C-2 base), 151.79 (s, C-4 base), 139.38 (s, C-8 base), 117.23 (s, C(CH3)2), 113.69 (s, 
C-5 base), 93.61 (s, C-1’), 91.19 (s, C-2’), 87.35 (s, C-3’), 81.88 (s, C-4’), 61.51 (s, 
CON(CH3)OCH3), 36.36 (s, CON(CH3)OCH3), 27.86 (s, 2 x C(CH3)2), 22.12 (s, CH3-
2’).
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6. Experimental procedures related to chapter 6 
6.1. Preparation of acyclic purine nucleosides 
Preparation of 1-(tertbutyldimethylsilyloxy)propan-2-one (183) 15 
	  
To a solution of hydroxyacetone (182) (90%, 10.0 mL, 146.1 mmol, 1 eq) and 
imidazole (9.91 g, 146.1 mmol, 1.0 eq) in anh. DMF (191 mL) was added TBDMSCl 
(21.88 g, 321.3 mmol, 2.2 eq). The reaction was left stirring for 36 hrs at RT. Water was 
added to the mixture and the organic phase was extracted with hexane. The solvent was 
evaporated under reduced pressure, and the residue was purified by flash 
chromatography using Petroleum Ether/EtOAc (15:1) to give the desired material 
(22.29 g, 118.35 mol, 81%) as colourless oil. 
1H NMR (500 MHz, CDCl3) δH (ppm): 4.14 (s, 2H, OCH2COCH3), 2.16 (s, 3H, 
OCH2COCH3), 0.93 (s, 9H, Si(CH3)2C(CH3)3), 0.09 (s, 6H, Si(CH3)2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 209.02 (s, OCH2COCH3), 69.64 (s, 
OCH2COCH3), 31.85 (s, Si(CH3)2C(CH3)3), 26.89 & 26.05 & 25.87 (3s, 
Si(CH3)2C(CH3)3), 18.76 (s, Si(CH3)2C(CH3)3),  -5.56 & -5.58 (2s, Si(CH3)2C(CH3)3). 
 
Preparation of ethyl-4-(tert-butyldimethylsilyloxy)-3-methylbut-2-enoate (184) 15, 16 
 
A supension of NaH (4.20 g, 106.0 mmol, 1.0 eq) in anh. THF (170 mL) was added 
dropwise triethylphosphonoacetate (17.0 mL, 127.18 mmol, 1.2 eq) at 0 °C, The 
solution was left stirring for 1 hr at RT. 1-(tertbutyldimethylsilyloxy)propan-2-one 
(183) (19.96 g, 105.98 mmol, 1.0 eq) was added and stirring was allowed for 1 hr. The 
solution was neutralized by AcOH and stirred with EtOAc. The organic phase was 
washed with brine, and the solvent was evaporated under reduced pressure. The residue 
was purified by flash chromatography using petroleum ether/EtOAc (2-3%) to recover 
both isomers E and Z (22%/78%) (13.85 g, 53.59 mmol, 51%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 6.00 (d, 1H, J = 1.4 Hz, CHCOOCH2CH3), 5.68 
(d, 1H, J = 1.6 Hz, CHCOOCH2CH3), 4.81 (q, 2H, J = 1.7 Hz, COOCH2CH3), 4.20-
4.17 (q, 2H, J = 1.6 Hz, COOCH2CH3,), 4.14 (s, 2H, CH2OSi(CH3)2C(CH3)3), 4.12 (s, 
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2H, CH2OSi(CH3)2C(CH3)3), 2.07 (t, 3H, J = 0.6 Hz, C(CH3)CH2OSiCH3)2C(CH3)3), 
1.98 (t, 3H, J = 0.6 Hz, C(CH3)CH2OSiCH3)2C(CH3)3), 1.31-1.27 (m, 6H, 2 x 
COOCH2CH3), 0.94 (s, 9H, Si(CH3)2C(CH3)3), 0.93 (s, 9H, Si(CH3)2C(CH3)3), 0.10 (s, 
6H, Si(CH3)2C(CH3)3), 0.09 (s, 6H, Si(CH3)2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 167.04 & 165.98 (2s, 2 x COOCH2CH3), 
160.73 & 157.05 (2s, 2 x C(CH3)CH2OSiCH3)2C(CH3)3), 114.98 & 113.41 (2s 
CHCOOCH2CH3), 67.11 & 62.70  (2s, 2 x CH2OSi(CH3)2C(CH3)3), 59.64 & 59.53 (2s, 
2 x COOCH2CH3), 34.12 & 3157 (2s, 2 x Si(CH3)2C(CH3)3), 26.91 & 26.54 & 26.17 & 
25.86 & 25.77 & 25.69 (6s, 6 x Si(CH3)2C(CH3)3), 21.37 & 20.14 (2s, 2 x 
C(CH3)CH2OSiCH3)2C(CH3)3), 18.26 & 18.01 (2s, 2 x Si(CH3)2C(CH3)3), 15.39 & 
14.33 (2s, 2 x OCH2CH3), -5.21 & -5.47 (2s, 2 x Si(CH3)2C(CH3)3). 
 
Preparation of 4-(tert-butyldimethylsilyloxy)-3-methylbut-2-en-1-ol (185) 16 
O
Si
OH
 
To a solution of ethyl 4-(tert-butyldimethylsilyloxy)-3-methylbut-2-enoate (184) (12.20 
g, 56.40 mmol, 1.0 eq) in anh. DCM (225 mL) was added dropwise DIBAL-H (1M in 
hexane, 119.0 mL, 119.0 mmol, 2.1 eq) at -20 °C. The mixture was left stirring at 0 °C 
for 2 hrs, after which MeOH (1.5 mL) and aq. sodium potassium tartrate tetrahydrate 
(140 mL) was added. The solution was stirred overnight at RT, and the organic layer 
was evaporated. The residue was purified by flash chromatography using petroleum 
ether/EtOAc (10 to 20%) to yield a mixture of isomer (82%/18%) (2.90 g, 13.40 mmol, 
24%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 6.53-5.60 (m, 1H, J = 6.5 Hz, 0.60 Hz, 
CHCH2OH), 5.56-5.53 (m, 1H, J = 4.9 Hz, 0.8 Hz, CHCH2OH), 4.15 (d, 2H, J = 6.7 
Hz, CHCH2OH), 4.10 (d, 2H, J = 6.6 Hz, CHCH2OH), 3.98 & 3.76 (2s, 4H, 2 x 
CH2OSi(CH3)2C(CH3)3), 1.68 & 1.59 (2s, 6H, 2 x C(CH3)CH2OSiCH3)2C(CH3)3), 0.86 
& 0.84 (2s, 18H, 2 x Si(CH3)2C(CH3)3), 0.03 & 0.02 (2s, 6H, 2 x Si(CH3)2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 138.90 & 137.65 (2s, 2 x 
C(CH3)CH2OSiCH3)2C(CH3)3), 125.75 & 122.93 (2s, 2 x CHCH2OH), 67.69 & 65.43 
(2s, 2 x CH2OSi(CH3)2C(CH3)3), 58.84 & 58.06 (2s, 2 x CHCH2OH), 26.90 & 26.13 & 
25.93 & 25.89 & 25.81 & 25.26 (6s, 6 x Si(CH3)2C(CH3)3), 20.84 & 20.13 (2s, 2 x 
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Si(CH3)2C(CH3)3), 13.96 & 13.31 (2s, 2 x C(CH3)CH2OSiCH3)2C(CH3)3), -5.49 & -
5.21 (2s, 2 x Si(CH3)2C(CH3)3). 
 
Preparation of (4-bromo-2-methylbut-2-enyloxy)(tert-butyl)dimethylsilane (186) 17, 18 
O
Si
Br
	  
A solution of 4-(tert-butyldimethylsilyloxy)-3-methylbut-2-en-1-ol (185) (0.49 g, 2.26 
mmol, 1.0 eq) and triphenylphosphine (0.66 g, 2.49 mmol, 1.1 eq) in anh. DCM (6.80 
mL), NBS (0.44 g, 2.49 mmol, 1.1 eq) was slowly added at 0 °C and stirred for 4 hrs at 
RT. DCM was added and the organic layer was washed with brine and H2O, and was 
filtrated through Celite. The solvent was evaporated under reduced pressure and the 
residue was purified by flash chromatography using petroleum ether/EtOAc (10%) to 
afford the desired molecule in only one major isomer (0.240 g, 0.86 mmol, 38%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 5.76 (m, 1H, J = 8.5 Hz, 1.4 Hz, CHCH2Br), 
4.01 (s, 2H, CH2OSiCH3)2C(CH3)3), 3.98 (d, 2H, J = 8.5 Hz, CHCH2Br), 1.63 (s, 3H, 
C(CH3)CH2OSiCH3)2C(CH3)3), 0.86 (s, 9H, Si(CH3)2C(CH3)3), 0.02 (s, 6H, 
Si(CH3)2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 140.84 (s, C(CH3)CH2OSiCH3)2C(CH3)3), 
119.36 (s, CHCH2Br), 67.21 (s, CH2OSiCH3)2C(CH3)3), 40.08 (s, Si(CH3)2C(CH3)3), 
28.46 (s, CHCH2Br), 25.84 & 25.74 & 25.64 (3s, Si(CH3)2C(CH3)3), 18.365 (s, 
Si(CH3)2C(CH3)3), 14.08 (s, C(CH3)CH2OSiCH3)2C(CH3)3), -5.31 & -5.22 (2s, 
Si(CH3)2C(CH3)3). 
 
Preparation of acyclic TBDMS protected adenine (187.a) 17 
	  
Route 1: A solution of (4-bromo-2-methylbut-2-enyloxy)(tert-butyl)dimethylsilane 
(186) (0.240 g, 0.86 mmol, 1.0 eq), adenine (0.38 g, 2.78 mmol, 3.2 eq), NaH (60% in 
dispersion oil, 0.17 g, 2.78 mmol, 3.2 eq) in anh. DCM (7 mL) was stirred overnight at 
RT. The reaction was quenched with water and diluted with EtOAc. The organic layer 
was washed with H2O and brine, and the solvent evaporated under reduced pressure. 
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The residue was purified by flash chromatography using DCM/MeOH (5%) to yield the 
desired material as a mixture of two isomers (6%/94%, 0.06 g, 0.18 mmol, 21%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.38 & 8.18 (2s, 2H, H-2 base), 7.81 & 7.74 (2s, 
2H, H-8 base), 6.47 & 5.83 (bs, 4H, 2 x NH2 base), 5.78-5.75 (m, 1H, J = 6.2 Hz & 1.3 
Hz, CHCH2-base), 5.65-5.62 (m, 1H, J = 7.2 Hz, 2.9 Hz, 1.45 Hz, CHCH2-base), 4.87 
(d, J = 6.2 Hz, CHCH2-base), 4.75 (d, 2H, J = 7.2 Hz, CHCH2-base), 4.09 & 3.98 (2s, 
4H, 2 x CH2OSi(CH3)2C(CH3)3), 1.80 & 1.69 (2s, 6H, 2 x 
C(CH3)CH2OSi(CH3)2C(CH3)3), 0.91 & 0.79 (2s, 18H, 2 x Si(CH3)2C(CH3)3), 0.08 & 
0.04 (2s, 212H, 2 x Si(CH3)2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 155.53 & 155.11 (2s, 2 x C-6 base), 152.85 & 
152.50 (2s, 2 x C-2 base), 149.31 (2s, 2 x C-4 base), 141.57 & 141.18 (2s, 2 x 
C(CH3)CH2OSiCH3)2C(CH3)3)), 140.18 & 139.89 (2s, 2 x C-8 base), 118.89 & 118.02 
(2s, 2 x C-5 base), 116.32 & 116.09 (2s, 2 x CHCH2-base), 67.07 & 66.16 (2s, 2 x 
CH2OSi(CH3)2C(CH3)3), 40.84 & 40.58 (2s, 2 x CHCH2-base), 25.87 & 25.67 (2s, 2 x 
Si(CH3)2C(CH3)3), 18.76 & 18.24 (2s, 2 x Si(CH3)2C(CH3)3), 13.71 & 13.47 (2s, 2 x 
C(CH3)CH2OSi(CH3)2C(CH3)3), -5.61 & -5.32 (2s, Si(CH3)2C(CH3)3). 
Route 2: To a stirred solution of adenine (0.11 g, 0.84 mmol, 1.1 eq) in anh. THF (11 
mL) at RT was added 4-(tert-butyldimethylsilyloxy)-3-methylbut-2-en-1-ol (185) (0.20 
g, 0.92 mmol, 1.1 eq) followed by triphenylphosphine (0.24 g, 0.92 mmol, 1.1 eq). 
After few minutes, DIAD (0.17 mL, 0.84 mmol, 1.0 eq) was added dropwise and the 
reaction was left stirring over 72 hrs. The solvent was evaporated under reduced 
pressure and the residue purified by flash chromatography using EtOAc and then 
DCM/MeOH (5%) to recover only one isomer of the desired material (0.08 g, 0,24 
mmol, 26%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.35 (s, 1H, H-2 base), 7.79 (s, 1H, H-8 base), 
6.09 (bs, 2H, NH2 base), 5.76-5.73 (t, 1H, J = 6.8 Hz, CHCH2-base), 4.84 (d, J = 6.8 
Hz, CHCH2-base), 4.07 (s, 2H, CH2OSi(CH3)2C(CH3)3), 1.78 (s, 3H, 
C(CH3)CH2OSi(CH3)2C(CH3)3), 0.89 (s, 9H, Si(CH3)2C(CH3)3), 0.05 (s, 6H, 
Si(CH3)2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 155.55 (s, C-6 base), 152.91 (s, C-2 base), 
149.93 (s, C-4 base), 141.46 (s, C(CH3)CH2OSi(CH3)2C(CH3)3), 139.86 (s, C-8 base), 
119.48 (s, C-5 base), 116.36 (s, CHCH2-base), 67.15 (s, CH2OSi(CH3)2C(CH3)3), 40.79 
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(2s, CHCH2-base), 25.83 (s, Si(CH3)2C(CH3)3), 18.32 (s, Si(CH3)2C(CH3)3), 13.66 (s, 
C(CH3)CH2OSiCH3)2C(CH3)3), -5.43 (s, Si(CH3)2C(CH3)3). 	  
Preparation of acyclic TBDMS protected 6-chloro-purine (187.b) 17 
N
N
N
N
Cl
OSi
	  
To a stirred solution of 6-chloro purine (0.325 g, 2.10 mmol, 1.0 eq) in anh. THF (28 
mL), was added 4-(tert-butyldimethylsilyloxy)-3-methylbut-2-en-1-ol (185) (0.500 g, 
2.31 mmol, 1.1 eq) followed by triphenylphosphine polymer bound (3 mmol/g, 0.77 g, 
2.31 mmol, 1.1 eq). After few minutes, DIAD (0.43 mL, 2.10 mmol, 1.0 eq) was added 
dropwise and the reaction was left stirring overnight at RT. The solvent was evaporated 
under reduced pressure and the residue purified by flash chromatography using EtOAc 
and then DCM/MeOH (3%) to recover only one isomer of the desired material (0.389 g, 
1.63 mmol, 70%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.69 (s, 1H, H-2 base), 8.12 (s, 1H, H-8 base), 
5.75 (t, 1H, J = 5.2 Hz, CHCH2-base), 4.92 (d, J = 6.0 Hz, CHCH2-base), 4.12 (s, 2H, 
CH2OSi(CH3)2C(CH3)3), 1.76 (s, 3H, C(CH3)CH2OSi(CH3)2C(CH3)3), 0.91 (s, 9H, 
Si(CH3)2C(CH3)3), 0.08 (s, 6H, Si(CH3)2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 151.69 (s, C-6 base), 151.60 (s, C-2 base), 
150.63 (s, C-4 base), 144.90 (s, C-8 base), 137.30 (s, C(CH3)CH2OSi(CH3)2C(CH3)3), 
131.40 (s, C-5 base), 118.61 (s, CHCH2-base), 65.71 (s, CH2OSi(CH3)2C(CH3)3), 41.33 
(s, CHCH2-base), 25.73 & 25.62 & 25.39 (3s, Si(CH3)2C(CH3)3), 18.17 (s, 
Si(CH3)2C(CH3)3), 13.57 (s, C(CH3)CH2OSi(CH3)2C(CH3)3), -5.56 (s, 
Si(CH3)2C(CH3)3). 	  
Preparation of acyclic TBDMS protected 6-O-methyl-guanine (187.c) 
N
N
N N
O
O
NH2
Si
	  
To a stirred solution of 6-O-methyl guanine (0.6936 g, 4.20 mmol, 1.0 eq) in anh. THF 
(60 mL), was added 4-(tert-butyldimethylsilyloxy)-3-methylbut-2-en-1-ol (185) (1.00 g, 
4.62 mmol, 1.1 eq) at RT, followed by triphenylphosphine polymer bound (3 mmol/g, 
1.54 g, 4.62 mmol, 1.1 eq). After few minutes, DIAD (0.83 mL, 4.20 mmol, 1.0 eq) was 
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added dropwise and the reaction was left stirring overnight. The crude product was 
purified by flash chromatography to recover the desired molecule as a mixture of 
isomers (13%/87%) (0.240 g, 0.66 mmol, 16%). 
1H NMR (500 MHz, CDCl3) δH (ppm): 7.61 (s, 1H, H-8 base), 7.58 (s, 1H, H-8 base), 
5.72-5.68 (tq, 1H, J = 1.5 Hz, 7.10 Hz, CHCH2-base), 5.45-5.42 (m, 1H, CHCH2-base), 
5.38 (bs, 2H, NH2 base), 4.97 (bs, 2H, NH2 base), 4.74 (d, 2H, J = 7.2 Hz, CHCH2-
base), 4.69 (d, 2H, J = 7.0 Hz, CHCH2-base), 4.11 (s, 3H, 6-OCH3 base), 4.10 (s, 3H, 6-
OCH3 base), 4.08 (s, 2H, CH2OSi(CH3)2C(CH3)3), 4.06 (s, 2H, CH2OSi(CH3)2C(CH3)3), 
1.80 (s, 3H, C(CH3)CH2OSi(CH3)2C(CH3)3), 1.76 (s, 3H, 
C(CH3)CH2OSi(CH3)2C(CH3)3), 0.91 (s, 9H, Si(CH3)2C(CH3)3), 0.89 (s, 9H, 
Si(CH3)2C(CH3)3), 0.12 (s, 6H, Si(CH3)2C(CH3)3), 0.10 (s, 6H, Si(CH3)2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 161.91 & 159.34 (2s, 2 x C-6 base), 153.76 & 
153.39 (2s, 2 x C-2 base), 147.23 & 147.15 (2s, 2 x C-4 base), 140.97 & 140.86 (2s, 2 x 
C(CH3)CH2OSi(CH3)2C(CH3)3), 138.83 & 137.23 (2s, 2 x C-8 base), 119.76 & 116.80 
(2s, 2 x CHCH2-base), 115.87 & 115.61 (2s, 2 x C-5 base), 67.93 & 67.24 (2s, 2 x 
CH2OSi(CH3)2C(CH3)3), 53.99 & 53.82 (2s, 2 x 6-OCH3 base), 40.52 & 40.24 (2s, 2 x 
CHCH2-base), 31.56 & 29.67 (2s, 2 x Si(CH3)2C(CH3)3), 25.85 & 25.59 (2s, 2 x 
Si(CH3)2C(CH3)3), 18.34 & 18.13 (2s, 2 x Si(CH3)2C(CH3)3), 14.08 & 13.65 (2s, 2 x 
C(CH3)CH2OSi(CH3)2C(CH3)3), -5.39 & -5.42 (2s, 2 x Si(CH3)2C(CH3)3 isomers). 
 
Preparation of acyclic TBDMS protected 6-chloro-guanine (187.e) 
N
N
N N
Cl
O
NH2
Si 	  
To a solution of 6-chloro guanine (0.356 g, 2.10 mmol, 1.0 eq) in anh. THF (24 mL), 
was added 4-(tert-butyldimethylsilyloxy)-3-methylbut-2-en-1-ol (185) (0.500 g, 2.31 
mmol, 1.1 eq), followed by triphenylphosphine polymer bound (3 mmol/g, 0.77 g, 2.31 
mmol, 1.1 eq), at RT. After few minutes, DIAD (0.42 mL, 2.10 mmol, 1.0 eq) was 
added dropwise and the reaction was left stirring overnight. The crude product was 
purified by flash chromatography to recover the desired molecule as a mixture of 
isomers (0.610 g, 1.66 mmol, 79%).  
1H NMR (50 MHz, CDCl3) δH (ppm): 7.98 & 7.39 (2s, 2H, 2 x H-8 base), 5.62 & 5.23 
(2t, 2H, J = 7.0 Hz, 7.6 Hz, 2 x CHCH2-base), 5.42 & 5.39 (2bs, 4H, 2 x NH2 base), 
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4.78 & 4.23 (2d, 4H, J = 7.0 Hz, 7.6 Hz, 2 x CHCH2-base), 4.32 & 4.03 (2s, 4H, 2 x 
CH2OSi(CH3)2C(CH3)3), 1.78 & 1.51 (2s, 6H, 2 x C(CH3)CH2OSi(CH3)2C(CH3)3), 0.96 
& 0.81 (2s, 18H, 2 x Si(CH3)2C(CH3)3), 0.29 & .0.08 (2s, 12H, 2 x Si(CH3)2C(CH3)3). 
13C NMR (125 MHz, CDCl3) δC (ppm): 159.28 & 156.66 (2s, 2 x C-6 base), 153.56 & 
151.01 (2s, 2 x C-4 base), 142.17 & 141.90 (2s, 2 x C-8 base), 138.14 & 137.47 (2s, 2 x 
C(CH3)CH2OSi(CH3)2C(CH3)3), 124.81 & 124.54 (2s, 2 x C-5 base), 118.03 & 115.99 
(2s, 2 x CHCH2-base), 62.04 & 61.57 (2s, 2 x CH2OSi(CH3)2C(CH3)3), 40.76 & 40.48 
(2s, 2 x CHCH2-base), 25.80 & 25.78 & 25.61 & 21.95 & 21.68 & 21.27 (6s, 2 x 
Si(CH3)2C(CH3)3), 18.29 & 18.22 (2s, 2 x Si(CH3)2C(CH3)3 isomers), 14.00 & 13.55 
(2s, 2 x C(CH3)CH2OSi(CH3)2C(CH3)3), -5.26 & -5.22 & -5.44 & -5.48 (4s, 2 x 
Si(CH3)2C(CH3)3). 
 
Preparation of acyclic adenine nucleoside (188) 17 
 
Acyclic TBDMS protected adenine (187.a) (0.08 g, 0.24 mmol, 1.0 eq) was dissolved in 
anh. THF (2.5 mL), and TBAF (1M in THF, 1.44 mL, 1.44 mmol, 6.0 eq) was added. 
The solution was left stirring for 1 hr. Purification by flash chromatography using 
CHCl3/MeOH (6%) was performed to recover the desired material and the isomers were 
separated ((E) (188.a), in mixture 0.0096 g, 0.044 mmol, 18%; (Z) (188.b), 0.021 g, 
0.096 mmol, 40%) (E/Z ratio: 31%/69%).  
HPLC (MeOH/H2O): Rt = 9.99 min (Z), 11.75 min (E),  
HPLC (ACN/H2O): Rt = 4.61 min (Z), 5.65 min (E) 
MS (TOF ES+): 242.28 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.23 (s, 1H, H-2 base), 8.21 (s, 1H, H-2 base), 
8.18 & 8.11 (2s, 2H, 2 x H-8 base), 5.74-5.71 (tq, 1H, J = 7.1 Hz, 1.4 Hz, CHCH2-
base), 5.54-5.51 (t, J = 7.3 Hz, CHCH2-base), 4.95 (d, J = 7.4 Hz, CHCH2-base), 4.92 
(d, J = 7.2 Hz, CHCH2-base), 4.29 (s, 2H, C(CH3)OCH2OH), 4.00 (s, 2H, 
C(CH3)OCH2OH), 1.87 (s, 3H, C(CH3)CH2OH), 1.85 (s, 3H, C(CH3)CH2OH). 
13C NMR (125 MHz, CDCl3) δC (ppm): 155.57 (s, C-6 base), 156.21 (s, C-6 base), 
153.71 (s, C-2 base), 153.59 (s, C-2 base), 149.76 (s, C-4 base), 149.12 (s, C-4 base), 
142.44 (s, C-8 base), 142.28 (s, C-8 base), 118.97 (s, C-5 base), & 118.25 (s, C-5 base), 
121.71 (s, CHCH2-base), 118.75 (s, CHCH2-base), 67.52 (s, C(CH3)OCH2OH), 61.64 
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(s, C(CH3)OCH2OH), 42.05 (s, CHCH2-base), 40.04 (s, CHCH2-base), 21.80 (s, 
C(CH3)CH2OH), 13.86 (s, C(CH3)CH2OH). 
 
Preparation of acyclic 6-chloro-purine nucleoside (189) 17 
N
N
N N
Cl
HO
 
Acyclic TBDMS protected adenine (187.b) (0.389 g, 1.63 mmol, 1.0 eq) was dissolved 
in anh. THF (17 mL) and TBAF (1M in THF, 9.78 mL, 9.78 mmol, 6.0 eq) was added. 
The solution was left stirring for 4 hrs. Purification by flash chromatography using 
CHCl3/MeOH (2.5%) was performed to recover the desired material and only one 
isomer (Z) was recovered (0.120 g, 0.50 mmol, 31%). 
HPLC (MeOH/H2O): Rt = 11.20 min 
HPLC (ACN/H2O):): Rt = 7.20 min 
MS (TOF ES-): 273.03 (M + Cl-), 511.11 (2M + Cl-). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.71 (s, 1H, H-2 base), 8.14 (s, 1H, H-8 base), 
5.76-5.74 (tq, 1H, J = 5.7 Hz, 1.4 Hz, CHCH2-base), 4.94 (d, 2H, J = 6.9 Hz, CHCH2-
base), 4.09 (s, 2H, C(CH3)CH2OH), 1.85 (s, 3H, C(CH3)CH2OH). 
13C NMR (125 MHz, CDCl3) δC (ppm): 151.88 (s, C-2 base), 151.62 (s, C-6 base), 
150.81 (s, C-4 base), 144.92 (s, C-8 base), 142.62 (s, C(CH3)CH2OH), 131.41 (s, C-5 
base), 116.08 (s, CHCH2-base), 66.76 (s, C(CH3)CH2OH), 41.51 (s, CHCH2-base), 
13.98 (s, C(CH3)CH2OH). 
 
Preparation of acyclic 6-O-methyl-guanine nucleoside (190) 
N
N
N N
O
HO
NH2  
Acyclic TBDMS protected 6-O-methyl-guanine (187.c) (0.463 g, 1.27 mmol, 1.0 eq) 
was dissolved in anh. THF (14 mL), and TBAF (1M in THF, 7.62 mL, 7.62 mmol, 6.0 
eq) was added. The solution was left stirring for 4 hrs. Purification by flash 
chromatography using CHCl3/MeOH (3%) was performed to recover the desired 
material as a mixture of separable isomers (0.100 g, 0.40 mmol, 32%) (E (190.a)/Z 
(190.b) ratio: 40%/60%). 
HPLC (MeOH/H2O): Rt (Z) = 7.45 min (Z), 11.89 min (E) 
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HPLC (ACN/H2O): Rt = 2.48 min (Z), 5.81 min (E) 
MS (TOF ES+): 250.13 (M + H+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.81 (s, 1H, H-8 base), 7.34 (s, 1H, H-8 base), 
5.71 (tq, 1H, J = 1.5 Hz, 7.0 Hz, CHCH2-base), 5.63 (t, 1H, J = 7.5 Hz, CHCH2-base), 
4.74 (d, 2H, J = 7.0 Hz, CHCH2-base), 4.74 (d, 2H, J = 7.5 Hz, CHCH2-base), 4.06 & 
4.02 (2s, 6H, 2 x 6-OCH3 base), 3.99 & 3.94 (2s, 4H, 2 x C(CH3)CH2OH), 1.85 & 1.84 
(s, 6H, 2 x C(CH3)CH2OH). 
13C NMR (125 MHz, MeOD) δC (ppm): 161.98 & 161.81 (2s, 2 x C-6 base), 160.97 & 
160.45 (2s, 2 x C-2 base), 154.09 & 153.96 (2s, 2 x C-4 base), 142.22 & 141.23 (2s, 2 x 
C(CH3)CH2OH), 139.81 & 139.5 (s, C-8 base), 120.16 & 117.43 (2s, CHCH2-base), 
114.33 (s, C-5 base), 66.97 & 61.52 (2s, 2 x C(CH3)CH2OH), 53.36 (s, 6-OCH3 base), 
41.34 & 40.70 (2s, 2 x CH2-base), 13.70 & 13.63 (2s, 2 x C(CH3)CH2OH). 
 
Preparation of acyclic guanine nucleoside (191) 17 
N
N
N NH
O
HO
NH2  
To as solution (E)-acyclic 6-O-methyl-guanine nucleoside (190.a) (0.033 g, 0.13 mmol, 
1.0 eq) in anh. ACN (5 mL), was added NaI (0.029 g, 0.20 mmol, 1.5 eq) and TMSCl 
(0.025 mL, 0.20 mmol, 1.5 eq). The reaction was left stirring for 1 hr at RT and 
preparative chromatography afforded the desired (E)-isomer (0.0024 g, 0.010 mmol, 
8%). 
HPLC (MeOH/H2O): Rt = 11.52 min 
HPLC (ACN/H2O): Rt = 2.73 min 
MS (TOF ES+): 236.11 (M + H+), 258.10 (M + Na+), 274.07 (M + K+), 299.12 (M + 
MeCNNa+), 471.22 (2M + H+), 493.20 (2M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 7.72 (s, 1H, H-8 base), 5.33 (t, 1H, J = 7.9 Hz, 
CHCH2-base), 4.76 (d, 2H, J = 7.0 Hz, CHCH2-base), 4.28 (s, 2H, C(CH3)CH2OH), 
1.85 (s, 3H, C(CH3)CH2OH). 
13C NMR (d-MeOD) δC (ppm): 158.83 (s, C-6 base), 154.17 (s, C-2 base), 153.96 (s, C-
4 base), 141.44 (s, C(CH3)CH2OH), 137.53 (s, C-8 base), 119.87 (s, CHCH2-base), 
114.33 (s, C-5 base), 63.27 (s, C(CH3)CH2OH), 40.85 (s, CHCH2-base), 13.82 (s, 
C(CH3)CH2OH). 
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6.2. Preparation of acyclic purine ProTides 
Preparation of α-naphthyl L-Alanine-neopentyl-ester (Z)-acyclic adenine ProTide 
(192.a) 
N
N
N
N
NH2
O
P
O
HN
O
O
O
(Z)
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.46 mL, 0.46 mmol, 2eq), (Z)-acyclic adenine (188.b) (0.051 mg, 0.23 mmol, 
1.0 eq) in anh. THF (0.68 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.177 g, 0.46 mmol, 2.0 eq) in anh. THF (0.68 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (5%) as eluents, and 
preparative chromatography to yield the desired molecule (0.024 g, 0.042 mmol, 18%). 
HPLC (MeOH/H2O): Rt = 27.22 min, 27.41 min 
HPLC (ACN/H2O): Rt = 17.45 min 
MS (TOF ES+): 567.25 (M + H+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.31 & 8.28 (2s, 2H, H-2 base 
diastereoisomers), 8.07-8.06 (m, 2H, H-4 Ar diastereoisomers), 7.82-7.77 (m, 2H, H-6 
Ar diastereoisomers), 7.70 (bs, 2H, H-8 base diastereoisomers), 7.65 (d, 2H, J = 8.0 Hz, 
H-9 Ar diastereoisomers), 7.51-7.43 (m, 6H, H-2, H-7, H-8 Ar diastereoisomers), 7.32 
(m, 2H, H-3 Ar diastereoisomers), 5.80 (bs, 4H, NH2 base diastereoisomers), 5.61 (t, 
2H, J = 6.5 Hz, CHCH2-base), 5.24 (t, 2H, J = 6.0 Hz, CHCH2-base), 4.76-4.70 (m, 4H, 
CHCH2-base diastereoisomers), 4.60-4.45 (m, 4H, C(CH3)CH2OP diastereoisomers), 
4.11-4.04 (m, 2H, NHCH(CH3)CO diastereoisomers), 3.80-3.71 (2m, 4H, 
COOCH2C(CH3)3 diastereoisomers), 1.75 & 1.73 (2s, 6H, C(CH3)CH2OP 
diastereoisomers), 1.36-1.22 (m, 6H, NHCH(CH3)CO diastereoisomers), 0.89 & 0.87 
(2s, 18H, COOCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, CDCl3) δc (ppm): 173.64 (d, J3P-N-C-C = 6.4 Hz, NHCH(CH3)CO), 
173.54 (d, J3P-N-C-C = 6.4 Hz, NHCH(CH3)CO), 155.53 & 155.19 (2s, C-6 base 
diastereoisomers), 152.96 & 152.90 (2s, C-2 base diastereoisomers), 149.74 & 149.68 
(2s, C-4 base diastereoisomers), 146.61 & 146.55 (2s, C-1 Ar diastereoisomers), 139.82 
& 139.76 (2s, C-8 base diastereoisomers), 136.53 (d, J3P-O-C-C = 3.8 Hz, 
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C(CH3)CH2OP), 136.53 (d, J3P-O-C-C = 2.6 Hz, C(CH3)CH2OP), 134.69 & 134.52 (2s, C-
5 Ar diastereoisomers), 127.79 & 127.77 (2s, C-6 Ar diastereoismers), 126.53 & 126.44 
(2s, C-10 Ar diastereoismers), 126.65 & 126.40 (2s, C-7 Ar diastereoisomers), 126.26 
& 126.08 (2s, C-8 Ar diastereoisomers), 125.48 & 125.31 (2s, C-3 Ar 
diastereoisomers), 124.80 & 124.65 (2s, C-9 Ar diastereoisomers), 121.45 & 121. 41 
(2s, CHCH2-base diastereoisomers), 120.64 & 120.32 (2s, C-4 Ar diastereoisomers), 
119.28 & 119.01 (2s, C-5 base diastereoisomers), 115.33 (d, J3P-O-C-C = 2.6 Hz, C-2 Ar), 
115.21 (s, J3P-O-C-C = 2.6 Hz, C-2 Ar), 74.72 & 74.54 (2s, OCH2C(CH3)3 
diastereoisomers), 70.58 (d, J2P-O-C = 3.8 Hz, C(CH3)CH2OP), 70.51 (d, J2P-O-C = 2.6 Hz, 
C(CH3)CH2OP), 50.51 (d, J2P-N-C = 2.6 Hz, NCH(CH3)CO), 50.43 (d, J2P-N-C = 3.8 Hz, 
NCH(CH3)CO), 40.70 & 40.67 (2s, CHCH2-base diastereoisomers), 31.40 & 31.34 (2s, 
OCH2C(CH3)3 diastereoisomers), 26.27 & 26.25 (2s, OCH2C(CH3)3 diastereoisomers), 
21.26 & 21.23 (2s, NCH(CH3)CO diastereoisomers), 13.80 & 13.78 (2s, C(CH3)CH2OP 
diastereoisomers).  
31P NMR (202 MHz, CDCl3) δP (ppm): 3.16 (s, 44%), 3.81 (s, 56%). 
 
Preparation of α-naphthyl L-Alanine-cyclohexyl-ester (Z)-acyclic adenine ProTide 
(192.b) 
N
N
N
N
NH2
O
P
O
HN
O
O
O
(Z)
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.34 mL, 0.34 mmol, 2eq), (Z)-acyclic adenine (188.b)  (0.037 mg, 0.17 mmol, 
1.0 eq) in anh. THF (0.50 mL), and α-naphthyl L-Alanine-cyclohexyl ester 
phosphochloridate (14.e) (0.135 g, 0.34 mmol, 2.0 eq) in anh. THF (0.50 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (5%) as eluents, and 
preparative chromatography to yield the desired molecule (0.018 g, 0.008 mmol, 47%). 
HPLC (MeOH/H2O): Rt = 27.49 min, 27.71 min 
HPLC (ACN/H2O): Rt = 18.36 min 
MS (TOF ES+): 579.25 (M + H+). 
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1H NMR (500 MHz, CDCl3) δH (ppm): 8.37 & 8.36 (2s, 2H, H-2 base 
diastereoisomers), 8.12-8.08 (m, 2H, H-4 Ar diastereoisomers), 7.83-7.08 (m, 2H, H-6 
Ar diastereoisomers), 7.73 (bs, 2H, H-8 base diastereoisomers), 7.64 (d, 2H, J = 8.2 Hz, 
H-9 Ar diastereoisomers), 7.54-7.47 (m, 6H, H-2, H-7, H-8 Ar diastereoisomers), 7.38 
(t, 2H, J = 7.9 Hz, H-3 Ar diastereoisomers), 5.79 (bs, 4H, NH2 base diastereoisomers), 
5.63 (t, 2H, J = 6.6 Hz, CHCH2-base), 5.63 (t, 2H, J = 6.5 Hz, CHCH2-base), 4.78-4.71 
(m, 4H, CHCH2-base diastereoisomers), 4.61-4.49 (m, 4H, C(CH3)CH2OP 
diastereoisomers), 4.13-4.06 (m, 2H, NHCH(CH3)CO diastereoisomers), 3.94-3.88 (m, 
2H, CH cHex diastereoisomers), 1.73 & 1.72 (2s, 6H, C(CH3)CH2OP diastereoisomers), 
1.41-1.39 (m, 4H, 2 x CH2 meta cHex), 1.37-1.35 (m, 4H, 2 x CH2 ortho cHex), 1.33-
1.23 (m, 18H, CH2 para cHex, NHCH(CH3)CO diastereoisomers, 2 x CH2 meta cHex, 2 
x CH2 ortho cHex). 
13C NMR (125 MHz, CDCl3) δc (ppm): 173.45 (d, J3P-N-C-C = 6.4 Hz, NHCH(CH3)CO), 
173.36 (d, , J3P-N-C-C = 6.4 Hz, NHCH(CH3)CO), 155.34 & 155.21 (2s, C-6 base 
diastereoisomers), 152.98 & 152.57 (2s, C-2 base diastereoisomers), 149.47 & 149.13 
(2s, C-4 base diastereoisomers), 146.70 & 146.65 (2s, C-1 Ar diastereoisomers), 140.03 
& 139.92 (2s, C-8 base diastereoisomers), 136.53 (d, J3P-O-C-C = 3.8 Hz, 
C(CH3)CH2OP), 136.53 (d, J3P-O-C-C = 2.6 Hz, C(CH3)CH2OP), 134.71 & 134.51 (2s, C-
5 Ar diastereoisomers), 127.77 & 127.43 (2s, C-6 Ar diastereoisomers), 126.72  & 
126.53 (2s, C-10 Ar diastereoisomers), 126.26 & 126.02 (2s, C-7 Ar diastereoisomers), 
126.22 & 126.08 (2s, C-8 Ar diastereoisomers), 125.51 & 125.11 (2s, C-3 Ar 
diastereoisomers), 124.76 & 124.31 (2s, C-9 Ar diastereoisomers), 121.52 & 121.46 (2s, 
CHCH2-base diastereoisomers), 120.63 & 120.54 (2s, C-4 Ar diastereoisomers), 120.36 
& 120.24 (2s, C-5 base diastereoisomers), 115.29 & 115.23 (2s, C-2 Ar 
diastereoisomers), 74.06 & 73.97 (2s, C ipso cHex diastereoisomers), 70.47 & 70.21 
(2s, C(CH3)CH2OP diastereoisomers), 50.51 & 50.48 (2s, NCH(CH3)CO 
diastereoisomers), 40.72 & 40.67 (2s, CHCH2-base diastereoisomers), 31.39 & 31.31 
(2s, CH2 ortho cHex diastereoisomers), 25.21 & 25.13 (2s, CH2 para cHex 
diastereoisomers), 21.56 & 21.43 (2s, NCH(CH3)CO diastereoisomers), 21.21 & 21.13 
(2s, CH2 meta cHex diastereoisomers), 13.83 & 13.78 (2s, C(CH3)CH2OP 
diastereoisomers).  
31P NMR (202 MHz, CDCl3) δP (ppm): 2.89 (s, 50%), 2.76 (s, 50%). 
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Preparation of α-naphthyl L-Alanine-benzyl-ester (Z)-acyclic adenine ProTide 
(192.c) 
N
N
N
N
NH2
O
P
O
HN
O
O
O
(Z)
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.46 mL, 0.46 mmol, 2eq), (Z)-acyclic adenine (188.b) (0.05 mg, 0.23 mmol, 
1.0 eq) in anh. THF (0.70 mL), and α-naphthyl L-Alanine-benzyl ester 
phosphochloridate (14.f) (0.19 g, 0.46 mmol, 2.0 eq) in anh. THF (0.70 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (6%) as eluents, and 
preparative chromatography to yield the desired molecule (0.088 g, 0.15 mmol, 65%). 
HPLC (MeOH/H2O): Rt = 26.29 min, 26.59 min 
HPLC (ACN/H2O): Rt = 17.15 min 
MS (TOF ES+): 587.22 (M + H+), 609.20 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.33 & 8.29 (2s, 2H, H-2 base 
diastereoisomers), 8.08-8.05 (m, 2H, H-4 Ar diastereoisomers), 7.84-7.79 (m, 6H, H-6 
naphthyl, 2 x CH meta Ph diastereoisomers), 7.71 (bs, 2H, H-8 base diastereoisomers), 
7.66 (d, 2H, J = 8.0 Hz, H-9 Ar diastereoisomers), 7.55-7.42 (m, 12H, 2 x CH ortho Ph, 
2 x CH para Ph, H-2, H-7, H-8 Ar diastereoisomers), 7.31 (m, 2H, H-3 Ar 
diastereoisomers), 5.63 & 6.58 (2t, 2H, J = 6.5 Hz, 6.0 Hz, CHCH2-base 
diastereoisomers), 5.01 & 4.99 (AB system, 2H, JAB = 8.5 Hz, OCH2Ph), 4.97 & 4.86 
(AB system, 2H, JAB = 8.0 Hz, OCH2Ph), 4.75-4.69 (m, 4H, CHCH2-base 
diastereoisomers), 4.59-4.40 (m, 4H, C(CH3)CH2OP diastereoisomers), 4.10-4.02 (m, 
2H, NHCH(CH3)CO diastereoisomers), 1.73 & 1.69 (2s, 6H, C(CH3)CH2OP 
diastereoisomers), 1.37-1.21 (m, 6H, NHCH(CH3)CO diastereoisomers). 
13C NMR (125 MHz, MeOD) δc (ppm): 173.61 (d, J3P-N-C-C = 6.4 Hz, NHCH(CH3)CO), 
173.53 (d, J3P-N-C-C = 6.4 Hz, NHCH(CH3)CO), 155.52 & 155.45 (2s, C-6 base 
diastereoisomers), 152.96 & 152.44 (2s, C-2 base diastereoisomers, 149.73 & 149.54 
(2s, C-4 base diastereoisomers), 146.60 & 146.56 (2s, C-1 Ar diastereoisomers), 139.80 
& 139.11 (2s, C-8 base diastereoisomers), 136.56 (d, J3P-O-C-C =  3.8 Hz, 
C(CH3)CH2OP), 136.51 (d, J3P-O-C-C = 2.5 Hz, C(CH3)CH2OP), 135.20 & 135.15 (2s, C 
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ipso Ph diastereoisomers), 134.71 & 134.26 (2s, C-5 Ar diastereoisomers), 128.61 & 
128.56 & 128.49 & 128.42 (4s, C meta, C ortho Ph diastereoisomers), 128.19 & 128.14 
(2s, C para Ph diastereoisomers), 127.76 & 127.73 (2s, C-6 Ar diastereoismers), 126.49 
& 126.41 (2s, C-10 Ar diastereoismers), 126.38 & 128.09 (2s, C-7 Ar diastereoismers), 
126.23 & 126.03 (2s, C-8 Ar diastereoismers), 125.49 & 125.21 (2s, C-3 Ar 
diastereoismers), 124.81 & 124.42 (2s, C-9 Ar diastereoismers), 121.43 & 121.40 (2s, 
CHCH2-base diastereoisomers), 120.62 & 120.46 (2s, C4 Ar diastereoismers), 119.67 & 
119.42 (2s, C-5 base diastereoismers), 115.32 (d, J3P-O-C-C = 2.5 Hz, C-2 Ar), 115.28 (d, 
J3P-O-C-C = 2.5 Hz, C-2 Ar), 70.59 (d, J2P-O-C = 3.8 Hz, C(CH3)CH2OP), 70.54 (d, J2P-O-C 
= 2.5 Hz, C(CH3)CH2OP), 67.76 & 67.25 (2s, COOCH2Ph diastereoisomers), 50.54 (d, 
J2P-N-C = 2.5 Hz, NCH(CH3)CO), 50.42 (d, J2P-N-C = 3.5 Hz, NCH(CH3)CO), 41.09 & 
41.89 (2s, CHCH2-base diastereoisomers), 21.23 & 21.19 (2s, NCH(CH3)CO 
diastereoisomers), 13.81 & 13.77 (2s, C(CH3)CH2OP diastereoisomers).  
31P NMR (202 MHz, MeOD) δP (ppm): 4.11 (s, 50%), 3.72 (s, 50%). 
 
Preparation of α-naphthyl L-Alanine-neopentyl-ester (Z)-acyclic 6-chloro purine 
ProTide (193.a) 
N
N
N
N
Cl
O
P
O
HN
O
O
O
(Z)
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.42 mL, 0.42 mmol, 2eq), (Z)-acyclic 6-chloro purine (189) (0.050 mg, 0.21 
mmol, 1.0 eq) in anh. THF (0.65 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.161 g, 0.42 mmol, 2.0 eq) in anh. THF (0.65 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (1.8%) as eluents, 
and preparative chromatography to yield the desired molecule (0.002 g, 0.002 mmol, 
2%). 
HPLC (MeOH/H2O): Rt = 24.12 min, 24.39 min 
HPLC (ACN/H2O): Rt = 17.72 min 
MS (TOF ES+): 609.18 (M + Na+). 
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1H NMR (500 MHz, CDCl3) δH (ppm): 8.69 & 8.68 (2s, 2H, H-2 base 
diastereoisomers), 8.45-8.43 (m, 2H, H-9 Ar diastereoisomers), 8.10-8.07 (m, 2H, H-6 
Ar diastereoisomers), 7.90 & 7.89 (2s, 2H, H-8 base diastereoisomers), 7.82-7.70 (m, 
2H, H-7 Ar diastereoisomers), 7.67-7.63 (m, 2H, H-8 Ar diastereoisomers), 7.60-7.57 
(m, 2H, H-2 Ar diastereoisomers), 7.48-7.43 (m, 2H, H-4 Ar diastereoisomers), 7.36-
7.33 (m, 2H, H-3 Ar diastereoisomers), 5.56-5.54 (m, 2H, CHCH2-base 
diastereoisomers), 4.80-4.77 (m, 4H, CHCH2-base diastereoisomers), 4.65-4.56 (m, 4H, 
C(CH3)CH2OP diastereoisomers), 4.18-4.03 (2m, 2H, NHCH(CH3)CO 
diastereoisomers), 3.80-3.76 & 3.74-3.72 (2m, 4H, OCH2C(CH3)3 diastereoisomers), 
1.91-1.90 & 1.88-1.84 (m, 6H, C(CH3)CH2OP diastereoisomers), 1.37-1.31 (m, 6H, 
NHCH(CH3)CO diastereoisomers), 0.90 & 0.89 (2s, 18H, OCH2C(CH3)3 
diastereoisomers). 
13C NMR (125 MHz, CDCl3) δc (ppm): 172.54 & 172.43 (2s, NHCH(CH3)CO 
diastereoisomers), 156.24 & 156.18 (s, C-6 base diastereoisomers), 152.58 & 152.25 
(2s, C-2 base diastereoisomers), 148.72 & 148.62 (2s, C-4 base diastereoisomers), 
146.86 & 146.72 (2s, C-1 Ar diastereoisomers), 145.28 & 145.01 (2s, C-8 base 
diastereoisomers), 138.45 & 137.89 (2s, C(CH3)CH2OP), 136.34 & 136.18 (2s, C-5 Ar 
diastereoisomers), 128.25 & 128.07 (2s, C-6 Ar diastereoisomers), 127.65 & 127.32 (2s, 
C-10 Ar diastereoisomers), 125.45 & 125.19 (2s, C-7 Ar diastereoisomers), 125.41 & 
125.22 (2s, C-8 Ar diastereoisomers), 124.36 & 124.14 (2s, C-3 Ar diastereoisomers), 
124.98 & 124.13 (2s, C-9 Ar diastereoisomers), 122.52 & 121.98 (2s, CHCH2-base 
diastereoisomers), 120.88 & 120.72 (2s, C-4 Ar diastereoisomers), 118.42 & 118.13 (2s, 
C-5 base diastereoisomers), 115.19 & 115.11 (2s, C-2 Ar diastereoisomers), 74.67 & 
74.45 (2s, OCH2C(CH3)3 diastereoisomers), 72.13 & 72.01 (2s, C(CH3)CH2OP 
diastereoisomers), 51.20 & 51.09 (2s, NHCH(CH3)CO diastereoisomers), 40.95 & 
40.23 (2s, CHCH2-base diastereoisomers), 31.56 & 31.34 (2s, COOCH2C(CH3)3 
diastereoisomers), 26.78 & 26.45 (2s, COOCH2C(CH3)3 diastereoisomers), 21.02 & 
20.88 (2s, NHCH(CH3)CO diastereoisomers), 14.02 & 13.86 (2s, C(CH3)CH2OP 
diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 2.82 (s, 36%), 2.63 (s, 64%). 
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Preparation of α-naphthyl L-Alanine-cyclohexyl-ester (Z)-acyclic 6-chloro purine 
ProTide (193.b) 
N
N
N
N
Cl
O
P
O
HN
O
O
O
(Z)
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.42 mL, 0.42 mmol, 2eq), (Z)-acyclic 6-chloro purine (189) (0.050 mg, 0.21 
mmol, 1.0 eq) in anh. THF (0.65 mL), and α-naphthyl L-Alanine-cyclohexyl ester 
phosphochloridate (14.e) (0.166 g, 0.42 mmol, 2.0 eq) in anh. THF (0.65 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (1.8%) as eluents, 
and preparative chromatography to yield the desired molecule (0.025 g, 0.041 mmol, 
20%). 
HPLC (MeOH/H2O): Rt = 24.28 min, 24.51 min. 
HPLC (ACN/H2O): Rt = 19.28 min. 
MS (TOF ES+): 621.22 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.75 & 8.74 (2s, 2H, H-2 base 
diastereoisomers), 8.10-8.07 (m, 2H, H-4 Ar diastereoisomers), 8.01 (s, 2H, H-8 base 
diastereoisomers), 7.82-7.80 (m, 2H, H-6 Ar diastereoisomers), 7.63 (d, 2H, J = 8.2 Hz, 
H-9 Ar diastereoisomers), 7.52-7.47 (m, 6H, H-2, H-7, H-8 Ar diastereoisomers), 7.37 
(m, 2H, H-3 Ar diastereoisomers), 5.58-5.55 (m, 2H, CHCH2-base diastereoisomers), 
4.84-4.83 (m, 4H, CHCH2-base diastereoisomers), 4.78-4.71 (m, 2H, NH 
diastereoisomers), 4.62-4.48 (m, 4H, C(CH3)CH2OP diastereoisomers), 4.13-4.04 (m, 
2H, CH cHex diastereoisomers), 3.94-3.88 (m, 2H, NHCH(CH3)CO diastereoisomers), 
1.83 & 1.82 (2s, 6H, C(CH3)CH2OP diastereoisomers), 1.79-1.54 (m, 16H, 2 x CH2 
meta cHex, CH2 para cHex diastereoisomers, 2 x CH2 ortho cHex), 1.40 (d, 6H, J = 7.1 
Hz, NHCH(CH3)CO), 1.36 (d, 6H, J = 7.1 Hz, NHCH(CH3)CO), 1.34-1.28 (m, 4H, 2 x 
CH2 ortho cHex). 
13C NMR (125 MHz, CDCl3) δc (ppm): 173.45 & 173.36 (2s, NHCH(CH3)CO 
diastereoisomers), 155.34 & 155.16 (2s, C-6 base diastereoisomers), 151.95 & 151.23 
(2s, C-2 base diastereoisomers), 147.47 & 147.12 (2s, C-4 base diastereoisomers), 
146.55 & 146.09 (2s, C-1 Ar diastereoisomers), 144.62 & 144.31 (2s, C-8 base 
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diastereoisomers), 137.87 & 137.36 (2s, C(CH3)CH2OP diastereoisomers), 135.78 & 
135.42 (2s, C-5 Ar diastereoisomers), 127.82 & 127.65 (2s, C-6 Ar diastereoisomers), 
126.55 & 126.36 (2s, C-10 Ar diastereoisomers), 126.27 & 126.19 (2s, C-7 Ar 
diastereoisomers), 126.14 & 126.04 (2s, C-8 Ar diastereoisomers), 125.50 & 125.19  
(2s, C-3 Ar diastereoisomers), 124.83 & 124.32 (2s, C-9 Ar diastereoisomers), 121.46 
& 121.40 (2s, CHCH2-base diastereoisomers), 120.48 & 120.14 (2s, C-4 Ar 
diastereoisomers), 119.24 & 119.07 (2s, C-5 base diastereoisomers), 115.20 & 115.16 
(2s, C-2 Ar diastereoisomers), 74.82 & 74.12 (2s, C ipso cHex diastereoisomers), 70.10 
& 69.94 (2s, C(CH3)CH2OP diastereoisomers), 50.20 & 50.03 (2s, NCH(CH3)CO 
diastereoisomers), 41.19 & 41.02 (2s, CHCH2-base diastereoisomers), 31.31 & 31.27 
(2s, 2 x CH2 ortho cHex diastereoisomers), 25.20 & 25.11 (2s, CH2 para cHex 
diastereoisomers), 21.25 & 21.19 (2s, 2 x CH2 meta cHex diastereoisomers), 13.86 & 
13.67 (2s, C(CH3)CH2OP).  
31P NMR (202 MHz, CDCl3) δP (ppm): 2.83 (s, 36%), 2.69 (s, 64%). 
 
Preparation of α-naphthyl L-Alanine-neopentyl-ester (Z)-acyclic 6-O-methyl guanine 
ProTide (194.a) 
N
N
N
N
O
O
P
O
HN
O
O
O
(Z) NH2 	  
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.28 mL, 0.28 mmol, 2eq), (Z)-acyclic 6-O-methyl guanine (190.b) (0.035 mg, 
0.14 mmol, 1.0 eq) in anh. THF (0.41 mL), and α-naphthyl L-Alanine-neopentyl ester 
phosphochloridate (14.d) (0.108 g, 0.28 mmol, 2.0 eq) anh. THF (0.41 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (2%) as eluents, and 
preparative chromatography to yield the desired molecule (0.039 g, 0.065 mmol, 47%). 
HPLC (MeOH/H2O): Rt = 22.92 min, 23.13 min 
HPLC (ACN/H2O): Rt = 17.44 min 
MS (TOF ES+): 597.29 (M + H+), 619.27 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.26-8.24 (m, 2H, H-8 base diastereoisomers), 
8.20-8.18 (m, 2H, H-4 Ar diastereoisomers), 7.85-7.82 (m, 2H, H-8 Ar 
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diastereoisomers), 7.77-7.76 (m, 1H, H-9 Ar), 7.59-7.56 (m, 1H, H-9 Ar), 7.50-7.48 (m, 
2H, H-7 Ar diastereoisomers), 7.45-7.39 (m, 4H, H-6, H-3 Ar diastereoisomers), 6.83 & 
6.83 (2d, 2H, J = 7.0 Hz, 7.5 Hz, H-2 Ar diastereoisomers), 5.69-5.64 (m, 1H, CHCH2-
base), 5.56-5.51 (m, 1H, CHCH2-base), 4.79 (d, 2H, J = 7.0 Hz, CHCH2-base), 4.72 (d, 
2H, J = 6.5 Hz, CHCH2-base), 4.58 (s, 2H, C(CH3)CH2OP), 4.45 (s, 2H, 
C(CH3)CH2OP), 4.02 & 4.00 (2s, 6-OCH3 base diastereoisomers), 3.76-3.67 (m, 4H, 
OCH2C(CH3)3 diastereoisomers), 3.57-3.54 (m, 2H, NHCH(CH3)CO diastereoisomers), 
1.95 & 1.94 (2s, 6H, C(CH3)CH2OP diastereoisomers), 1.22 (d, 3H, J = 7.0 Hz, 
NHCH(CH3)CO), 1.20 (d, 3H, J = 7.0 Hz, NHCH(CH3)CO), 0.92 & 0.90 (2s, 
OCH2C(CH3)3 diastereoisomers). 
13C NMR (125 MHz, CDCl3) δc (ppm): 171.96 & 171.65 (2s, NHCH(CH3)CO 
diastereoisomers), 161.20 & 161.14 (2s, C-6 base diastereoisomers), 159.14 & 159.02 
(2s, C-2 base diastereoisomers), 153.98 & 153.92 (s, C-4 base diastereoisomers), 148.34 
& 148.12 (2s, C-1 Ar diastereoisomers), 138.72 & 138.62 (2s, C-8 base 
diastereoisomers), 135.43 & 135.15 (2s, C(CH3)CH2OP diastereoisomers), 134.28 & 
134.12 (2s, C-5 Ar diastereoisomers), 126.63 & 126.21 (2s, C-6 Ar diastereoisomers), 
126.12 & 126.01 (2s, C-10 Ar diastereoisomers), 125.98 & 125.53 (2s, C-7 Ar 
diastereoisomers), 125.16 & 125.06 (2s, C-8 Ar diastereoisomers), 124.83 & 124.32 (2s, 
C-3 Ar diastereoisomers), 124.42 & 124.24 (2s, C-9 Ar diastereoisomers), 121.54 & 
121.18 (2s, CHCH2-base diastereoisomers), 120.97 & 120.86 (2s, C-4 Ar 
diastereoisomers), 115.22 (d, J3P-O-C-C = 3.5 Hz, C-2 Ar), 115.14 (d, J3P-O-C-C = 3.3 Hz, 
C-2 Ar), 104.83 & 104.67 (2s, C-5 base diastereoisomers), 82.10 & 81.89 (2s, 
OCH2C(CH3)3 diastereoisomers), 70.32  (d, J2P-O-C = 5.5 Hz, C(CH3)CH2OP),  70.15 (d, 
, J2P-O-C = 5.0 Hz, C(CH3)CH2OP), 53.86 & 53.79 (2s, 6-OCH3 base diastereoisomers), 
50.43 (d, J2P-N-C = 8.3 Hz, NHCH(CH3)CO), 50.37 (d, J2P-N-C = 8.0 Hz, 
NHCH(CH3)CO), 40.84 & 40.64 (2s, CHCH2-base diastereoisomers), 30.98 & 30.76 
(2s, OCH2C(CH3)3 diastereoisomers), 26.57 & 26.19 (2s, OCH2C(CH3)3 
diastereoisomers), 20.96 & 20.93 (2s, NHCH(CH3)CO diastereoisomers), 13.64 & 
13.60 (2s, C(CH3)CH2OP diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 4.23(s, 39%), 3.91 (s, 61%). 
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Preparation of α-naphthyl L-Alanine-cyclohexyl-ester (Z)-acyclic 6-O-methyl 
guanine ProTide (194.b) 
N
N
N
N
O
O
P
O
HN
O
O
O
(Z) NH2
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.28 mL, 0.28 mmol, 2eq), (Z)-acyclic 6-O-methyl guanine (190.b)  (0.035 mg, 
0.14 mmol, 1.0 eq) in anh. THF (0.41 mL), and α-naphthyl L-Alanine-cyclohexyl ester 
phosphochloridate (14.e) (0.112 g, 0.28 mmol, 2.0 eq) anh. THF (0.41 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (2.5%) as eluents, 
and preparative chromatography to yield the desired molecule (0.037 g, 0.061 mmol, 
44%). 
HPLC (MeOH/H2O): Rt = 23.25 min, 23.48 min 
HPLC (ACN/H2O): Rt = 17.32 min 
MS (TOF ES+): 609.29 (M + H+), 631.28 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.26-8.24 (m, 2H, H-8 base diastereoisomers), 
8.20-8.18 (m, 2H, H-4 Ar diastereoisomers), 7.85-7.83 (m, 2H, H-8 Ar 
diastereoisomers), 7.77-7.76 (m, 1H, H-9 Ar), 7.60-7.55 (m, 1H, H-9 Ar), 7.50-7.48 (m, 
1H, H-7 Ar), 7.45-7.39 (m, 3H, H-6 Ar diastereoisomers, H-7 Ar), 7.34-7.25 (m, 2H, H-
3 Ar diastereoisomers), 6.83 (d, 1H, J = 7.5 Hz, H-2 Ar), 6.81 (d, 1H, J = 7.5 Hz, H-2 
Ar), 5.78-5.76 & 5.74-5.71 (2m, 2H, CHCH2-base diastereoisomers), 4.81-4.79 (m, 2H, 
CHCH2-base diastereoisomers), 4.45-4.40 (m, 4H, C(CH3)CH2OP diastereoisomers), 
4.05 & 4.03 (2s, 6-OCH3 base diastereoisomers), 3.99-3.96 (m, 2H, CH cHex 
diastereoisomers), 3.87-3.82 (m, 2H, NHCH(CH3)CO diastereoisomers), 1.95 & 1.94 
(2s, 6H, C(CH3)CH2OP diastereoisomers), 1.91-1.89 (m, 8H, 2 x CH2 ortho cHex 
diastereoisomers), 1.37-1.31 (m, 12H, 2 x CH2 meta, CH2 para cHex diastereoisomers), 
1.22 (d, 3H, J = 7.0 Hz, NHCH(CH3)CO),  1.20 (2 d, 3H, J = 7.0 Hz, NHCH(CH3)CO). 
13C NMR (125 MHz, CDCl3) δc (ppm): 171.90 & 171.74 (2s, NHCH(CH3)CO 
diastereoisomers), 161.60 & 161.43 (2s, C-6 base diastereoisomers), 159.41 & 159.32 
(2s, C-2 base diastereoisomers), 153.54 & 153.19 (2s, C-4 base diastereoisomers), 
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148.24 & 148.08 (2s, C-1 Ar diastereoisomers), 138.77 & 138.41 (2s, C-8 base 
diastereoisomers), 135.87 & 135.57 (2s, C(CH3)CH2OP diastereoisomers), 134.68 & 
134.39 (2s, C-5 Ar diastereoisomers), 128.43 & 128.18 (2s, C-6 Ar diastereoisomers), 
126.31 & 126.30 (2s, C-10 Ar diastereoisomers), 126.19 & 125.98 (2s, C-7 Ar 
diastereoisomers), 125.46 & 125.21 (2s, C-8 Ar diastereoisomers), 124.62 & 124.24 (2s, 
C-9 Ar diastereoisomers), 123.15 & 123.04 (2s, C-3 Ar diastereoisomers), 121.40 & 
121.09 (2s, CHCH2-base diastereoisomers), 120.00  & 119.92 (2s, C-4 Ar 
diastereoisomers), 115.32 (d, J3P-O-C-C = 3.2 Hz, C-2 Ar),  115.20 (d, J3P-O-C-C = 3.2 Hz, 
C-2 Ar), 108.87 & 108.52 (2s, C-5 base diastereoisomers), 70.73 (d, J2P-O-C = 5.0 Hz, 
C(CH3)CH2OP), 70.65 (d, J2P-O-C = 5.1 Hz, C(CH3)CH2OP), 74.12 & 74.01 (2s, C ipso 
cHex diastereoisomers), 54.18 & 54.12 (2s, 6-OCH3 diastereoisomers), 49.98 (d, J2P-N-C 
= 8.0 Hz, NHCH(CH3)CO), 49.68 (d, J2P-N-C = 8.2 Hz, NHCH(CH3)CO), 41.60 & 41.25 
(2s, CHCH2-base), 30.75 & 30.52 (2s, 2 x CH2 ortho cHex diastereoisomers), 30.43 & 
30.12 (2s, CH2 para cHex diastereoisomers), 23.73 & 23.41 (2s, 2 x CH2 meta cHex 
diastereoisomers), 20.50 & 20.34 (2s, NHCH(CH3)CO diastereoisomers), 13.86 & 
13.21 (2s, C(CH3)CH2OP diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 3.09(s, 43%), 2.90 (s, 57%). 
 
Preparation of α-naphthyl L-Alanine-benzyl-ester (Z)-acyclic 6-O-methyl guanine 
ProTide (194.c) 
N
N
N
N
O
O
P
O
HN
O
O
O
(Z) NH2
 
This ProTide was prepared according to the Standard Procedure D, using tBuMgCl (1M 
in THF, 0.24 mL, 0.24 mmol, 2eq), (Z)-acyclic 6-O-methyl guanine (190.b)   (0.030 
mg, 0.12 mmol, 1.0 eq) in anh. THF (0.29 mL). and α-naphthyl L-Alanine-benzyl ester 
phosphochloridate (14.f) (0.097 g, 0.24 mmol, 2.0 eq) anh. THF (0.30 mL). After 
overnight stirring at RT, the solvent was removed under reduced pressure and the 
residue was purified by flash chromatography, using CHCl3/MeOH (3%) as eluents, and 
preparative chromatography to yield the desired molecule (0.033 g, 0.053 mmol, 44%). 
HPLC (MeOH/H2O): Rt = 22.00 min, 22.29 min 
HPLC (ACN/H2O): Rt = 16.33 min 
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MS (TOF ES+): 617.26 (M + H+), 639.25 (M + Na+). 
1H NMR (500 MHz, CDCl3) δH (ppm): 8.09-8.06 (m, 4H, H-8 base, H-4 Ar 
diastereoisomers), 7.82-7.80 (s, 2H, 2 x CH meta Ph), 7.65-7.20 (m, 4H, H-8, H-9 Ar 
diastereoisomers), 7.49-7.47 (m, 6H, H-2, H-6 Ar diastereoisomers, 2 x CH meta Ph), 
7.37-7.24 (m, 10H, H-7, H-3 Ar, 2 x CH ortho, CH para Ph diastereoisomers), 5.60 (td, 
1H, J = 1.5 Hz, 7.0 Hz, CHCH2-base), 5.55 (td, J = 1.5 Hz, 7.4 Hz, CHCH2-base), 5.09 
(s, 2H, OCH2Ph), 4.96 (s, 2H, OCH2Phe), 4.61-4.57 (m, 4H, CHCH2-base 
diastereoisomers), 4.53-4.41 (m, 4H, C(CH3)CH2OP diastereoisomers), 4.18-4.11 (m, 
2H, NHCH(CH3)CO diastereoisomers), 4.08 & 4.05 (2s, 6H, 6-OCH3 
diastereoisomers), 1.76 & 1.72 (2s, 6H, C(CH3)CH2OP diastereoisomers), 1.38 (d, 3H, J 
= 7.0 Hz, NHCH(CH3)CO), 1.35 (d, 3H, J = 7.5 Hz, NHCH(CH3)CO). 
13C NMR (125 MHz, CDCl3) δc (ppm): 171.90 & 171.74 (2s, NHCH(CH3)CO), 161.60 
& 161.13 (2s, C-6 base diastereoisomers), 159.41 & 159.26 (2s, C-2 base 
diastereoisomers), 153.54 & 153.36 (2s, C-4 base diastereoisomers), 148.24 & 148.02  
(2s, C-1 Ar diastereoisomers), 138.77 & 138.72 (2s, C-8 base diastereoisomers), 135.87 
& 135.52 (2s, C(CH3)CH2OP diastereoisomers), 135.19 & 135.01 (2s, C ipso Ph 
diastereoisomers), 134.68 & 134.41 (2s, C-5 Ar diastereoisomers), 128.61 & 128.56 & 
128.49 & 128.42 (4s, C meta, C ortho Ph diastereoisomers), 128.19 & 128.14 (2s, C 
para Ph diastereoisomers), 126.56 & 126.11 (2s, C-10 Ar diastereoisomers), 126.31 & 
126.30 (2s, C-6 Ar diastereoisomers), 126.11 & 125.98 (2s, C-7 Ar diastereoisomers),  
125.49 & 125.12 (2s, C-8 Ar diastereoisomers), 124.83 & 124.68 (2s, C-9 Ar 
diastereoisomers), 124.61 & 124.42 (2s, C-3 Ar diastereoisomers), 121.83 & 121.52 (2s, 
C-4 Ar diastereoisomers), 121.40 & 121.09 (2s, CHCH2-base diastereoisomers), 115.32 
(d, J3P-O-C-C = 3.3 Hz, C-2 Ar), 115.20 (d, J3P-O-C-C = 3.3 Hz, C-2 Ar), 104.38 & 104.17 
(2s, C-5 base diastereoisomers), 70.73 (d, J2P-O-C = 5.2 Hz, C(CH3)CH2OP), 70.65 (d, 
J2P-O-C = 5.1 Hz, C(CH3)CH2OP), 67.23 & 67.79 (2s, OCH2Ph diastereoisomers), 53.88 
& 53.80 (2s, 6-OCH3 base diastereoisomers), 50.45 (d, J2P-N-C = 8.3 Hz, 
NHCH(CH3)CO), 50.41 (d, J2P-N-C = 8.2 Hz, NHCH(CH3)CO), 40.48 & 40.46 (2s, 
CHCH2-base diastereoisomers), 20.95 & 20.91 (2s, NHCH(CH3)CO diastereoisomers), 
13.74 & 13.70 (2s, C(CH3)CH2OP diastereoisomers). 
31P NMR (202 MHz, CDCl3) δP (ppm): 4.22 (s, 33%), 3.82 (s, 67%). 
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Preparation of α-naphthyl L-Alanine-neopentyl-ester (Z)-acyclic guanine ProTide 
(195.a) 
N
N
N
NH
O
O
NH2
P
O
HN
O
O
O
(Z)
 
To a solution of α-naphthyl L-Alanine-neopentyl-ester (Z)-acyclic 6-O-methyl guanine 
ProTide (194.a) (0.015 g, 0.025 mmol) in anh. ACN (0.84 mL), NaI (0.006 mg, 0.038 
mmol, 1.5 eq) was added followed by TMSCl (0.004 mL, 0.038 mmol, 1.5 eq). The 
reaction was left stirring for 2 hrs at RT and the solvent was evaporated under reduced 
pressure. The residue was purified by preparative HPLC to recover the desired material 
(0.002 g, 0.0003 mmol, 2%). 
HPLC (MeOH/H2O): Rt = 21.75 min, 22.00 min 
HPLC (ACN/H2O): Rt = 14.57 min 
MS (TOF ES-): 581.23 (M - H+), 617.21 (M + Cl-). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.15-8.13 (m, 2H, H-9 Ar diastereoisomers), 
7.87-7.85 (m, 2H, H-6 Ar diastereoisomers), 7.69-7.67 (m, 2H, H-4 Ar 
diastereoisomers), 7.61 & 7.59 (2s, 2H, H-8 base diastereoisomers), 7.52-7.49 (m, 4H, 
H-3, H-8 Ar diastereoisomers), 7.47-7.36 (m, 4H, H-2, H-7 Ar diastereoisomers), 5.55-
5.50 (m, 2H, CHCH2-base diastereoisomers), 4.66-4.59 (2m, 4H, CHCH2-base 
diastereoisomers), 4.57-4.52 (2m, 4H, C(CH3)CH2OP diastereoisomers), 4.08-4.05 (m, 
2H, NHCH(CH3)CO diastereoisomers), 3.82-3.79 & 3.76-3.74 (2m, 4H, OCH2C(CH3)3 
diastereoisomers), 1.81-1.79 (m, 6H, C(CH3)CH2OP diastereoisomers), 1.38-1.35 (m, 
6H, NHCH(CH3)CO diastereoisomers), 0.92 & 0.91 (2s, 9H, OCH2C(CH3)3 
diastereoisomers). 
13C NMR (125 MHz, MeOD) δc (ppm): 171.21 & 171.19 (2s, NHCH(CH3)CO 
diastereoisomers), 156.54 & 156.32 (2s, C-6 base diastereoisomers), 152.75 & 152.12 
(2s, C-2 base diastereoisomers), 146.27 & 146.09 (2s, C-4 base diastereoisomers), 
145.92 & 145.90 (2s, C-1 Ar diastereoisomers), 142.50 & 142.32 (2s, C-8 base 
diastereoisomers), 136.64 & 136.44 (2s, C(CH3)CH2OP diastereoisomers), 135.29 & 
135.12 (2s, C-5 Ar diastereoisomers), 127.81 & 127.43 (2s, C-6 Ar diastereoisomers), 
126.83 & 126.51 (2s, C-10 Ar diastereoisomers), 126.25 & 126.07 (2s, C-7 Ar 
diastereoisomers), 125.98 & 125.11 (2s, C-8 Ar diastereoisomers), 125.46 & 125.03 (2s, 
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C-3 Ar diastereoisomers), 124.85 & 124.12 (2s, C-9 Ar diastereoisomers), 121.47 & 
121.42 (2s, CHCH2-base diastereoisomers), 120.44 & 120.21 (2s, C-4 Ar 
diastereoisomers), 119.02 & 118.87 (2s, C-5 base diastereoisomers), 115.20 & 115.01 
(2s, C-2 Ar diastereoisomers), 81.23 & 80.98 (2s, OCH2C(CH3)3 Ar diastereoisomers), 
70.01 & 69.92 (2s, C(CH3)CH2OP diastereoisomers), 49.68 & 49.51 (2s, NCH(CH3)CO 
diastereoisomers), 40.81 & 40.23 (2s, CHCH2-base), 31.29 & 31.01 (2s, OCH2C(CH3)3 
diastereoisomers), 26.45 & 26.32 (2s, OCH2C(CH3)3 diastereoisomers), 20.97 & 20.80 
(2s, NCH(CH3)CO diastereoisomers), 14.02 & 14.00 (2s, C(CH3)CH2OP 
diastereoisomers). 
31P NMR (202 MHz, MeOD) δP (ppm): 4.12 (s, 41%), 3.93 (s, 59%). 
 
Preparation of α-naphthyl L-Alanine-cyclohexyl-ester (Z)-acyclic guanine ProTide 
(195.b) 
N
N
N
NH
O
O
NH2
P
O
HN
O
O
O
(Z)
 
To a solution of α-naphthyl L-Alanine-neopentyl-ester (Z)-acyclic 6-O-methyl guanine 
ProTide (194.b) (0.015 g, 0.025 mmol) in anh. ACN (0.84 mL), NaI (0.004 mL, 0.026 
mmol, 1.03 eq) was added followed by TMSCl (0.004 mL, 0.026 mmol, 1.03 eq). The 
reaction was left stirring for 4 hrs at RT and the solvent was evaporated under reduced 
pressure. The residue was purified by preparative HPLC to recover the desired material 
(0.002 g, 0.0003 mmol, 2%). 
HPLC (MeOH/H2O): Rt = 22.11 min, 22.37 min 
HPLC (ACN/H2O): Rt = 15.24 min 
MS (TOF ES-): 593.24 (M - H+), 529.21 (M + Cl-). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.13-8.11 (m, 2H, H-9 Ar diastereoisomers), 
7.90-7.85 (m, 4H, H-6, H-4 Ar diastereoisomers), 7.69-7.67 (m, 2H, H-8 base 
diastereoisomers), 7.60-7.59 (m, 2H, H-2 Ar diastereoisomers), 7.52-7.50 (m, 2H, H-7 
Ar diastereoisomers), 7.46-7.38 (m, 4H, H-3, H-8 Ar diastereoisomers), 5.54-5.50 (m, 
2H, CHCH2-base diastereoisomers), 4.66-4.64 (m, 4H, CHCH2-base diastereoisomers), 
4.57-4.52 (m, 4H, C(CH3)CH2OP diastereoisomers), 4.16-4.13 (m, 1H, CH cHex), 4.01-
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3.98 (m, 1H, CH cHex), 2.85-2.83 (m, 2H, NHCH(CH3)CO diastereoisomers), 1.81 & 
1.79 (2s, 6H, C(CH3)CH2OP diastereoisomers), 1.75-1.50 (m, 16H, 2 x CH2 meta cHex, 
CH2 para cHex diastereoisomers, 2 x CH2 ortho cHex), 1.35 (d, 3H, J = 7.1 Hz, 
NHCH(CH3)CO), 1.31 (d, 3H, J = 7.1 Hz, NHCH(CH3)CO), 0.92-0.90 (m, 4H, CH2 
ortho cHex). 
13C NMR (125 MHz, MeOD) δc (ppm): 171.20 & 171.18 (2s, NHCH(CH3)CO 
diastereoisomers), 156.64 & 156.23 (2s, C-6 base diastereoisomers), 152.95 & 152.72 
(2s, C-2 base diastereoisomers), 146.17 & 146.02 (2s, C-4 base diastereoisomers), 
145.95 & 145.93 (2s, C-1 Ar diastereoisomers), 142.52 & 142.16 (s, C-8 base 
diastereoisomers), 136.67 & 136.46 (2s, C(CH3)CH2OP diastereoisomers), 135.28 & 
135.12 (2s, C-5 Ar diastereoisomers), 126.82 & 126.42 (2s, C-6 Ar diastereoisomers), 
126.25 & 126.02 (2s, C-10 Ar diastereoisomers), 126.17 & 126.02 (2s, C-7 Ar 
diastereoisomers), 125.97 & 125.84 (2s, C-8 Ar diastereoisomers), 125.45 & 125.19 (2s, 
C-3 Ar diastereoisomers), 124.83 & 124.72 (2s, C-9 Ar diastereoisomers), 121.64 & 
121.31 (2s, CHCH2-base diastereoisomers), 120.48 & 120.13 (2s, C-4 Ar 
diastereoisomers), 119.04 & 118.96 (2s, C-5 base diastereoisomers), 115.19 & 115.03 
(2s, C-2 Ar diastereoisomers), 74.22 & 74.11 (2s, C ipso cHex diastereoisomers), 69.89 
& 69.43 (2s, C(CH3)CH2OP diastereoisomers), 49.97 & 49.65 (2s, NCH(CH3)CO 
diastereoisomers), 41.20 & 41.15 (2s, CHCH2-base), 31.01 & 30.98 (2s, 2 x CH2 ortho 
cHex diastereoisomers), 25.19 & 25.12 (2s, CH2 para cHex diastereoisomers), 21.45 & 
21.19 (2s, 2 x CH2 meta cHex diastereoisomers), 21.08 & 20.97 (2s, NCH(CH3)CO 
diastereoisomers), 14.11 & 14.07 (2s, C(CH3)CH2OP diastereoisomers). 
31P NMR (202 MHz, MeOD) δP (ppm): 4.19 (s, 46%), 3.96 (s, 54%). 
 
Preparation of α-naphthyl L-Alanine-benzyl-ester (Z)-acyclic guanine ProTide 
(195.c) 
N
N
N
NH
O
O
NH2
P
O
HN
O
O
O
(Z)
 
To a solution of L-Alanine-benzyl-ester (Z)-acyclic 6-O-methyl guanine ProTide 
(194.c) (0.033 g, 0.054 mmol) in anh. ACN (2.00 mL), NaI (0.012 mg, 0.081 mmol, 1.5 
eq) was added, followed by TMSCl (0.017 mL, 0.081 mmol, 1.5 eq). The reaction was 
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left stirring for 1 hr at RT and the solvent was evaporated under reduced pressure. The 
residue was purified by preparative HPLC, followed by preparative HPLC to recover 
the desired molecule (0.0031 g, 0.005 mmol, 10%). 
HPLC (MeOH/H2O): Rt = 25.35 min, 25.62 min 
HPLC (ACN/H2O): Rt = 15.60 min 
MS (TOF ES+): 625.19 (M + Na+). 
1H NMR (500 MHz, MeOD) δH (ppm): 8.13 (d, 2H, J = 11.2 Hz, H-9 Ar 
diastereoisomers), 7.87 (d, 2H, J = 7.9 Hz, H-6 Ar diastereoisomers), 7.68 (2H, d, J = 
8.1 Hz, H-4 Ar diastereoisomers), 7.59 & 7.57 (2s, H-8 base diastereoisomers), 7.52-
7.35 (m, 8H, 2 x CH meta Ph, H-3, H-8 Ar diastereoisomers), 7.31-7.26 (m, 10H, 2 x 
CH ortho, CH para Ph, H-2, H-7 Ar diastereoisomers), 5.49-5.47 (m, 2H, CHCH2-base 
diastereoisomers), 5.09 & 5.08 (2s, 4H, OCH2Ph diastereoisomers), 4.63-4.61 (m, 4H, 
CHCH2-base diastereoisomers), 4.49 & 4.48 (2s, 4H, C(CH3)CH2OP diastereoisomers), 
4.06-4.05 (m, 2H, NHCH(CH3)CO diastereoisomers), 2.04 & 2.03 (2s, 6H, 
C(CH3)CH2OP diastereoisomers), 1.36 & 1.34 (2s, 6H, NHCH(CH3)CO 
diastereoisomers). 
13C NMR (125 MHz, MeOD) δc (ppm): 171.20 & 171.18 (2s, NHCH(CH3)CO 
diastereoisomers), 156.64 & 156.42 (2s, C-6 base diastereoisomers), 152.65 & 152.32 
(2s, C-2 base diastereoisomers), 146.17 & 146.03 (2s, C-4 base diastereoisomers), 
145.95 & 145.93 (2s, C-1 Ar diastereoisomers), 142.52 (2s, C-8 base diastereoisomers), 
136.67 & 136.46 (s, C(CH3)CH2OP), 135.28  & 135.12 (2s, C-5 Ar diastereoisomers), 
128.76 & 128.51 (2s, C meta Ph diastereoisomers), 127.80 & 127.69 (2s, C para Ph 
diastereoisomers), 126.82 & 126.62 (2s, C-6 Ar diastereoisomers), 126.57 & 126.43 (2s, 
C ortho Ph), 126.25 & 126.12 (2s, C-10 Ar diastereoisomers), 126.17 & 126.04 (2s, C-7 
Ar diastereoisomers), 125.97 & 125.38 (2s, C-8 Ar diastereoisomers), 125.45 & 125.11 
(2s, C-3 Ar diastereoisomers), 124.83 & 124.65 (2s, C-9 Ar diastereoisomers), 121.76 
& 121.38 (2s, CHCH2-base diastereoisomers), 120.48 & 120.32 (2s, C-4 Ar 
diastereoisomers), 119.04 & 118.86  (2s, C-5 base diastereoisomers), 115.19 & 115.01 
(2s, C-2 Ar diastereoisomers), 69.98 & 69.23 (2s, C(CH3)CH2OP diastereoisomers), 
67.18 & 67.05 (2s, COOCH2Ph diastereoisomers), 49.65 & 49.13 (2s, NCH(CH3)CO 
diastereoisomers), 40.75 & 40.43 (2s, CHCH2-base diastereoisomers), 20.85 & 20.79 
(2s, NCH(CH3)CO diastereoisomers) 14.00 & 13.94 (2s, C(CH3)CH2OP 
diastereoisomers). 
31P NMR (202 MHz, MeOD) δP (ppm): 4.10 (s, 44%), 3.71 (s, 56%). 
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7. Enzymatic assays: standard procedures 
Carboxypeptidase Y assays 
1 to 5 mg of phosphoramidate/phosphoradiamidate was dissolved in 50 to 200 µL of 
deuterated solvent (D2O or d6-acetone) and 100 to 400 µL of Trizma buffer (pH ~ 7.6). 
31P-NMR was recorded as reference (t = 0 min). 0.1 mg of carboxypeptidase Y 
(purchased from Sigma, EC 3.4.16.1) dissolved in 50 to 200 µL of Trizma buffer (pH ~ 
7.6) was added to the previous mixture. 31P-NMR spectra were recoreded overnight 
(over 14 hours), every 2 to 7 minutes, at RT. 
 
Cell lysate assays 
The cell lysate experiments were performed using Huh-7 human hepatoma cells lysate 
(107 cells), which were incubated with the phosphoramidate dissolved in D2O. 31P-NMR 
spectra were recoreded overnight (over 14 hours), every hour, at 37 °C. 
 
Adenosine deaminase assays 
Stock solution of nucleoside analogue was dissolved in phosphate buffer (pH ~ 7.5, 
0.05 M) to reach a final concentration of 44 µM. To a solution of adenosine deaminase 
from calf intestinal mucosa (solution in 50% glycerol, 0.01 M potassium phosphate, pH 
~ 6.0, Sigma-Aldrich), phosphate buffer (pH ~ 7.5, 0.05 M) was added to reach a final 
volume of 2.0 mL. 
For each assay, 1 mL of the solution of 44 µM of nucleoside analogue was place in a 1 
cm UV cuvet, and one UV spectrum was recorded over the range of 400 to 220 nm, at 
25 °C. 30 to 500 µL of the enzyme solution was added to the cuvet and UV spectra were 
recorded in 1 min interval for 30 min, and then at every 30 min or every hour, over 4 to 
hours. 
 
 
8. Molecular modelling 
Molecular modelling was performed using MOE software (version 2008 and 2010) with 
the crystal structure of cathepsin A enzyme (PNB 1YSC), of human Hint-1 enzyme 
with AMP co-crystallised structure (PNB 1KPF), and the homology model of adenosine 
deaminase-like protein-1 (ADAL-1) created by Dr. A. Brancale. 
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ABSTRACT: We herein report phosphorodiamidates as a significant new phosphate prodrug motif. Sixty-seven
phosphorodiamidates are reported of two 6-O-alkyl 2′-C-methyl guanosines, with significant variation in the diamidate structure.
Both symmetrical and asymmetric phosphorodiamidates are reported, derived from various esterified amino acids, both D and L,
and also from various simple amines. All of the compounds were evaluated versus hepatitis C virus in replicon assay, and
nanomolar activity levels were observed. Many compounds were noncytotoxic at 100 μM, leading to high antiviral selectivities.
The agents are stable in acidic, neutral, and moderately basic media and in selected biological media but show efficient processing
by carboxypeptidases and efficiently yield the free nucleoside monophosphate in cells. On the basis of in vitro data, eight leads
were selected for additional in vivo evaluation, with the intent of selecting one candidate for progression toward clinical studies.
This phosphorodiamidate prodrug method may have broad application outside of HCV and antivirals as it offers many of the
advantages of phosphoramidate ProTides but without the chirality issues present in most cases.
■ INTRODUCTION
There is an urgent ongoing need for improved therapeutic
agents for hepatitis C Virus (HCV) infection, with an
increasing emphasis on direct acting antivirals (DAAs), and in
particular, inhibitors of the viral NS5B RNA polymerase.1
Nucleoside-based inhibitors of the polymerase are considered
particularly valuable on the basis of the high genetic barrier to
resistance.2 Thus, a number of nucleoside modifications (1−4,
Figure 1) have emerged with anti-HCV activity in vitro, and
several have progressed to clinical evaluation.
One issue common to all nucleoside analogues, either
antiviral or anticancer, is an absolute need for nucleoside
kinase-mediated activation to their 5′-monophosphate forms. In
some cases, as in the present anti-HCV field, further
phosphorylation to the 5′-triphosphate is also required, and in
general the first phosphorylation step is considered rate-
limiting.3 With this in mind, and given that the free phosphate
derivatives are not considered useful drug entities due to poor
cell uptake, a number of phosphate (nucleotide) prodrug motifs
have emerged.4 These have included our aryl phosphoramidate
(“ProTide”) approach,5 the amidate diester method of Wagner6
and McKenna,7 the lipid diester approach of Hosteller,8
thioester approaches of Gosselin,9 cytochrome based meth-
ods,10 and the chemical driven cycloSAL method of Meier.11
Each of these methods has its strengths and weaknesses. In
general, fully blocked prodrugs (ProTides, CycloSAL, etc.) may
give better delivery but do often generate a chiral phosphate
center leading to isomer issues. Phosphate diester methods
avoid the chirality issue but may have delivery challenges.4
Despite this, several phosphate prodrugs of antiviral nucleosides
have progressed into clinical trials. This includes Inhibitex’s
INX-18912 (5, Figure 2) and Pharmasset’s PSI-797713 (6), both
based directly on phosphoramidate ProTides, and Idenix’s
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IDX18414 (7), which is a hybrid phosphoramidate/SATE
prodrug. Each of these is now in human trials for efficacy versus
HCV.
Most chiral nucleotide prodrugs that have entered into the
clinic to date have been progressed as diastereoisomeric
mixtures at the phosphate center. NewBiotics’ anticancer
agent NB1011 is a further example in this category.15 In
general, when tested, both stereoisomers often display similar
biological activity in vitro and always release the same
pharmacophore after initial metabolism.16 One exception to
this in the HCV field to date is Pharmasset, who has developed
a large scale separation technique for their mixed compound
PSI-7851, now pursued as the single stereoisomer 6 as above.13
With this in mind, we sought to revisit the notion of an
achiral phosphate prodrug motif with a phosphoramidate core.
In addition, we particularly wanted to formulate a prodrug
whose promoieties were nontoxic and preferably natural. Thus
our attention turned to phosphorodiamidates. Indeed, over 20
years ago, our group was among the first to report
phosphorodiamidate-based nucleotide prodrugs. Thus, seeking
to deliver the 5′-monophosphate of the anti-HIV agent AZT
into cells, we prepared a series of L-amino acid phosphor-
odiamidates with a variety of esters.17 There have since been
reports of this motif on phosphonates18 and non-nucleosides19
but little further work on nucleosides.20−22
In this paper, we report the very promising profile of a family
of such phosphorodiamidates of 2′-C-methylguanosine and its
derivatives, leading toward selection of a clinical candidate.
■ CHEMISTRY
Following the success of 5 in early clinical trials for HCV23 and
our recent disclosure that alternative 6-alkoxy (and other)
groups may be equally effective,24 we used the 6-alkoxy
derivatives of 2′-C-methylguanosine as our starting point. These
were prepared by methods we have described.12 Following our
much earlier reports on phosphoramidates of AZT,17 we used a
single synthetic route based on treating the unprotected
nucleoside with phosphoryl chloride to generate the
intermediate dichloridate which was not isolated (Scheme 1).
In the first instance, we used the 6-methoxy analogue 8, the
base nucleoside behind 5. Reaction with POCl3 in THF in the
presence of Et3N for 45 min (when
31P NMR showed no
presence of POCl3) followed by addition of an excess of various
amino acid esters (or other amines), lead to compounds 10−76
as shown in Table 1.
As L-alanine is often a preferred motif in phosphoramidate
ProTides and the final putative activating step for these
diamidates would be the same loss of amino acid, we thought
that L-alanine may be beneficial here, so our first SAR family
was symmetrical substituted L-alanines with linear esters
methyl-(10), ethyl-(11), n-propyl-(12), n-butyl-(13), and n-
pentyl-(14); branched esters isopropyl-(15) and (R,S)-2-butyl-
(16), and 3,3-dimethylbutyl-(17); followed by cyclic esters
cyclobutyl-(18), cyclopentyl-(19) cyclohexyl-(20), and 2-
tetrahydropyranyl-(24). We have often reported that benzyl
esters can be rather effective in ProTides, so we prepared the
benzyl-(21), S-phenethyl-(22), 2,4-difluorobenzyl-(23), and 2-
indanyl-(25) L-alanine esters. Given the extremely high potency
Figure 1. Some anti-HCV nucleoside analogues.
Figure 2. Some anti-HCV phosphate prodrug compounds in clinical trials.
Scheme 1. Synthetic Route to Phosphorodiamidatesa
aReagents and conditions: (a) Et3N (1 equiv), POCl3 (1 equiv), dry THF; (b) for symmetrical diamidates, amine (5 equiv), Et3N (10 equiv), dry
DCM; for asymmetric diamidates, amine 1 (1 equiv), Et3N (2 equiv) then amine 2 (5 equiv), Et3N (10 equiv), dry DCM.
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Table 1. Replicon Data and Cytotoxicity of Nucleoside Analogues and Phosphorodiamidates
EC50 (μM) EC90 (μM)
compd AA ester/amine AA ester/amine nucleoside av SD av SD CC50 (μM)
4 2′CMeG 2.2 1.4 8.3 7.5 >100
8 6OMe2′CMeG 4.4 2.2 19.4 10.2 >100
9 6OEt2′CMeG 9.5 1.84 24.5 1.78 >100
5 L-Ala OCH2tBu NaphO 6OMe2′CMeG 0.01 0.01 0.04 0.02 7.01
10 L-Ala OMe L-Ala OMe 6OMe2′CMeG 5.90 0.76 >10 >100
11 L-Ala OEt L-Ala OEt 6OMe2′CMeG 1.20 0.08 4.10 0.09 >100
12 L-Ala OnPr L-Ala OnPr 6OMe2′CMeG 0.28 0.05 1.20 0.53 >100
13 L-Ala OButyl L-Ala OButyl 6OMe2′CMeG 0.07 0.01 0.23 0.02 >100
14 L-Ala OPentyl L-Ala OPentyl 6OMe2′CMeG 0.03 0.01 0.11 0.02 65
15 L-Ala OiPr L-Ala OiPr 6OMe2′CMeG 0.49 0.18 2.10 0.09 >100
16 L-Ala O-(R,S)-2Bu L-Ala O-(R,S)-2Bu 6OMe2′CMeG 0.15 0.00 0.53 0.10 >100
17 L-Ala O-3,3-dimethylbutyl L-Ala O-3,3-dimethylbutyl 6OMe2′CMeG 0.02 0.01 0.09 0.07 71
18 L-Ala OcBu L-Ala OcBu 6OMe2′CMeG 0.32 0.05 0.80 >100
19 L-Ala OcPentyl L-Ala OcPentyl 6OMe2′CMeG 0.06 0.01 0.22 0.03 >100
20 L-Ala OcHx L-Ala OcHx 6OMe2′CMeG 0.05 0.02 0.19 0.08 >100
21 L-Ala OBn L-Ala OBn 6OMe2′CMeG 0.49 1.60 >100
22 L-Ala OSPhEt L-Ala OSPhEt 6OMe2′CMeG 0.49 1.70 88
23 L-Ala O-2,4-diFBn L-Ala O-2,4-diFBn 6OMe2′CMeG 0.26 0.21 1.07 0.92 54
24 L-Ala OTHP L-Ala OTHP 6OMe2′CMeG 13.33 13.02 29.30 15.14 >100
25 L-Ala OIndanol L-Ala OIndanol 6OMe2′CMeG 0.58 0.39 1.30 0.10 70
26 L-Ala OCH2tBu L-Ala OCH2tBu 6OMe2′CMeG 0.06 0.04 0.20 0.12 >100
27 L-Ala OCH2iPr L-Ala OCH2iPr 6OMe2′CMeG 0.07 0.01 0.26 0.01 >100
28 L-Ala OCH2cPropyl L-Ala OCH2cPropyl 6OMe2′CMeG 0.21 0.00 0.66 0.001 >100
29 D-Ala OCH2tBu D-Ala OCH2tBu 6OMe2′CMeG 0.11 0.03 0.50 0.19 >100
30 L-Asp OMe L-Asp OMe 6OMe2′CMeG 10.18 3.17 >40 >100
31 L-Asp OBn L-Asp OBn 6OMe2′CMeG 0.61 0.08 1.90 0.14 >100
32 L-Gly OBn L-Gly OBn 6OMe2′CMeG 0.60 0.13 1.80 0.09 >100
33 L-Gly OCH2tBu L-Gly OCH2tBu 6OMe2′CMeG 0.13 0.02 0.60 0.20 >100
34 L-Leu OcHx L-Leu OcHx 6OMe2′CMeG 0.45 0.52 2.00 2.15 20
35 L-Leu OBn L-Leu OBn 6OMe2′CMeG 0.38 0.02 1.31 0.21 39
36 L-Leu OCH2tBu L-Leu OCH2tBu 6OMe2′CMeG 0.47 0.15 2.40 0.71 27
37 L-Ile OMe L-Ile OMe 6OMe2′CMeG 5.17 1.94 29.5 2.66 >100
38 L-Ile OcHx L-Ile OcHx 6OMe2′CMeG 4.00 0.47 7.10 1.16 14
39 L-Ile OBn L-Ile OBn 6OMe2′CMeG 0.40 0.11 1.56 0.10 24
40 L-Ile OCH2tBu L-Ile OCH2tBu 6OMe2′CMeG 2.90 0.33 6.30 1.36 15
41 L-Met OcHx L-Met OcHx 6OMe2′CMeG 0.60 0.17 2.60 0.11 51
42 L-Met OBn L-Met OBn 6OMe2′CMeG 0.25 0.04 0.77 0.24 >100
43 L-Met OCH2tBu L-Met OCH2tBu 6OMe2′CMeG 2.22 5.00 >100
44 L-Phe OcHx L-Phe OcHx 6OMe2′CMeG 0.50 0.59 2.00 2.20 25
45 L-Phe OBn L-Phe OBn 6OMe2′CMeG 0.32 0.14 1.35 1.07 67
46 L-Phe OCH2tBu L-Phe OCH2tBu 6OMe2′CMeG 0.05 0.02 0.21 0.12 24
47 L-Pro OBn L-Pro OBn 6OMe2′CMeG 0.52 0.21 1.80 0.23 >100
48 L-Pro OCH2tBu L-Pro OCH2tBu 6OMe2′CMeG 0.81 0.05 2.00 0.21 56
49 L-Val OcHx L-Val OcHx 6OMe2′CMeG 2.50 0.35 10.00 0.72 20
50 L-Val OBn L-Val OBn 6OMe2′CMeG 0.12 0.04 0.66 0.35 49
51 L-Val OCH2tBu L-Val OCH2tBu 6OMe2′CMeG 0.72 2.50 32
52 L-Tyr (tBu) OMe L-Tyr (tBu) OMe 6OMe2′CMeG 0.11 0.04 0.50 0.10 89
53 L-PhG OcHx L-PhG OcHx 6OMe2′CMeG 0.32 0.00 1.80 0.04 18
54 L-PhG OCH2tBu L-PhG OCH2tBu 6OMe2′CMeG 0.27 0.03 1.50 0.09 24
55 L-Val-L-Ala OCH2tBu L-Val-L-Ala OCH2tBu 6OMe2′CMeG 0.54 0.26 2.40 0.46 >100
56 β-Ala OBn β-Ala OBn 6OMe2′CMeG 3.80 2.03 >10 >100
57 butylamine butylamine 6OMe2′CMeG 37.80 3.80 >40 >100
58 morpholine morpholine 6OMe2′CMeG >100 >100 >100
59 L-Ala OcPentyl L-Ala OcHx 6OMe2′CMeG 0.04 0.01 0.16 0.03 >100
60 L-Ala OCH2tBu L-Ala OBn 6OMe2′CMeG 0.15 0.04 0.40 0.07 >100
61 L-Ala OCH2tBu L-Ala OtBu 6OMe2′CMeG 0.15 0.01 0.57 0.08 >100
62 L-Ala OCH2tBu L-Ala OcHx 6OMe2′CMeG 0.04 0.01 0.15 0.02 >100
63 L-Ala OCH2tBu L-Pro OMe 6OMe2′CMeG 0.49 2.20 >100
64 L-Ala OCH2tBu L-Val OMe 6OMe2′CMeG 0.17 0.06 0.69 0.15 >100
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of the neopentyl alanine compound as a naphthyl ProTide
(5),12 we were keen to explore the methylene bridged family
starting with the neopentyl-(26) and 2-methylpropyl-(27)
compounds and also the methylene cyclopropyl-(28).
On the basis of our recent report that the 6-ethoxy group can
well substitute for the purine 6-methoxy as a core nucleoside
for anti-HCV ProTides,21 we applied the diamidate method to
the O6-ethyl-2′-C-methylguanosine nucleoside, preparing the
symmetrical cyclohexyl-(74), benzyl-(75), and neopentyl-(76)
L-alanine analogues.
In aryl phosphoramidate ProTides, we have reported on
several occasions the sometimes strong preference, for L-amino
acids over D-analogues,25 and all of the first examples reported
here are L-amino acid derived. However, we did synthesize the
neopentyl-D-alanine analogue 29 of 8.
Although L-alanine is generally strongly preferred, other
natural and unnatural amino acids are also effective as
ProTides,26 and so we did vary the amino acid motif itself.
An attempt was made to consistently select from the same three
ester groups, neopentyl, cyclohexyl, and benzyl, for each new
amino acid to facilitate comparison. Thus, symmetrical
diamidates were prepared from dimethyl-(30) and dibenzyl-
(31) L-aspartic acid, benzyl-(32) and neopentyl-(33) glycine,
cyclohexyl-(34), benzyl-(35), and neopentyl-(36) L-leucine,
methyl-(37), cyclohexyl-(38), benzyl-(39), and neopentyl-(40)
L-isoleucine, cyclohexyl-(41), benzyl-(42), and neopentyl-(43)
L-methionine, cyclohexyl-(44), benzyl-(45), and neopentyl-
(46) L-phenylalanine, benzyl-(47) and neopentyl-(48) L-
proline, and cyclohexyl-(49), benzyl-(50), and neopentyl-(51)
L-valine. The tyrosine methyl ester diamidate was also prepared
as its para-O-tert-butyl ether-(52). Diamidates of the unnatural
amino acid L-phenylglycine were prepared as its cyclohexyl-
(53) and neopentyl-(54) esters. In a prior program on
ProTides of d4T for HIV, we reported a complete loss of
activity on extending from alanine to β-alanine and beyond,27
but it was unclear whether similar restrictions would apply here,
hence we prepared the symmetrical benzyl-β-alanine diamidate-
(56).
Finally, in this series, we wondered if the chemistry
methodology would extend to a dipeptide and whether such
an adduct might be active and so we successfully incorporated
an L-valyl-L-alanine neopentyl ester (55).
Simple amines have not been found to be useful as the amino
component of aryl phosphoramidates, although Idenix has
successfully incorporated benzylamine into their clinical
analogue IDX184.14 However, for diamidates, the SAR was
unknown, and so we prepared the symmetrical butylamine-(57)
and morpholinyl-(58) diamidates. Notably, from a synthetic
perspective, none of the above amino acid and amine variations
presented particular challenges although the yields from these
reactions were not high and remain unoptimized.
Besides seeking to probe the SAR and potential advantages
of symmetrical diamidates, as above, we also wondered if the
synthetic method would allow access to asymmetrically mixed
diamidates. To do this, we slightly adapted the synthetic route
(Scheme 1) to allow the stepwise introduction of two separate
amino acids or one amino acid and one amine. To limit the
large number of possible combinations, and to facilitate
interpretation of the data, one of the amines was generally
kept constant as neopentyl L-alanine and variations were made
in the second amine. Initially, different L-alanine esters, benzyl-
(60), tert-butyl-(61), and cyclohexyl-(62), were combined with
neopentyl L-alanine, followed by different amino acids methyl L-
proline-(63) and methyl L-valine-(64), and then a number of
different simple amines (65−73). Synthetically, it did not
matter much which amine was introduced first. Each of these
asymmetric diamidates was isolated as a roughly 1:1 mixture of
phosphate diastereoisomers as revealed by 31P NMR and
HPLC. No attempt was made to separate the diastereoisomers,
and they were tested as mixtures.
In this way, a substantial set of symmetrical and asymmetric
phosphorodiamidates of 6-O-methyl-2′-C-methylguanosine and
three derivatives of the 6-O-ethyl analogue were prepared and
fully characterized. As expected, all of the symmetrical
diamidates reported above were observed as one peak by 31P
NMR and one signal on analytical HPLC. The 31P NMR shifts
of the symmetrical amino aryl diamidates were ca. 13 ppm,
being rather downfield of our usual aryloxy phosphoramidate
ProTides.28 The asymmetric diamidates gave two peaks by 31P
NMR and for HPLC, in roughly 1:1 ratios, as typically observed
for phosphoramidate ProTides. Other spectroscopic and
analytical data fully confirmed the structure and purity of the
diamidates herein reported.
■ BIOLOGICAL ACTIVITY IN REPLICON
Each of the diamidates described above were tested for HCV
inhibition in a replicon assay, with the clinical anti-HCV
ProTide (5) as positive control (Table 1). Both EC50 and EC90
values are reported, along with standard deviations, in a 72 h
HCV replicon assay. In general EC90 values were 2−5-fold
higher than EC50 values, and the discussion below will focus on
Table 1. continued
EC50 (μM) EC90 (μM)
compd AA ester/amine AA ester/amine nucleoside av SD av SD CC50 (μM)
65 L-Ala OBn butylamine 6OMe2′CMeG 0.44 0.28 1.68 0.94 >100
66 L-Ala OCH2tBu butylamine 6OMe2′CMeG 0.41 0.28 1.50 0.75 >100
67 L-Ala OCH2tBu pentylamine 6OMe2′CMeG 0.11 0.02 0.52 0.05 >100
68 L-Ala OCH2tBu cyclopropylamine 6OMe2′CMeG 0.87 0.11 4.70 0.45 >100
69 L-Ala OCH2tBu BnNH 6OMe2′CMeG 0.43 0.02 1.90 0.11 >100
70 L-Ala OCH2tBu PhNH 6OMe2′CMeG 0.27 0.01 0.82 0.00 >100
71 L-Ala OCH2tBu NaphNH 6OMe2′CMeG 0.13 0.05 0.56 0.18 >100
72 L-Ala OCH2tBu diethylamine 6OMe2′CMeG 3.70 >10 >100
73 L-Ala OCH2tBu pyrrolidine 6OMe2′CMeG 0.87 0.02 4.00 0.16 >100
74 L-Ala OcHx L-Ala OcHx 6OEt2′CMeG 0.05 0.00 0.15 0.02 69
75 L-Ala OBn L-Ala OBn 6OEt2′CMeG 0.29 0.04 1.00 0.29 62
76 L-Ala OCH2tBu L-Ala OCH2tBu 6OEt2′CMeG 0.04 0.01 0.11 0.04 72
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the EC50 numbers. In addition, the cell cytotoxicities (CC50) in
the replicon cell line (Huh7) are reported.
As noted in Table 1, the three parent nucleosides, 2′-C-
methyl guanosine 4 and the 6-methoxy 8 and 6-ethoxyl 9
analogues, display only modest anti-HCV activity, with EC50
values in the 2−10 μM range. By comparison, 5 is active at
nanomolar levels, with an EC50 of 10 nM and an EC90 of 40
nM, representing a ca. 400-fold potency boost over the
respective nucleoside.12 Compound 5 does show some
cytotoxicity to Huh7 cells in this assay at 7 μM, but its high
potency still leads to a significant SI of ca. 700.
Examining the potency of the first family of symmetrical L-
alanine phosphorodiamidates, we note a consistent and clear
increase in potency for the n-alkyl esters as they extended from
methyl (10 EC50 = 6 μM) to n-pentyl (14 EC50 = 0.03 μM).
The n-pentyl L-alanine 14 is thus about 3 times less active than
5, but notably it is also about 10 times less cytotoxic. It is
interesting to note that the calculated lipophilicity (ClogP)
values for this series range from 0.5 (methyl) to 4.7 (n-pentyl).
It maybe that lipophilicity and potency correlate, however,
there are exceptions. Clearly, the n-pentyl 14 is an interesting
compound with a very attractive SI.
Branching the amino acid ester at the α (Table 1, 15, 16), β
(26, 27), or γ (17) position does not significantly change
activity or toxicity relative to the straight chain compounds.
Thus, the isopropyl ester 15 and the n-propyl ester 12 have
Table 2. Replicon Activity for Symmetrical Phosphorodiamidates
replicon EC50 (μM)
(R2)
amino acid compd cyclohexyl benzyl neopentyl CC50 in Huh7 cells (μM)
L-alanine 20 0.05 >100
21 0.49 >100
19 0.06 >100
D-alanine 29 0.11 >100
glycine 32 0.60 >100
33 0.13 >100
L-leucine 34 0.45a 20
35 0.38 39
36 0.47 27
L-isoleucine 38 4.0 14
39 0.40 24
40 2.9 15
L-valine 49 2.5 20
50 0.12 49
51 0.72b 32
L-proline 47 0.52 >100
48 0.81 56
L-methionine 41 0.60 51
42 0.25 >100
43 2.22b >100
L-phenylglycine 53 0.32 18
54 0.27 24
L-phenylalanine 44 0.50a 25
45 0.32 67
46 0.05 24
L-aspartic (OBn) 31 0.61 >100
aLarge standard deviation. bSingle assay result.
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similar activities, and the β branched neopentyl ester 26 is
similar to the n-pentyl ester 14. Indeed, several of these
branched esters such as compounds 17 and 27 are very potent,
with excellent SI values. We were particularly interested in the
neopentyl L-alanine analogue 26 given its similarity to our
clinical agent 5. This compound reveals an EC50 of 0.06 μM
and EC90 of 0.2 μM and is only 5-fold less active in this assay
than 5. However, in common with many of the phosphor-
odiamidates, this compound is significantly less cytotoxic, with
CC50 >100 μM. Thus, the SI for 26 is >1600, which exceeds
that of 5.
Cyclic esters of L-alanine such as cyclopentyl-(19) and
cyclohexyl-(20) are also very potent in the replicon assay and
show no Huh7 cell toxicity at 100 μM. However, the cyclobutyl
derivative 18 is about 5-fold less active with an EC50 of 0.32
μM, and the tetrahydropyranyl ester 24 is more than 200-fold
less active compared to 20.
Interestingly, the benzyl ester derivatives of L-alanine (Table
1, 21−23) are somewhat less active than many of the alkyl ester
analogues, being 5−10-times less active than the cyclohexyl
compound for example. This is in marked contrast to the
phosphoramidate ProTides SAR and much of our prior
experience.28
An observation from our phosphoramidate SAR is that the
purine C-6-substituent can be varied considerably and that the
6-ethoxy may be particularly effective.24 As noted in Table 1,
the same applies to this series, with the cyclohexyl-(74), benzyl-
(75), and neopentyl-(76) purine C-6-ethoxy derivatives all
being equipotent with their C-6-methoxy analogues. Indeed,
with an EC90 of 110 nM, the neopentyl L-alanine analogue of
the 6-ethoxy nucleoside 76 emerged as one of the most potent
compounds in the present study.
The SAR next turned to symmetrical phosphorodiamidates
with amino acids other than L-alanine. The subtlest change was
to make the D-alanine analogue as its neopentyl ester 29. In
contrast to our earlier work on D-amino acids in aryl
phosphoramidate ProTides,25 here we see only a slight (ca.
2-fold) loss of activity. This again points to quite a new and
separate SAR for these diamidates as compared to aryloxy
phosphoramidates.
In generating the amino acid SAR in this series of
symmetrically substituted phosphorodiamidates, effort was
made to use three similar esters for each different amino acid
derivative to facilitate comparison. The three ester groups
selected were the cyclohexyl, benzyl, and neopentyl. Table 2
shows the compiled data.
A number of observations can be made from the data in
Table 2. First, the benzyl esters do not greatly distinguish the
different amino acids. The replicon activities for nine amino
acids with benzyl ester groups range from 0.25 to 0.61 μM, only
2- to 3-fold, which is similar to the variability in the replicon
assay.
The neopentyl and cyclohexyl ester groups distinguish the
different amino acids and give a similar rank order. Thus, the
best amino acid for both the cyclohexyl and the neopentyl
esters is the L-alanine, whereas the worst is L-isoleucine.
Overall evaluation of the amino acid SAR leads to conclusion
that small amino acid substituents like glycine or alanine are
preferred and that increasing the size of the amino acid R1
group as for L-leucine and L-methionine is detrimental to
replicon activity, as is branching of the amino acid as for L-
valine, L-isoleucine, and L-phenylglycine.
The exception to this rule is that the neopentyl L-
phenylalanine derivative 46 is very potent (EC50 = 0.05 μM)
in the replicon assay. The cyclohexyl L-phenylalanine derivative
44 was tested twice, and one value was 10-fold higher than the
other (EC50 = 0.083 and 0.92). It is possible that further testing
would refine these data. Further supporting this surprising L-
phenylalanine SAR, the L-tyrosine derivative 52, as the para-O-
tert-butyl ether, also had good activity and limited toxicity in the
replicon assay (EC50 = 0.11 μM, CC50 = 89 μM).
A further observation in this series of symmetrical
phosphorodiamidates is that some cytotoxicity is observed in
Huh7 cells for the amino acids other than alanine and glycine.
In fact, the cyclohexyl L-isoleucine 38 demonstrates that not all
phosphorodiamidates are equivalent. Compound 38 has an
EC50 of 4 μM and a CC50 of 14 μM, for an SI of only ca. 4, and
being the most cytotoxic diamidate studied.
As an extension of the growing symmetrical phosphorodia-
midate SAR, a more complicated, dipeptide, L-Val-L-Ala
neopentyl ester 55, in which the L-valine nitrogen forms the
phosphoramidate linkage, was prepared. Testing in the replicon
assay shows that 55 has similar replicon activity (Table 1, EC50
= 0.54 μM) as the neopentyl L-valine derivative 51. It is unclear
how this dipeptide would fit in with the putative metabolic
process (see Scheme 2) and may suggest the existence of
another metabolic pathway leading to the triphosphate
formation for this compound.
Working the SAR in the opposite direction, simple amine
substituted phosphorodiamidates were tested in the replicon
assay. The n-butyl amine analogue 57, which may be
Scheme 2. Putative Initial Activation Route of
Phosphorodiamidates
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considered similar to the L-leucine derivatives, but without the
α carboxylate, has a replicon EC50 of 38 μM, which is about
100-fold less active than the L-leucine derivatives. This is
consistent with the proposed metabolic route (Scheme 2)
where the carboxylate anion plays a key role. The positioning of
the carboxylate β to the amine, as for the β-alanine analogue 56,
results in moderate activity in the replicon assay (Table 1, EC50
= 3.8 μM). The morpholino phosphorodiamidate 58, an
example of a secondary amine, is inactive even at 100 μM in the
replicon assay. Both of these simple amine phosphorodiami-
dates 57 and 58 are much less active than the parent nucleoside
8 in the replicon assay, supporting our understanding that there
is a limited direct cleavage of the P−O bond, leading to free
nucleoside, in the replicon assay.
Although one of the key motivations for this new ProTide
motif was to generate an achiral phosphate center, we were
interested in understanding some aspects of the asymmetric
diamidate SAR. Our synthetic route (Scheme 1) did allow the
stepwise addition of two different amines. Each of these
asymmetric diamidates were isolated as a roughly 1:1 mixture of
phosphorus diastereoisomers, and no attempt was made to
separate them and they were tested as mixtures. To facilitate
comparison, generally, one of the two amines was maintained as
the L-alanine neopentyl ester (Table 1).
From this basis, our SAR study was focused in three areas.
First, we explored compounds 60−62 in which the second
amine was also L-alanine but with different ester groups. The
replicon results indicated that the presence of the L-alanine
neopentyl ester provides good antiviral potency even in the
presence of difficult to cleave29 tert-butyl L-alanine ester 61.
The presence of two easily cleavable esters such as for
derivatives 59 and 62 slightly increased the replicon activity
comparing to 61 but one “cleavable” group was sufficient.
Next, the SAR of asymmetrical phosphorodiamidates, where
the neopentyl L-alanine is combined with different amino acids
was briefly explored. The methyl L-proline 63 and the methyl L-
valine 64 amino acids had moderate replicon activity (Table 1),
more similar to the symmetrical L-prolines and L-valines than
the very potent symmetrical neopentyl L-alanine 26. It might be
that compounds 63 and 64 have different metabolic
intermediates (78, Scheme 2) than does 26.
Third, the phosphorodiamidate SAR of simple amines
combined with neopentyl L-alanine was extensively studied
(66−73, Table 1). In general, these compounds had moderate
to good activity, with EC50 values ranging from 0.1 to 0.9 μM
for monosubstituted amines, more active than the symmetrical
simple amines, but less active than the symmetrical neopentyl L-
alanine derivative (26). Presumably, conversion of compounds
66−73 involves cleavage of the L-alanine neopentyl ester
followed by the elimination of the simple amine to form the key
metabolic intermediate (78, Scheme 2). Thus, it might be
expected that the amines that make the best leaving groups
such as phenylamine 70 and naphthylamine 71, would be the
most active (EC50 = 0.27 and 0.13 μM) and that a poor leaving
group such as diethyl amine, in derivative 72, would be the least
active (EC50 = 3.7 μM, Table 1).
In conclusion, all but one of the 67 phosphorodiamidates
tested in the replicon assay were active at or below micromolar
concentrations, with 55 of them active below 1 μM and 12
active below 100 nM. Many are noncytotoxic at high μM levels,
some at 100 μM, giving attractive SI values for many
compounds. Clearly several of these compounds were worthy
of advancing to in vivo studies.
■ STABILITY ASSAYS
Given the new structural motif we are reporting and the very
promising replicon data (as described above), we sought to
establish some outline stability data under a variety of
conditions. To begin with, the lead symmetrical neopentylala-
nine compound 26 was dissolved in pH 7 phosphate buffer at
Figure 3. 31P NMR kinetic study of 26 in the presence of carboxypeptidase Y. Conditions: 5.0 mg of 26 in 200 μL of acetone-d6 + 400 μL of Trizma
buffer (pH 7.4), 0.3−0.5 mg of carboxypeptidase Y in 200 μL of Trizma buffer (pH 7.4).
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25 °C and monitored by 31P NMR over 14 h. Compound 26
was observed at 13.2 ppm, and no additional signal(s) appeared
over the course of the experiment (see Supporting Information
for stability spectra). HPLC also indicated no detectable
decomposition. We have previously reported acid stability
data27 for several acyclovir aryloxy phosphoramidate ProTides.
As a representative example, the phosphorodiamidate (26) was
dissolved in citric acid−HCl buffer at pH 2 and maintained at
either 37 or 47 °C while being monitored by 31P NMR over 14
h. Despite the acidic pH and elevated temperatures, the
samples remained entirely stable over the course of the assay. A
base stability study was conducted on compound 26 at pH 8.5/
37 °C and pH 11/37 °C, and these studies revealed slow
decomposition. After 17 h at pH 11, the majority species was
still unchanged (26), with only minor peaks at 6.9 ppm and
−4.3 ppm. The peak at 6.9 ppm corresponds to an amino acid
phosphoramidate derivative similar to compound 77 (see
Scheme 2 below), suggesting one phosphorodiamidate P−N
bond on compound 26 had been hydrolyzed under the aqueous
basic conditions. However, the decomposition is rather slow,
with a half-life exceeding 100 h (if first order). From this initial
stability data, it seems possible that the phosphorodiamidates
have a pH stability profile that is consistent with oral dosing.
Next, we studied the stability of compound 26 with human
serum at 37 °C. As before, the solution was monitored at 1 h
intervals over by 31P NMR over 12 h. The phosphorodiamidate
26 gave a peak at 14.5 ppm under these conditions, and no sign
of degradation was observed by 31P NMR. Thus, as noted for
aryloxy phosphoramidates,30 the present phosphorodiamidates
seem essentially stable in human serum, certainly for periods of
hours appropriate for human dosing.
As we have reported previously,12,30 the initial step of the
conversion of aryloxy amino acid ester phosphoramidates
(ProTides) to phosphates is thought to involve an enzyme-
mediated cleavage of the amino acid ester group. We have also
reported on the use of 31P NMR and a buffered solution of the
enzyme carboxypeptidase Y as an in vitro model for studying
the initial steps of ProTide30 activation. We sought to apply this
method to our new family of anti-HCV phosphorodiamidates.
Thus, compounds of interest were dissolved in acetone-d6 and
TRIZMA buffer at pH 7.4, and the 31P NMR spectrum was
recorded as the baseline. Then carboxypeptidase Y (cathepsin)
was added and spectra recorded at intervals up to 13 h (Figure
3). The data from these experiments were used to map a
possible phosphorodiamidate metabolic pathway (Scheme 2).
The first compound studied was the symmetrical neopentyl
ester of L-alanine 26, which has a 31P NMR shift of 14.2 ppm at
baseline (Figure 3). After 10 min, a small downfield metabolite
peak is observed at 14.9 ppm, which is consistent with cleavage
of the neopentyl ester. The peak at 14.9 ppm builds up for
approximately one hour, then diminishes, with a new peak
emerging at 6.95 ppm. This is first observed at ca. 40 min and
continues to grow through the course of the experiment. The
peak at 6.95 corresponds to the key amino acid phosphate
derivative 77 (R = CH3) (Scheme 2). This was determined by
synthesizing compound 77 (R = CH3) and using it as an
analytical reference standard (data not shown). Intermediate 77
could form by intramolecular attack of the amino acid
carboxylate anion onto the phosphorus, with elimination of
the second amino acid, followed by spontaneous hydrolysis of
the cyclic, mixed anhydride intermediate 78a,b. No direct 31P
NMR evidence (Figure 3) was obtained for this cyclic
compound, consistent with it being a short-lived metabolic
intermediate. As discussed in our publications on aryloxy amino
acid phosphoramidates, final conversion to the nucleoside
monophosphate is generally thought to be effected by enzymes
of the histidine triad nucleotide binding (Hint) family (Scheme
2).30,33
This initial evidence indicates that nucleoside phosphor-
odiamidates are converted to nucleoside monophosphates in a
similar fashion as aryl phosphoramidates, that is, via metabolite
77. To further support this hypothesis, a second phosphor-
Figure 4. 31P NMR kinetic study of 21 in the presence of carboxypetidase Y. Conditions: 5.1 mg of 21 in 200 μL of acetone-d6 + 400 μL of Trizma
buffer (pH 7.4), 0.3−0.5 mg of carboxypeptidase Y in 200 μL of Trizma buffer (pH 7.4).
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odiamidate, the symmetrical benzyl L-alanine derivative 21, was
studied in the same system (Figure 4). In this case, a similar 31P
NMR pattern, with the formation of the same key metabolite at
6.94 ppm (77, R = CH3) is observed, but there are subtle
differences. Parent 21 shows one phosphorus 31P NMR peak at
14.08 ppm at baseline, which disappears within the first 30 min
upon incubation with enzyme. However, in this case, two
downfield singlet peaks are observed, one small and transient at
14.46 ppm and the other larger and longer lived at 14.78 ppm.
Three possibilities exist to explain these two new downfield
peaks: (a) one specific benzyl ester is cleaved by carbox-
ypeptidase Y to give either 79a or 79b, but not both, followed
by a second ester cleavage to give 80; (b) both pro-pR and pro-
pS benzyl esters are cleaved by carboxypeptidase Y and both
79a and 79b are observed, but cleavage of both benzyl esters
does not occur; (c) the peak at 14.46 ppm represents mono
ester cleavage, where the 31P NMR signals of 79a and 79b
overlap, and the peak at 14.78 represents diester cleavage to
give 80.
Regardless of how the amino acid ester groups are cleaved by
this particular enzyme, the important information from the 31P
NMR experiments is that compound 21 goes through the same
common intermediate 77 (R = CH3) as does compound 26.
In Supporting Information, we present further detail of the
kinetics of appearance of each species in the carboxypeptidase Y
mediated cleavage of 21.
It should be noted that 26 is nearly 10-fold more active than
21 in the HCV replicon assay (Table 1), however comparison
Figure 5. 31P NMR kinetic study of 65 in the presence of carboxypetidase Y. Conditions: 4.9 mg of 65 in 200 μL of acetone-d6 + 400 μL of Trizma
buffer (pH 7.4), 0.3−0.5 mg of carboxypeptidase Y in 200 μL of Trizma buffer (pH 7.4). * Phosphate impurity in Trizma buffer; in blank and
remains unchanged throughout.
Figure 6. 31P NMR kinetic study of 73 in the presence of carboxypetidase Y. Conditions: 5.3 mg of 73 in 200 μL of acetone-d6 + 400 μL of Trizma
buffer (pH 7.4), 0.3−0.5 mg of carboxypeptidase Y in 200 μL of Trizma buffer (pH 7.4).
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of Figures 3 and 4 shows that the speed of carboxypeptidase Y
processing is very similar for the two prodrugs, and thus the
replicon and enzyme assays do not correlated directly, but we
do regard enzyme mediated ester cleavage as a useful tool to
study our prodrugs in vitro.
If a carboxylate anion intermediate such as 79a, 79b, or 80
can eliminate an amino acid moeity to give intermediate 77, we
wondered if simple primary or secondary amines could likewise
be eliminated from asymmetric phosphorodiamidates such as
65 and 73. Figure 5 shows the 31P NMR traces for an
experiment with the benzyl L-alanine, n-butyl amine derivative
65, and carboxypeptidase Y.
Because 65 is asymmetrical, two peaks are seen in the
baseline 31P NMR (16.59 and 16.75 ppm). Both peaks
disappear within 120 min, but the diastereomer at 16.75 is
cleaved faster. Once again. a peak at 6.94, identified as
compound (77, R = CH3), is observed growing in magnitude
during the course of the experiment. A very similar pattern is
observed in Figure 6, when the neopentyl L-alanine, pyrrolidine
asymmetrical phosphoramidate 73 was incubated with
carboxypeptidase Y. Again compound 77 (R = CH3) is
observed at 6.94 ppm and grows in over 14 h. Interestingly, in
this case, only one of the two diastereomers of compound 73
(31P NMR δ = 15.54 ppm) is cleaved by carboxypeptidase Y
over the course of the experiment.
Summarizing this portion or our work, we have built on our
previous understanding that aryloxy groups are eliminated from
asymmetrical phosphoramidates containing an amino acid
carboxylate by showing that a second amino acid or a primary
amine or a secondary amine can also be eliminated to give the
key intermediate 77. The data on 21, 26, 65, and 73 supports
the notion that only one ester cleavage is necessary and that the
second amine loss is rapid following the first ester cleavage.
Docking Studies. To further support the above, we
conducted some docking studies on several asymmetric
diamidates, using published31 crystal structure of carboxypepti-
dase Y. Thus, as shown in Figure 7a,b the Sp diastereomer of
65 binds significantly better than the Rp diastereomer.
In the case of the Sp isomer, the stabilization by H-binding of
two glycine residues (Gly52, 53) is notable and the nucleophilic
active site of Ser146 is also well positioned. These docking data
would then suggest that one diastereoisomer of 65 might be
processed better than the other. On the basis of the clear
kinetic difference noted above (Figure 5), perhaps the more
downfield species in 31P NMR of 65 is the Sp isomer. It is
interesting to wonder if the differing kinetics of metabolism
here may lead to a difference in biological potency as we have
noted in some cases for aryl phosphoramidates.5 However, we
were unable to separate the compound 65 diastereomers to test
this hypothesis.
Pharmacokinetics. The HCV replicon, stability, and
carboxypeptidase Y data suggests that our new phosphor-
odiamidate prodrug strategy may be a promising means of
delivering 2′-C-methylguanosine triphosphate into cells. The
Figure 7. (a) Docking of compound 65−Rp isomer within the catalytic site of carboxypeptidase Y. (b) Docking of compound 65−Sp isomer within
the catalytic site of carboxypeptidase Y.
Table 3. Rat Liver Triphosphate Levels from PK Analysis of Phosphorodiamidates
compd AA ester replicon EC50 (μM) Cmax
a (ng/g) Clast
b (ng/g) Tmax
c (h) AUC0−t
d (ng·h/g)
5e L-Ala OCH2tBu 0.01 1446.7 983.3 8.0 24557
26 L-Ala OCH2tBu 0.06 1580.0 800.0 8.0 25147
13 L-Ala O-n-butyl 0.07 1553.3 719.7 8.0 27671
14 L-Ala O-n-pentyl 0.03 1042.3 506.0 8.0 18600
16 L-Ala O-(R,S)-2-butyl 0.15 907.7 538.7 8.0 16252
19 L-Ala O‑cyclopentyl 0.06 1523.3 610.0 8.0 24546
25 L-Ala O-2‑indanol 0.58 632.0 632.0 24.0 10642
29 D-Ala OCH2tBu 0.11 598.3 441.7 8.0 11608
50 L-Val OBn 0.12 359.5 73.6 4.0 4478
aCmax: Maximum observed concentration.
bClast: Concentration at the last measurable time-point.
cTmax: Time at which maximum concentration was
observed. dAUC0−t: area under the concentration−time curve from time 0 to the last measurable concentration. eCompound 5 is a the
phosphoramidate INX-189 (see Figure 2).
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next hurdle was to determine if this prodrug strategy works in
vivo in a rodent. Because of our growing experience with
phosphoramidates such as 5 in rats, we decided to continue
with the rat as our initial PK model for the phosphorodiami-
dates. Eight symmetrical derivatives were selected for rat PK
studies (13, 14, 16, 19, 25, 26, 29, and 50, Table 3) based on
activity in the replicon assay and structural considerations. We
focused on symmetrical diamidates because they are
represented by single diastereoisomers, which would simplify
further development. All but two were L-alanine derivatives
because we wanted to fully explore the ability of these relatively
simple derivatives to provide sufficient liver triphosphate levels.
Compounds were formulated in 95% Capmul MCM/5%
Tween 80, and doses of 10 mg/kg were administered by oral
gavage to male Sprague−Dawley rats. Liver samples were
collected up to 24 h postadministration and were snap-frozen in
liquid nitrogen. Liver concentrations of 2′-C-methylguanosine
triphosphate were determined by LC-MS/MS. Results for these
eight phosphorodiamidates are compared to 5 in Table 3.
The main observation is that all compounds tested produced
significant levels of triphosphate in rat livers from a 10 mg/kg
dose, further validating phosphorodiamidates as effective
phosphate prodrugs. In addition, several of the phosphor-
odiamidates provide similar liver triphosphate exposures as the
clinical compound 5, which has shown efficacy against HCV in
phase Ib clinical trials.23 The amount of 2′-C-methylguanosine
triphosphate necessary to achieve an EC90 in the replicon assay
can be determined by measuring triphosphate levels in the
replicon cells upon incubation with a 2′-C-methylguanosine
based inhibitor such as 5. This EC90 triphosphate level in cells
can be extrapolated to EC90 triphosphate levels in the liver, as
measured in ng of triphosphate/gram of liver tissue. The value
we have calculated is 243 pmol of triphosphate per gram of liver
(equal to 131 ng/g).32 Thus, for all phosphorodiamidates
tested, except for 50, the level of triphosphate 24 h post dose, is
several fold above 131 ng/g level necessary to achieve 90%
inhibition of HCV replication (Table 3).
An important part of our evaluation of any new prodrug
approach for delivering 2′-C-methylguanosine triphosphate,
including these phosphorodiamidates, is measurement of
systemic nucleoside (2′-C-methylguanosine, 4) levels after
oral dosing of the prodrug. Our desire is to limit the systemic
exposure of this nucleoside. The plasma 2′-C-methylguanosine
levels for these eight phosphorodiamidates were measured, and
all but compound 13 had lower nucleoside Cmax values than 5
(<100 nM), and it is only slightly higher (data not shown).
The neopentyl L-alanine diamidate 26 has both the highest
Cmax and Clast of any diamidate tested. Figure 8 shows rat liver
triphosphate levels after a 10 mg/kg dose for the clinical
compound 5 and for 26. Triphosphate levels were measured at
eight time points over 24 h. It is clear that both prodrug
strategies produce similarly high levels of triphosphate. The n-
butyl L-alanine ester 13 has the highest overall triphosphate
AUC (Table 3), and the cyclopentyl ester 19 also has excellent
AUC and Clast values. These compounds along with the n-
pentyl ester 14 were advanced to monkey PK studies. A
combination of rat PK, monkey PK, and preliminary rodent
toxicology studies will be used to help select a clinical
candidate. These additional studies will be reported elsewhere
upon completion.
■ CONCLUSIONS
In conclusion, we report on a new family of phosphate
prodrugs based on phosphorodiamidates. This type of 5′-
monophosphate prodrug has the advantage that it can be
designed to be achiral at the phosphate center if desired. We
report on a range of novel prodrugs derived from amino acids
and simple amines and build a substantial HCV replicon SAR
for both symmetrical and asymmetrical phosphorodiamidates of
2′-C-methyl-6-O-methylguanosine. The replicon data suggests
that one aminoacyl ester is essential for potent activity versus
HCV. The phosphorodiamidates are stable in acid and mild
base and also in human serum. Carboxypeptidase Y is able to
activate these compounds to a nucleoside aminoacid phosphate
key intermediate, which is also the essential metabolic
intermediate for our earlier aryloxy ProTides. Many of the
novel compounds in this study show low nanomolar activity
versus HCV in replicon coupled with low cytotoxicity in the
Huh7 replicon cell line. Eight potent HCV inhibitors were
advanced to PK studies in Sprague−Dawley rats, and it was
demonstrated that they all provided substantial 2′-C-methyl-
guanosine triphosphate levels, in rat livers, that were
maintained over a period of 24 h. This body of work has
validated phosphorodiamidates as prodrugs for 2′-C-methyl-
guanosine both at the in vitro and the in vivo levels. Further in
vivo studies are underway that are intended to lead toward
selection of a phosphorodiamidate prodrug for HCV clinical
studies.
■ EXPERIMENTAL SECTION
General. Anhydrous solvents were purchased from Aldrich and
used without further purification. All reactions were carried out under
an argon atmosphere. Reactions were monitored with analytical TLC
on silica gel 60-F254 precoated aluminum plates and visualized under
UV (254 nm) and/or with 31P NMR spectra. Column chromatography
was performed on silica gel (35−70 μM). Proton (1H), carbon (13C),
and phosphorus (31P) NMR spectra were recorded on a Bruker
Avance 500 spectrometer at 25 °C. Spectra were autocalibrated to the
deuterated solvent peak, and all 13C NMR and 31P NMR were proton-
decoupled. Analytical and semipreparative HPLC were conducted by
Varian Prostar (LC Workstation-Varian prostar 335 LC detector)
using Varian Polaris C18-A (10 μM) as an analytic column and Varian
Polaris C18-A (10 μM) as a semipreparative column; elution was
performed using a mobile phase consisting of water/acetonitrile in
gradient (system1, 90/10 to 0/100 v/v in 30 min) or water/methanol
(system 2, 90/10 to 0/100 v/v in 30 min). High-resolution mass
spectra (HRMS) was performed as a service by Cardiff University,
using electrospray (ES). Compound purity was assured by a
Figure 8. Rat liver 2′-C′-methyl guanosine triphosphate levels from
compounds 5 and 26.
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combination of high field multinuclear NMR (H, C, P) and HPLC.
Purity by the latter was always >95% with no detectable parent
nucleoside for all final products.
Standard Procedure A: Synthesis Of Symmetrical Diami-
dates. To a suspension of the nucleoside (1.0 mol equiv) in
anhydrous tetrahydrofuran, triethylamine (1.0−1.2 mol equiv) was
added. After stirring for 30 min at room temperature, phosphoryl
chloride (1.0−1.2 mol equiv) was added dropwise at −78 °C. The
reaction mixture was stirred for 30 min at −78 °C and then allowed to
warm to room temperature. Anhydrous dichloromethane was added,
followed by amino acid ester (5.0 mol equiv) and triethylamine (10.0
mol equiv) at −78 °C. After stirring at room temperature for 20 h,
water was added and the layers are separated. The aqueous phase was
extracted with dichloromethane and the organic phase washed with
brine. The combined organic layers were dried over anhydrous sodium
sulfate, filtered, and evaporated to dryness. The resulting residue was
purified by silica gel column chromatography using as an eluent a
gradient of methanol in dichloromethane or chloroform. In some
cases, a subsequent repurification was necessary either by preparative
HPLC (gradient of methanol in water) or preparative TLC.
Standard Procedure B: Synthesis of Symmetrical Diami-
dates. To a solution of the nucleoside (1.0 mol equiv) in anhydrous
triethylphosphate was added phosphoryl chloride (2.0 mol equiv) at 0
°C. The reaction mixture was stirred for 24 h at 5 °C. Anhydrous
dichloromethane was added to the reaction mixture followed by amino
acid ester (5.0 mol equiv) and diisopropylethylamine (10.0 mol equiv)
at 0 °C. After stirring at 5 °C for 5 days, water was added and the
layers were separated. The aqueous phase was extracted with
dichloromethane and the organic phase washed with brine. The
combined organic layers were dried over anhydrous sodium sulfate,
filtered, and evaporated to dryness. The resulting residue was purified
by silica gel column chromatography using as an eluent a gradient of
methanol in dichloromethane. A subsequent repurification, if
necessary, was accomplished either by preparative HPLC (gradient
of methanol in water) or preparative TLC.
Standard Procedure C: Synthesis of Asymmetrical Diami-
dates. To a suspension of the nucleoside (1.0 mol equiv) in
anhydrous tetrahydrofuran, triethylamine (1.0 mol equiv) was added.
After stirring for 30 min at room temperature, phosphoryl chloride
(1.0 mol equiv) was added dropwise at −78 °C. The reaction mixture
was stirred for 30 min at −78 °C and then allowed to warm to room
temperature. Anhydrous dichloromethane was added, followed by the
addition of amino acid ester or amine (1 mol equiv) and anhydrous
triethylamine (2 or 1 mol equiv, respectively) at −78 °C. Reaction was
warmed to room temperature and monitored by 31P NMR. When
NMR indicated completion of the reaction (no starting material,
presence of monosubstituted product), a second amino acid ester or
amine (5 mol equiv) was added followed by the addition of
triethylamine (10 or 5 mol equiv, respectively) at −78 °C. After
stirring at room temperature for 16−20 h, water was added and the
layers were separated. The aqueous phase was extracted with
dichloromethane. The combined organic layers were dried over
anhydrous sodium sulfate, filtered, and evaporated to dryness. The
resulting residue is purified by silica gel column chromatography using
as an eluent a gradient of methanol in chloroform.
Example: Synthesis of 2-Amino-6-methoxy-9-(2′-C-methyl-
β-D-ribofuranosyl) Purine 5′-O-Bis(methoxy-L-alaninyl) Phos-
phate (10). The phosphorodiamidate 10 was prepared according to
the standard procedure B.
In a first step, a suspension of 6-O-methyl-2′-C-methylguanosine
(250 mg, 0.803 mmol) in anhydrous tetrahydrofuran (4 mL) was
reacted with triethylamine (135 μL, 0.964 mmol) and phosphorus
oxychloride (89 μL, 0.964 mmol). In a second step, anhydrous
dichloromethane (4 mL), L-alanine methyl ester hydrochloride salt
(561.1 mg, 4.02 mmol), and triethylamine (1.12 mL, 8.03 mmol) were
added.
After workup, silica gel column chromatography and preparative
HPLC, 19.8 mg of (10) was obtained in 4.4% yield as an off-white
solid. 1H NMR (500 MHz, MeOD-d4) δ 7.99 (s, 1H, H-8), 5.99 (s,
1H, H1′), 4.44−4.34 (m, 2H, H5′), 4.31 (d, 1H, J = 8.9 Hz, H3′),
4.21−4.16 (m, 1H, H4′), 4.07 (s, 3H, OCH3), 3.98−3.89 (m, 2H, 2×
CHα Ala), 3.70, 3.69 (2s, 6H, 2× OCH3 ester), 1.33 and 1.32 (2d, 6H,
J = 7.1 Hz, CH3 Ala), 1.00 (s, 3H, CH3).
13C NMR (126 MHz, MeOD-d4) δ 176.10 (2d,
3JC−C−N−P = 4.8 Hz,
2× CO Ala), 162.75 (C6), 161.95 (C2), 154.21 (C4), 139.33 (C8),
115.54 (C5), 93.19 (C1′), 82.33 (d, 3JC−C−O−P = 7.6 Hz, C4′), 80.02
(C2′), 74.73 (C3′), 66.13 (d, 2JC−O−P = 4.8 Hz, C-5′), 54.21 (OCH3),
52.72 (2× CH3 ester), 51.01, 50.93 (2d,
2JC−N−P = 2.3 Hz, 2× CH Ala),
20.86, 20.67 (2d, 3JC−C−N−P = 6.2 Hz, 2× CH3 Ala), 20.27 (2′-CH3).
31P NMR (202 MHz, MeOD-d4) δ 14.00. HPLC tR = 8.86 min
(system 1).
Example: Synthesis of 2-Amino-6-methoxy-9-(2′-C-methyl-
β-D-ribofuranosyl) Purine 5′-O-Bis(benzoxy-L-alaninyl) Phos-
phate (21). The phosphorodiamidate 21 was prepared according to
the standard procedure B.
In the first step, a solution of 6-O-methyl-2′-C-methylguanosine
(250 mg, 0.803 mmol) in anhydrous triethylphosphate (1 mL) was
reacted with phosphorus oxychloride (148 μL, 1.61 mmol). In the
second step, anhydrous dichloromethane (4 mL), the tosylate salt of
benzoxy-L-alanine (1.41 g, 4.02 mmol), and diisopropylethylamine
(1.40 mL, 8.03 mmol) were added to the previous mixture. After
workup, silica gel column chromatography and preparative HPLC,
50.1 mg of 21 was obtained in 8.7% yield as an off white solid. 1H
NMR (500 MHz, MeOD-d4) δ 7.96 (s, 1H, H-8), 7.34−7.25 (m, 10H,
2× Ph), 5.99 (s, 1H, H1′), 5.16−5.02 (m, 4H, 2× CH2 ester), 4.41−
4.31 (m, 2H, H-5′), 4.29 (d, 1H, J = 9.0 Hz, H3′), 4.21−4.15 (m, 1H,
H4′), 4.04 (s, 3H, OCH3), 4.02−3.94 (m, 2H, 2× CH Ala), 1.33 (d,
6H, J = 7.1 Hz, 2× CH3 Ala), 0.99 (s, 3H, CH3).
13C NMR (126 MHz,
MeOD-d4) δ 175.42, 175.36 (2d, 2× CO, 3JC−C−N−P = 6.3 Hz,
ester), 162.72 (C6), 161.91 (C2), 154.56 (C4), 139.31 (C8), 137.32,
137.29 (d, 2× C ipso OCH2Ph), 129.55, 129.5, 129.24, 129.21
(OCH2Ph), 115.55 (C5), 93.17 (C1′), 82.37 (C4′), 80.01 (C2′), 74.81
(C3′), 67.89,67.87 (2× OCH2Ph), 66.26 (C5′), 54.19 (OCH3), 51.13,
51.08 (2d, 2× Cα Ala), 20.79−20.58 (2d, 3JC−C−N−P = 6.3 Hz, 2× CH3
Ala), 20.26 (2′CCH3).
31P NMR (202 MHz, MeOD-d4) δ 13.93.
HPLC tR = 13.16 min (system 1).
Example: Synthesis of 2-Amino-6-methoxy-9-(2′-C-methyl-
β-D-ribofuranosyl) Purine 5′-O-[(Benzoxy-L-alaninyl)-(2,2-dime-
thylpropoxy-L-alaninyl)] Phosphate (60). The phosphorodiami-
date 60 was prepared according to the standard procedure C.
In the first step, a solution of 6-O-methyl-2′-C-methylguanosine
(250 mg, 0.803 mmol) in anhydrous tetrahydrofuran (5 mL) was
allowed to react with triethylamine (110 μL, 0.803 mmol) and
phosphorus oxychloride (70 μL, 0.803 mmol). The tosylate salt of
benzoxy-L-alanine (282 mg, 0.803 mmol) and triethylamine (110 μL,
0.803 mmol) were added. Anhydrous dichloromethane (4 mL) and
the tosylate salt of neopentyloxy-L-alanine (1.33 g, 4.02 mmol) and
triethylamine (1.12 mL, 8.03 mmol) were added as described in
method C. After workup and silica gel column chromatography, 25 mg
of the prodrug was obtained in 4% yield as an off-white solid. 1H NMR
(500 MHz, MeOH-d4) 7.97, 7.96 (2s, 1H, H8), 7.36−7.30 (m, 5H,
OCH2Ph), 5.98, 5.97 (2s, 1H, H1′), 5.18- 5.09 (m, 2H, OCH2Ph),
4.39−4.33 (m, 2H, H5′), 4.28 (2d, J= 8.00 Hz, 1H, H3′), 4.20−4.16
(m, 1H, H4′), 4.06, 4.05 (2s, 3H, 6OCH3), 4.02−3.94 (m, 2H, 2×
CHα Ala), 3.84, 3.82, 3.72, 3.67 (2AB, JAB= 10.50 Hz, 2H,
CH2C(CH3)3), 1.39−1.32 (m, 6H, 2× CH3 Ala), 0.97 (s, 3H,
2′CCH3), 0.93, 0.91 (2s, 9H, CH2C(CH3)3).
13C NMR (126 MHz,
MeOH-d4) 175.54, 175.43, 175.39 (CO ester), 162.73, 162.71
(C6), 161.93, 161.89 (C2), 154.57, 154.55 (C4), 139.32, 139.08 (C8),
137.39 (ipso OCH2Ph), 129.55, 129.35, 129.25, 129.23, 129.20,
129.16, 128.27, 128.00 (OCH2Ph), 116.19, 115.54 (C5), 93.34, 93.18
(C1′), 82.39, 82.33 (C4′), 80.01, 79.99 (C2′), 75.34, 75.04 (CH2C-
(CH3)3), 74.84, 74.82 (C3′), 67.88, 67.85 (OCH2Ph), 67.86 (d,
2JC−O−P = 3.75 Hz, C5′), 66.36 (d,
2JC−O−P = 5.50 Hz, C5′), 54.18,
54.01 (6OCH3), 49.69, 49.64, 49.52, 49.46 (2× Cα Ala), 32.28, 32.25
(CH2C(CH3)3), 26.74, 26.71 (CH2C(CH3)3), 21.07, 20.90, 20.79,
20.66 (4d, 3JC−C−N−P = 6.25 Hz, 2× CH3 Ala), 20.39, 20.25 (2′CCH3).
31P NMR (202 MHz, MeOH-d4) 13.98, 13.94. HPLC tR = 16.11, 16.80
min (system 1). MS (TOF ES+) m/z: 716.28 (M + Na+, 100%).
HRMS C30H44N7O10P1 calculated, 694.2966; found, 694.2956
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Biological Methods. Replicon Assays. The HCV inhibitory
activity of compounds was evaluated in an Huh7 cell line expressing a
stable, bicistronic subgenomic HCV genotype 1b (Con1) replicon
encoding the Renilla luciferase reporter gene (Apath, LLC, Brooklyn,
NY) as previously described.32 Cellular cytotoxicity was evaluated
using the CellTiter-Glo Luciferase assay (Promega, Madison WI). A
day before testing, 2 × 104 Huh7 cells were seeded in 96-well flat
bottom white plates (Nunc, Roskilde, Denmark). Four-fold serial drug
dilutions were made in growth medium and added to the cells. No
drug controls were included in each plate. The plates were incubated
in the presence of test compound for 3 days at 37 °C with 5% CO2.
Luciferase reagent was added to cells and plates were incubated for 20
min before measuring relative luminescent units (RLU) in a
luminometer (Veritas, Turner Biosystems, Sunnyvale, CA).
Pharmacokinetic Studies in Rats. Rat studies were conducted at
Inhibitex, Inc., in accordance with NIH Guidelines and following
protocols approved by the Institutional Animal Care and Use
Committee (IACUC) of Inhibitex, Inc. Studies were carried out as
previously described.32 Test compounds were formulated in 95%
Capmul MCM (ABITEC Corp., Janesville, WI)/5% Tween 80 (Sigma,
St. Louis, MO), and doses of 10 mg/kg were administered by oral
gavage to male Sprague−Dawley rats (Taconic Farms, Germantown,
NY). Liver samples were collected as a terminal procedure up to 24 h
postadministration and were snap-frozen immediately upon collection
in liquid nitrogen. Liver samples were stored frozen at ≤−80 °C prior
to analysis.
Bioanalysis of Pharmacokinetic Samples. The concentration of
2′-C-MeGTP in liver samples from rats was measured by LC-MS/MS
as described previously.28 The assay was linear (r2 ≥ 0.99) in the
concentration range of 100−4000 ng per gram of tissue with ≥85%
accuracy and ≤2% CV. Noncompartmental pharmacokinetic analyses
were performed on the liver concentration data using WinNonlin v5.2
software (Pharsight, St. Louis, MO) as described previously.32
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a b s t r a c t
7-Deazapurines are known to possess broad antiviral activity, however the 20-C-methylguanosine ana-
logue displays poor cell permeation and limited phosphorylation, thus is not an efﬁcient inhibitor of hep-
atitis C virus (HCV) replication. We previously reported the 6-O-methyl entity as a prodrug moiety to
increase liphophilicity of guanine nucleosides and the ProTide approach applied to 20-C-methyl-6-O-
methylguanosine has lead to potent HCV inhibitors now in clinical trials. In this Letter, we report the syn-
thesis and biological evaluation of 20-C-methyl-6-O-methyl-7-deaza guanosine and ProTide derivatives.
In contrast to prior studies, removal of the N-7 of the nucleobase entirely negates anti-HCV activity com-
pared to the 20-C-methyl-6-O-methylguanosine analogues. To understand better this signiﬁcant loss of
activity, enzymatic assays and molecular modeling were carried out and suggested 20-C-methyl-6-O-
methyl-7-deaza guanosine and related ProTides do not act as efﬁcient prodrugs of the free nucleotide,
in marked contrast to the case of the parent guanine analogue.
 2012 Elsevier Ltd. All rights reserved.
Identiﬁed in 1989,1 Hepatitis C is an infectious disease affecting
approximately 180 million people worldwide.2 The standard treat-
ment of care currently administered to patients consists of the gen-
eral antiviral agent ribavirin combined with pegylated interferon
and one of the recently discovered non-nucleoside inhibitors tela-
previr or boceprevir. This treatment is not only long but has limited
efﬁcacy3 and causes numerous side effects,4 hence the need of
more efﬁcient therapy. Several modiﬁed purine nucleosides, such
as b-20-C-methyl purines and nucleobase modiﬁed purines, have
exhibited signiﬁcant anti-HCV activity.5 After phosphorylation to
their triphosphates b-20-C-methyl modiﬁed nucleosides are direct
inhibitors of HCV replication,6 and they are known as Direct Acting
Antivirals (DAAs). This includes several 7-deaza purines, particu-
larly b-20-C-methyl-7-deaza adenosine (1) (Fig. 1) which is
reported to be a potent inhibitor of HCV replication (EC50 =
0.25 lM, CC50 >100 lM),5,6 whereas its guanosine analogue is inac-
tive (EC50 >100 lM, CC50 >100 lM). The loss of inhibitory activity is
likely to be due to its poor cell uptake and inefﬁcient intracellular
metabolism to its 50-triphosphate form.6,7 This membrane perme-
ation issue was previously addressed and modiﬁcations at the
6-position of nucleobase lead us to develop b-20-C-methyl-6-O-
methyl guanosine (2) (Fig. 1), being however ﬁvefold less potent
in HCV replicon than its b-20-C-methyl guanosine analogue.8 Nev-
ertheless the ProTide technology applied to this nucleoside not
only boosted the lipophilicity but also enabled by-pass of the lim-
iting ﬁrst phosphorylation step, delivering efﬁciently inside the
host cell the corresponding 50-monophosphate form.9 The L-Ala-
nine neopentyl phosphoramidate of b-20-C-methyl-6-O-methyl
guanosine (3) (Fig. 1) ,8 also known as INX-08189 or BMS-
986094, is one of the examples of a ProTide developed for HCV
treatment.
It has previously been reported that both 20-C-methyl guanosine
7-deaza and 7-aza guanosine triphosphates exhibited sub-micro-
molar inhibitory potencies against the polymerase (respectively
IC50 = 0.12 lM and IC50 = 0.13 lM).6 Hence, the polymerase does
not discriminate between 7-aza and 7-deaza derivatives. We thus
0960-894X/$ - see front matter  2012 Elsevier Ltd. All rights reserved.
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decided to synthesise 7-deaza analogues of 20-C-methyl-6-O-
methyl guanosine and related ProTides in order to increase inhibi-
tory potency against HCV.
b-20-C-Methyl-6-O-methyl-7-deaza guanosine nucleoside (8)
was synthesized in two stages: ﬁrst the formation of the nucleo-
base (4) (Fig. 2), followed by coupling with the commercial 3,5-
bis-O-(2,4-dichlorophenylmethyl)-20-C-methyl-1-O-methyl-a-D-
ribofuranose (5) (Fig. 2).
7-Deaza-6-chloroguanine (4) was formed in moderate yield
over two steps as described in the literature.10,11 Displacement of
the 6-chlorine of 4 by sodium methoxide was undertaken under
reﬂux for 5 days but lead mainly to degradation and generation
of 6-methoxy-7-deaza guanine in very poor yield (3%). It was then
decided to perform this step directly at the nucleoside level. Con-
densation with the ribofuranose moiety (5) was performed, as de-
scribed in the literature,6 by in situ conversion to the 1-bromo
analogue followed by subsequent reaction with 7-deaza-6-chloro-
guanine potassium salt (formed in situ with potassium hydroxide
powder) to afford only the b-anomer of 6 (Fig. 2). Treatment of 6
with boron trichloride in dichloromethane resulted in the depro-
tection of dichlorophenylmethyl group to yield 20-C-methyl-6-
chloro-7-deazaguanosine (7). The latter was then converted to
the 6-O-methyl analogue by substitution of the chlorine with
sodium methoxide in methanol under reﬂux,8 affording 20-C-
methyl-6-O-methoxy-7-deaza guanosine (8) after column
chromatography, in 50–60% yield. Without prior protection of the
nucleoside 8, three 50-ProTides (9–11) bearing the L-Alanine as
amino acid moiety were synthesized following our standard proce-
dure12 using tert-butyl magnesium chloride as a base13 (Fig. 2).
Puriﬁcation by column chromatography and preparative TLC were
required to obtain pure compounds. NMR and analytical HPLC con-
ﬁrmed the structure with purity of at least 95% for all phosphoram-
idates. They were each obtained in 12–13% yield as a mixture of
two diastereoisomers, which were only separated in the case of
the L-alanine-O-cyclohexyl ester ProTide (9a and 9b).
The three phosphoramidates (9–11) and their parent nucleoside
(8) were evaluated in a HCV replicon assay (EC50) and for cytotox-
icity in Huh-7 cells (CC50) (Table 1). Table 1 compares the biologi-
cal results of synthesized compounds (9–11) and their 20-C-
methyl-6-O-methyl guanosine analogues (2, 3, 12–13).
In vitro results (Table 1) suggest that 20-C-methyl-6-O-methyl-
7-deaza guanosine (8) is not an inhibitor of HCV replication
whereas its corresponding ProTides (9–11) boost the antiviral
activity from 3- to 10-fold. So, to some extent the ProTide approach
applied to 20-C-methyl-6-O-methyl-7-deaza guanosine is effective
and the results conﬁrm the delivery of the 50-triphosphate inside
the cells, whereas the N-7 modiﬁcation of the parent nucleoside
(8) does not show the improvement of potency desired and either
lacks of cell permeation or is a poor substrate for nucleoside ki-
nases responsible for phosphorylation. The separated diastereoiso-
mers 9a and 9b exhibit similar potency in replicon assays showing
little if any inﬂuence of phosphorus stereochemistry on bioactiva-
Figure 1. Structures of potent anti-HCV b-20-C-methyl nucleosides (1–2) and ProTide (3).
Figure 2. Synthesis of 20-C-methyl-6-O-methyl-7-deaza guanosine (8) and ProTides (9–11). Reagents and conditions: (a) anhyd CH2Cl2, HBr (33% in acetic acid, 6.7 equiv),
0 C to rt, 2 h; anhyd ACN, KOH (3.0 equiv), TDA-1 (0.2 equiv), rt, 1 h; (b) anhyd CH2Cl2, BCl3 (10 equiv), 78 C, 2 h then 20 C, 2 h 30 min; (c) anhyd MeOH, NaOMe
(3.0 equiv), reﬂux, overnight; (d) anhyd THF, tBuMgCl (1.2 equiv), naphthyl L-Alanine ester phosphochloridate (1.2 equiv), rt, overnight.
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tion and potency. However, comparing the 7-deaza to the parent
guanine series, it is remarkable that the removal of the N-7 of
the nucleobase leads to a loss of potency over 1000-fold in the case
of the neopentyl and benzyl derivatives (3 vs 10 and 13 vs 11).
Their C logP values being similar (3.14 to 4.00), cell uptake is prob-
ably not the main issue in this case.
However, phosphoramidates 9–11 are somewhat cytotoxic to-
wards Huh-7 cells resulting in a poor selectivity index in compar-
ison to their of 20-C-methyl-6-O-methyl guanosine analogues.
Because the 20-C-methyl modiﬁcation of 7-deaza adenosine re-
sulted in signiﬁcant loss of cellular toxicity7 and neither 20-C-
methyl guanosine nor its 7-deaza analogue exhibited cytotoxicity
in Huh-7 cells,6 and because 7-deaza guanosine lacks antiviral
properties in cell cultures but is reported to be orally active
in vivo against numerous RNA viruses without high toxicity,14
the cytotoxicity may result from the 6-O-methyl modiﬁcation. A
similar trend has already been reported by our group8 and this
modiﬁcation would ideally be metabolised to its guanine deriva-
tive affording the delivery of the potent 20-C-methyl-7-deaza gua-
nosine 50-triphosphate (IC50 = 0.12 lM).6 However, our key
observation is that the removal of the 7-aza moiety greatly reduces
anti-HCV efﬁcacy in this series of nucleosides and activity is not
greatly restored by the ProTide.
To further understand the impact of the methine group replac-
ing the N-7 of the nucleobase in the biological activation pathway,
some enzymatic assays and molecular docking were carried out
with the 7-deaza analogue (10) of 3.
Preliminary UV experiments were carried out incubating 8with
adenosine deaminase (ADA). As expected, the conversion of b-20-C-
methyl-6-O-methyl-7-deaza guanosine into b-20-C-methyl-7-dea-
za guanosine does not occur at a nucleoside level (Fig. 3a). How-
ever molecular docking of b-20-C-methyl-6-O-methyl-7-deaza
guanosine 50-monophosphate in an homology model of adenosine
deaminase-like protein1 (ADAL-1),15 recently reported as the en-
zyme involved in metabolism of 6-O/N-substituted purine mono-
phosphates,16 predicted that the later is a relatively good
substrate (Fig. 3b). Thus, the b-20-C-methyl-7-deaza guanosine 50-
monophosphate should be delivered intracellularly.
To further investigate if 20-C-methyl-6-O-methyl-7-deaza gua-
nosine phosphoramidates deliver the corresponding 50-monophos-
phate intracellularly and thus may lead to the bioactive 20-C-
methyl-7-deaza guanosine 50-triphosphate, enzymatic experi-
ments were carried out to mimic the different stages of the puta-
tive mechanism of ProTide activation (Fig. 4). After incubation
with carboxypeptidase Y (CPY) in Trizma buffer, enzymatic cleav-
age of the amino acid ester of phosphoramidate 10 was monitored
by 31P NMR. Spectra were recorded regularly and selected spectra
are shown in Figure 5. The two peaks at dP 4 ppm correspond to
the two diastereoisomers of phosphoramidate 10. The two phos-
phorus signals decrease over time conﬁrming conversion of 10 to
the amino acyl phosphate 15 lacking both the naphthyl and neo-
pentyl ester moieties represented by the peak at 7.10 ppm
(Fig. 5). While 50% of the diastereoisomer corresponding to dP
4.04 ppm is converted after 5 h, more than 9 h is necessary for
50% of the disatereoisomer which peak appears at dP 3.55 ppm,
to be converted to its amino acyl phosphate derivative 15. This dif-
ference in metabolism rate is probably a result of different ﬁtting in
the enzymatic catalytic site. These observations correspond to a
metabolic conversion rate of 10 over 20-times slower than its ana-
logue 3.8 This may partly explain the considerable loss of activity
exhibited in replicon assays. It is to some extent rather surprising
that the remote 7-deaza modiﬁcation has such an impact on the
deesteriﬁcation step on the ProTide. Compound 15 is a key metab-
olite for further enzymatic conversion to the corresponding 50-
monophosphate 16 by phosphoramidase type enzymes.
To explain this difference of reactivity towards carboxypeti-
dase-type enzymes, some molecular docking was performed using
cathepsin A (PNB 1YSC) whose structure and substrate speciﬁcity
is similar to CPY.17 Preliminary docking of phosphoramidate 10
predicted that the Sp isomer ﬁts best in the cathepsin pocket, thus
Table 1
Biological activity of 20-C-methyl-6-O-methyl-7-deaza guanosine (8) and 20-C-methyl-6-O-methyl guanosine (2) and their corresponding phosphoramidates
R 20-C-Methyl-6-O-methyl-7-deaza guanosine 20-C-Methyl-6-O-methyl guanosine
Compd EC50 (lM) CC50 (lM) Compd EC50 (lM) CC50 (lM)
8 >100 >100 2 3 >100
cHex 9a 13.3 18 12 0.03 6
cHex 9b 8.9 13 — — —
CH2tBu 10 12.9 27 3 0.01 6
Bn 11 27.3 27 13 0.02 11
Figure 3. (a) UV spectra of conversion of 20-C-methyl-6-O-methyl-7-deaza guanosine (8) into 20-C-methyl-7-deaza guanosine (14) by adenosine deaminase assay; (b)
docking of b-20-C-methyl-6-O-methyl-7-deaza guanosine 50-monophosphate (grey sticks) in ADAL-1 (green line: natural substrate adenosine 50-monophosphate).
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Sp isomers of both 10 and analogue 3were docked into the cathep-
sin active site (Fig. 6a). The removal of N-7 provokes an undesirable
effect on the position of the amino acid ester carbonyl group of 10,
which lies towards the front of the pocket and is quite far from the
essential catalytic residues Gly52, Gly53 and Ser146, whereas the
carbonyl group of 3 faces inside the catalytic pocket resulting in
faster ester cleavage. This would suggest that a hydrogen bond
with the N-7 in the nucleobase pocket is probably essential to lock
the nucleobase in a conﬁguration that enables a good ﬁt of the
phosphoramidate carbonyl into the catalytic site of carboxyester-
ase-type enzymes. Thus, modeling data support the slow release
of amino acid monophosphate 15 seen during CPY assays.
The second step of activation was investigated in order to con-
ﬁrm the release of the 50-monophosphate 16. ProTide 10 was incu-
bated with Huh-7 cell lysates. Mass spectra and 31P NMR spectra
(data not shown) were recorded and suggested the formation of
the desired 50-monophosphate 16 (M+Na+ = 413). Nevertheless
conversion of 10 is very slow and even after 48 h, 10 remains the
main specie present in the medium (M+H+ = 658, M+Na+ = 680,
M+K+ = 696). This result is in correlation with the predictive dock-
ing in Human Hint-1 (PNB 1KPF) (Fig. 6b), where the phosphorus
lies far from the optimal position near the catalytic residues based
on adenosine monophosphate, the natural substrate.
To conclude, we report the synthesis of 7-deaza derivatives of b-
20-C-methyl-6-O-methyl guanosine. Despite the efﬁciency of the
ProTide technology, replacement of N-7 by a methine group leads
to a signiﬁcant loss of potency against HCV and loss of antiviral
selectivity which cannot be salvaged by the ProTide motif. A much
Figure 4. Putative mechanism of activation of 20-C-methyl-6-O-methyl-7-deaza guanosine phosphoramidates.
Figure 5. Carboxypetidase Y assay on phosphoramidate 10.
Figure 6. (a) Docking of SP isomers of 3 (blue) and 10 (yellow) in the catalytic site of cathepsin A (red: oxygen, pink: phosphorus). (b) Docking of aminoacyl intermediate of 10
(grey stick) and adenosine 50-monophosphate (AMP, red line) in the catalytic site of human Hint-1.
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reduced rate of processing of the ProTide to the key amino acyl
intermediate and the slow release of the 50-monophosphate specie
may be the reasons for this outcome, since the conversion to b-20-
C-methyl-7-deaza guanosine 50-monophosphate by ADAL-1 should
be efﬁcient. The remarkable loss of potency at the ProTide level on
formation of the 7-deaza species is a surprising outcome of this
study and it shows the need to tune the ProTide motif, and under-
stand its interplay with the nucleoside, on each occasion. More-
over, the lack of activity of these 7-deaza guanosine derivatives
is not expected to be due to differences of afﬁnity at the polymer-
ase level compared to guanosine derivatives.6
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